B-Cell Receptor Signalling in Chronic Lymphocytic Leukaemia. by Butler, Tom
B-Cell Receptor Signalling in Chronic Lymphocytic Leukaemia.
Butler, Tom
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/8693
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
 1 
B-Cell Receptor Signalling in Chronic 
Lymphocytic Leukaemia 
 
 
 
Tom Butler 
 
A thesis submitted for the degree of Doctor 
of Philosophy at the University of London 
 
 
Centre for Haemato-Oncology 
Barts Cancer Institute 
 
 2 
1.Abstract 
Chronic Lymphocytic Leukaemia (CLL) cells may depend on B-cell receptor (BCR) 
signalling as well as other microenvironmental survival signals. A peculiarity of CLL is 
that cells preserve IgD signalling in the presence of reduced IgM signalling, a pattern 
mimicking anergic B-cells, and consistent with autoantigen exposure. This aim of this 
thesis was to examine the differing roles of IgM and IgD in CLL. 
 
IgM and IgD expression was examined in CLL cells from peripheral blood (PB) and 
lymph node (LN). Co-expression of IgM and IgD was common, but levels of expression 
of IgD and IgM vary independently within these compartments, implying they may 
have differing roles. Most PB CLL samples underwent calcium (Ca) flux after IgD 
ligation, with evidence of relative IgM anergy. Incubation of cells for 24h in vitro 
partially restored IgM Ca flux, further supporting an anergic model. A pro-survival role 
of the BCR was suggested by the finding that BCR ligation was associated with reduced 
apoptosis in vitro.  
 
Mechanistic differences of IgM and IgD signalling were examined using mass-
spectrometry based phosphoproteomics. Six CLL samples were compared to five tonsil 
controls, and >5000 unique phosphopeptides identified. CLL and tonsil 
phosphoproteomes were compared. BCR induced changes in phosphoproteins and 
kinases differed between IgM and IgD ligation, and between CLL and tonsillar B-cells. 
Recognised and novel pathways included BCR, spliceosome and Notch signalling. 
Evidence in support of anergic signalling in CLL was observed. 
 
Anergic IgM signalling is contrasted with IgD as a dynamic process, different in the 
tissue compartments of CLL. Phosphoproteomics offers a powerful tool for 
interrogating intracellular signalling, with phosphorylation networks characterizing 
pathway topology. BCR signalling in healthy B-cells has not previously been studied 
using this approach and comparisons with CLL highlight known as well as novel 
pathways that may well represent novel treatment targets.  
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2.Introduction 
2.1 Chronic Lymphocytic Leukaemia (CLL) 
Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in the western 
world. It affects predominantly elderly individuals, with fewer than a third of patients 
being under the age of 60 at presentation,1 and has a median age of diagnosis of 72 
years2. The incidence of CLL is 3.9 per 100,000 people per year, the incidence in men is 
nearly twice that of women and there is geographical variation in CLL incidence, with 
high incidences in North America and Europe1,2. The disease presents in the lymph 
nodes without leukaemic involvement in 5% of cases and the disease is then known as 
small lymphocytic lymphoma (SLL). In the current World Health Organization (WHO) 
classification CLL and SLL represent different aspects of the same disease (CLL/SLL).
  
 
The diagnosis is made by the detection of a clonal population of small B-
lymphocytes/B-cells in peripheral blood (PB) or bone marrow (BM), or by lymph node 
(LN) biopsy showing cells expressing the characteristic morphology and 
immunophenotype. CLL cells express CD19, dim CD20, CD5, CD23, and CD79a and 
weakly express surface IgM and IgD. Expression of CD38 is variable and has prognostic 
significance in this disease3,4. The international workshop on Chronic Lymphocytic 
Leukemia (iwCLL) revised guidelines require a B-cell lymphocytosis of greater than 
5000/µl maintained for more than 3 months with the cells expressing the characteristic 
immunophenotype to reach a diagnosis of CLL5. CLL is increasingly an incidental finding 
in asymptomatic individuals when a lymphocytosis is found at the time of a routine 
blood count. Intriguingly, the increasing use of immunophenotyping has led to the 
identification of apparently healthy individuals with circulating clonal B-cells, often 
with the characteristic phenotype of CLL, but below the 5000/µL threshold demanded 
by CLL guidelines, and without any symptoms attributable to CLL. These cases have 
been catered for by the creation of a new entity, monoclonal B-cell lymphocytosis 
(MBL). The prevalence of MBL in the population is higher than that of CLL, with 
estimates of 3-5%6. On follow up, it has been noted that most of these individuals 
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never achieve the B-cell count threshold required for a formal diagnosis of CLL, and the 
majority of those that do develop CLL do not require subsequent treatment. A model 
of a universal asymptomatic precursor state has been supported by the finding of 
preceding MBL in almost all stored samples of patients latterly diagnosed with CLL6. 
This pre-leukaemic state is analogous to the model of monoclonal gammopathy of 
undetermined significance (MGUS) as an asymptomatic precursor of multiple 
myeloma, and of the models suggesting adenomas and carcinomas-in-situ as the 
precursors to full-blown epithelial tumours7.  
 
It is suggested that MBL precedes all cases of CLL6 and strikingly, data suggest that CLL-
like cells are detectable in almost all adults older than 70 years, and can be identified 
in a high proportion of those in younger age groups, provided sensitive enough 
techniques are employed (immunophenotyping of at least 50mL of peripheral blood)8. 
The process of ageing results in a narrowing of the B-cell repertoire,9 and a speculative 
model may suggest an evolutionary continuum from oligoclonal B-cell senescence to 
monoclonal B-cell lymphocytosis to full-blown CLL. Oligoclonality is evident amongst 
low-count MBL cases, illustrating the transitions from polyclonality to oligoclonality en 
route to monoclonal MBL and CLL10. Oligoclonality or clonality of the T-cell repertoire 
has also been demonstrated in older individuals as well as in MBL11 and CLL12. More 
recently, it has been suggested that the apparently non-malignant haemopoietic stem 
cells of patients with CLL have an inherent tendency to progress to CLL13. Transplant of 
CLL patients’ purified CD34+CD38- haemopoietic stem cells into mice recapitulated 
polyclonal haemopoiesis, as one might expect with healthy stem cells, but a bias 
towards B-cell differentiation was observed, as well as an eventual development of B-
cell clonality with ageing. These B-cell clones were characteristic of CLL in terms of 
immunophenotype and a biased repertoire of immunoglobulin gene usage, but the 
actual immunoglobulin genes used differed from the original CLL clone. These 
provocative data require replication but may suggest CLL patients exhibit defects at 
earlier stages of B-cell differentiation than have been hitherto described.  
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2.2 Treatment of CLL 
CLL follows a highly variable clinical course. Approximately 25% of patients require 
therapy at diagnosis due to bone marrow failure or to symptoms such as bulky 
adenopathy, organomegaly, fatigue or B-symptoms such as fevers, night sweats, 
weight loss or extreme fatigue. Some individuals diagnosed at an early stage remain 
asymptomatic for the rest of their lives, with their lifespan unaffected by CLL, while 
others develop an aggressive form of the disease. Treatment guidelines state that 
therapy should be reserved for those with advanced, symptomatic or progressive 
leukaemia5. Treatment is considered palliative due to the incurable nature of the 
disease with conventional chemotherapeutic agents and the often-advanced age of the 
patient. Several trials involving more than 2,000 patients with early disease have 
shown no survival benefit to treating patients with alkylating chemotherapeutic agents 
with early versus deferred therapy 14. 
More recently, there has been improvement in the overall survival of CLL, particularly 
since the 1980s and in older age groups. This is not explained by lead-time bias due to 
the greater use of automated blood counters picking up early-stage disease1. There 
has been significant improvement over the past decade in the results of treatment of 
CLL with the use of combination chemotherapy and chemo-immunotherapy. This has 
resulted in improvements in response rates, complete remission (CR) rates and in 
progression free survival (PFS), but only recently has there been a demonstration of 
improved overall survival (OS) with chemo-immunotherapy15.  
The German CLL Study Group (GCLLSG) – led CLL8 study comparing the use of 
Fludarabine and Cyclophosphamide (FC) with Rituximab, Fludarabine and 
Cyclophosphamide (FCR) has shown that patients treated with FCR 
chemoimmunotherapy achieved a significant improvement in PFS and OS compared to 
patients treated with chemotherapy using FC alone15. Whilst trials showing 
improvements in survival with combination chemo-immunotherapy are heartening, 
there is still an unmet need: the CR rates in the CLL8 study were only 44% with FCR, 
and only 5% in patients with the high risk cytogenetic abnormality of 17p deletion. 
Toxicities were not negligible, and the trial was conducted in generally fit patients with 
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a median age of 61.15 Failure to respond and relapse are still major challenges, and 
there is no standard of care for patients in this situation. The use of allogeneic stem 
cell transplantation has led to a long-term cure in the minority of patients for whom 
this approach is indicated. The efficacy, toxicity and cost of the various treatment 
regimes are highly variable.  
In parallel with new therapeutic manoeuvres, there has been dramatic progress in the 
understanding of the basic biology of CLL, and the development of a panoply of 
prognostic factors that led many to hope that tailored therapy would improve 
responses. The knowledge gained with use of these prognostic factors has rarely led to 
clarification of the wisest plan for treatment of individual patients, but has provided 
important insights into CLL biology16.  
Newer agents are in development, and are showing promise in the laboratory and in 
initial trials17-20. An increasing understanding of the biology of the disease is driving 
these new treatments, but their appropriate use will need to be defined in clinical 
trials, and it is envisaged that no single agent will prove a ‘magic bullet’. Because of 
CLL’s incurable nature, and the often-advanced age of the patient at presentation, 
there is a need for better therapy, in terms of improved response rates and lower 
toxicities. 
2.3 Pathophysiology of CLL 
Cancers develop and progress via a combination of intrinsic cell changes interacting 
with extrinsic microenvironmental alterations21,22. There has been an increasing 
recognition that whilst a focus on intrinsic tumour cell abnormalities has led to 
profound insights, the surrounding tissues that do not form part of the malignant clone 
do have an important effect on tumour biology. These microenvironmental alterations 
are often considered secondary to intrinsic cell changes such as mutations in genes, 
with the malignant cell inducing abnormalities in surrounding non-malignant tissue 
such as stromal and immune cells. By inducing such perturbations in their 
microenvironment the cancer creates for itself a protective niche conducive to cancer 
cell survival and resistance to damage21. These mechanisms may also permit the 
evasion of the anti-tumour effects of the healthy immune system23. Conversely, 
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microenvironmental abnormalities may create or promote cell-intrinsic changes as a 
secondary effect. The tendency for squamous cell carcinomas (Marjolin Ulcers24) to 
arise in ulcers and old wounds has been recognised since the first century AD25. 
Persistent inflammation may promote the development of tumours by the continuous 
stimulation of cells by inflammatory mediators. Alternatively, an abnormal 
microenvironment may arise and provide a niche that allows cells with oncogenic 
mutations which would otherwise perish to ‘seed’ themselves in a favourable ‘soil’21. It 
is difficult to establish causal primacy of microenvironment or cell-intrinsic 
abnormalities in the ultimate origins of malignancy, but is now clear that established 
tumours exhibit changes in both the malignant clone and the associated non-clonal 
tissues. It follows that therapy may need to target both mechanisms of 
tumourigenesis.  
 
Much progress has been made in elucidating the cell-intrinsic genetic changes 
underlying CLL pathogenesis. A number of recurrent cytogenetic abnormalities have 
been identified, with aberrations detected by fluorescent in situ hybridization (FISH) 
being detected in most cases of CLL, and these convey prognostic significance26. The 
common chromosomal abnormalities observed include deletion of the long arm of 
chromosome 13 (del 13q), del 11q, trisomy 12, del 17p and del 6q26,27. These recurrent 
abnormalities point to the loci of candidate genes involved in pathogenesis. The most 
common abnormality is del 13q14, which occurs in 55% of cases, and has been 
associated with a favourable prognosis26. The first report linking microRNAs to cancer 
was in CLL, with the demonstration that two microRNA clusters, mir-15a and mir16-1, 
were located within the minimally deleted region at 13q1428. These microRNA 
deletions appear to act partly by enhancing expression of the anti-apoptotic protein 
Bcl-2. Mouse models suggest that the sizes of deletion at 13q14 influences the 
resulting CLL phenotypes, suggesting that more than simply these microRNAs are 
important29. 
 
Although it generally occurs in fewer than 10% of patients at diagnosis, del 17p is 
associated with rapid progression of disease, poor response to therapy and short 
survival, conveying the greatest impact on prognosis and treatment26. The deletion 
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involves the TP53 locus at 17p13, and it is clear that mutations in the TP53 gene can 
also contribute to disease progression and alter the sensitivity of CLL cells to 
chemotherapy agents30,31. Emerging data are demonstrating that concurrent P53 
mutation and 17p deletions occur more frequently than initially realised32-37. As well as 
predicting resistance to most commonly used therapeutic drugs, P53 abnormalities 
often arise during disease progression, possibly as expansion of a previously 
unappreciated subclone31. Whilst guidelines on P53 mutation analysis have been 
recently published38, there is a currently unmet need in providing effective and non-
toxic therapy for this group of patients. 
 
Most recently, several studies employing modern high-throughput techniques to 
sequence CLL genomes have identified recurrent somatic mutations that may be 
presumed to be involved in pathogenesis39,40. Activating mutations of NOTCH1 have 
been found in 5-15% of cases of CLL, with higher incidences in cases with poorer 
prognosis and chemorefractory disease41, and lower frequency in the pre-leukaemic 
MBL42,43. Mutations in the splicing factor 3b, subunit 1 (SF3B1) are seen at a similar 
frequency, and are also associated with more aggressive disease44,45. These high-
throughput sequencing methods also identified the known mutations of P53 and ATM 
genes (5-15%) as well as new recurrent mutations in the MYD88, XPO1, MAPK and 
other genes at frequencies of a few percent each in large patient cohorts40,44,46,47. 
Whilst these recently discovered recurrent mutations will no doubt lead to new 
avenues for research and therapy, their low frequency highlights the fact that current 
methodologies suggest that there is no obvious unifying somatic DNA mutation that 
causes all or most cases of CLL. The scenario whereby each patient may have an 
infrequent or unique combination of mutations is becoming increasingly familiar in 
cancer research in general48. This leads to challenges in elucidating the causes and 
drivers of these cancers. Furthermore, designing sufficiently powerful randomised 
trials to test new therapies poses enormous challenges in an era of personalised 
genomic medicine, where each patient may have a unique combination of targetable 
mutations48.  
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Single mutations have pleiotropic effects, and most cancers have multiple mutations. 
In leukaemias, there may be generally fewer mutations than in solid tumours (1 
mutation/Mb in some haematologic cancers compared to 10-100 mutations/Mb in 
some melanomas48), but this still implies that several mutations interact and must be 
targeted in even the ‘simpler’ cancers. Whilst the ultimate causes of cancer are 
mutations in DNA, many insights have been gained into their effect on the malignant 
cell, manifested by abnormalities in epigenetics, gene expression, protein expression, 
apoptosis and proliferation. Some unifying principles may be derived when it is seen 
that apparently disparate mutations may influence only a few common pathways. In 
CLL, this may be illustrated by the finding of mutations of MYD88, DD3X and MAPK, 
each at low frequency, but all components of the same inflammatory pathway44. 
 
Further complexity arises when cell-intrinsic changes subsequent to mutations interact 
with microenvironmental abnormalities to produce the full phenotype of cancer21, and 
it has been suggested that CLL has a particularly unique dependence on its 
microenvironment22,49. CLL cells are most obvious in the peripheral blood, and the 
ease of access to this bodily compartment explains why many researchers have 
focussed on cells taken from patients’ blood samples. However, it has always been 
clear that CLL proliferates in the bone marrow (BM) and secondary lymphoid tissues 
such as the lymph nodes (LN) and spleen50-52. Whilst many insights into CLL 
pathogenesis have been gained by the study of the peripheral blood leukaemic 
lymphocytes, it is recognised that the most important events that drive the disease 
occur in these other tissues, and there are differences between leukaemic cells from 
these varying compartments, even within the same patient 53,54. 
 
The CLL microenvironment is composed of T-cells, monocyte-derived nurse-like cells 
mesenchymal stromal cells, extracellular matrix components and soluble factors22,55. 
CLL cells cultured in vitro generally undergo apoptosis without additional support in 
the form of cytokines or stromal cell support56. Interactions with these cellular and 
other components appear to be necessary for CLL cell survival and proliferation. In 
addition, resistance to chemotherapeutic agents is conferred by stimuli received by 
these microenvironmental elements22,57-59. Trafficking and tissue retention are 
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regulated by chemokines and their receptors60. Signals from T-cells such as CD40 
ligand, B-cell-activating factor of the tumour necrosis factor family (BAFF) and a 
proliferation-inducing ligand (APRIL) are essential for normal B-cell development and 
the generation of immune responses, and CLL cells are hyperresponsive to these T-cell-
derived survival factors61-63. Once stimulated by their cellular neighbours and 
chemokines, CLL cells also recruit further accessory cells by the secretion of cytokines 
such as CCL3, demonstrating that the malignant cells actively shape their 
microenvironment22,64. Numerous other factors felt to influence CLL cell survival via 
their role in its microenvironment include CD38, CD49d, TLRs, CXCR4, and VLA-422,65-67. 
Many of these factors were identified as important to CLL pathophysiology via the 
influence of their expression level on prognosis. 
 
The role of T-cells in B-cell development appears to be corrupted by CLL in two 
fashions. Firstly, they may promote survival of the leukaemic cell. The 
microenvironment of the lymph node (LN) or bone marrow (BM) seems to provide 
anti-apoptotic and proliferative stimuli that result in the formation of characteristic 
proliferation centres or pseudofollicles, an entity not seen in other B-cell lymphomas51. 
It has been speculated that CLL cells within these histological structures recruit 
accessory cells to create a microenvironment that mimics the germinal centre in which 
B-cells respond to antigenic stimulus68,69. The in vitro stimulation of CD40 on CLL cells 
via CD40L on T-cells recapitulates the physiological immune response whereby T-cells 
support B-cell growth in the germinal centre, and is synergistic with B-cell Receptor 
(BCR) signalling52. Several anti-apoptotic pathways are induced, including survivin70 
and NF-kB71 . 
 
Furthermore, T-cells and related Natural Killer cells have an important role to play in 
eliminating tumours. CLL and other cancers can create an immune defect that permits 
escape of the tumour cell from immunosurveillance72-75. Our group has shown how CLL 
induces changes in T-cells, with notable changes in gene expression76 and defective 
immune synapse formation23. Targeting the immune defect in CLL by use of 
immunomodulatory drugs such as lenalidomide reverses some of these abnormalities 
and has shown clinical efficacy in CLL23,77. 
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Disrupting the interaction of the CLL cells with their microenvironment is beginning to 
show promising therapeutic effects in CLL22,78. Interruption of the CXCR4-CXCL12 axis 
can mobilise CLL cells from their protective microenvironmental niches in the tissues, 
rendering them more susceptible to attack with conventional chemotherapeutic 
agents66. Some of the more promising novel agents are small molecule inhibitors of 
pathways downstream of the B-cell receptor (BCR) 22,79,80. The rationale for their use is 
based on the premise that one of the most important microenvironmental influences 
on CLL survival is received via the BCR. There is evidence to suggest that antigen in the 
microenvironment may act as a survival factor via its role as the BCR ligand. It is 
suggested that the malignant B-cell recapitulates the interaction of a healthy B-cell 
with its specific antigen, a process fundamental to the normal development of B-cells 
and the generation of an immune response. The role of the BCR in CLL is discussed 
further, but first the function of the BCR in normal B-cell development is described. 
 
2.4 Normal B-cell development  
To understand the classification and pathophysiology of malignant B-cells it has proved 
helpful to study the developmental stages of their normal counterparts81. B-cell 
development can be considered as occurring in two general stages: i) Antigen-
independent differentiation of B-cell precursors from an haematopoietic stem cell 
(HSC) to naïve B-lymphocytes in the bone marrow (BM) and ii) the partially antigen-
dependent maturation to memory/effector cells in secondary lymphoid tissues: lymph 
node (LN), mucosa associated lymphoid tissue (MALT), BM and spleen. Trafficking 
between these compartments is reflected in B-cell subsets present in peripheral blood 
(PB)82. The ultimate drive in B-cell development is the production of a flexible immune 
cell repertoire that is capable of recognising and eliminating a huge range of microbes 
that would otherwise cause tissue damage and death of the organism. 
The stages in B-cell maturation have been mainly classified by immunohistochemical 
examination of the BM and LN82. Correspondingly, leukaemias and lymphomas have 
been classified according to similarity to normal B-cell morphology, location and 
immunophenotype in BM, LN and spleen81,83. Murine models have also been used to 
aid classification of normal and malignant B-cells, however it is clear that mouse B-cell 
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subsets do not precisely reflect those of B-cells in humans84. The cell of origin 
hypothesis suggests that a B-cell malignancy arises from transformation of these 
normal counterparts, and therefore the classification of leukaemias and lymphomas 
recapitulates the classification of B-cells during their ontogeny81.  
 
Key to understanding the development of healthy and malignant B-cells is 
consideration of the generation of antigen receptor diversity. The immune system is 
able to recognise a vast array of foreign antigens, mediated in B-cells by the BCR. The 
BCR complex is composed of two components: the recognition unit constituted by 
surface membrane-bound immunoglobulin (sIg) and the transmission unit composed 
of co-receptors CD79a (Ig , mb-1) and CD79b (Ig , B29)85. The sIg is a heterodimer 
composed of 2 heavy chains (IGH) and 2 light chains (IGK or IGL) bonded by disulfide 
bridges. Each chain has 2 distinct parts: the N-terminal variable (V) domain responsible 
for antigen binding, and the C-terminal constant (C) domain responsible for membrane 
insertion and various effector functions. The C region is the determinant of the 
immunoglobulin isotype of the BCR or antibody. There are 5 different isotypes: IgM, 
IgG, IgA, IgE and IgD86. When inserted in the B-cell membrane they may exhibit 
differences in the downstream pathways activated by ligation of antigen, but for 
immunologists their more manifest role lies in the fact that B-cells at different stages 
of development express different isotypes and produce different classes of secreted 
antibody. The expression of IgM and IgD is generally associated with early stages of B-
cell development, whilst IgG, IgA and IgE expressing cells are described as class-
switched and reflect later developmental stages. Immunoglobulin secreted by B-cells 
forms antibody, and each antibody isotype has a different function that the immune 
system deploys depending on the nature of the antigenic challenge82,87,88. 
 
Fundamental to the generation of antigen receptor diversity in B-cells is the unique 
genomic organisation in the germline that permits rearrangement of the 
immunoglobulin gene loci during B-cell ontogeny89. The genes encoding the 
immunoglobulin heavy chain (IGH) are located on chromosome 14q32, span about 
1.23Mb and are organised in 4 clusters V, D, J and C in a 5’-3’ orientation. There are 
123-129 IGHV genes on chromosome 14, depending on the haplotype, of which 38-46 
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are functional. Allele variants have been described for many IGHV genes, with some 
genes (e.g.IGHV1-69 and IGHV4-34) having up to 13 alleles. There are 27 IGHD genes 
(23 functional) and 9 IGHJ genes (6 functional). Finally, there are 9 functional IGHC 
genes90.  
 
The light chain genes are located on chromosomes 2 and 22. The IGK locus is on 2p11, 
with 34-38 functional IGKV genes, 5 functional IGHKJ genes and a single IGKC gene. The 
IGL locus is at 22q11, with 29-33 functional IGLV genes and 4-5 functional IGLC genes90.  
 
The antigen-binding V domain of heavy chains (VH) is encoded by the variable (V), 
diversity (D) and joining (J) genes, while the V domain of light chains (VL) is encoded by 
V and J genes 90. The combination of V,D,J and C genes during B-cell development 
results in the generation of messenger RNA (mRNA) encoding the heavy and light 
chains that compose the full immunoglobulin (Ig) molecule (see Fig.2.1) 
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Figure 2.1: Generation of the primary B-cell repertoire 
Variation in the antigen-binding region of the B-cell Receptor is generated by random 
DNA recombination of V, D and J gene segments. Further diversity is produced by 
introduction of mutations in the V, D and J genes by somatic hypermutation during 
the germinal centre reaction. 
 
 
 
 
 
 
 
The V domain contains 4 relatively conserved framework regions (FR) that maintain 
the overall structure of the domain. In between are 3 highly variable complementarity 
determining regions (CDRs) that form loops that directly interact with antigens. The 
CDR3 is at the junction of the V, D and J domains and has the highest variability and 
influence on antigen binding90. 
 
Assembly of the DNA encoding the Ig heavy and light chains occurs at particular stages 
of B-cell development. The stage of development is implied by the state of 
organisation of the IG loci, and the expression of various proteins involved in the Ig 
production process89. The first stage in the foetal BM and liver is antigen-independent. 
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It consists of the assembly, by DNA rearrangement, of the V, D and J genes to encode 
variable domain DNA for first heavy then light chains. These are then transcribed and 
translated into proteins that are assembled into Ig that is expressed on the cell surface 
as the pre-BCR and subsequent BCR. Only B-cell progenitors that successfully assemble 
and express surface BCR survive to subsequent stages, in a process of positive 
selection. A subsequent negative selection process then operates to eliminate 
autoreactive B-cells: central tolerance91. In order to eliminate B-cells with a BCR that is 
reactive against self-antigens, those B-cells whose BCR is strongly stimulated by 
antigen within the bone marrow are deleted from the B-cell repertoire82. Alternatively, 
immature B-cells that bind self-antigens in the BM also have an opportunity to 
rearrange their IGL loci in an attempt to eliminate BCR autoreactivity (receptor 
editing)92. If they fail to produce a non-autoreactive BCR after receptor editing, they 
will be deleted. Immature B-cells that successfully navigate this negative selection step 
become naïve mature B-cells, express the BCR as IgM and IgD, and leave the BM to 
circulate in the PB82. This process of central tolerance by negative selection cannot 
eliminate all autoreactive clones, and additional mechanisms such as anergy exist to 
control autoreactivity at later developmental stages. Indeed, it has been suggested 
that a degree of autoreactivity of the pre-BCR and BCR is necessary for positive 
selection93. Positive and negative selection may be perhaps considered within the 
context of a continuum of BCR autoreactivity94. 
 
The next developmental stage occurs in the periphery, within the secondary lymphoid 
organs. Naïve B-cells that have exited the BM circulate in the PB and enter the LN and 
spleen at the T-cell zone through high endothelial venules95. They recirculate between 
the PB and lymphoid tissues, and will die within several days if they fail to locate their 
cognate antigen (Ag). Binding of antigen to the BCR in the presence of appropriate 
accessory signals results in activation of the B-cell, resulting in proliferation and 
antibody production and the elimination of the offending antigen. Depending on the 
type and strength of BCR signals from their microenvironment they will become either 
plasma cells, marginal zone or follicular B-cells82. The immune system further refines 
the affinity and function of B-cells during the germinal centre (GC) reaction96.  
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In the classical scenario of a B-cell binding a T-dependent antigen, follicular B-cells and 
helper T-cells migrate into the primary follicles of the lymphoid organs. These then 
mature into secondary follicles with a germinal centre97. The B-cells undergo intense 
proliferation as centroblasts in the dark zone of the germinal centre. Somatic 
hypermutation (SHM) introduces random point mutations, deletions and insertions in 
the variable regions of the immunoglobulin genes at rates of 10-3/base pair/division, 
about 106 higher than the background spontaneous mutation rate98. Mutations extend 
1.5-2kb from the promoter of the V gene, with a maximal frequency on the rearranged 
V(D)J genes, sparing the C region. Non-Ig genes such as BCL-6 can also be targeted at a 
lower frequency, occasionally resulting in oncogenic mutations and translocations99,100. 
The initial step is mediated by activation-induced cytidine deaminase (AID), which 
deaminates C to U, followed by error-prone repair by generic repair mechanisms to 
produce sequence changes97. SHM preferentially targets particular sequence motifs, 
and can be silent (S) or result in replacement (R) of an amino acid at a given position. 
Mutations may occur in the framework region (FR) or the antigen-binding 
complementarity-determining region (CDR). Because higher affinity BCRs are selected 
for in the GC reaction, R mutations will tend to accumulate in CDRs, whilst S mutations 
in FRs are selected for in order to preserve the overall structure of the domain. Thus, 
raised R/S ratios in CDR compared to FR can imply evidence of antigen selection90.  
 
These mutations produce a wide diversity of BCRs, related to the original clone, but 
with varying binding affinities for antigen. B-cells then migrate to the light zone of 
germinal centres, where they compete with one another to bind antigen displayed on 
the surface of follicular dendritic cells97. High affinity for antigen results in survival 
signals and further proliferation, whilst relatively low affinity BCRs will lead to 
apoptosis, which is the fate of the majority of B-cells in the proliferating and 
diversifying clone. T-cell help is necessary for the GC reaction97. Each B-cell undergoes 
Darwinian selection by competing for survival signals received from antigen and T-
cells. This affinity maturation process refines the binding of BCRs and secreted 
immunoglobulins to antigen, thereby enhancing the immune response to microbial 
invaders. 
 
 33 
In parallel with affinity maturation, centrocytes also undergo isotype class-switch 
recombination (CSR) at the genomic level97. Class Switch of Ig isotype allows the 
production of antibodies that perform distinct effector functions101. CSR generally 
requires T-cell help through the engagement of CD40 receptors and the secretion of 
various cytokines such as IL-4 and IL-10101. The nature of the isotype depends on the 
type of antigen, the site of stimulation and the type of T-cell help provided. CSR is 
mediated by the deletional recombination of specific DNA sequences (switch sites) 
located upstream of each C region. The IGHM switch region is recombined to that of 
another C region and the intervening DNA is deleted by loop excision, leading to 
replacement of the original C  region with either C , C  or C 101. This results in the 
same VDJ rearrangement being apposed to a new C region, resulting in production of a 
new isotype with the same antigen specificity. Its molecular control has many 
similarities with SHM, including dependence on AID. Whilst SHM and CSR classically 
and most frequently occur in the GC, the process can occur occasionally in marginal 
zone B-cells via a GC-independent route102. The CSR process results in either the 
production of high-affinity class-switched memory B-cells or differentiated plasma 
cells, which then secrete Ig as antibody82.  
 
The stochastic combinatorial process of V domain formation produces approximately 
2x106 different possible combinations of heavy and light chains. Further diversity is 
also added via a number of mechanisms such as modification of the junctions between 
V, D and J genes, and SHM. These mechanisms for diversity generation result in the 
production of 1011-1012 different BCRs within one individual, sufficient to bind almost 
all conceivable antigens that may be encountered during that individual’s lifetime90. 
The actual expressed repertoire within an individual might be more limited, with 
studies showing that the normal blood repertoire is biased with certain V genes being 
over-represented (such as IGHV4-34, IGHV3-23) and others under-represented. This 
bias may arise due to rearrangement efficiency, predilection for particular light and 
heavy chain pairings, selection at various stages, type of B-cell subset, chronic viral 
infection, age and genetic factors103,104. This bias must be taken into consideration 
when considering the repertoire of B-cells, but extensive data on healthy B-cell V gene 
usage are unavailable.  
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The complex process of Ig gene rearrangements leaves a unique signature in the 
genome of each B-cell. This can provide investigators with a read-out of the life history 
of an individual B-cell, confirm the clonal nature of a B-cell neoplasm, and imply the 
putative cell of origin of B-cell tumours81. The entire process of diversity generation is 
dependent on DNA damage and chromosomal rearrangements that occasionally result 
in mutations and translocations that may cause lymphoma99,100. 
2.5 Cellular origin of B-cell lymphomas and leukaemias  
Debates exist regarding the nature of a putative ‘cell of origin’ in cancer, the normal 
cell that acquires the first cancer-promoting mutation(s). It is important to distinguish 
this from the ‘cancer stem cell’, the putative cellular subset within a cancer that 
sustains malignant growth105,106. The classification of lymphomas and lymphoid 
leukaemias employs various techniques, including histology and immunophenotyping. 
In some lymphomas these approaches suggest an obvious healthy B-cell 
developmental stage as a counterpart, and by extension a presumed cellular origin, 
but in many cases the parallel between a lymphoma and an equivalent normal tissue 
cannot be drawn by tissue morphology or immunophenotyping alone. Analysis of the 
DNA encoding the IGHV genes has led to the ability to study the life history of an 
individual B-cell and an elucidation of the model of the equivalent normal ‘cell of 
origin’ of many lymphomas (see figure 2.2) 81. It is important to realise that whilst this 
model is highly successful in making sense of lymphoma ontogeny, it does not provide 
a complete picture of classification. Obviously, malignant cells will exhibit phenotypic 
and genomic differences from normal equivalents. Several entities known as ‘gray-
zone’ lymphomas are not readily classified using this schema107. Furthermore, the 
similarity of phenotype and genotype of a lymphoma and a putative normal 
counterpart does not in itself constitute definitive proof of a tissue of origin105. What is 
generally assumed is that the B-cell will proceed along known developmental 
pathways at least until the initial transforming mutation, and possibly after this event. 
It might also be expected that if B-cell development does proceed after 
transformation, it will not necessarily proceed in a conventional fashion. To overlay 
further complexity, the process of SHM, classically thought to be a marker of the 
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germinal centre reaction, has been shown to also occur via other developmental 
pathways, albeit at low frequency108. Therefore, the cell of origin model does not 
provide a definitive cell of origin assignment in all lymphomas. This uncertainty is very 
apparent in the case of CLL109-111. 
Figure 2.2: Cellular Origin of B-cell lymphomas and leukaemias  
(after Kuppers et al)81 
The developmental stages of the normal B-cell are shown, with passage through the 
germinal centre and antigenic stimulation resulting in Somatic Hypermutation 
(SHM). The presence or absence of SHM and other markers can indicate the life 
history of an individual cell. The cell of origin hypothesis implies that B-cell 
lymphomas and leukaemias arise from a B-cell at a particular stage of development 
that has acquired mutations that convert a healthy B-cell into a neoplastic 
counterpart. The characteristics of the lymphoma cell are similar to the cell of origin, 
including the presence of SHM. The existence of CLL cells with and without SHM 
implies different cells of origin for these two subgroups, which also differ in terms of 
disease aggressiveness.  
 
When the IGHV genes of B-cell lymphomas were sequenced, most carried somatic 
mutations81. The types exhibiting SHM include follicular lymphoma, Burkitt lymphoma, 
diffuse large B-cell lymphoma (DLBCL), mucosa-associate lymphoid tissue (MALT) 
lymphomas, splenic lymphomas with villous lymphocytes, prolymphocytic leukaemias, 
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hairy cell leukaemias, lymphoplasmacytoid (LPC) lymphomas, multiple myeloma and 
some CLL81. The pattern of SHM is generally taken to indicate whether the lymphoma 
originates from a cell at a stage of development prior to the germinal centre (GC) 
reaction, or a post-GC cell. In follicular lymphoma, there is ongoing SHM within the 
tumour clone,112 identifying it as a GC tumour. This also occurs in LPC lymphoma and 
occasionally in Burkitt, DLBCL and MALT lymphomas. Among mature B-cell 
lymphomas, unmutated IGHV genes are encountered in marginal zone lymphomas and 
some CLL, both CD5+ B-cell tumours. This implies that they have arisen from B-cells 
that have not experienced the germinal centre.81 The developmental stage of the B-
cell that gives rise to CLL is unclear, as approximately half of CLL cases exhibit SHM (M-
CLL) and half do not (U-CLL)3,113. The conventional threshold for assignment to the U-
CLL group is that of >98% homology to germline IGHV gene sequences. 
 
In summary, the study of rearranged variable-region genes in B-cell 
lymphomas/leukaemias has led to the model of lymphomas as B-cells transformed at 
different stages of B-cell development, with SHM implying experience of the germinal 
centre reaction81. The normal germinal centre processes of SHM and CSR may also 
produce translocations and mutations as an undesirable effect, leading to lymphoma 
pathogenesis. These findings have led to wide acceptance of the cell of origin model to 
explain some aspects of lymphomagenesis. However, because CLL appear to be 
comprised of two different subsets with and without SHM, the cell of origin is less 
obvious than with other lymphomas109-111. This may lead to difficulties in considering 
appropriate control healthy B-cells for comparison with CLL. This peculiarity of CLL also 
introduces the concept that the developmental routes whereby a B-cell produces a 
functional BCR are somewhat askew in CLL. 
 
Further exploration of the configuration of the IGHV genes in these malignancies has 
led to the curious finding of a bias in the inherently stochastic process of VDJ gene 
rearrangements, and this is most apparent in CLL.  This has led to the suggestion that 
antigenic selection may contribute to CLL pathogenesis49,90, and many investigators 
therefore implicate the BCR as a critical molecule in CLL pathogenesis49,114-117. 
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2.6 The role of Antigen in CLL pathogenesis 
2.6.1 The BCR in lymphoid malignancies 
Inducible deletion of the BCR in mature cells leads to cell death118. The finding that 
BCR expression is essential for the survival of mature B-cells led to the concept of 
‘tonic’ BCR signalling, whereby signals from an intact BCR are vital to resting B-cell 
existence, even in the absence of ligand binding119-122. Most neoplastic B-cells express 
surface immunoglobulin, and the pattern of SHM in their IGHV genes often indicates 
that they or their precursors were selected for antigen-receptor expression during the 
germinal centre reaction. Transforming chromosomal translocations to 
immunoglobulin loci are targeted to the non-rearranged allele123, permitting 
expression of the BCR derived from the other allele. This has been taken as evidence 
that, like normal B-cells, most B-lymphoid malignancies require BCR expression118. The 
exception to this rule is Hodgkin lymphoma, where the malignant B-cells seem to arise 
from germinal centre B-cells that have lost the ability and requirement for expression 
of the BCR81. Even in this situation, the malignant cell may in some cases derive BCR-
analogous survival signals from the Epstein-Barr Virus-encoded protein LMP2A that 
mimics an activated BCR124.  
 
Other features may also indicate a dependence of tumour growth on triggering by 
antigen. Indeed, a variety of infectious agents have been identified as associated with 
lymphoma, some in a directly causal fashion. It is estimated that worldwide, 16% of all 
cancers are caused by infectious agents125. The organisms include herpes viruses 
(Epstein Barr Virus is linked with Burkitt, central nervous system and Hodgkin 
lymphomas126; Human herpesvirus 8 is associated with Castleman’s diseases and 
primary effusion lymphoma127), single-stranded RNA viruses (hepatitis C virus and 
splenic marginal zone lymphomas128), retroviruses (human T-cell leukaemia virus type 
1 and adult T-cell lymphoma129), spirochaetal bacteria (Borrelia burgdorferi and 
cutaneous mucosa-associated tissue lymphoma130), and gastrointestinal bacteria 
(Campylobacter jejuni and immunoproliferative small intestinal disease131). There is a 
recognised association between the ocular anexae lymphoma subtype of marginal 
zone lymphoma and infection with Chlamydia psitacci, and recent data suggest that 
eradication of the infection is an effective treatment, in combination with 
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chemotherapy132. It is not suggested that all these microorganisms all exert their 
effects via BCR ligation, but that the principle of microbial lymphomagenesis is 
established. 
 
A well-recognised association is between gastric marginal zone mucosa-associated 
(MALT) lymphoma and Helicobacter pylori infection133, but again it is unclear as to the 
importance of BCR signalling as some effects are probably exerted via T-cells or more 
general inflammatory processes. Eradication of H. pylori at early stages of MALT 
lymphoma can result in disappearance of the tumour in 75% of cases134, and the 25% 
of cases that do not respond to antibiotics are characterised by a clinically advanced 
stage and the t(11;18)(q21;q21) translocation. This translocation is felt to contribute to 
pathogenesis by activating the NF-kB pathway135, known to be downstream of the BCR 
and other pathways. Therefore, it could be argued that whilst early stage gastric MALT 
lymphoma is dependent on microenvironmental signals from H. pylori infection, more 
advanced stages have acquired secondary lesions that result in constitutive activation 
of BCR signalling pathways, independent of antigenic stimulus. This concept is often 
invoked to suggest that more aggressive tumours in general have less dependence on 
microenvironmental signals than their more indolent counterparts, and that such 
independence may be gained by simulating microenvironmental support by 
constitutively activating pathways that are conventionally induced by external 
ligands21,22. This model is supported by the finding of multiple mutations in NF-kB 
signalling components in diffuse large B-cell lymphoma, which has been described as 
supporting lymphoma cell survival and proliferation by simulating ‘chronic’ BCR 
signalling136-138. 
 
It is therefore speculated that BCR signalling may contribute to lymphoma 
pathogenesis via a variety of mechanisms: tonic signalling in the absence of ligand is 
required for B-cell survival, ligand-dependent signalling provides a conduit for 
antigenic survival or proliferative signals from the microenvironment and chronic 
signalling may arise when pathways conventionally induced by ligand are constitutively 
activated. This highlights the centrality of the BCR to B-cells in both physiology and 
pathology. 
 39 
2.6.2 Immunoglobulin genes in chronic lymphocytic leukaemia 
A variety of data have led many authors to posit the centrality of the BCR to CLL 
pathogenesis, mainly based on analyses of the genes encoding the antigen binding (V) 
regions of the BCR49,90. As well as suggesting divergent developmental pathways, the 
level of somatic hypermutation (SHM) in the V genes of individual CLL cases can also 
subdivide the disease into two patient groups with distinct clinical outcomes3,113. Some 
have therefore suggested that CLL, previously considered as a single entity, might best 
be considered as two distinct tumours, one arising from a cell at a stage prior to the 
germinal centre, and one arising after SHM has occurred49. The cases that have not 
undergone SHM (unmutated, U-CLL) have a more aggressive behaviour, as measured 
by shorter time to treatment and overall survival, than those that have undergone 
SHM (mutated, M-CLL). There are also differences in the pattern of IGHV, IGKV and 
IGLV gene utilization between the two groups, further implying separate 
developmental pathways without inter-conversion. The association of mutation status 
with prognosis is strong, and clinical trials are beginning to assess the use of this 
marker to guide therapy of CLL16. This association of SHM with prognosis is sometimes 
taken to be an indicator that normal immune mechanisms have an important influence 
over CLL biology, though the mechanistic details of how SHM affects disease 
aggressiveness in CLL are still obscure. More evidence for the role of the BCR in CLL has 
been provided by analysis of the IGHV gene repertoire used in CLL. 
 
IGHV gene analysis in CLL reveals restrictions in which of the 38-46 functional IGHV 
genes a particular tumour expresses90. Similar analyses have found biases in gene use 
at the light chain loci, though most studies have focussed on the heavy chains. Usage 
of particular IGHV genes at frequencies higher than expected by chance is generally 
interpreted as an indicator of selective drive on a B-cell population via an antigen or 
superantigen90. Superantigens are mainly microbial products, often polymeric, which 
bind to framework regions of particular V domains139,140. For example, Staphylococcal 
protein A (SpA) binds to IGHV3 subgroup domains140. By binding outside the 
conventional antigen-binding site, superantigens can activate a large proportion of B-
cells, with 30-40% activated by SpA. However, the restriction of the IGHV gene 
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repertoire in CLL is generally taken as evidence of antigenic rather than superantigenic 
drive as the antigen-binding regions exhibit marked peculiarities90.  
 
Restricted IGHV gene usage is a particular feature of CLL, the most striking being an 
increased usage of the IGHV1-69 gene by U-CLL113,141-143 and of IGHV4-34 by M-
CLL113,142. In contrast, this biased repertoire is not characteristic of follicular lymphoma, 
or of diffuse large B-cell lymphoma, though it does occur to a certain extent in some 
other mature B-cell neoplasms such as splenic marginal zone lymphoma144 and mantle 
cell lymphoma145.  
 
The IGHV1-69 gene bias is the most prominent in CLL. The expansion of B-cells using 
IGHV1-69 has been noted in other conditions such as salivary gland extranodal 
marginal zone lymphoma of mucosa-associated tissue (salivary MALT)146. There is also 
a suggested link between IGHV1-69 , hepatitis C virus (HCV) infection and splenic 
marginal zone lymphomas147. HCV can infect B-cells and cause chronic stimulation, 
with an increase in IGHV1-69 expressing B-cells that respond to the HCV E2 antigen 
and expressed by the HCV-associated lymphomas148. HCV is also a major association of 
mixed cryoglobulinaemia (MC), which can proceed to lymphoma149. The IgM 
rheumatoid factors produced in this disease are commonly derived from IGHV1-69 and 
tend to be combined with the IGKV3-20 (A27) light chain, a combination also 
frequently found in CLL150. Suggestion of molecular mimicry linking autoimmunity and 
viral infection is indicated by the finding of a cross-reactivity between the IgG-Fc 
recognized by rheumatoid factors in MC and the NS3 protein of HCV151. It is not 
suggested that HCV plays a role in CLL, and the lack of homologous CDR3 sequences 
argues against specificity for HCV in CLL, but this is an example whereby stimulation of 
B-cells by antigen can lead to both IGHV gene bias and provide the circumstances for 
transforming events that may lead to lymphoma. 
 
The second most utilised IGHV gene in CLL is IGHV4-3490. The IGHV4-34 gene encodes 
intrinsically autoreactive antibodies because of universal recognition of the N-
acetyllactosamine (NAL) antigenic determinant present in the I/i blood group 
antigen152 and in the B-cell isoform of CD45153. A hydrophobic cluster of amino acids in 
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the FR1 of IGHV4-34 binds directly to the red cell I/i carbohydrate antigen154, therefore 
this autoantigen acts as a superantigen. The I/i antigen may be expressed in oxidised 
apoptotic cells, and B-cells whose receptors bind to apoptotic cells may serve 
‘housekeeping’ functions to remove cellular debris155.  
 
The IGHV4-34 gene is over-expressed in cold agglutinin disease156, and in 40% of 
primary central nervous system lymphomas157-159. All cases of cold agglutinin disease 
secrete IgM derived from this gene, and its induction by EBV accounts for the known 
association between EBV infection and transient cold agglutination160.  A rise in IGHV4-
34 antibodies is seen in acute infections with Epstein-Barr Virus (EBV)  
and infection has major effects on the immune system of older people and may drive 
both CLL and the age-associated IGHV4-34 expansion126,161,162. 
 
IGHV4-34-utilising B-cells are also increased in systemic lupus erythematosus (SLE), 
and encode anti-DNA antibodies163,164. IGHV4-34 expression occurs at a high frequency 
in the B-cell progenitors of healthy individuals, however they are censored at multiple 
checkpoints during development155,165. To explain the low frequency of actual IGHV4-
34 usage in the mature healthy repertoire, it has been suggested that in normal B-cell 
development, IGHV4-34 B-cells are excluded from the GC to prevent autoimmune 
disease155. It may be that this blockade is overcome in autoimmune disease and in 
particular infections.  
 
The IGHV4-34 gene is frequently used in CLL, particularly in M-CLL166, perhaps 
reflecting the need for the inherently IGHV4-34 sequences used by B-cell precursors of 
CLL to undergo SHM to lose autoreactivity and be permitted to enter the repertoire142.  
Support for this hypothesis was provided by Chiorazzi’s group who cloned and 
expressed in vitro recombinant antibodies from M- and U-CLL B-cells and tested their 
reactivity to a panel of antigens167. U-CLL expressed highly polyreactive antibodies 
whereas most M-CLL B-cells had a more restricted reactivity profile. When M-CLL non-
autoreactive CLL antibody sequences were reverted to their configuration that would 
have existed prior to SHM, they subsequently encoded polyreactive and autoreactive 
antibodies. They speculate that both U-CLLs and M-CLLs originate from self-reactive B-
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cell precursors and that the influence of SHM on prognosis may be understood as 
actually decreasing BCR autoreactivity167. This may explain why M-CLL cases have a 
better prognosis than U-CLL: The process of SHM actually reduces polyreactivity and 
therefore potentially the range or binding affinity of available ligands for use as 
survival factors.  
2.6.3 Stereotyped B-cell receptors in CLL 
Biases in IGHV gene use alone are evidence for antigenic selection, but further insight 
has been provided by a more detailed examination of the structures of the antigen-
binding CDR3 domains that have the greatest influence on antigen binding. In the mid 
1990s, two groups independently demonstrated that unrelated cases, especially those 
using the IGHV1-69 gene, had distinctive VH CDR3 domains characterized by increased 
length and shared amino acid motifs143,168.  There was also evidence of favoured 
combinations of genes, for example 90% of the IGHV3-7 genes were associated with 
the IGHJ4 gene, whereas 50% of the IGHV1-69 and IGHV4-34 genes were associated 
with the IGHJ6 gene. Similar findings are apparent when other gene combinations are 
considered104,169-173. 
 
It seems that particular V/D/J and light chain gene combinations are favoured in 
different patients with CLL. These are termed ‘stereotyped’, and criteria for stereotypy 
have been described174. To fulfil these criteria, there must be usage of the same 
IGHV/D/J genes, the same IGHD reading frame, and VH CDR3 amino acid homology 
60%.  
 
Subsequent studies have extended these findings, with large international series 
suggesting that up to 30% of CLL cases  (particularly U-CLL) exhibit restricted and 
stereotyped CDR3s and may be grouped into >100 subsets111,142,175. The largest series 
(2662 patients) found that the CDR3 sequences of the 30% of cases expressing 
stereotyped receptors formed 11 higher order clusters111.  Some of these stereotyped 
sequences are homologous to those seen in mouse B-1 B-cells, leading the authors to 
make the suggestion that the 30% of CLL cases exhibiting stereotyped CDR3s may arise 
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from the human equivalent, via a T-independent route, which would explain the 
association of stereotypy with U-CLL.  
 
There is some evidence for biased IGHV gene utilisation having influences on other 
areas of CLL biology. The risk of transformation of CLL to an aggressive lymphoma in 
Richter’s Syndrome (RS) is 3-16%. Stereotyped CDR3s occur in 50% of RS cases, in 
particular the IGHV4-39 subset176(subset 8). IGHV4-39 has no prognostic relevance for 
CLL progression per se, whereas the well-described poor prognostic factor IGHV3-21 
usage had no influence of risk for RS. There was also association with Trisomy 12, 
previously shown to associate with IGHV4-39177. Trisomy 12 is known to associate with 
RS in other studies, and with NOTCH1 mutations178.  An association of particular IGHV 
genes with microRNA abnormalities has also been suggested in CLL179. 
 
These examples of stereotypy in CLL are in contrast to the normal B-cell repertoire, 
where there is no reported preferential pairing between specific heavy and light 
chains. Comparison of CLL CDR3s with large public databases of non-CLL CDR3 
sequences has shown only 0.7% sharing of homologous CDR3s between CLL and 
normal B-cells.90 It has also been shown that VH CDR3 restriction was infrequent in 
other B-cell lymphomas, and resembled that of normal B-cells, suggesting that other 
lymphomas may arise stochastically from the normal B-cell repertoire180. It is not yet 
possible to predict specificity by sequence analysis alone, but comparisons with known 
antibody specificities has been performed and shown CLL cases with identical CDR3 
structures to B-cells specific for autoantigens181 182. 
 
Since CLL occurs more commonly in older individuals, it has been suggested that there 
may be a shift in the normal B-cell repertoire with age, which would therefore be 
reflected in an equivalent shift in V gene usage in tumours that were stochastically 
selected from this ageing repertoire. There is no increase in IGHV1-69 usage with 
age183, however there is evidence of increased usage of IGHV4-34 by the B-cells of 
healthy elderly indivduals184. This may be due to the reactivation of herpes viruses, and 
may offer a partial explanation of the high frequency of IGHV4-34 usage in CLL90.  
Investigators have not yet conclusively answered these issues about pre-existing bias 
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in healthy B-cells. Could CLL arise stochastically from a B-cell subset that has an 
inherent restriction in its IGHV gene usage? There are early suggestions that some CLL 
stereotyped CDR3s have counterparts in the B-cells of healthy age-matched 
individuals, and it is suggested that these are the source population that may acquire 
transforming events that lead to some subgroups of leukaemia103. 
 
In summary, analysis of the gene sequences encoding the antigen-binding regions of 
the BCR has demonstrated marked biases in CLL, with some evidence of bias in similar 
lymphomas. The bias is even more apparent if the actual amino acid structure of these 
antigen-binding CDR3s is considered. These findings demonstrate that patients from 
opposite ends of the world may have B-cell receptors with identical antigen-binding 
regions, a finding that is highly unlikely given the stochastic nature of the generation of 
the antigen-binding capabilities of the BCR. The obvious implication is that these 
different cases of CLL are binding the same antigen. It must be noted that the same 
antigen is not suggested to be common to all CLL, as there are >100 subsets of 
stereotyped CDR3s, and it seems that no more than 30% of all CLL cases fall into one of 
these subsets90. Nonetheless, these findings have led to the suggestion that antigen is 
intimately involved in stimulating and/or selecting CLL cells, a corruption of the normal 
processes of B-cell ontogeny49,114,117.  
2.6.4 Antigens, Autoimmunity and CLL 
If an antigen is involved the selection of these B-cell clones, then the question arises as 
to the nature of the antigen185.  Early findings suggested an association of IGHV 
stereotypy and autoantigen specificity49,114,186. The cells involved in autoimmunity and 
lymphoma are the same and the overlapping treatment options and similarities in 
biology have led many to try to marry these two fields187. Chronic antigen stimulation 
could plausibly favour malignant transformation of B-cells, akin to the relationship 
between H.Pylori and gastric MALT lymphoma. It has also been suggested that 
persistent autoantigen stimulation is involved in lymphomas that arise within salivary 
glands in Sjogren’s syndrome188, or thyroid tissue in Hashimoto’s thyroiditis189. 
Pseudofollicles in CLL resemble similar structures observed in inflamed tissues in 
patients with the autoimmune diseases rheumatoid arthritis and multiple sclerosis190. 
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However, there are difficulties, not least due to the heterogeneity of phenomena that 
are known as ‘autoimmunity’.  
 
Is autoimmunity a predisposing factor to the development of lymphoma? 
Retrospective epidemiological studies suggest that the development of lymphoid 
malignancies is more common in patients with autoimmune disease or with a family 
history of autoimmunity191 192-194. There are a variety of associated autoimmune 
diseases, the most frequent being primary Sjogren’s syndrome, rheumatoid arthritis 
and Systemic lupus erythematosus (SLE). There is also a higher risk associated with 
treatment with cytotoxic or biological agents, which may reflect disease activity, 
inflammation in general or the immunosuppressive effects of the agents 
themselves191.   
 
Are lymphomas associated with autoimmunity? Paraproteins in MM and the similar 
disorder Waldenstrom’s Macroglobulinaemia may be autoreactive, particularly to 
nerve constituents, red cell antigens and clotting factors190. CLL and some other 
lymphoproliferative disorders are particularly associated with organ-specific 
autoimmune disease such as autoimmune haemolytic anaemia (AIHA), idiopathic 
thrombocytopenia (ITP) and autoimmune neutropenia5. However, in these cases, 
autoantibodies are produced by non-malignant ‘bystander’ B-cells, so we cannot draw 
conclusions about the autoreactivity of the BCR expressed by the malignant clone195. In 
the case of CLL, suppression and derangement of the normal B-cell populations leads 
to hypogammaglobulinaemia as well as autoantibody production. This may occur 
indirectly as an effect of CLL cells on T-cells68. It might be hypothesised that CLL 
produces a microenvironment conducive to the survival of autoreactive B-cells in 
general. 
 
Cells from some CLL cases have the capacity to make autoantibodies in vitro, with the 
IgM on CLL cells often possessing rheumatoid factor (RF) activity, or binding activity for 
the Fc portion of human IgG196. Cultured CLL cells stimulated with phorbol 12-
myristate 13-acetate (PMA) produce small amounts of monoclonal IgM that in one 
study reacted with a variety of self-antigens in 86% of cases197. The antigens include 
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IgG, ssDNA, dsDNA, histones, cardiolipin, and cytoskeletal determinants198,199. 
Collectively, early studies suggested that most CLL patients can produce polyreactive 
autoantibodies, albeit under somewhat artificial conditions, and most of these are IgM 
RFs. Similar IgM autoantibodies can also be detected in the sera of all individuals and 
so they have been termed ‘natural autoantibodies’200. Natural antibodies have been 
implicated in the clearance of cellular debris, and there is some evidence for their role 
in clearing oxidised lipids and other harmful debris in protecting against 
atherosclerosis201. The obvious suggestion is that the IgM of CLL cells have natural 
antibody activity, however autoreactivity has been detected in 8 of 26 cases of 
follicular lymphoma202, so this may not be a specific finding in CLL.  
The early studies showing autoreactivity of CLL BCR were hampered by the small 
amounts of antibody secreted by CLL cells in vitro. By generating monoclonal 
antibodies (mAb) from the IGHV sequences of CLL cases using heterohybridoma and 
other techniques, several autoantigens have been better characterised. In one study 
recombinant antibodies from 28 U-CLL and 29 M-CLL cases were derived and 
compared to 31 antibodies derived from the CD5+ cells of 3 healthy donors167. 20% of 
CD5+ B-cells, 57% of M-CLL and 90% of U-CLL were reactive by indirect 
immunofluorescence assays (IFA) to panels of cell line antigens. There were common 
reactivity patterns within each CLL subset. Most antibodies recognised cytoplasmic 
structures, (often with very similar IFA patterns implying the same antigen) with a 
minority binding to nuclear components. In terms of polyreactivity against a panel of 
specific antigens, 3.2% of CD5+ cells, 13.3% of M-CLL cells, and 79% of U-CLL cells 
expressed polyreactive mAbs.  Polyreactivity was common in some U-CLL stereotyped 
subsets and not others. There was also high reactivity to oxidised Low Density 
Lipoprotein (ox-LDL) and oxidised Bovine Serum Albumin, neo-epitopes that may arise 
as a result of conjugation of metabolites of lipid peroxidation to membrane molecules. 
Oxidised LDL may have a role in the clearance of cell debris by natural IgM201. The 
mAbs with the broadest range of autoantigen binding were also those with the 
strongest binding to neoantigens. Apoptosis can make autoantigens accessible for 
recognition203, and also create neo-epitopes by chemical modifications203-205. B-cells 
recognising these epitopes are often found in the B-1 cell compartment, the source of 
natural antibody. 
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Chiorazzi’s group has performed further characterization of antigens, identifying non-
muscle myosin heavy chain IIA (MYHIIA) as an autoantigen recognised by stereotyped 
subset 6 derived mAbs 206,207. Subset 6 mAbs have a characteristic CDR3 sequence 
involving rearrangement of unmutated IGHV1-69, IGHD3-16 and IGHJ3 paired with a 
light chain with a characteristic sequence usually involving IGKV3-20. MYHIIA is a large 
cytoplasmic protein with functions in cell shape and movement. In order for the CLL 
BCR to bind MYHIIA, the authors suggested that it is exposed on the surface of 
apoptotic cells. Immunoglobulins from healthy volunteers also bound these apoptotic 
cells, and they suggest this reflects the presence of natural antibodies. U-CLL exhibited 
higher binding, as did patients with a poorer prognosis, with prognosis correlating 
more with binding than with mutation status. It is difficult to draw too many 
conclusions about prognostic impact from this small series of patients (n=24), but a 
different group has also correlated binding patterns to a panel of antigens and 
polyreactivity with prognosis in a group of 100 patients208. 
 
A Swedish group established 9 EBV-transformed CLL cell lines and harvested the mAbs 
secreted by them209. Autoantigen binding was exhibited for cytoskeletal and 
cytoplasmic antigens in various cell lines.  The antibodies isolated bound several 
antigens, these were analysed by Matrix-assisted laser desorption/ionization (MALDI-
TOF) mass spectrometric proteomics and protein tissue microarrays. Identified 
antigens were vimentin, filamin B, cofilin-1, PRAP-1, phosphorylcholine, cardiolipin, 
oxidised low-density lipoprotein, and Streptococcus pneumoniae polysaccharides. 
Vimentin is a cytoskeletal protein that is secreted as a stress response to bacterial 
insult and is exposed on apoptotic cells. Modified citrullinated vimentin (the Sa 
antigen) can generate autoantibodies in RA210. The survival-promoting effects of 
vimentin in an in vitro CLL culture system are reduced by the use of recombinant 
soluble anti-vimentin Ig to block antigen binding114. 
 
The finding of microbial antigens bound by CLL BCRs may also be relevant. BCRs from 
U-CLL utilising IGHV1-69 seem to have a marked propensity to bind pUL32, a large 
Cytomegalovirus-encoded phosphoprotein211. There is also evidence of molecular 
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mimicry between S.pneumoniae polysaccharides and oxidised LDL212 and between 
vimentin and phosphorylcholine (present in many bacterial cell membranes)209. These 
antigens are recognised by CLL mAb, and the demarcation between autoantigen and 
microbial antigen may not be strict. The risk of CLL is higher in individuals with a 
preceding infection (pneumonia or cellulitis), even when infections during the 5 year 
period prior to CLL diagnosis are excluded213. One interpretation is that infection may 
stimulate the growth of malignant B-cells, consistent with the antigenic stimulus 
hypothesis. An alternative explanation is that a degree of immunosuppression may 
well be apparent years before a diagnosis of CLL is made, increasing the risk of 
infection. Supporting this second hypothesis, recent data suggest that MBL itself is 
associated with a greater risk of hospitalization for infection214. A currently recruiting 
trial is assessing the efficacy of using antibiotics in the treatment of early stage CLL, 
based on the hypothesis of microbial stimulation of CLL progression215.  
 
Most recently, an intriguing study has raised a new possibility for the nature of the 
antigen for which the CLL BCR has specificity216.  The authors of this study have 
previously characterised the binding specificities of recombinant CLL 
immunoglobulins208. They have also shown that the presence of constitutive signalling 
in developing B-cells is dependent on pre-BCR binding to invariant structural motifs 
within the pre-BCR itself93. As a synthesis of their previous work, this study suggests 
that in a limited number of characterised cases, the CLL BCR has specificity for the 
framework region of the BCR itself. Though they describe this as ‘…driven by antigen-
independent cell-autonomous signalling’, it might be better described as driven by 
antigen, but the antigen happens to be the BCR itself, on the same cell. This finding 
requires extension to a larger set of patients, but may provide much explanatory 
power. However, it makes certain other aspects of B-cell receptor signalling in CLL 
difficult to explain (discussed further in Chapter 8). 
 
In summary, when the antigen-specificity of the BCRs of CLL patients are sought, a 
diverse range of putative antigens is identified, many of them autoantigens, These are 
often the products of cell apoptosis and oxidation or cytoskeletal components (such as 
vimentin, cofilin-1, MYHIIA and filamin B, often these are exposed on the surface of 
 49 
apoptotic cells) 167,198,199,217. Some individual cases of CLL (particularly U-CLL cases) 
appear to be polyreactive in that they bind multiple antigens, which may explain their 
more aggressive disease course208 167,198,199,217. If the hypothesis that antigens 
stimulate the growth of CLL is correct, it is not inconceivable that each individual 
patient’s leukaemia may be responsive to their own unique antigen(s). The existence 
of a limited number of subsets (albeit >100) implies that it is more likely that a narrow 
range of antigens are shared among patients90,117. Several questions remain 
unanswered. If antigenic selection is occurring, is this only at the early stages of MBL or 
CLL growth, or does it apply in more aggressive disease or even Richter’s 
transformation? Generally, microenvironmental influences are felt to be less 
important for later stages of tumourigenesis, but there is no reason why they may not 
still have an effect. Does antigenic stimulation promote tumourigenesis by causing 
increased proliferation and therefore increasing the rate of mutagenesis? Do 
mutations have an effect by causing aberrantly enhanced responses to antigenic 
stimuli? It may be that MBL and CLL coincidentally arise from transformation of a B-cell 
subset that happens to exhibit a restricted repertoire due to the nature of antigens 
that the subset generally deals with, and that after transformation has occurred 
antigen ceases to be relevant to pathogenesis. 
 
There is circumstantial evidence supporting ongoing antigen encounter in CLL. The 
phenotype 218and gene expression profile219 of CLL cells suggests similarity to memory 
B cells, as compared to naïve, tonsil GC and cord blood CD5+ cells.  Classical memory B 
cells, previously exposed to antigen, respond more rapidly to a second antigenic 
challenge, and have greater BCR avidity for antigens produced as part of the SHM 
process that occurs with T-cell help within the GC. Typically, there is also isotype 
switch to non-IgM/IgD sIg. This definition does not cover B cell responses to T-
independent antigens, which can generate an enhanced number of cells recognizing a 
particular antigen without SHM or CSR. Immature B cells at earlier stages can also 
recognise antigen via their BCR. Therefore, ‘antigen-experienced’ does not equate to 
‘memory’. Whilst M-CLL could be analogous to classical memory B cells, U-CLL may 
well be derived from a B cell at an earlier stage, yet still have ‘experienced’ antigen 
binding without undergoing SHM. 
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There is some evidence of ongoing antigenic stimulation in CLL. One study analysed 71 
CLL cases to search for intraclonal diversification (ID)220. Most cases did not display ID, 
but there was a subgroup of 13 IgG-switched cases in stereotyped subset 4 that 
displayed extensive ID.  Others have found similar evidence of ID, and there are 
numerous reports of ongoing class-switch recombination (CSR) and AID expression in 
CLL subclones, indicating that the processes that operate in the germinal centre 
response to antigen are still extant in at least some cases of CLL221,222. AID and CSR 
generally seem to occur more often in U-CLL, and have been variably associated with 
prognosis. It may that ongoing BCR stimulation by antigen may promote mutagenesis 
by promoting proliferation, and Chiorazzi has suggested that AID may play an 
important role in genomic instability in CLL cases where it is highly expressed223. The 
role of AID in causing transforming mutations in other B-cell lymphomas is well 
recognised, the germinal centre being a dangerously mutagenic locale100. 
 
It might be expected that if CLL BCRs are autoreactive then autoimmune phenomena 
might be more apparent. Whilst there is a well-established association between 
autoimmune cytopenias and CLL, the autoreactive B-cells in these cases are not part of 
the CLL clone224. These are presumed to be dysregulated because of a general defect in 
eliminating autoreactive cells, perhaps because of T-cell defects73,225, or an increase in 
B-cell survival factors such as BAFF, raised serum levels of which are known to 
associate with both CLL226-228 and autoimmune disease229,230. Furthermore, it seems 
that ‘healthy’ B-cells also express autoreactive BCRs, albeit at a lower frequency than 
in CLL, and these may produce natural antibodies that are part of the body’s 
mechanism for clearing cellular debris. There is an increase in autoantibody production 
with age, particularly for antibodies against cardiolipin, DNA, antinuclear antibodies 
(ANA) and rheumatoid factor (RF). However, this is not generally accompanied by a 
corresponding increase in autoimmune disease per se231. 
Autoreactive BCRs are therefore surprisingly common in health and disease, and 
autoreactivity alone is insufficient as a simple explanation for BCR abnormalities in CLL.  
To understand this complexity further, it may be helpful to consider how autoreactive 
B-cells are dealt with by the immune system.   
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2.7 B-cell Anergy  
Given the mechanism of generation of antigen receptor diversity, a means for inducing 
tolerance for self-antigens at the same time as recognising a huge range of foreign 
antigens is necessary. At an early stage in their development, T and B-cells are subject 
to either clonal deletion or receptor editing in the bone marrow: ‘central tolerance’232. 
As many as 75% of newly generated B-cells are autoreactive, and whilst many of these 
are deleted in the process of central tolerance, an estimated 40% of recent emigrants 
from the bone marrow are autoreactive and must be silenced to prevent development 
of autoimmune disease233. Additional autoreactive cell silencing mechanisms operate 
in the periphery, and include regulatory T-cells, idiotypic regulatory networks and 
anergy234.  
 
Anergic cells have a phenotype suggesting developmental arrest at the transitional 
stage, however this does not automatically imply that developmental arrest has 
occurred as mature cells also acquire this phenotype and become anergic upon 
encounter with antigen in the absence of second co-stimulatory signal232. Anergic B-
cells persist in the periphery for 5 days and continue to express the BCR, albeit at 
reduced levels. However, BCR has lost its ability to transduce activating signals upon 
antigen binding. Anergy requires more than simply the absence of co-stimulatory 
signals, with maintenance of the unresponsive state requiring chronic occupancy of a 
significant proportion of receptors by antigen232. Chronic BCR binding would be 
characteristic of a ubiquitously expressed autoantigen, and in the absence of co-
stimulatory signals that indicate the presence of a foreign invader, leads to attenuation 
of further signalling to produce a desirable state of anergy to the autoantigen234. 
 
The mechanisms of anergy have been elucidated in animal models. Goodnow et al 
expressed hen egg lysozyme (HEL) as a neo-autoantigen in mice235,236. Utilising mice in 
which transgenic HEL was coupled to a heavy metal-responsive promoter could induce 
the expression of HEL induced at various developmental stages. These ML5 mice were 
then crossed with the MD3 mouse line that are transgenic for expression of a BCR with 
known high affinity for HEL. The presence of HEL did not lead to deletion in these mice; 
in fact HEL-specific B-cells were present in the periphery in almost normal numbers at 
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immature stages, but these were unable to mount effective responses to the HEL 
antigen. B-cells that became anergic in the presence of soluble HEL were deleted when 
the MD3 mouse was crossed to a mouse expressing HEL in a membrane-bound 
form237, highlighting the importance of the context in which antigen is encountered. 
Occupancy of <5% of receptors led to development of B-cells that were ‘ignorant’ of 
antigen, 5-45% occupancy to anergy, whereas higher occupancy led to deletion236.  
 
Constant BCR occupancy is required to maintain anergy, and anergy is reversible. The 
transfer of anergic B-cells into an environment lacking HEL results in loss of the anergic 
phenotype and the reacquisition of the ability to produce antibody responses to 
HEL238. The anergic state is associated with reduced expression of IgM, as might be 
expected if the cell is seeking to reduce responses to antigen via reduction in BCR 
expression. Unexpectedly, IgD is maintained at levels similar to naïve cells, a finding 
that has been widely replicated yet not explained. These transgenic models have been 
criticised for their unphysiologic nature239, and so evidence of anergic cells have been 
sought in other models. A population of IgMlowIgDhigh (An1) B-cells with other markers 
of anergy exists in the normal B-cell repertoire of wild-type mice that have been 
suggested to be naturally occurring anergic cells236,240.  
 
Given that so many newly formed B-cells are autoreactive233,239, anergy is probably a 
major mechanism of tolerance induction. This may explain the presence of a 
surprisingly high frequency of autoreactive BCRs in the repertoire in the absence of 
overt autoimmune disease. A logical question is whether these anergic cells form a 
source of autoreactive B-cells that may subsequently cause autoimmune disease. 
There is some evidence that this may be the case as the An1 population is reduced in 
autoimmune disease mouse models234. Whilst murine models have been increasingly 
well characterised, much less is known about the human counterparts. The human 
equivalent of these anergic cells appears to be IgD+IgMlo/-CD27-, have unmutated IGHV 
genes and constitute 2.5% of peripheral blood B-cells241. They are unresponsive to BCR 
stimulation as measured by calcium flux and protein tyrosine phosphorylation. This 
population is also enriched for B-cells that recognize ssDNA and Hep-2 cell antigens, 
well-known autoantigenic culprits in autoimmune disease. 
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Various features of An1 cells reduce their participation in immune responses. One is 
reduced lifespan. The half-life of follicular B-cells is 40 days, as opposed to 5 days for 
anergic B-cells242,243. The reduced lifespan is only apparent when non-anergic B-cells 
are also present to compete for B-cell activating factor (BAFF), an important survival 
factor for peripheral B-cells244. Anergic cells appear to have reduced BAFF receptor 
expression or reduced BAFF receptor signalling competence230. As might be predicted, 
over-expression of BAFF leads to autoimmunity229. BAFF and its related molecule APRIL 
may play an important role in CLL cell survival227,245, yet the picture is confusing as 
BAFF and APRIL levels may be raised in CLL, yet the BAFF-Receptor levels are reduced 
and reports are conflicting. Other mechanisms of decreased survival involves high 
expression of the proapoptotic BCL family member BIM in anergic B-cells, and anergy 
is lost in anti-HEL mouse B-cells lacking BIM246. Anergic B-cells may also undergo 
apoptosis initiated by FAS signalling by encounter with FASL+CD4+ T-cells247.  In 
contrast, it is well known that CLL cells exhibit a defect in apoptosis, with higher 
expression of anti-apoptotic BCL family members248. A model of CLL as an equivalent of 
anergic B-cells has been suggested115,116,249. It would be consistent with the concept of 
CLL cells as chronically binding autoantigens in vivo.  One curious feature of both 
anergic and CLL cells is that they generally exhibit low expression of IgM whilst 
preserving the expression of IgD. Why this occurs is unknown, but if the BCR in CLL is 
to be studied, then it must be considered in both its expressed isotypes: IgM and IgD.  
2.8 IgD   
2.8.1 Introduction 
When antigen binds the V region of the BCR, the signal is propagated to the interior of 
the cell via the constant (C) region of the immunoglobulin molecule122,250.  The 
structure of the C region determines the isotype of the BCR. The properties of this 
signal (and the effector properties of the antibody synthesized by the same B-cell) are 
dependent on the isotype.  Each B-cell clone encodes one V region with specificity for 
a single antigenic epitope (or several similar epitopes in polyreactivity). One of the 
means by which a B-cell can modify its response to the same antigen is to switch 
isotype, with this switch resulting in altered signalling or altered effector function of 
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secreted antibody101. A curious feature of B-cells in the early stage of maturation is 
that they have dual expression of both IgM and IgD, and this is true of most cases of 
CLL251-253. Membrane IgD shares many properties with its more famous cousin IgM. 
Why both normal and malignant B-cells express two different isotypes with identical 
antigen-binding regions is still a mystery, with phraseology of review articles on IgD 
function often employing the words ‘enigma’ and ‘riddle’254,255.   
 
Evolutionarily, the immunoglobulins first appeared in jawed vertebrates around 500 
million years ago256. IgD is only expressed in teleosts (bony fish) and mammals, though 
there is a homologue (IgW) in cartilaginous fish and more homologs are being 
discovered as genomes of various species are sequenced. Its widespread and long-
standing usage suggests some evolutionary advantage. Whilst IgM remains stable over 
evolutionary time, IgD has shown greater structural plasticity and may be expressed 
predominantly as a transmembrane or secreted molecule depending on the species 
studied. This has led to suggestions that IgD has been preserved as a structurally 
flexible locus to complement the functions of IgM255. The CH gene encoding the human 
 chain is located in the IgH cluster at 14q32 on chromosome 14. It may be a result of 
duplication of the c  gene during evolution257. It spans 10kb and has eight exons. 
 
IgD was initially discovered in 1964 after investigation of a novel paraprotein in 
multiple myeloma sera258. The reasons for naming the new immunoglobulin ‘D’ 
included its ‘difference’ from the other immunoglobulins, and the fact that IgA, IgB (a 
name for murine immunoglobulins, now fallen out of use) IgE and IgG were already 
used. The letter C has no Greek equivalent, and so IgC was never employed86.  
Subsequently, a large number of studies identified it as a major immunoglobulin that 
constitutes the BCR in both mice and humans259.  
 
IgD represents 0.25% of the total serum immunoglobulin and has a wide range of 
concentrations between individuals irrespective of age, but dependent on infection 
history255. Antigenic challenge can produce specific IgD, and IgD with autoantigen 
specificity has been identified260. In addition to blood, IgD is also present in various 
secretions. IgD does not bind to neutrophils or monocytes, does not cross the 
placenta, and does not activate complement strongly. Both CD4+ and CD8+ T-cells have 
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putative IgD receptors that can ligate both aggregated serum secreted IgD (secIgD) and 
surface IgD during antigen presentation by B-cells259. Stimulation of basophils and 
other cells with secIgD leads to the release of many cytokines that may favour B-cell 
survival and activation, including BAFF261. It therefore seems to have a role in 
promoting inflammation and links the adaptive and innate immune systems. 
2.8.2 Structure of IgD molecule 
The heavy chains of IgD on the surface of B-cells are covalently linked by only one 
disulphide bridge, which allows a higher degree of mobility for the antigen-binding 
sites compared to other immunoglobulin isotypes262. The high carbohydrate content 
(9-14%) of  chains explains why its molecular mass (175kDa) is higher than that of 
chains. The structure of C 1 and C 2 domains is similar to other isotypes, whilst the 
C 3 domain is different with the lack of several proline residues and by the presence of 
two N-linked carbohydrates. Evidence suggests that these structural features explain 
many of the differing biological effects of IgD compared to other isotypes. Despite 
having the same V gene regions, it has been shown that the binding properties of IgM 
and IgD may be different because of the structural features of the receptor, with IgM 
binding having a higher functional affinity at higher antigenic concentrations263. The 
co-expression of IgM and IgD may therefore facilitate the recognition of the same 
antigen at different concentrations, or in different structural arrangements. 
 
IgD appears to preferentially associate with  light chains, while the secreted form 
associates with chains 262.  It is not obvious why this is, though various hypotheses 
have been suggested250,251. The intracytoplasmic tail of IgD is particularly short, is 
identical to that of IgM in humans and contains only three residues (Lys-Val-Lys). 
Surface IgD is anchored in the membrane via its transmembrane hydrophobic domain, 
and is non-covalently linked to heterodimers of Ig  (CD79a) and Ig (CD79b). Due to 
different carbohydrate contents, IgM- and IgD-associated Ig  and Ig  chains have 
different molecular masses264. As with the other sIg, Ig  and Ig  play an essential role 
in IgD BCR signal transduction. Whilst IgM produced in the absence of Ig -Ig  is 
retained in the endoplasmic reticulum through its interaction with chaperone proteins 
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such as calnexin, IgD may be transported to the membrane in the absence of Ig -Ig  
and calnexin is not required in this process265.  
 
IgM and IgD may be associated with different molecules264-266. Two accessory proteins, 
the BCR-associated proteins (BAP) 29 and BAP 31 are also part of the IgD BCR complex, 
whereas BAP 32, 37 and 41 are associated with IgM267. These may be involved in 
functional differences, however the nature of these molecules has not been fully 
investigated since these early reports. 
 
In some contexts, an alternative and minor form of IgD is linked to the plasma 
membrane by a glycosyl-phosphatidylinositol (GPI) anchor268. It is sensitive to 
phospholipase C and hence may be released in soluble form. The GPI-linked isoform of 
IgD normally forms a minority of IgD, but selectively activates cAMP-dependent 
pathways, which may support calcium flux via canonical BCR signaling269.  
2.8.3 Regulation of IgD synthesis 
The methods of regulation of IgD synthesis vary according to developmental stage of 
the B-cell. Two mechanisms result in IgD expression: Alternative splicing of a common 
IgM and IgD mRNA transcript and Class Switch Recombination (CSR).  
 
Differential splicing of long primary mRNA transcripts is the main mechanism of 
simultaneous expression of IgM and IgD. It is not certain why immature B-cells only 
express IgM. In the mouse, central immature B-cells contain no  mRNA, whereas 
peripheral immature B-cells express amounts of  mRNA similar to that found in 
mature B-cells. How this differential splicing occurs is uncertain. There is a specific 
region between the  and  genes, which attenuates the transcription complex and 
forces IgM mRNA production by default. Binding of lineage specific regulatory proteins 
may alter the ratio of processing of the primary mRNA transcripts270,271. The 200 bp att 
attenuator site is located 1650 bp downstream to the  polyadenylation site in the -  
intron and contains cis-acting repressors of  gene transcription. Deletion of att leads 
to long -  transcripts, but these are processed into mature  transcripts only in 
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mature B-lymphocytes270. The -  intron also contains a binding site for the myc-
associated zinc finger protein MAZ that terminates  transcription272. 
 
Post-transcriptional controls involve translational and post-translational modifications. 
The density of IgD on mature B-cells is often much higher than that of IgM in spite of 
lower levels of the  mRNA compared to  mRNA273. This is partly explained by a more 
rapid turnover of IgM than IgD and lower stability of  RNA compared to that of  
mRNA. The loss of IgD expression after mature B-cell activation is accompanied by a 
sharp drop of  mRNA content and an increase in  chain half-life274.  There is usually 
no detectable IgD expression by the memory B-cell stage275.  
 
IgD expression can also occur via Class Switch Recombination (CSR). The absence of a 
canonical switch region 5’ to the  gene would seem to rule out the classical class 
switch from  to  analogous to the switch from  to other isotypes. However, 
deletional recombination of c  has been demonstrated in murine myeloma, human 
Hairy Cell Leukaemia B-cells and normal tonsillar B-cells with a region containing G-rich 
pentameric repeats located within the -  intron able to recombine with the S  region 
and act as a switch region276.276 B-cells from tonsillar germinal centres have the highest 
frequency of IgD expression in health and are enriched in cells that exhibit IgD class 
switching and a have a high level of V gene somatic mutations277. These IgD-switched 
B-cells predominantly use  light chains and can differentiate into plasma cells. Since 
most secreted IgD is  light chain restricted, it is likely that these switched cells are the 
source of most secreted IgD. Also, these switched cells use a subset of V genes 
associated with autoreactivity and have evidence of receptor editing278.  
 
One study found that >50% of human IgD switched lymphocytes were autoreactive, as 
they encoded antibodies that bound antigens such as antinuclear antigens (ANAs), 
single- and double-stranded DNA and were often polyreactive279. It may be that the 
cryptic C switch region is targeted in autoreactive B-cells, or that these cells are 
inhibited from switching to other isotypes. Alternatively, selection of IgD switched cells 
may occur after class switch, with survival of autoreactive clones, suggesting a role for 
survival signals via IgD. High levels of SHM are also exhibited by IgD switched B-cells 
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compared to IgG+ and IgM+ cells. This SHM may indicate either antigenic selection or 
an attempt to reduce the polyreactivity of autoreactive BCRs259. 
 
The superantigenic binding of certain bacterial proteins to the carbohydrate moieties 
of constant domains is peculiar to IgD. The Fc fragment of IgD binds nonspecifically to 
bacteria, including Moraxella catarrhalis and Haemophilus influenzae, and 
streptococcal groups A, C and G280,281. Moraxella catarrhalis binds to IgD and has a 
strong mitogenic effect. The specific Moraxella IgD-binding protein (MID) has been 
isolated, and it is stably expressed by all strains of M. catarrhalis tested282. It interacts 
with C 1 region of the heavy chain and acts as a superantigen. M Catarrhalis can be 
found in the mantle zone of human tonsils, and it is suggested that this accounts for 
the high prevalence of IgD+ cells in the nasopharynx.  
 
Serum IgD is often increased in patients with autoimmune diseases, such as 
rheumatoid arthritis and systemic lupus erythematosus (SLE)255, consistent with the 
finding that many IgD class-switched cells are autoreactive in healthy individuals279. As 
further implication of their role in autoimmunity, selective depletion of IgD+ B-cells in a 
mouse model of autoimmune arthritis leads to amelioration of the condition283.  
2.8.4 IgD in B-cell development 
IgD, coexpressed with IgM, is the major antigen receptor isotype on naive peripheral B-
cells259. In general, IgD expression is confined to this stage of differentiation, whilst 
IgM has a somewhat greater range. During development, IgM is the initial BCR isotype 
synthesized, and is later expressed during the GC reaction, whilst IgD is 
downregulated. IgD is expressed once a B-cell has emigrated from the marrow to 
populate spleen, lymph nodes and intestinal mucosa. When B-cells leave the bone 
marrow they are termed transitional type 1 (T1) cells, and are particularly susceptible 
to negative selection (deletion on receptor ligation). It has been suggested that IgD 
rescues cells from IgM-induced apoptosis during tolerance induction and possibly the 
negative selection of immature B-cells results from low IgD expression284. At the end of 
the T1 stage they start to express IgD as well as IgM and become more resistant to 
negative selection. Though it is sometimes assumed that most autoreactive clones are 
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eliminated by this stage, low-affinity self-reactive clones can still be readily detected 
and IgD expression may promote their survival.  
 
The T2 stage is less susceptible to negative selection and is associated with high levels 
of IgM and IgD expression and protection by anti-apoptotic factors, as well as different 
coupling to signalling pathway components (such as the involvement of PKC  and 
Btk)285. The levels of BCR expression can guide B-cell development into different 
subsets286. Other signalling pathways such as TLR4, TLR9, CD40, BAFFR, BCMA and TACI 
also have an effect on the survival of T2 cells. 
 
Geisberger et al suggest that IgD, by its expression at the T2 stage of development, 
supports the survival of B-cells at this stage, and that there must be a difference in 
signalling between IgM and IgD because the combined signalling at this stage would 
lead to a very large signal and elimination of the B-cell clone254. Perhaps by modulating 
the ratio of IgD and IgM the B-cell can regulate its own survival by modulating the total 
signal received by both isotypes and therefore altering the thresholds of negative and 
positive selection. Upon antigen stimulation during the germinal centre reaction, 
mature B-cells rapidly lose IgD before undergoing terminal maturation toward IgM 
plasma cell or class switching287.  
2.8.5 Signalling differences between IgD and IgM  
Evolutionary conservation, differential expression at certain stages of B-cell 
development and co-expression with IgM at others implies that the IgD and IgM 
isotypes of the BCR differ functionally. In general the similarities are pronounced, with 
the  heavy chain compensating for the  heavy chain in early B-cell development, and 
vice versa288-290. Dual knockout of the  and  genes leads to arrest at the pre-B cell 
stage, as no functional BCR can be produced291.   knockout mice exhibit a slight 
reduction in peripheral mature B-cells289, and delayed affinity maturation during T-
dependent antigen responses288. Mice with  gene deletion exhibit some defects in 
CSR, with slightly reduced B-cell numbers291,295. This suggests that IgM and IgD can 
largely substitute for each other during development, but that optimal B-cell 
maturation requires both IgM and IgD.  
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As discussed, downregulation of IgM compared to IgD is a feature of autoimmune mice 
models and anergic B-cells236. In immunoglobulin-transgenic mice co-expressing hen 
egg lysozyme (HEL)-specific IgM and IgD, the response to constitutive exposure to HEL 
(simulating autoantigen) results in downregulation of IgM with relative preservation of 
IgD235,292. The decrease of IgM is explained by persistent engagement of BCR by 
antigen resulting in downregulation of the BCR to prevent overstimulation of the B-cell 
and subsequent possible autoreactivity, but this does not explain why IgD is not 
decreased. 
 
IgD and IgM selective knockouts were explored further by crossing with mice that 
expressed B-cells specific for hen-egg lysozyme (HEL)292.  Both IgM and IgD-only cells 
could mount comparable T-independent and T-dependent responses to acute 
exposure to HEL antigen, with IgD only mice actually generating anti-HEL antibody with 
greater efficiency. Constitutive expression of HEL in a membrane-bound form led to 
deletion of HEL-specific cells from the repertoire, as might be expected via central 
tolerance. Similar to previous models, constitutive soluble HEL allowed maturation up 
to the transitional stage, but both IgD- and IgM-only B-cells were rendered anergic. As 
with other anergic models, IgM was downregulated 10-100-fold, whilst IgD was only 
downregulated by 5-fold in IgD-only cells. Despite both isotypes able to mediate the 
functional process of anergy, there is still a perplexing difference in the level of 
receptor downregulation during this process, even when the other isotype is absent. 
IgM appears to have a greater plasticity of expression level as compared to IgD. 
 
Early explorations of signal transduction found no differences between IgM and IgD 
signalling293, yet subsequent studies have found subtle differences. Binding of antigen 
by IgD can induce phosphorylation of multiple substrates that is earlier, stronger and 
more prolonged than after IgM binding in a study on a myeloma cell line294. In both a 
lymphoma-derived cell line and healthy human peripheral blood B cells, only anti-IgM 
induced growth arrest and cell death, in spite of similar tyrosine phosphorylation, 
calcium flux, activation of PKC and expression of transcription factors such as c-fos and 
Egr-1295.  
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There is increasing evidence that mobility in membranes and interactions with the 
cytoskeleton have a critical role in regulating BCR signaling296. Single molecule imaging 
techniques suggest that IgD diffuses more slowly than IgM297, and that the movement 
and clustering of BCR complexes is dependent on ezrin and the actin cytoskeleton. 
Similar techniques also show that IgD exists in pre-clustered complexes compared to 
the more diffuse, unclustered IgM298.  
 
Interactions between IgM and IgD signalling may occur. It can be shown that 
engagement of one receptor isotype results in unresponsiveness of the reciprocal 
isotype, probably by uncoupling of Ig from Ig -  which lasts for more than 24 hours299.  
Other early results suggested that ligation of IgM but not IgD can induce negative 
responses300-303 (growth arrest, anergy, apoptosis), which is consistent with a model 
whereby antigen exposure at an early (IgM only) stage of development leads to 
deletion or apoptosis, whereas mature cells (expressing IgM and IgD) generally 
undergo proliferation after encountering antigen. The teleological rationale for this 
would be that antigen encountered at an early stage is likely to be autoantigen, 
whereas mature B-cells would be expected to more often encounter foreign 
pathogens that require a robust response. IgD signalling in this model counteracts 
‘negative’ signals delivered via IgM. In other models both IgM and IgD can transmit 
negative (apoptosis-inducing) signals in immature cells in irradiated mice, whilst IgM 
and IgD engagement in mature cells generally results in proliferation293,294.  
 
 
The differing role of signalling via IgD or IgM is not clear. Discrepancies may be 
explained by the differing developmental stages of the B-cells used as models, as well 
as differing receptor density. Similarities between IgM and IgD signaling are often 
more pronounced than their differences. The reason why B-cells have dual expression 
of IgM and IgD at various stages and how BCR signalling via these two isotypes differs 
still remains somewhat of a mystery. Nonetheless, the conservation of these isotypes 
throughout evolution and the sometimes-divergent responses to stimulation do 
suggest that they have differing roles in B-cell development and physiology. 
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2.8.6 IgD in CLL 
It is an established finding that CLL expresses surface immunoglobulin at reduced 
density as compared with healthy B-cells and other B-cell neoplasms304. This ‘weak’ or 
‘dim’ expression as detected by flow cytometry is a peculiarity of CLL that has been 
incorporated into diagnostic criteria, but never satisfactorily explained5,49. The other 
established finding is that CLL generally co-expresses IgD and IgM. The exact 
proportions and combinations of IgD and IgM vary by method of detection and 
publication, and are discussed further in Chapter 5. 
 
Few researchers have examined the effect of IgD signalling in CLL. Lanham et al’s main 
aim was to measure the outcome of IgM signalling, as judged by global protein 
phosphorylation and Syk phosphorylation305. Of 40 CLL samples, 15 (38%) did not 
respond to IgM cross-linking. All samples expressed IgM, and IgD.  Of the 15 samples 
tested that did not respond to anti-IgM, 10 (66%) were responsive to anti-IgD and 12 
(80%) were responsive to anti-CD79a. The 3 samples that did not respond to anti-CD79 
were nonresponsive to either anti-IgM or anti-IgD. The study was used as an 
illustration of dysfunctional IgM signalling, with preservation of IgD signalling in CLL305. 
The same group have published similar data demonstrating preserved IgD signalling in 
the presence of decreased IgM signalling in another study116. Intriguingly, this second 
study suggested that IgM expression and signalling capacity could be restored by 
incubation of cells in vitro, analogous to the scenario with anergic B-cells. This is 
discussed further in Chapter 6. 
 
Zupo et al306 examined 10 CD38 positive CLL cases, as it had been suggested that these 
cases have a better response to BCR ligation307. They suggest that IgM crosslinking 
results in CLL apoptosis, as have many other researchers, though published data are 
often conflicting on this outcome. They also suggest that IgD ligation results in less 
apoptosis as compared to IgM ligation, and in some conditions where cocktails of 
cytokines are employed, IgD ligation can result in differentiation to plasma cells. These 
studies do suggest that IgD and IgM have differing roles in CLL, and are discussed 
further in Chapter 6. 
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2.8.7 IgD Summary 
Membrane IgD is a somewhat mysterious molecule, sharing many properties with its 
more famous cousin IgM. It has not been established why CLL and naïve B-cells express 
IgD, often in combination with IgM. It is known that BCR stimulation via IgD has 
generally more effect on measures of BCR signalling in CLL. The outcomes of IgM 
stimulation in CLL are notoriously heterogeneous, as measured by the effect on cell 
survival (discussed further in Chapter 6). What is known is that IgD is more reliably 
expressed in CLL, despite the fact that most investigators have studied the effects of 
BCR stimulation via IgM, probably due to an assumption that IgM is the canonical 
surface immunoglobulin isotype in normal B-cells. 
 
An analogy between CLL cells and anergic autoreactive B-cells has been suggested 
(discussed further in Chapter 6), as reflected by a downregulation of IgM and 
preservation of IgD expression, a pattern which has yet to be explained in either 
healthy or malignant B-cells. Whatever the underlying causes of the differences 
between IgD and IgM expression and signalling in healthy and malignant B-cells, any 
consideration of the BCR in CLL is obliged to consider both IgM and IgD. If we accept 
the hypothesis that antigen binding to the BCR of CLL cells may exert a selective or 
growth-promoting effect on CLL then we must expect that this antigen binds both to 
IgD and IgM since both isotypes will have identical V-regions with the same epitope 
specificity. In fact, given the generally greater expression of IgD we might expect that 
this interaction was more important than that of antigen-induced BCR signalling via 
IgM. Therefore, to study BCR signalling in CLL, we cannot avoid consideration of the 
signals produced by both IgD and IgM ligation. It is possible that such studies will also 
illuminate some areas of IgD function in normal physiology. 
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2.9 B-Cell Receptor Signalling  
Hitherto, we have discussed the role of the BCR in CLL without considering the events 
occurring after the B-cell contacts its cognate antigen. The mechanisms of BCR 
signalling have been extensively studied in a variety of models, and different 
publications emphasise different aspects, depending on the scientific paradigms of the 
authors. Below is an attempt to summarise some of what is known about general 
aspects of BCR signalling, as well as an attempt to discuss BCR signalling in CLL, and in 
anergy. 
 
B-cells can respond to multivalent antigens in solution by BCR clustering and capping, 
with potential endpoints of proliferation and differentiation if appropriate support is 
received. Whilst much information about intracellular cascades has been elucidated, it 
is only recently that techniques in live cell imaging have enabled investigators to begin 
to establish how antigen binding to BCR ectodomains is translated across the 
membrane to trigger signalling cascades, and the importance of B-cell recognition of 
antigen on the surface of antigen-presenting cells246,317. Even so the underlying 
mechanisms of signal transmission by the BCR across the plasma membrane are still 
somewhat of a mystery 
 
The BCR comprises membrane-bound immunoglobulin (either IgM, IgD, sIgG, sIgA or 
sIgE) and a disulphide-linked heterodimer composed of Ig  (CD79a) and Ig (CD79a). 
These are transmembrane proteins with intracellular domains that each contain an 
immunoreceptor tyrosine-based activation motif (ITAM). On antigen binding, the BCR 
is phosphorylated on its ITAM tyrosines initially by LYN kinase, then by SYK kinase 
recruited to phosphorylated ITAMs via its SH2 domain. These events result in the 
initiation of several downstream signalling cascades.250  
 
In the absence of antigen, B-cells are often described as ‘resting’. This may be a 
misnomer, as there is evidence that the cells are hovering near a tipping point of 
activation308. The expression of the BCR is essential for all stages of B-cell 
development, leading to the hypothesis that the BCR provides low-level ‘tonic’ signals 
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that promote survival, either spontaneously or on interaction with ubiquitous 
microenvironmental ligands120. The phosphoinositide-3-kinase (PI3K) signalling 
pathway is crucial for the survival of mature B-cells and this pathway may be 
connected to the BCR in resting cells by the GTPase TC21 (also known as RRAS2), which 
connects the catalytic subunit of PI3K to the unphosphorylated ITAM of the BCR121,309. 
Generally, however, the nature of the pathways underlying tonic BCR signalling is 
poorly understood as yet.   
 
Phosphorylation of ITAMs by LYN initiates the formation of the signalosome, an 
assembly of intracellular signalling molecules such as the kinase SYK, phospholipase 
C 2, PI3K, Bruton’s tyrosine kinase (BTK), B-cell linker (BLNK) and VAV310. This 
signalosome allows the coordinated regulation of downstream cellular events such as 
calcium flux, antigen internalization and changes in gene expression (See Figure 2.3).  
Because the recognition of physically constrained antigen involves alteration of B-cell 
morphology, the cytoskeleton is seen to play a more important role than previously 
appreciated311,312.  
 
Cambier suggests that the BCR could be considered as a switch in three states313. 
Unoccupied receptors would have unphosphorylated ITAMs, acute occupancy of the 
BCR by antigen leads to biphosphorylation of ITAMs, activation of SYK and 
downstream pathways that lead to immune activation of the B-cell. Only once the two 
SH2 domains of SYK are engaged by dual ITAM phosphorylation is SYK activated by 
tyrosine phosphorylation314. Chronic receptor occupancy, as occurs in anergy, leads to 
predominantly ITAM monophosphorylation and therefore predominantly engagement 
of the LYN tyrosine kinase. As well as having a role in positive regulation of BCR 
signalling via activation of SYK, anergic B-cells display increased Ig /  ITAM 
phosphorylation, but only monophosphorylation234,313. This may allow the inhibitory 
functions of LYN signalling to dominate315.  Consistent with this, the LYN substrates 
SHIP-1 and DOK are constitutively phosphorylated in anergic B-cells234, and these are 
involved in the negative regulation of downstream pathways. It is likely that other LYN 
targets such as CD22 and the phosphatases SHP-1 and SHP-2 also participate in the 
maintenance of anergy234. 
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Figure 2.3: B-cell Receptor Signalling pathways 
Binding of antigen to cognate B-cell receptor leads to conformational changes that 
cause phosphorylation of cytoplasmic ITAM residues of CD79a/b by LYN kinase. 
Subsequent activation of SYK, other downstream kinases and linker proteins amplify 
these initial events, leading to the formation of a multimolecular signalosome 
complex, in association with clustering of multiple BCRs. This leads to events such as 
release of Ca2+ from the endoplasmic reticulum (ER), cytoskeletal changes, and gene 
expression changes. Negative regulation of signalling is provided by phosphatases 
such as SHP that associate with co-receptors such as CD22 and PIRB. Amplification of 
signalling can be provided by co-receptors such as CD19.  Pathways derived from 
multiple papers.116,117,119,246,316,317,320,325-328 Details on individual components are in 
the text. 
 
  
2.10 Abnormalities of B-cell Receptor Signalling in CLL 
The downstream components of BCR signalling have been studied to an extent in CLL, 
and we briefly consider the components of normal BCR signalling and abnormalities 
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seen in CLL and other lymphoid malignancies. In general, crosslinking of the BCR by 
monoclonal antibodies has been used to simulate antigenic encounter, a technique 
that has also been used by studies of normal BCR signalling, though in some other 
contexts it has been possible to use specific antigen in studies of non-malignant B-cells, 
classically in the HEL mouse models316. Partly inspired by the model of abnormal BCR 
signalling in CLL, several novel small molecule inhibitors of some of the BCR pathway 
components have been developed, in particular targeting BTK, PI3K, SYK and LYN. 
These are discussed further below, and the remarkable clinical efficacy displayed by 
some of these compounds is perhaps one of the strongest arguments for the role of 
abnormal BCR signalling in CLL. 
 
2.10.1 Mutation status 
In terms of CLL mutation status, most studies have suggested that BCR signalling is 
more potent in U-CLL, whether measured by calcium flux, apoptosis, proliferation or 
the phosphorylation of various downstream molecules305,317-322. However, because of 
the association between mutation status and ZAP70, CD38 or sIg expression, the 
increase in signalling capacity may be more associated with these other confounding 
factors116,318. 
 
2.10.2 CD79a/CD79b 
One reason for poor BCR signalling in CLL may be low levels of CD79a/b, with either 
resultant low sIg expression, or poorer signalling323. Dissociation of the CD79a/b 
subunits from the sIg may be a mechanism whereby BCR signalling is decreased in 
anergic B cells299. Splice variants of CD79b have been noted to be used preferentially in 
CLL, and some have noted constitutive CD79a ITAM phosphorylation317,324. Recently, 
CD79a/b has been shown to play a critical role in diffuse large B cell lymphoma cell 
survival, via chronic activation of BCR downstream pathways such as NF-kB, with 
activating mutations in CD79b ITAMs detected in a high proportion of primary 
lymphoma cells of this subtype325. 
2.10.3 Calcium flux  
Initial BCR signalling events typically activate phospholipase C (PLC), which results in 
abrupt rises in cytoplasmic calcium concentration ([Ca2+]i flux). Calcium flux is often 
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taken to be a surrogate marker or sine qua non of BCR signalling. The abrupt rise in 
intracellular Ca2+ concentration ([Ca2+]i) modifies a diverse range of intracellular 
processes326. Early reports suggested that 50-75% of CLL cells are able to display [Ca2+]i 
flux in response to crosslinking IgM327,328. The patterns of calcium flux response to IgM 
ligation have been likened to those seen in anergic B-cells329. 
Anergic B-cells exhibit elevated baseline intracellular [Ca2]i and BCR ligation fails to 
evoke large transient increase in [Ca2+]i 234. In CLL, PLC phosphorylation after BCR 
ligation is heterogeneous, with greater phosphorylation in U-CLL.312,332,342 
Calcium flux in CLL and anergic B-cells is discussed further in Chapter 6. 
 
2.10.4 LYN tyrosine kinase 
Several studies have consistently shown elevated LYN expression and constitutive 
activation in CLL cells305,317,330. Dasatinib is an src and abl kinase inhibitor that inhibits 
LYN and induces CLL cell apoptosis. It has clinically significant effects in CLL331,332. 
 
2.10.5 Spleen tyrosine kinase (SYK) 
SYK mutations have been found in diverse cancer cells333. Sequencing of 40 CLL 
patients did not reveal any mutations or unusual frequencies of SNPs in SYK 334. CLL 
cells exhibit constitutive Tyr525/526 autophosphorylation and an increase on BCR 
ligation, which is reduced by a SYK inhibitor335,336. CLL cases with proliferative 
responses to BCR ligation have higher levels of SYK than anergic cells329, whilst others 
found that SYK expression was homogeneous in CLL337. BCR and SYK activation also 
modulate cell adhesion and chemotaxis of B cells338-340, and SYK inhibition can reduce 
the protective effect of the microenvironment in CLL, suggesting that SYK may play a 
role other than downstream of the BCR341. Fostamatinib is a prodrug of R406 under 
clinical development for treatment of rheumatoid arthritis and immune 
thrombocytopenic purpura. A phase I/II trial showed reasonable safety and response 
rates, with a combined PR and CR rate of 55% in pre-treated CLL/SLL patients 342, 
however further trials in lymphoma are not currently planned. Patients treated with 
Fostamatinib exhibited an initial lymphocytosis that has been since recognised as a 
BCR antagonist class effect. It is likely that it results from disruption of the CXCR4-
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CXCL12 axis and other adhesion factors (perhaps including BCR) in the bone marrow 
and lymph node, leading to mobilization of B-cells into the peripheral blood.  
 
2.10.6 ZAP-70 
In a study comparing the gene expression of U-CLL with M-CLL, it was found that only a 
small number of differentially expressed genes separate the two groups,343 the most 
specific being a gene encoding a 70 kDa zeta-associated protein (ZAP-70)344. Most 
mutated cases are ZAP-70 negative and unmutated cases ZAP70 positive. B cells 
generally lack ZAP-70, using the homologous kinase SYK for BCR signal transduction. 
SYK and ZAP70 have partially overlapping roles in early lymphocyte development345. 
ZAP-70 expression appears to be higher in sites of tissue proliferation of CLL54. ZAP-70 
expression is associated with increased capacity for BCR signalling in CLL, as measured 
by global and SYK phosphotyrosine levels after IgM crosslinking 346. Given that CLL 
expresses SYK as well as ZAP-70, and that SYK has an approximately 100-fold greater 
intrinsic PTK activity than ZAP-70347, it is unclear what role ZAP-70 plays in BCR 
stimulation. It may be that it simply associates with other factors such as mutation 
status that enhance BCR signalling, though some have suggested that BCR signalling 
capacity is more associated with ZAP-70 than mutation status334. ZAP-70 negative cells 
transduced with an adenoviral vector encoding ZAP-70 increased BCR signalling 
capacity334. However, it has been subsequently shown that the enhancement of BCR 
signalling was independent of ZAP-70’s kinase activity348, suggesting that ZAP-70 may 
act as a scaffolding protein that perhaps enhances BCR translocation into lipid rafts, or 
reduces BCR internalization. 
 
2.10.7 Bruton’s tyrosine kinase (BTK) 
The initial step in activation of BTK is recruitment to the plasma membrane through 
interaction between its pleckstrin homology (PH) domain and PIP3, a product of PI3K 
activity349. BTK, together with SYK, phosphorylates and activates PLC 2 after 
stimulation. BTK is generally overexpressed in CLL, though not always constitutively 
active, and novel BTK inhibitors are amongst the most promising new therapeutic 
agents in CLL350,351. Ibrutinib (formerly PCI-32765) has shown remarkable efficacy in 
relapsed/refractory patients with CLL, with few adverse effects, and trials combining it 
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with other agents are ongoing. Again, the class effect of lymphocytosis was noted, 
coupled with shrinkage of lymph nodes. 
 
2.10.8 Phosphoinositide 3-kinase (PI3K) 
Phosphatidylinositol-3-kinase (PI3K) stimulation and resultant production of 
phosphatidylinositol-3,4,5-triphosphate (PIP3) occurs in parallel to SYK activation. This 
occur by multiple mechanisms, including direct interaction with LYN352, or the adaptors 
BCAP and CD19353. CD19 also mediates further activation of LYN, and recruits other 
positive signal mediators such as BTK and VAV354. Various effectors, including VAV, 
BTK, PLC , AKT and SOS, are recruited by their pleckstrin homology (PH) domains to 
the membrane by binding PIP3. These effectors are therefore brought into close 
proximity to the BCR, upstream activators such as SYK and downstream targets such as 
PIP2. Generally, all the principal signalling pathways downstream from the BCR are 
dependent on PI3K and the accumulation of PIP3. 
CLL cells receive survival signals via CD40 and BCR ligation, which are abolished by use 
of a PI3K inhibitor62. Constitutive PI3K activation has been noted in CLL 355,356 . 
The Inositol phosphatase PTEN negatively regulates PI3K activity by degrading PIP3 and 
terminating signalling. PTEN is reduced in approximately half of CLL cases357. Activation 
of the PI3K pathways in CLL ultimately leads to upregulation of Mcl-1, whilst inhibition 
of PI3K leads to cell death via loss of Mcl-162,320,356. The PI3K  isoform-selective 
inhibitor GS1101 (formerly CAL101) has showing promising in vitro and clinical effects 
in CLL358,359.  Clinical experience with GS1101 is perhaps the most mature in terms of 
trials, and results in combination with other agents are beginning to be reported360.  
AKT is one of the most important downstream effectors of PI3K, and mice with 
constitutively active AKT develop lymphomas361. Some studies in CLL have detected 
the presence of phosphorylated AKT in unstimulated CLL cells320,362,363, while others 
have not, despite PI-3K activity62,115,355,356. One study used sonication coupled with lysis 
to reveal constitutive Akt activity in all CLL cases studied, coupled with sensitivity to 
Akt inhibitors, indicating that the method used for Akt activity estimation is crucial362. 
2.10.9 Protein kinase C (PKC) 
The PKC family of enzymes are activated by the presence of Ca2+, diacylglycerol (DAG) 
or other factors and they function in an array of cellular processes that can be specific 
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for a particular cell type. In B cells, PKC , PKC , PKC  and PKC  play important roles in 
regulating signals generated by the BCR364. PKC  is a classical PKC that can be activated 
by Ca2+, DAG and phospholipids and is important for NF- B activation upon BCR 
engagement365. PKC II comprises 0.53% of total cellular protein in CLL, far in excess of 
the other PKC isoforms364. PKC-  inhibition with enzastaurin results in CLL cell 
apoptosis366. In the Tcl-1 transgenic mouse (which develops a CLL-like leukaemia), 
knockout of PKC-  abrogates the leukaemia phenotype367. There is pronounced 
variability in expression between CLL cases, with no correlation with IGHV gene 
mutation status or CD38 expression, but higher levels in patients with 11q and 17p 
deletion. There is also a correlation with stage, with higher levels in advanced Binet 
stage. CLL cells with higher PKC II activity have lower levels of BCR-induced Ca2+ 
flux364. Pre-treatment with the PKC inhibitor LY379196 restores Ca2+ flux, and 
bryostatin (activator of PKC II) leads to falls in levels of Ca2+ flux in cells with low 
PKC II activity. It has been suggested that this variation in enzyme activity may explain 
the heterogeneity of BCR signalling (as measured by Ca2+ flux) in CLL. Abrams et al 
suggest that PKC II may act as a feedback loop that keeps cell activation below a 
proapoptotic level364.  
 
2.10.10 Mitogen activated protein kinase pathways (MAPK): RAS/RAF/ERK 
The MAPK cascades constitute a group of signal transduction pathways involving 
successive phosphorylation of coupled serine/threonine or dual specificity kinases. 
There are four main groups of MAPK pathways: The p38 MAPK pathway, the 
extracellular signal-regulated kinase (ERK) family, the c-Jun NH2-terminal kinase (JNK) 
family and the ERK5 kinase family. The ERK and JNK pathways are relevant to BCR 
signalling368. Suboptimal antigen stimulation, as occurs with soluble autoantigens, can 
induce tolerogenic signalling that is characterized by the sole activation of ERK and 
NFAT369. In CLL, there appears to be variable ERK phosphorylation, with some authors 
reporting constitutive phosphorylation317,319,370. Farnesyltransferase inhibitors block 
RAS activity and ERK phosphorylation, resulting in CLL cell apoptosis371. The effects are 
mostly seen in combination with standard chemotherapeutic agents and are thought 
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to partly result from downregulation of downstream ERK targets such as Bcl-2, Bcl-xL 
and inhibitor of apoptosis proteins (IAPs).      
 
Simultaneous activation of AKT, ERK and JNK is required for CLL cell proliferation 
induced by CpG ODN372.  In both anergic B cells and CLL, antigen stimulation induces 
low calcium oscillations and activates NFAT and ERK, but does not activate NF- B or 
JNK369. Whilst BCR ligation induces AKT and ERK activation in most CLL cases, JNK is not 
activated in the majority, and incomplete degradation of the NF-kB inhibitor IkB is 
observed 320. Thus CLL signalling exhibits poor activation of the immunogenic JNK and 
NF-kB pathways, and some authors suggest that that constitutive activation of MAP 
kinase signalling pathway in the absence of AKT activation along with NFAT activation 
is similar to that seen in anergic B cells115. 
 
2.10.11 Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) 
The signalling pathway controlling BCR-induced regulation of the NF- B transcription 
factor plays a critical role in B cell activation and in lymphomas. Genetic defects in the 
NF- B pathway lead to various immune deficiencies, whereas aberrant activation leads 
to autoimmunity and cancer373. CLL cells have high basal levels of nuclear NF- B (p65, 
cRel and p50 subunits) compared with normal B cells374. This is variable between 
different patients, and correlates with in vitro cell survival and resistance to 
Fludarabine71. CLL cells with higher NF- B levels are more sensitive to NF- B 
inhibition375. The PI3K/AKT pathway is important in CLL cell survival, and is an 
upstream activator of NF- B363. Glycogen synthase kinase-3  (GSK3 ) regulates NF- B-
mediated BCL2 and XIAP expression in CLL, and inhibitors of this kinase prevent NF- B 
binding to target gene promoters376. Other pathways in CLL that stimulate NF- B 
signalling include TNF-related apoptosis-inducing ligand (TRAIL)377 and BAFF63. 
Contact with stromal cells and soluble factors in the bone marrow appear to be 
important in CLL cell survival, and microenvironmental stimuli are one way in which 
NF- B pathways may become activated56. Contact with BM stromal cells has a greater 
effect on CLL NF- B activation than stromal cell-conditioned medium alone378, though 
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soluble factors produced by stromal cells such as CXCL12 and BAFF do have an impact 
on this pathway379,380. 
 
Activating mutations of the NF- B pathway are known in other leukaemias, myeloma 
and lymphoma, though not in CLL. Although proteasome inhibitors were initially 
thought to selectively target the NF- B pathway, their effects are multiple, which may 
explain their disappointing results in treating patients with CLL. The cyclin dependent 
kinase inhibitor flavopiridol has some efficacy in CLL, and there are suggestions that it 
has an effect via NF- B pathway inhibition381.  
 
2.10.12 Phosphatases: SHIP, SHP-1, CD45 
Multiple feedback mechanisms modulate BCR signalling. Phosphatases are intimately 
involved in regulating BCR signalling, yet the picture is complex as each phosphatase 
has multiple targets, and individual phosphorylation sites may be dephosphorylated by 
multiple phosphatases382. PIP3 accumulation is inhibited by the SH2-domain containing 
phosphatidylinositol 5-phosphatase (SHIP-1) and by phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN). The SHP-1 phosphatase also plays a 
role in feedback inhibition by dephosphorylating Ig , Ig , SYK, VAV, and BLNK via 
recruitment to the Immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on CD22 
and CD72383. CLL is characterized by its low expression of CD22 compared to normal B 
cells384. Autoantibody production is greater in SHIP-1 and SHP-1 knockout mice 
compared to PTEN knockouts, therefore it is suggested that the former play a more 
important role in maintaining anergy234. Anergic cells contain reduced levels of PIP3, 
which may be a result of high SHIP-1 and PTEN activity. SHIP-1 is phosphorylated upon 
BCR stimulation and recruited to LYN via the DOK adaptor234. 
 
One study showed expression of SHP-1 and SHIP-1 in all 49 CLL cases studied by 
western blotting. SHIP-1 expression and constitutive phosphorylation were generally 
higher in ZAP70- cases, and BCR crosslinking caused increased SHIP-1 phosphorylation 
in ZAP70- cases only385. SHP1 hypermethylation has been detected in CLL. The protein 
tyrosine phosphatase receptor type O (PTPROt) is suppressed by methylation in 
various solid cancers, and a truncated version of PTPROt may be involved in 
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lymphomagenesis. PTPROt is methylated and suppressed in a majority of CLL, and re-
expression induces apoptosis. The repression of this phosphatase in CLL may suggest 
enhancement of BCR signalling, as SYK is one of its substrates.386 LYN and ZAP-70 are 
also substrates of PTPROt, and it may also play a role in BCR signalling and SYK activity 
in DLBCL387. Recent work has suggested that the PTPN22 phosphatase is highly 
expressed in CLL, and that pro-survival pathways may be preferentially activated after 
BCR ligation is CLL as a result of PTPN22 activity linking the BCR to Akt388. Interestingly, 
genetic variants of PTPN22 have been associated with increased risks of 
autoimmunity389. 
 
2.10.13 CD38 and other co-receptors 
CD38 is both a cell surface enzyme (ectoenzyme) and a surface receptor that has been 
much studied in CLL390-393. CD38 expression may influence BCR signalling in CLL. In one 
study of 20 patients with CLL307, two groups were distinguished by CD38 expression. 
IgM levels were the same between the two groups. Low CD38 expressors did not 
exhibit calcium flux. Crosslinking CD38 did not produce a Ca flux, nor alter BCR-induced 
Ca flux. Apoptosis occurred in high CD38 expressors stimulated by BCR, but not the low 
CD38 group. Others have found similar relationships between CD38 positivity and BCR 
signalling capacity, though it is difficult to tease out whether enhanced BCR signalling 
is due to the expression of Ig, CD38, ZAP70 or mutation status305,319.  
 
Another co-receptor that may be relevant in CLL is CD40. In the initiation of an 
adaptive immune response, multiple signals are necessary. The primary signal is 
engagement of the antigen-specific receptor (BCR in B cells), but generally speaking 
secondary stimulatory signals are required in order for the B cells to become activated 
in response to antigen. The exemplar costimulatory pathway is the interaction of CD40 
on B cells with CD40 ligand (CD40L, CD154) on T-cells394.  CD40L may be expressed by 
the T-cells in the microenvironment or by the CLL cells themselves395,396.  Increased 
expression of CD40L may also be a consequence of enhanced NF- B activity, as CD40L 
is a target gene of NF- B397.  The NF- B activity resultant on CD40L stimulation is able 
to block the pro-apoptotic effect of fludarabine398. Both intracellular and surface 
expression of CD79a, CD79b and IgM is increased by CD40 stimulation in CLL399. BCR 
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ligation leads to pERK and pAKT in half of patients, whereas CD40L/IL-4 treatment 
produces phosphorylation in all cases. 400. Apoptosis inhibition by CD40 ligation has 
been seen395,401-403, but the effects of CD40L are not simple, with some studies finding 
that CD40L stimulation sensitizes cells to rituximab404 or  SYK inhibition-induced 
apoptosis 336. 
 
Other microenvironmental influences have effects on BCR signalling, and are in turn 
affected by BCR ligation. BCR engagement modulates B cell responsiveness to several 
chemokines, including CXCL12338,405, suggesting that BCR signalling has an effect on B 
cell migration, as one might expect for a cell that seeks antigen. SYK activation is 
important for cell adhesion and chemotaxis of healthy and CLL B cells338-340,406, as well 
as in BCR signalling. Toll-like Receptors (TLRs) are important for detection of 
inflammation and link the adaptive and innate immune systems. BCR stimulation can 
upregulate TLR expression, and signals from the BCR and TLRs generally synergise via 
common NF-kB pathways to promote B cell survival407-409. 
 
2.10.13 Summary: BCR signalling 
Normal BCR signalling is complex, and not all pathways have been fully elucidated. 
Many of the most important pathways exhibit abnormalities in CLL, and yet there is 
marked heterogeneity of findings within and between studies of BCR signalling in CLL, 
suggesting that factors as yet unconsidered are crucial. Perhaps some of the more 
persuasive arguments for the centrality of the BCR to CLL pathogenesis derive from the 
data on therapeutic targeting of these pathways. Small molecule inhibitors of pathway 
components such as SYK, PI3K and BTK are showing promising activity in patients with 
CLL and other lymphomas. An understanding of normal BCR signalling pathway 
mechanisms has enabled researchers to study corresponding abnormalities that 
influence CLL and other diseases of B-cells such as autoimmunity. A crucial ‘measure’ 
of BCR signalling is the output of such signalling: the effect on the B-cell itself after BCR 
ligation. The teleological ‘drive’ for BCR signalling is that of elimination of pathogenic 
microbes via the humoral arm of the adaptive immune system. Recognition of 
microbial antigens via the BCR ideally leads to activation and proliferation of specific B-
cells that subsequently act as antigen presenting cells or produce specific antibody. 
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Conversely, in order to avoid  the ‘horror autotoxicus’410 of autoimmunity, B-cells 
encountering autoantigen via their BCR should undergo anergy or clonal deletion via 
apoptosis. Therefore, apoptosis or proliferation may be seen as polar alternative 
outcomes of BCR signalling. These differing cellular fates consequent on BCR ligation 
have been studied in CLL, and are discussed in detail in Chapter 6. However, the main 
determinant of such outcomes remains the pattern of activated intracellular pathways 
after BCR ligation. Whilst exploring these pathways has led to insights into CLL 
pathogenesis and is leading to new treatments, understanding is sill fragmentary. In 
particular, the role of IgD as compared to IgM is ill defined, and the mechanistic 
differences (if any) between IgD and IgM signalling are as yet obscure. In order to gain 
a more complete picture of the mechanisms of BCR signalling, it may be helpful to 
consider how new models of intracellular signalling in general are proving useful. 
2.11 Principles of analysing signalling pathways 
2.11.1 Challenges to existing models of signalling pathways 
New technologies such as high-throughput genomic sequencing are revealing hitherto 
unexpected genomic complexity in cancers. Despite their seeming phenotypic 
homogeneity, tumours of one tissue type have highly heterogeneous sets of defects in 
dozens of different genes in different patients411, and intra-tumour heterogeneity 
within each patient is rapidly becoming the rule rather than the exception412. 
Leukaemias are often cited as examples of relatively ‘simple’ cancers that exhibit a 
limited repertoire of driver mutations compared to their solid counterparts, but the 
number of oncogenic mutations is still estimated to be at least ten in even the simpler 
leukaemias413, though chronic myeloid leukaemia (CML) and its dependence on BCR-
ABL may be an informative exception.  Similarly, RNA interference studies show that a 
large number and wide spectrum of gene products contribute to tumour phenotype411. 
Thus, it seems that a simple relationship between genomic aberrations and tumour 
phenotype remains elusive413.  
 
In line with this, studies of CLL have not uncovered a single genetic defect present in 
more than 15% of unselected cases, suggesting that this leukaemia also has a complex 
genetic landscape40,44,47. One group has specifically targeted the BCR signalling 
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pathway in a search for novel mutations. They sequenced 301 known BCR-signalling 
and NF-kB related genes in 10 patients using modern high-throughput techniques, and 
found only 4 non-synonymous mutations in 3 patients (in KRAS, SMARCA2, NFKBIE and 
PRKD3)414. One study sequenced 70 of the known 95 tyrosine kinase genes in 95 CLL 
patients, no somatic mutations were observed415. Similarly, another group sequenced 
515 kinases from 23 CLL patients and found only 6 non-synonymous mutations (WEE1, 
NEK1, BRAF, KDR, MAP4K3 and TRPM6)416. Because of its potential for therapeutic 
targeting, the BRAF gene was sequenced in an additional 120 cases, with only 4 BRAF 
mutations in this validation set.  
 
Moreover, even when a specific gene is identified as important to tumour pathology, 
manipulation of that gene product does not often lead to an avenue for effective 
treatment because of the complex consequences propagated through downstream 
transcriptional, translational and posttranslational circuits411. Despite the complexity 
of genomic aberrations in cancer, some general organizing principles have been 
suggested. One emerging principle is that the same limited cohort of key pathways 
governing cell phenotypes may be altered by disparate genetic defects417. In CLL, this 
may be illustrated by the finding of mutations of MYD88, DD3X and MAPK, each at low 
frequency, but all in the same inflammatory pathway44. A pathway-centric approach is 
a promising therapeutic strategy since a pathway (or multiple pathways) can be 
targeted via any of its components rather than targeting each mutated oncogene 
product which might require a unique approach tailored to each patients’ repertoire of 
mutations48. An example of this is the use of the mammalian target of rapamycin 
(mTOR) inhibitors such as temsirolimus that are effective in patients with renal cell 
carcinomas. The predominant genetic defect in these tumours is loss of the Von-Hippel 
Lindau tumour suppressor, rather than any mutations related to the mTOR gene itself 
418. 
 
However, even this pathway-centric approach is incomplete, because of the increasing 
realisation of the importance of cross-talk among regulatory pathways419. Any given 
molecular component of a pathway can be identified to be associated with or interact 
with multiple signalling, transcriptional regulation, metabolic or cytoskeletal pathway 
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components411. Thus, pathways can never be considered in isolation of one another, as 
alteration of one leads directly or indirectly to changes in others. It follows that cancer 
and other diseases are most productively conceived of as a dysregulation of a 
multipathway intracellular network411,420. Moreover, these cell-intrinsic networks 
connect to components beyond the malignant cells themselves, to networks that 
represent the tumour microenvironment.  
 
It has been claimed that cells are best conceived of as complex systems rather than as 
a collection of linear pathways421. The study of systems consisting of tens of thousands 
of interacting components is very complicated, and simplifying abstractions are 
necessary. Networks are one way in which disciplines as diverse as sociology, 
epidemiology, molecular biology and physics are attempting to model complex 
systems421. The main goal is to build networks from large datasets and link biological 
function to the topology of these networks. Many authors have suggested that a 
corresponding shift in methodology is required: from understanding dysregulated 
linear pathways based on reductionist techniques to considering these interlinked 
networks using data derived from high-throughput methods. Paradoxically, it is hoped 
that by taking a systems biology approach to analysing large datasets, truly descriptive 
models of tumour signalling pathways will help unify the often disparate genomic 
lesions underlying cancer. The true power of these new models will be tested by their 
ability to predict therapeutic targets and model drug resistance. 
2.11.2 High-throughput methodologies for modelling signalling networks 
An obvious technique that generates large amounts of data that might benefit from 
consideration as part of a network model is gene expression microarray analysis. One 
group combined >200 transcriptional profiles from follicular lymphoma, Burkitt 
lymphoma, mantle cell lymphoma and normal B cells422. Interactions were defined by 
co-expression variation correlates. An interesting finding was that 80% of the 65,000 
network interactions identified appeared to be common across tumours and normal B 
cells, implying a network ‘backbone’ that operates consistently across various cellular 
backgrounds.  Nonetheless, hundreds of interactions appeared to be tumour-specific, 
cutting across diverse pathways, and dysregulated pathways often occurred 
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independent of mutations in components of those pathways. The basal gene 
expression profile of CLL cells is similar to antigen-stimulated B-cells.219,343 By studying 
gene expression at time points after BCR ligation, our group identified a gene 
expression pattern over time common to CLL and healthy B-cells423 and this result was 
subsequently confirmed by others336. Gene expression analysis has driven many of the 
analytical and computational tools in systems biology424. 
 
Although the causes of cancer lie ultimately in genetic and epigenetic changes, the 
manifestations are at the protein level, causing the cancer phenotype425. Therefore, to 
understand cell function, we need to understand cellular proteomes: the set of 
expressed proteins in a given cell or tissue at any one time. Moreover, for functional 
understanding, we need to consider more than just the expression level of proteins, 
but also post-translational modifications (PTMs) that regulate protein function. The 
growing interest in functional proteomics is not only influenced by new developments 
in complex network analysis, but also by advances in high-throughput proteomic 
techniques425-427. Mass spectrometry techniques now enable the routine analysis of 
several thousand proteins and PTMs per experiment. PTMs are extensively studied 
dynamic processes in cell signalling, playing fundamental roles in regulating signalling 
pathways and encoding information. The most important PTM in terms of protein 
function and signalling is reversible phosphorylation of tyrosine, serine and threonine 
residues. About 30% of human proteins contain covalently bound phosphate at any 
one time 428, and it could be suggested that phosphorylation is the most common 
‘word’ in the intracellular signalling ‘language’. 
 
Post-translational modifications modify proteins and alter enzymatic activity, binding 
affinity and conformation428. Protein phosphorylation on serine (85% of protein 
phosphorylation), threonine (10-15%) and tyrosine (1-2%) residues is reversible and 
can produce rapid changes in protein tertiary structure that in turn affect protein 
function and cellular signalling pathways429. Despite its low relative abundance, 
regulated tyrosine phosphorylation is critically involved in most membrane-proximal 
signal transduction processes, and so is best characterised. This is also reflected by the 
number of diseases that are associated with mutations in tyrosine kinases. 
 80 
Phosphorylation can regulate a variety of important functions, including subcellular 
localization, degradation and stabilization. PTMs control the binding of transcriptional 
regulatory elements to their regulatory sequence elements and alter the actions of 
RNA processing enzymes as well as the classically conceived regulation of biochemical 
activities of enzymes such as kinases430.  
 
Phosphorylation is a reversible post-translational modification mediated by protein 
kinases and reversed by phosphatases. The kinases are highly conserved in eukaryotes, 
and are sub classified into three major subfamilies, based on the residue that they 
modify (Serine/threonine, Tyrosine and dual specificity kinases). Tyrosine kinases 
appear to have evolved later than the Ser/Thr kinases430. In humans, the genome 
contains 518 protein kinases and 140 phosphatases431,432. There are a number of 
diseases that result from mutations in particular protein kinases and phosphatases430. 
With most proteins having multiple phosphosites and most kinases and phosphatases 
numerous substrates, phosphorylation cannot be understood as pair-wise interactions 
in linear pathways. Phosphorylation networks are defined by their kinases, 
phosphatases and substrates. Furthermore, analysis of isolated kinase-substrate 
relationships in a simplified in vitro assay fails to capture the regulatory molecules, 
subcellular localisation and other influences that operate in vivo433. 
 
Drugs that inhibit protein kinases or phosphatases are being developed to target 
cancer and other diseases. The overexpression of growth factor receptor tyrosine 
kinases or their mutation to constitutively active forms is important in the 
pathogenesis of several cancers. An example of a particularly successful targeting of a 
constitutively active kinase is imatinib, which is a potent inhibitor of the Abelson 
tyrosine kinase (abl) that is abnormal in CML. The use of imatinib has revolutionised 
the treatment of this disease434.  
 
One of the best-characterized phosphoproteomes is that downstream of the 
Epidermal Growth Factor Receptor (EGFR)435,436. Growth factors such as epidermal 
growth factor (EGF) activate the classical mitogen-activated protein kinase (MAPK) 
cascade to cause cell proliferation. The uncontrolled activation of this pathway can 
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cause cancer437. Time-course studies have detailed the multiple phosphorylations that 
occur after EGF ligation. Increasing levels of particular EGFR mutants shifts signalling 
away from ERK and STAT3 towards the PI3K pathway, and induces phosphorylation 
and transactivation of the hepatocyte growth factor MET. Based on this finding, 
combination of EGFR and MET inhibitors synergised to kill tumour cells in vitro, a 
rational combination based on analyses of phosphoproteomic signalling networks435.  
 
The particular combination of kinase and phosphatase activation determines the 
topology of intracellular signalling networks. The understanding of these networks in 
cancer cells will be necessary to understand how therapies that target tumour cells 
affect signalling, and how resistance to therapy arises by bypassing particular network 
elements. Inhibitors of kinases are promising in their efficacy and lack of toxicity, often 
due to their selective targeting of kinases. Phosphoproteomics will be instrumental in 
determining the modes of action of these kinases, as well as the off-target effects and 
mechanisms of resistance of these kinases. This understanding should lead to better 
treatments for patients.  
 
Phosphoproteomic studies of CLL and BCR signalling in cell lines have already identified 
a number of signalling pathways, but techniques have evolved whereby each 
experiment can generate greater number of phosphopeptides for consideration than 
early studies. The newer techniques have not been applied to the study of BCR 
signalling in any primary B-cells, malignant or otherwise. 
2.12 Summary 
CLL is currently incurable using conventional therapy, and there is a need for more 
effective and less toxic treatments. Small molecule inhibitors of BCR signalling 
pathways are beginning to show remarkable efficacy. These new therapies are based 
on the premise that the BCR is central to CLL pathophysiology. Much evidence points 
towards antigen, in particular autoantigen, as a pro-survival ligand in the CLL 
microenvironment. Various studies have highlighted abnormalities of BCR signalling 
pathways in CLL, with some likening CLL cells to anergic B-cells. Conventional 
conceptions of signalling as linear molecular pathways may be inadequate to 
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encompass all these abnormalities. The BCR in CLL is manifest as two isotypes, IgM and 
IgD, and IgD signalling is relatively unexplored in this field. 
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3. Aims and Objectives 
Using primary CLL/SLL patient samples from the Barts Cancer Institute Tissue Bank, I 
aimed to explore the role of IgM and IgD in this disease, and hopefully establish new 
avenues for targeted therapeutic manoeuvres. The approach taken was as follows: 
 
1. Establish and confirm the pattern of expression of the IgM and IgD BCR isotypes in 
peripheral blood, bone marrow and lymph node CLL cells.  
This is outlined in Chapter 5. 
 
2. Establish and clarify the outcome of BCR signalling via IgD and IgM in CLL, as 
determined by immediate events such as calcium flux and later outcomes such as cell 
proliferation and apoptosis.  
This is outlined in Chapter 6. 
 
3. Establish the mechanisms of BCR signalling via IgD and IgM in CLL and healthy B-cells 
by using the novel techniques of phosphoproteomics.  
This is outlined in Chapter 7. 
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4 Materials and Methods 
4.1 Patient Material 
The patients for whom tissue and clinical data were available for 
immunohistochemistry and peripheral blood samples were identified from the St 
Bartholomew’s Hospital (Barts Health NHS Trust) database. Established in 1967, it 
holds clinical details of all patients who have received treatment at Barts. This 
database is linked to a second database of stored tissue samples of patients who have 
consented for storage of material intended for research. Details of data stored, and 
the methods used by clinical laboratories are in Section 5.2. Tissue samples were 
stored in accordance with guidelines from the Human Tissue Authority. Ethical 
approval for the use of anonymised patient samples and data to perform this research 
was provided by the East London and City Health authority (Ethics approval number 
05/Q0605/140) 
4.2 Immunohistochemistry of Small Lymphocytic Lymphoma (SLL) lymph node 
sections 
4.2.1 Introduction 
Paraffin embedded blocks of lymph node and spleen fragments were cut into sections 
4 M thick. Antigen specific staining was carried out using commercial antibodies and 
optimised for the tonsil and SLL lymph node sections. Immunohistochemistry relies on 
the specific binding of antibody to the target antigen for detection. The signal is 
amplified by subsequent binding of a multimeric compound capable of binding 
horseradish peroxidase. The presence of the antibody-enzyme complex is determined 
by addition of a substance (Diamino Benzoic Acid, DAB) that is chemically altered by 
the enzyme, producing a dark brown/black colour when acted upon by peroxidase 
enzyme. 
 
Staining was optimised for temperature, duration of reagent exposure and antibody 
concentration on tonsil sections, and subsequently larger numbers of slides were   
stained using an automatic staining system consisting of a slide rack, robot arm   with 
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nozzles to dispense reagents, pump system and reservoirs of bulk reagents   and a 
dispensing rack for the various primary antibodies and secondary   
amplification/colourimetric reagents, controlled by an incorporated software   package 
(Dako   Autostainer   Plus). As a counterstain, nucleus-specific blue/purple   dye 
haematoxylin was used.   
4.2.2 De-waxing & dehydration 
1. Place slides in oven overnight at 60oC in plastic racks   
2. Remove paraffin using xylene: 5 minutes suspension, shake off excess, 5 minutes 
in second xylene pot 
3. Transfer to industrial methylated Spirits (IMS) for 2 minutes 
4. Block endogenous peroxidase activity by placing slides into 2% hydrogen 
peroxide/IMS for 2 minutes x2 
5. Transfer to IMS for 2 minutes 
6. Rinse in running tap water 
4.2.3 Antigen Retrieval 
7. Heat 3L of antigen unmasking solution in a pressure cooker to 100oC. Once 
boiling, immerse dewaxed, dehydrated slides in the boiling solution 
8. Increase heat to 120-130 oC and leave for 10 minutes 
9. Remove from heat and cool slides with running tap water for 5 minutes 
10. Place slides in trough of wash buffer. Slides are now ready for staining 
4.2.4 Immunohistochemistry staining using Dako Autostainer Plus 
11. Mark slides using hydrophobic marker pen around edge of section & cover in 
wash buffer 
12. Program Autostainer software specifying number of slides, reagents and 
incubation times. Top up Autostainer reagents 
13. Start Autostainer. Process takes 2-3 hours 
14. Rinse in tap water for 5 minutes 
15. Counter stain in haematoxylin for 5 minutes, rinse in tap water for 5 minutes 
16. Plunge into acid alcoholx7 and then into tap water for 30 seconds 
17. Dip in Scott’s solution x30, then into tap water for 5 minutes 
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18. Dehydrate slides through 3xIMS 
19. Clarify in xylene 
20. Apply DPX mountant and cover slip. Air Dry and label 
An additional haematoxylin-eosin slide was prepared for morphology. 
4.2.5 Reagents  
Table 4.1: List of reagents and antibodies used in immunohistochemistry 
Reagent Supplier 
Antigen Unmasking Solution Vector Laboratories 
Hydrogen Peroxide VWR 
Wash Buffer Dako 
Xylene Sigma 
Industrial Methylated Spirits VWR 
Haematoxylin Gill 2 Merck 
Scotts Solution VWR 
DAB buffer Biogenix 
Liquid DAB Biogenix 
SS Label Polymer HRP Biogenix 
DPX Mountant Sigma 
Antibody Dilution Supplier 
Ki-67 (MIB-1) 1:2000 Dako 
IgD monoclonal (clone DRN1C) 1:1000 Novocastra 
IgM monoclonal (clone 8H6) 1:1000 Novocastra 
4.2.6 Image Analysis 
Slide Images were captured using the 3D HISTECH scanner microscope and Panoramic 
Viewer software (3D HISTECH Ltd). Cells were counted manually using the Panoramic 
Viewer Marker Counter function. Further Details are available in Chapter 5. 
4.3 Peripheral Blood samples 
Patient peripheral blood (PB) samples were collected after informed consent was 
obtained. Samples were collected into sterile clinical grade vacutainers containing 
ethylenediamine tetraacetic acid (EDTA). All samples were processed in laminar flow 
hoods designed for cell culture. Enrichment of mononuclear cells was performed by 
density centrifugation: 
 
Whole blood samples in EDTA were layered onto Ficoll-Paque (Miltenyi) in sterile 15mL 
falcon tubes and centrifuged at 1500rpm for 25 minutes. The peripheral blood 
mononuclear cell layer aspirated and was then washed in RPMI-1640 medium (PAA) 
and resuspended in 90% foetal bovine serum (PAA)/10% dimethyl sulphoxide (Fisher) 
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and stored in liquid nitrogen. Storage was in the St Bartholomew’s Hospital Tissue 
Bank, Centre for Haemato-Oncology, John Vane Science Centre, Charterhouse Square, 
London. 
4.4 Tonsil Samples  
Tonsils from patients requiring tonsillectomy were used after obtaining informed 
consent from patients or parents. Fresh tonsils were disrupted using forceps and 
scalpel in sterile conditions and suspended in RPMI. Suspensions were filtered through 
a 70 M mesh, washed twice in RPMI and enriched for CD19 positive B-cells using 
negative selection by magnetic beads. The AutoMACS pro automated selection 
machine (Miltenyi biotec) was used in conjunction with B-cell isolation kit II (Miltenyi 
biotec). Non-B cells are labelled with CD2, CD14, CD16, CD36, CD43, and CD235a were 
depleted from cell suspension by binding to beads. Following this, cells were washed in 
RPMI, resuspended in 90% foetal bovine serum (PAA)/10% dimethyl sulphoxide 
(Fisher) and stored in liquid nitrogen. Purity of B-cells was confirmed after thawing, 
with CD19 positivity of >90% in all cases. 
4.5 Cell Lines 
The RL lymphoma cell lines, readily available in our laboratory, was used for 
optimisation of techniques, as it produced robust calcium flux on IgD or IgM 
crosslinking. This is derived from an undifferentiated B-Non Hodgkin Lymphoma 
(www.dsmz.de). Culture and stimulation of cells were performed on cell suspensions 
at 0.5-1x106/mL. 
4.6 Cell Culture 
4.6.1 Culture Medium and Conditions 
All cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (PAA) 
supplemented with 10% heat-inactivated Fetal Bovine Serum (PAA), 2 mM L-
glutamine, and 1 mM sodium pyruvate (Invitrogen, Carlsbad, CA) supplemented with 
gentamicin (Gibco) at a final concentration of 50 g/mL. Cell culture was performed at 
37°C in a humidified atmosphere containing 5% CO2.  
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Frozen samples were thawed, washed twice in RPMI-1640 and resuspended in RPMI-
1640 medium (PAA) supplemented with 10% heat-inactivated Fetal Bovine Serum 
(PAA), followed by determination of cell numbers and viability.  Cells were cultured at 
37°C in a humidified atmosphere containing 5% CO2for 2-3 hours prior to experiments. 
Generally, experiments were performed at 0.5-4 x106/mL, further details in relevant 
sections. 
4.6.2 Determination of Cell Viability 
Cell viability was assessed by the trypan blue dye exclusion method using the 
automated V-Cell XR (Beckman Coulter). Only cells with viability >90% were used in 
experiments. 
4.6.3 Stimuli 
BCR crosslinking with soluble F(ab’)2  specific to surface IgD or IgM was used 
(Cambridge Biosciences) at a concentration of F(ab’)2 of 1-20 g/mL for initial 
optimisation. Subsequently, a concentration of 10 g/mL was utilised as stimulus, as 
this typically produced robust calcium flux. Control comprised the pH 8.2 100mM 
borate buffered saline (Sigma).  Buffer was reconstituted in sterile distilled water, 
filtered (0.2 M sterile mesh) and heated at 90oC for one hour. 0.5mg/mL Fetal Bovine 
Serum (PAA) was added and the buffer stored at 4oC. In some cases, soluble F(ab’)2  
specific to surface IgG (Cambridge Biosciences) was also employed as a control.   
4.6.4 PI3K inhibitor treatment of cells 
CAL101 (GS1101) was obtained from Active Biochem and resuspended in dimethyl 
sulphoxide (DMSO).  For cell treatments, CAL101 or equal amounts of DMSO vehicle 
were added to a final concentration of 10 M. 
 
4.7 Flow Cytometry 
4.7.1 Introduction 
Flow cytometry permits the simultaneous detection of different molecules present on 
cells in liquid suspension flowing in a stream within a flow cytometer. Lasers of 
different frequencies illuminate cells; filters and detectors can distinguish different 
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wavelengths of fluorescence.  Monoclonal antibodies coupled to fluorochromes can 
determine the presence or absence of specific antigens on the cell surface or within 
cells after fixation and permeabilisation. The relative fluorescence intensity detected 
on single cells provides an estimation of the number of molecules on the cell. The use 
of DNA binding dyes such as propidium iodide (PI) can distinguish live from dead cells 
(as dead cells expose DNA once plasma membrane integrity is lost), and also 
determine the amount of DNA in single cells.  
 
Flow Cytometry was performed on the FACScalibur flow cytometer equipped with a 
15mW argon ion laser emitting at 488nm and a 635 nm. Isotype controls consisted of 
fluorochromes conjugated to non-specific antibodies to provide an estimate of 
background staining. These were used to define cells as negative for a particular 
marker, when suitable internal control negative populations were unavailable.  Flow 
cytometric data were analysed using CellProquest and FloJo software. 
4.7.2 Antibodies 
Table 4.2 List of antibodies (all from BD Biosciences) 
Antigen Isotype Fluorochrome 
CD19 IgG1k FITC 
CD5 IgG2ak APC 
IgD (clone IA6-2) IgG2ak FITC 
IgM (clone G20-127) IgG1k APC 
IgM (clone G20-127) IgG1k FITC 
CD27 IgG1k APC 
 
4.7.3 Determination of CD19, CD5, CD27, Immunoglobulin M (IgM) and D (IgD) 
expression on primary CLL cells 
Wash cells and resuspend in 50 L 2% PBS/Fetal Bovine Serum (FBS) (PAA) + 0.1% 
sodium azide (Sigma). Add Fc blocker (human gamma globulins, HAG, Sigma) (50 L per 
million cells). Incubate for 20 min at 40C. Add 5 L Ab, incubate for 30 min at 40C. 
1. IgD-FITC+ IgM-APC 
1. CD19-FITC + CD5-APC 
2. IgD-FITC + CD27-APC 
3. CD19-FITC alone 
4. Relevant isotype controls 
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Wash with PBS/FCS/azide. Resuspend in 400 L PBS/FCS/azide. Maintain at 40C. For 
selected CD19 staining, add 1 L of stock Propidium Iodide (10mg/mL, Sigma) solution. 
Fluorescence at wavelengths of 530 and 630nm was detected after excitation at 
488nm on a BD FACScalibur flow cytometer. 
4.7.4 Calcium Flux 
Cells at 1x106/mL were incubated with 1 mM Fluo-3 AM and 0.02%(v/v) Pluoronic F-
127 (Molecular Probes) for 30 minutes at 37oC with 5% CO2.
438 Cells were washed in 
RPMI and resuspended at 0.5x106/mL in RPMI and kept on ice.  For early experiments, 
the medium in which the cells were suspended for analysis was varied. Either RPMI or 
phosphate-buffered saline (PBS) was used. Ethylene glycol tetraacetic acid (EGTA, 
similar to EDTA but with greater selectivity for chelating Ca2+ over Mg2+) added to the 
medium was used to chelate extracellular Ca2+.  
 
Suspended cells were warmed to 37oC for at least 15 minutes prior to stimulation. 
Fluorescence at a wavelength of 530nm was detected after excitation at 488nm on a 
BD FACScalibur flow cytometer. Ionomycin (Sigma-Aldrich) at a concentration of 1 M 
was used to produce calcium flux as a positive control. Borate buffer was used as 
negative control. Stimuli were Goat F(ab’)2 Anti-Human IgD, IgM or IgG (Cambridge 
Biosciences) warmed to 37oC. The tube containing 1mL of suspended cells was 
removed, 100 L stimulus added with 2x pipetting to mix and replaced on the 
platform, all within 5 seconds. The tube was also surrounded by a water bath (beaker) 
at 37oC during acquisition. 
 
Flow cytometric data were analysed using CellProquest and FloJo software. A bivariate 
plot of fluorescence intensity at the desired wavelength (in our case utilising the FL1 
sensor) against time was produced. In optimisation experiments, crosslinking of CD10 
and CD20 was performed with unconjugated rabbit IgG (Dako). In order to provide a 
quantitative measure to enable comparison between experiments, threshold intensity 
was chosen based on unstimulated cells’ fluorescence at the 85th centile, and 
percentage of cells rising above the threshold were calculated (see results for details). 
The percentage of cells undergoing calcium flux 1 minute after stimulation was 
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measured, 15% was subtracted and was divided by the same measurement derived 
from ionomycin to yield a calcium flux as a proportion of maximum. 
 
4.7.5 Apoptosis assays using Annexin V and Propidium Iodide 
Cells were stimulated as indicated in the relevant sections. Positive controls were 
produced by exposure to UV light for 5 minutes 24h prior to assay. Apoptosis was 
determined at baseline, 24 and 48 hours. The Apotarget Annexin V-FITC/Propidium 
Iodide apoptosis assay kit (Invitrogen) was used to stain cells and Fluorescence at 
wavelengths of 530 and 630nm was detected after excitation at 488nm on a BD 
FACScalibur flow cytometer. Flow cytometric data were analysed using CellProquest 
and FloJo software. Plots of Annexin V vs PI staining were divided into quadrants based 
on populations seen. These were used to characterise cells into viable, early apoptotic 
and late apoptotic/necrotic populations.  
 
4.7.6 Cell cycle analysis using Ki67 and Propidium Iodide 
Cells were stimulated as indicated. Cell cycle stage was determined at baseline, 24 and 
48 hours. Cells were fixed and permeabilised in paraformaldehyde and Triton (BD 
biosciences) and stained with Ki67-FITC monoclonal antibody (Invitrogen) and 
Propidium Iodide (PI, Sigma). Fluorescence at wavelength of 530 and 630nm was 
detected after excitation at 488nm on a BD FACScalibur flow cytometer. Flow 
cytometric data were analysed using CellProquest and FloJo software. Doublet 
discrimination was performed based on FL3-W. Plots of Ki67-FITC vs DNA content/PI 
were divided into quadrants based on isotype controls. These were used to divide cells 
into G0/G1/G2/S phases of the cell cycle. 
4.8 Phosphoproteomics by Mass Spectrometry 
4.8.1 Introduction 
In order to generate a global view of serine, threonine and tyrosine phosphorylation 
within a sample, enrichment techniques are used. The label free approach for 
enrichment and quantification of phosphopeptides used in this study has been 
previously published439,440. CLL cells were stimulated as indicated, and rapidly chilled 
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and washed before freezing as cell pellets. A parallel sample was taken for western 
blotting. Calcium flux was performed an hour before proteomic samples were 
stimulated to ensure viability and capacity for signalling. The pellet was then lysed in 
Urea containing phosphatase inhibitors. Lysate containing 0.5mg was then denatured, 
cysteines alkylated, and the sample digested to fragment peptides using trypsin. 
Samples were desalted and then enriched using Titanium dioxide (TiO2) beads. The 
phosphorylated peptides were then dried before analysis by liquid chromatography-
mass spectrometry. Data analysis was carried out using MASCOT (phosphopeptide 
identification) and PESCAL (quantification based on normalised peak height) software. 
Triplicates for each experimental condition were compared. Further analysis details 
are available in Chapter 7. 
4.8.2 Bradford Assay for protein concentration 
Bradford (Biorad) working solution was prepared at 1:5 dilution, and assay performed 
using flat-bottomed 96-well plates (Fisher) in a PolarStar plate reader (BMG Labtech). 
Absorbance at 595nm was measured. Comparison with a standard curve derived from 
solutions of Bovine serum albumin was used as comparison, with Pearson correlation 
coefficient >0.99. 
 
4.8.3 Stimulation 
Cells at 4x106/mL were suspended in medium and stimulated with control borate 
vehicle, anti-IgM and anti-IgD F(ab’)2 at 10 g/mL. Triplicates of 15-20x10
6 cells were 
harvested after 5 minutes and rapidly chilled in Phosphate Buffered Saline with 
phosphatase inhibitors (1 mM Na3VO4, 1 mM NaF). An additional aliquot of 5-10x10
6 
cells for western blotting validation were taken off into a separate pellet.  
4.8.4 Cell lysis 
 Base Lysis Buffer composition is as follows: 
8M Urea in 20mM HEPES (ph8) with 1 mM Na3VO4, 1 mM NaF, 2.5 mM Na4P2O7, 1 mM 
β-glycerol-phosphate 
 The volume of buffer required is as follows: 1ml of Lysis Buffer: 10 x 106 cells. Chill 
protein lo-bind eppendorfs 
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a. Add 1 ml of Lysis Buffer preparation to each cell pellet and vortex the sample to  
thoroughly resuspend and homogenize the sample. Quick spin.  
b. Cell suspension can then be sonicated (Soniprep 150 MSE) at 50% intensity, 3 times 
for 15 seconds. 
Ensure that the tube containing the cell suspension is immersed in ice. This will 
ensure that heat build up from sonication does not adversely affect phospho-
protein content. 
c. Centrifuge cell suspension at 20,000g for 10 minutes at 5oC, and recover 
supernatant to a protein lo-bind tube. 
d. Bradford assay for total protein count can then be performed and sample(s) can be 
progressed to the next stage after normalisation to 500 g of protein. Make up to 
1mL total volume with 20mM HEPES. 
4.8.5 Denaturation 
 Reduction of Disulphide bridges: 
a. Add 10μl of 1M Dithiothreitol (DTT) to sample(s).  
b. Vortex sample well and incubate at room temperature for 15 minutes in the dark. 
 Alkylation of cysteines: 
a. Add 40μl of 415mM Iodoacetamide (IAM) to sample(s). 
b. Vortex sample well and incubate at room temperature for 15 minutes in the dark. 
4.8.6 Digestion 
 Protein digestion is achieved with the use of immobilized Trypsin beads (TLCK-
trypsin 20 TAME units/mg, Sigma). The following indicates the number of beads 
required: 80μl of Trypsin beads for 500 g of protein. Approx 160 L of 50% slurry. 
Spin down and measure volume to make 80 L per sample 
a. Trypsin bead conditioning: Transfer beads to a fresh tube and centrifuge at 2000g 
for 5 minutes at 5oC. 
b. Discard supernatant and re-suspend beads in 20mM HEPES (double the volume i.e. 
if sampled 80μl of beads add 160μl of HEPES buffer). Vortex suspension 
thoroughly. 
c. Centrifuge beads at 2000g for 5 minutes at 5oC. Discard supernatant. 
d. Repeat this process 2 more times. 
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e. Resuspend beads , add the same volume of 20mM HEPES as originally sampled i.e. 
80μl. 
f. Dilute the sample 1 in 4 with 20mM HEPES to a final volume of 4ml in 50mL falcon 
g. Add 80μl of conditioned beads to each sample and incubate at 37oC for 16 hours 
with shaking. 
shake tube to suspend beads prior to overnight incubation. Beads can have a 
tendency to settle if allowed to solution allowed to rest. 
4.8.7 De-salting 
a. Chill centrifuge. Acidify digest to 1% of the final volume with Trifluoroacetic Acid 
(40μl for a 4ml digest). 
b. Centrifuge samples at 2000g for 5 minutes at 5oC and transfer supernatant to a 
fresh tube. Sample can now be processed further. 
 
The resultant peptide solutions were desalted by solid phase extraction (SPE) using 
Oasis HLB extraction cartridges (Waters UK Ltd., Manchester, UK) according to 
manufacturer instructions with some modifications 
Assemble vacuum manifold as follows: 
- Insert waste container into glass chamber and then seal with the vacuum/taps lid. 
- Connect the assembled manifold to a vacuum tap or pump. Ensure that the 
connection is tight. 
- Insert OASIS cartridge (one cartridge/sample) into the tap (s) on the lid and press 
firmly to ensure a tight fit.  
- Close the valve next to the dial and apply the vacuum. Adjust vacuum to 
approximately 5 mmHg.  
De-salt sample (s) as follows:  
1. Wash cartridge with 1ml of 100% ACN (LC-MS grade). Add the ACN and purge 
leaving a little solution behind. 
2. NB: it is very important to maintain the cartridge fully solvated. When purging, 
don’t allow the solution to pass through completely, as this may introduce air 
into the cartridge. This may impact on peptide binding and elution at a later 
stage. 
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3. Wash cartridge with 1ml of 98% @H2O (+ 2% ACN, 0.1% TFA). Purge and then 
top up with a further 0.5 ml and purge. This is to ensure complete removal of 
ACN prior to addition of protein digest sample. 
4. Add 1ml of protein digest sample to the cartridge and purge the sample slowly 
(this is to enhance the binding of peptides to the reversed-phase material in 
the cartridge). Continue to top up the sample as it passes through the cartridge 
until all the sample has passed through. Do this for all samples and the go to 
step 5. 
5. Wash cartridge with 1ml of 98% @H2O (+ 2% ACN, 0.1% TFA). Purge solution. 
6. Elute peptides with 0.5ml of 1M Glycolic Acid (+ 80% ACN, 5% TFA). Purge 
slowly so that as much peptide is recovered as possible. Eluent can now be 
used for further work i.e. TiO2 phosphopeptide enrichment. 
 
4.8.8 Phospho-peptide enrichment with TiO2 beads 
Phosphopeptide enrichment was performed using a TiO2 protocol adapted for label 
free quantitative proteomics. 
TiO2 bead resuspension 
 Re-suspend TiO2 beads (50% slurry, GL Sciences Inc., Japan) by adding 1ml of 1% 
TFA to glass vial containing 500µg of beads. Seal the vial and homogenize 
thoroughly before use.  
Solutions 
Prepare the following solvents before starting the enrichment. Rinse out glass beakers. 
Use glass pipette for elution solution. 
Equilibration Solution: 1M Glycolic Acid in 80% ACN/5% TFA 
Wash solution 1: 50% ACN. 
Wash solution 2: 20mM Ammonium Acetate in 50% ACN (pH 6.8). Prepare fresh just 
before the enrichment. 
Elution solution: (5% NH4OH) 250µl of NH3.H20 stock solution + 750µl of 50% ACN. 
Prepare fresh just before the enrichment. Check pH is 10-11. Use glass vial. 
Enrichment 
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1. Adjust all sample volumes to 1000µl with Equilibration Solution. Ensure enough 
beads. 
2. Add 25µl of re-suspended TiO2 beads to the OASIS eluted fraction(s).  
3. Incubate sample(s) at room temperature for 5 minutes with rotation.  
4. Spin column equilibration  
(PepClean C-18 Spin Columns, Thermo Scientific, Rockford, IL) 
 Remove column(s) caps and place column(s) in standard 2ml eppendorfs.  
 Apply 300µl of Equilibration Solution to the very top of the walls of the column(s). 
This is to ensure that the reverse phase RP-C18 material (powdery material in the 
column) is fully exposed to the solution and that it all gathers above the filter at 
the bottom of the column. 
 Centrifuge column(s) at room temperature for 30 seconds at 2000rpm. 
 Discard flow through.  
 Repeat step 4. 
5. After 5 minutes of incubation, apply 500µl of TiO2 beads /sample solution (ensure 
sample(s) is/are well homogenized) to an equilibrated spin column.  
6. Centrifuge column(s) at room temperature for 30 seconds at 2000rpm. Discard 
flow through. Repeat steps 5 & 6 with the remaining 500µl of sample. 
7. Wash 1: Removal of non-phosphorylated peptides. Apply 300µl of Equilibration 
Solution to spin column(s). Centrifuge column(s) at room temperature for 30 
seconds at 2000rpm. Discard flow through. 
8. Wash 2:  Apply 300µl of Wash Solution 1 to spin column(s). Centrifuge column(s) 
at room temperature for 30 seconds at 2000rpm. Discard flow through. 
9. Wash 3: Removal of strongly acidic non-phosphorylated peptides. Apply 300µl of 
Wash solution 2 to the spin column(s). Centrifuge column(s) at room temperature 
for 30 seconds at 2000rpm. Discard flow through. 
10. IMPORTANT: transfer spin column(s) to fresh 2ml protein lo-bind eppendorfs. 
11. Phospho-peptide elution: Apply 50µl of Elution Solution directly to the RP-
C18/TiO2 layer in the column(s). Allow to absorb for 1 minute. Centrifuge column(s) 
at room temperature for 30 seconds at 2000rpm. Keep flow through. 
12. Repeat step 11 two more times and combining all 3 elutions in the same tube. 
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13. IMPORTANT: Centrifuge sample at 10000rpm for 1 minute and check that there is 
no deposition present at the bottom. If there is, remove supernatant to fresh 
protein lo-bind tube and proceed to step 13. Deposition may indicate that TiO2 
beads have managed to get through the RP-C18 and filter layers. The presence of 
beads during acidification and drying may radically impact on phospho-peptide 
recovery! 
14. Acidification: Acidify sample to 10% Formic Acid final concentration (15µl of neat 
FA to 150 µl eluted peptides). 
15. Place samples in SpeedVac dryer until fully dry.  (36-48h) 
16. Add 13 L of reconstitution buffer/enolase. Leave 1h at 4oC. 
17. Spin 5min 13,0000 at 4oC. Take 12 L clear supernatant and put into labelled 
eppendorfs in MS inserts. Put cap on. Dispose/snap freeze remainder.  
18.  
4.8.9 Nanoflow-Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) 
 (performed with A Montoya and P Cutillas) 
For LC-MS/MS analysis, dried phosphopeptides were dissolved in 12 μl of 0.1% TFA 
containing a known concentration of enolase standard and analyzed in a LTQ-Orbitrap 
XL mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead, UK) connected 
online to a nanoflow ultra-high pressure liquid chromatography (nanoAcquity, 
Waters). This ultra-high pressure liquid chromatography delivered a flow rate of 5 
μl/min (loading) and 400 nL/min (gradient elution) with an operating back pressure of 
about 3000 psi. Separations were performed in a BEH 100 μm × 100 mm column 
(Waters). The mobile phases were solution A: 0.1% formic acid in LC-MS grade water; 
and solution B: 0.1% formic acid in LC-MS grade acetonitrile. Gradient runs were from 
1% B to 35% B in 100 min followed by a 5 min wash at 85% B and a 7 min equilibration 
step at 1% B. Full scan survey spectra (m/z 350–1600) were acquired in the Orbitrap 
with a resolution of 60,000 at m/z 400. A data dependent analysis was employed in 
which the five most abundant multiply charged ions present in the survey spectrum 
were automatically mass-selected, fragmented by collision-induced dissociation 
(normalized collision energy 35%), and analyzed in the LTQ. Thus, Full-MS scans were 
followed by a maximum of five MS/MS scans (m/z 50–2000) resulting in a maximum 
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duty cycle of 2.5 s. Because chromatographic peaks were about 30 s at the base, these 
settings ensured that there were at least 10 data points per extracted ion 
chromatogram (XIC). Dynamic exclusion was enabled with the exclusion list restricted 
to 500 entries, exclusion duration of 40 s and mass window of 10 ppm.  
4.8.10 MS Data Analysis 
Searches were automated with Mascot Daemon (v2.2.2; Matrix Science, London, UK). 
The parameters included, choosing trypsin as digestion enzyme with two missed 
cleavage allowed, carbamidomethyl (C) was set as fixed modification, and Pyro-glu (N-
term), Oxidation (M) and Phospho (STY) were variable modifications. Data sets were 
searched with a mass tolerance of ±7 ppm and a fragment mass tolerance of ±800 
mmu. Hits were considered significant when they had an Expectation value <0.05 (as 
returned by Mascot). False discovery rates were ∼2% as determined by decoy 
database searches.  
 
An in-house script was used to extract Mascot results, which were then placed in Excel 
files for further analysis. For peptides with multiple potential phosphorylation sites, 
the delta score between the first and second hits reported by Mascot was used to 
identify the correct position441 
 
Pescal442 was used to automate the generation of extracted ion chromatograms (XIC) 
and to calculate the peak heights and areas. Because of undersampling and the 
stochastic nature of peak selection for fragmentation in data dependent acquisition 
experiments, MS/MS data was not obtained from all the phosphopeptides in all the 
runs. To overcome this issue, phosphopeptides identified by Mascot with a statistical 
significant threshold were placed in a database of peptides quantifiable by LC-MS. 
PESCAL was used to quantify the intensities of the peptides present in the database 
across all the samples. PESCAL uses the m/z and retention time of the selected 
peptides to construct extracted ion chromatograms (XICs) for the first three isotopes 
of each ion. This applies restrictions on the molecular mass, retention time, charge, 
and isotope distribution, which permits the identification of the LC-MS elution profiles 
corresponding to the studied phosphopeptides with high confidence (false positive 
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discovery rate < 5%). Windows for XIC construction were 3 ppm and 5 min for m/z and 
retention time, respectively. The intensity values could then be calculated by 
determining the peak height and areas of each individual XIC. The resulting 
quantitative data were parsed into Excel files for further normalization and statistical 
analysis. Peptide intensities were normalized to the total chromatogram intensity and 
expressed as a percentage. Phosphopeptide enrichment was >85% for all samples. 
4.9 Western Blotting 
5-10 x106 cells were stimulated with vehicle, anti-IgM and anti-IgD F(ab’)2 at 10 g/mL 
in parallel to samples used for proteomics. These were then rapidly chilled in PBS with 
1 mM Na3VO4, 1 mM NaF and washed twice in chilled PBS with 1 mM Na3VO4, 1 mM 
NaF. Cell pellets were snap frozen on dry ice and maintained at -80oC until cell lysis. 
 
The RL cell line was used to provide control protein. Cells at a concentration of 
1x106/mL were stimulated with 1mM pervanadate to produce non-specific 
phosphorylation. Unstimulated RL cell samples were also used. 
For 100mM pervanadate: 
800 L Na3VO4 (100mM) 
8.8 L 30% H2O2 
15 min standing, protect from light. NB:turns yellow 
dilute to final conc of 1mM.  
 
For lysis, 200 L of Cell- Lytic cell lysis solution (Invitrogen) plus 1 mM Na3VO4, 1 mM 
NaF, 2.5 mM Na4P2O7, 1 mM β-glycerol-phosphate was mixed with pellets for 15 min 
on ice, then spun at 14,000 rpm at 40C for 10 minutes. Clear supernatant was taken off 
and protein concentration determined using the Bradford Assay (Biorad). 
 
20-30 g of protein was used for per well. Proteins were separated using sodium 
dodecyl sulphate -containing polyacrylamide gel electrophoresis (SDS-PAGE), 4-12% 
Bis-Tris Nupage gels (Invitrogen) at 140V. To visualize the molecular weight of the 
proteins a standard containing 9 pre-stained protein bands in the range of 20 to 
220kDa was placed in the 1st & last well of each gel (Novex Magic Mark XP Protein 
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Standard, Invitrogen). After electrophoresis, the separated proteins were transferred 
onto a Polyvinylidene fluoride (PVDF) membrane by Western Blotting,443 using the 
iBlot dry method (Invitrogen). Transfer was at 20V, one for 7 minutes (standard 
transfer), one for 9 minutes (optimised for transfer of high molecular weight proteins). 
  Blocking with 5% BSA in Tris-buffered saline (TBS) pH 7.6 plus 0.1% Tween-20 (TBST) 
was used to reduce non-specific binding of the primary antibody. Probed proteins and 
phosphoproteins were chosen based on known signalling pathways and previous 
publications as described (See Table 4.3) 
4.9.1 Primary Antibodies 
Table 4.3: Primary antibodies used in western blotting.  
(Phospho)protein Species Modification Supplier Dilution 
Filamin A rabbit S2152 Abcam 1:1000 
40S ribosomal protein S6 rabbit S235/S236 NE Biolabs 1:2000 
Lymphocyte-specific protein 1 rabbit S204 Anaspec 1:500-1:1000 
Myosin regulatory light 
polypeptide 9 
mouse S20 NE Biolabs 1:500-1:1000 
Myosin-9 rabbit S1943 
ECM 
biosciences 
1:500-1:1000 
Wiskott-Adrich syndrome 
protein 
rabbit Y291 Abcam 1:500-1:2000 
Syk rabbit Y352 NE Biolabs 1:500-1:1000 
Akt rabbit S473 NE Biolabs 1:500-1:1000 
Stathmin rabbit S16 Santa Cruz 1:500-1:2000 
Btk rabbit T223 NE Biolabs 1:1000 
Total Protein Species Supplier Dilution 
GAPDH rabbit NE Biolabs 1:2000 
Filamin A rabbit Abcam 1:1000 
40S ribosomal protein S6 rabbit NE Biolabs 1:2000 
Akt mouse NE Biolabs 1:1000 
Btk rabbit NE Biolabs 1:1000 
Syk rabbit NE Biolabs 1:1000 
  
A secondary antibody conjugated to Horseradish peroxidase  (Dako) against the 
relevant species of primary antibody was added at. 1:2,000 dilution. This produces a 
colorimetric marker by enzymatically degrading the ECL plus developing agent (GE 
healthcare), the product of which was photographed using the Fujifilm Luminescent 
Image Analyzer. 
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Images were stored as TIFF files. Densitometry was performed using the ImageJ 
software (rsb.info.nih.gov). Images were analysed by optical density, rectangles 
highlighted the central one third of the band, and area of the peak measured444. 
Further details are in the relevant section.  
4.10 Statistics 
The GraphPad Prism 5 (GraphPad software) and Excel 2008 (Microsoft Corporation) 
were used to analyse data. Details of analyses are indicated in relevant results 
sections.  
 102 
5. Results-Immunoglobulin Expression in CLL  
5.1 General Introduction and Objectives 
In order to determine the role of the B-cell receptor and its IgM and IgD isotypes in 
CLL, we explored expression of the receptor isotypes in different contexts. We sought 
to examine the expression of IgM and IgD in peripheral blood, bone marrow and lymph 
node CLL/SLL cells from patients seen at Barts Cancer Centre. Association with 
prognosis or other biological characteristics was determined in order to ascertain the 
effect, if any, on biology of the disease. Expression was determined in three contexts:  
1. Peripheral Blood IgD and IgM expression in CLL clinical database (section 5.2) 
2. Peripheral Blood IgD and IgM expression in stored tissue samples (section 5.3) 
3. Bone marrow and lymph node IgD and IgM expression (section 5.4) 
5.2 Peripheral Blood IgD and IgM expression: CLL clinical database 
5.2.1 Introduction 
Various studies have examined the expression of IgM and IgD in CLL by flow cytometric 
immunophenotyping, and attempted to associate them with other factors, including 
prognosis. The published studies span a number of decades and a variety of 
techniques, making direct comparison of studies challenging. In addition, the reporting 
of methods and results in each paper varies such that details of techniques for 
immunophenotyping, criteria for positivity and other methodological aspects are often 
not explicit or unavailable from the published papers. Nonetheless, some 
commonalities can be observed. 
 
In general, IgD and IgM co-expression is found to be a common pattern (IgD+M+), with 
IgD+M- or IgD-M+ expression noted at lower frequencies by some authors, though it is 
often unclear as to how these criteria for positivity  were established. Table 5.1 below 
is an attempt to summarise published results from all papers examining IgD and IgM 
expression in CLL, where the data regarding the relative proportions in the IgD and IgM 
characterising subsets are explicit. Figure 5.1 graphically represents the mean values 
derived from all series. 
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Table 5.1: Published series examining IgD and IgM expression in CLL.  
The lowest row ‘Total’ takes the number of cases in all published series to derive a 
mean proportion in each group. Note that some papers do not separate IgD+IgM- 
cases, and in these cases a value of zero is shown. 
n=number of patients in study 
Paper n 
IgD+M+ 
% 
IgD+ M- 
% 
IgD-M+ 
% 
 
IgG+ 
% 
Other notes 
Rudders et 
al (1976)253 
 
26 
15 
 
0 85 19 
1/26 IgA & 
IgG 
All IgD+M+, 
cases 
associated 
with IgG or IgA 
Hamblin & 
Hough 
(1977)445 
 
60 25 
0 
 
47 0 
17/60 light 
chain only 
No changes 
over time (up 
to 12y) 
Baldini et al 
(1985)446 
76 54 0 38 0 1 IgA+ 
IgD-M+cases 
worse 
prognosis 
Kimby et al 
(1985)447 
66 38 0 33 8 
10 light 
chain only 
IgD-M+cases in 
advanced 
disease 
Hamblin et 
al (1987)448 
200 43 0 34 3 1 IgA 
IgD-M+ cases 
longer survival 
Geisler et al 
(1991)449 
540 73 7 12 6 IgG/A 7% no Ig 
IgD-no 
prognostic 
impact. IgM+ 
lower overall 
survival. 30% 
cut-off for 
positives 
Shen et al 
(2001)450 
76 72 21 4 1 IgG/A  
IgD+M- only 
associated 
with 
favourable 
prognostic 
factors 
Marantidou 
et al 
(2010)451 
184 88.6 0 0 11.4  
IgG cases 
mostly IGHV 
mutated 
Total 1228 63.8 4.4 19.3 5.7 5.5  
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Figure 5.1: IgD and IgM expression in published studies 
Summary means of all 1228 cases in 8 published series in each subgroup. 
Approximately half the IgD-M- cases express IgG or IgA, but in many cases light chain 
only is detected (though in some series IgG/IgA was not sought) 
 
 
The 540 patients in the Geisler et al paper dominate these data. In this series, it is 
sometimes difficult to ascertain the precise methods used. Mean time between 
diagnosis and immunophenotyping was 10 months (7-17 months). IgM and IgD 
staining (proportion of cells positive) followed a continuous distribution, and they 
select an arbitrary cut-off of >30% as a threshold for positivity. The effects of 
expression on prognosis as assessed by overall survival was not significant for IgD or 
IgM positivity using the 30% cut-off, but only for IgM mean fluorescent intensity as a 
continuous variable, but details on how this conclusion was derived are unavailable. 
There was no attempt to correlate with other biological factors.  
 
Only two publications have examined the pattern of immunoglobulin expression in the 
recent era where CD38, ZAP70 and IGHV mutation status were known to be important 
prognostic factors in CLL. Shen et al divided cases (n=76) into IgD+IgM+, IgD+IgM- and 
IgD- groups, and suggest an association between IgD+IgM- cases and low white blood 
count and CD38 negativity, and by implication good prognosis450. The primary aim of 
Marantidou et al’s study was to explore the use of AID splice variants in CLL (N=195), 
and there is a brief mention of 184 cases that had immunoglobulin isotype data 
available. Of these, there is no differentiation between IgD and IgM expression (all 
cases are ‘IgMD’), and the IgG positive cases (11%) mostly had mutated IGHV genes.  
M+D+ 
65% 
M-D+ 
4% 
M+D- 
20% 
M-D- 
11% 
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What might be concluded from these various studies is that IgD expression ( 70%) is 
common, as is IgM expression ( 85%), with dual expression forming the largest single 
subgroup. However, methods varied between series, in particular many papers did not 
attempt to distinguish IgD+IgM+ cases from IgD+IgM- or IgD-IgM+ cases, cases often 
designated ‘IgMD’. Critically, the levels of expression for a definition of positivity are 
generally not mentioned, and where they are, it seems that an arbitrary threshold for 
positivity is chosen, as the level of expression is a continuous variable449. There may or 
may not be an association with prognosis, more often publications have associated the 
pattern of expression with other known prognostic markers, rather than to associate 
with prognosis per se. 
 
A few more recent studies have considered the expression of IgD and IgM in 
conjunction with IgG or other class-switched isotypes452,453. These studies do not 
compare IgD and IgM expression as the methods involved generally examine mRNA 
expression to detect  transcripts, and it is known that the regulation of IgD and IgM 
expression is post-transcriptional255. Conventionally, class switching will result in the 
recombinational deletion of DNA encoding the  and  chains that are required for IgM 
and IgD surface expression. Therefore, IgG or IgA expression is in theory incompatible 
with IgD/IgM expression. Many of the studies mentioned above (Table 5.1) did suggest 
co-expression of IgD/IgM and IgG, though the expression was assessed for each 
isotype staining the bulk population, rather than triple positivity on single cells. More 
often authors suggest that the IgG-positive cells reflect a minority sub-clone, with the 
majority being IgM/IgD positive454,455. 
 
One explanation for the expression of IgG in this situation is a technical one. B-cells 
express Fc receptors whose function is to bind to the constant regions of 
immunoglobulin, typically IgG. Therefore, CLL cells are often coated with a layer of 
adsorbed IgG or IgA that mimics expression of those isotypes, whereas it actually 
reflects polyclonal IgG or IgA present in the patient’s plasma. The authors of the first 
study reporting this in 1975 observed that incubating at pH 5 or in standard culture 
media for 20 minutes at 37 oC removed this adsorbed IgG without changing expression 
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of IgM456. This may well explain much of the IgG positivity of CLL in early and 
subsequent studies.  
 
However, others claim that multiple isotype expression is genuinely possible, and has 
been observed in cell lines, malignant B-cells and during the primary immune 
response457. Many studies have reported the expression of mRNA for  and  mRNA as 
well as  mRNA in CLL, consistent with IgG/M/D co-expression453. An explanation for 
this is intraclonal diversity, and one group suggest that different isotype transcripts 
utilise the same VDJ segment mRNA, but that mutations had occurred, highlighting the 
occasional process of ongoing SHM/CSR within CLL, particularly within CLL that 
expresses IgG458. This is supported by several other studies459,460, though some authors 
have claimed that true dual IgM and IgG expression in a single cell can still occur455,461. 
It is difficult to definitively establish whether CLL cells that express IgM/IgD genuinely 
co-expresses IgG or other isotypes, or whether such findings are due to technical 
issues or intraclonal diversity. Clearly, caution is required when interpreting surface 
immunoglobulin isotype data.  
5.2.2 Methods 
Patients seen at the Barts Cancer Centre are invited to consent for storage of their 
clinical details and tissue storage for the purposes of research. Data gathered included 
dates of Diagnosis, follow-up, treatment and death. Clinical characteristics such as cell 
count, lymphadenopathy, immunophenotyping, cytogenetics and results of specialised 
tests are also included. A variety of assays are performed for diagnostic and treatment 
purposes, the details of which follow. 
 
5.2.3 Immunophenotype by flow cytometry 
The clinical immunophenotyping laboratory of Barts Health NHS trust performed 
assays. All patients with suspected CLL have immunophenotyping performed by flow 
cytometry. Samples with suspected CLL are gated on CD19+CD5+ cells.  B-cell clonality 
is determined by light chain restriction (>10:1 bias  or ). An immunophenotypic 
‘CLL score’304 is allocated to confirm diagnosis. The percentage of CD19+CD5+ cells 
expressing surface IgM, IgD and IgG is determined, and positivity defined as >30% of 
cells expressing the immunoglobulin isotype. Internal negative control lymphocytes 
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are used as a threshold for positivity. The following is from the immunophenotyping 
standard operating procedure for immunoglobulin analysis on suspected B-cell 
lymphoproliferative disorders: 
‘This tube is used to identify the IgH chain expression.  The gate is usually set according 
to internal negative control lymphocytes.  Frequently however, some cells in the 
internal negative gate will stain positive and overall, there is more variation between 
specimens than is usually seen for most other antigens investigated.  The CD19+ 
population may also appear a little higher in background fluorescence compared to 
other (negative) lymphocytes.  True IgH expression is usually seen as a clear shift above 
background negative fluorescence.  As a general rule, a cut-off of 25-30% should be 
used for reporting IgH positivity.’ 
 
Typically, immunoglobulin heavy chain expression is ‘weak’ or ‘dim’ in CLL, in fact this 
is one of the diagnostic criteria5. Weak Ig expression is generally poorly defined, but is 
locally stated to be present if expression is within one logarithm of non-expressing 
lymphocytes. Results where >5% CLL cells are ZAP-70 positive are recorded as positive 
cases. CD38 positivity is defined at a 30% cut-off. 
 
5.3.2 Cytogenetics 
The clinical cytogenetics laboratory of Barts Health NHS trust performed assays. 
Cytogenetic data were included, with the results of G-banding in addition to 
Fluorescent in situ hybridisation (FISH) for the commonly found abnormalities seen in 
CLL26: deletions of 13q, 11q, 17p, and 6q; trisomy 12 cyclin D1, (as mantle cell 
lymphoma is considered as a possible diagnosis with atypical morphology or CLL score 
3/5).  
 
5.2.4 Other data 
Other markers such as immunoglobulin IGHV gene mutation status (assay performed 
by Royal Free NHS trust laboratories), tissue biopsy and bone marrow biopsy were 
recorded where available. The dates and types of treatment, and response to 
treatment were recorded. Treatment Free survival is defined as the time between 
diagnosis and first treatment. 
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5.2.5 Statistical analysis 
Data were tabulated in Microsoft Excel and statistical comparisons were made using 
GraphPad Prism. Unless otherwise indicated, all statistical comparisons were made 
using tests designed for use with non-parametric data, as in most cases data was not 
normally distributed, or could not be assumed to be so. Probability of differences in 
means being due to chance was calculated using Mann-Whitney test462 for unpaired 
data and Wilcoxon test463 for paired data. Correlations were calculated using 
Spearman’s test. Where patient groups were segregated by IgD/IgM positivity or 
negativity, the differences in overall survival and treatment free survival were assessed 
using the Kaplan Meier survival method464. Censorship occurred at date of last follow 
up or date at which event (treatment or death) occurred. Time to that point was 
measured from date of diagnosis. The log rank test was used to compare survival 
distributions and generate a probability for the differences in survival being due to 
chance465.  
 
 
5.2.6 Characteristics of patients 
We attempted to estimate how representative the patients within the Barts database 
were of the general population. Almost all requests for immunophenotyping from local 
networks covering approximately 4 million people in NE London and southern Essex 
are processed at the Royal London Hospital Flow Cytometry laboratory. The database 
held details on 1,182 with a diagnosis of CLL/SLL.  
 
Median age at CLL diagnosis was 67.6 years (range 25-99). Published data give median 
ages at diagnosis of 72 years (US)2 or 71 years (Haematological Malignancy Research 
Network website, www.hmrn.org: UK data). The slightly younger median age at 
diagnosis may reflect the tertiary nature of our local referral centre, or the local 
population, or other factors. Strikingly, the minimum age at diagnosis was 25, with 
16/1182 (1.4%) patients having an age at diagnosis less than 35 years. Published data 
from the comprehensive US SEER database looking at CLL/SLL diagnoses 1987-2004 
identified 0.095% of patients <25 years with CLL/SLL and 0.68% <35 years2.  
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5.2.7 Crude Incidence of CLL 
The local population served by the immunophenotyping flow cytometry laboratory 
comprises approximately 1.5 million people (NE London Cancer Network), but since 
the flow cytometry laboratory receives samples from South Essex and other locations 
outside the cancer network, a wider population of 3.7 million people  (based on 
numbers in the region) is partially covered. See Table 5.2. 
Table 5.2: Crude Incidence of CLL 
The local population served by the network divides the number of new cases 
detected by the local flow cytometry laboratory. It would be expected that all 
diagnoses within the Cancer network population are made in the tertiary centre, but 
since referrals from outside the network are also made, the denominator local 
population is larger. Both incidence rates are reported. 
Year New diagnoses 
Incidence per 100,000 
per year (Cancer 
network) 
Incidence per 100,000 
per year (wider 
population) 
2009 130 8.67 3.51 
2008 138 9.20 3.73 
2007 121 8.07 3.27 
2006 116 7.73 3.14 
2005 105 7.00 2.84 
2004 76 5.07 2.05 
2003 80 5.33 2.16 
2002 59 3.93 1.59 
 
The crude incidence of CLL/SLL for the last three years is between 3.27-9.20 per 
100,000 per year, compared to published crude incidences of 4.2 per 100,000 patient 
years466. The slightly lower incidence estimates may be explained by a younger median 
age of the population in our area, but may also be explained by incomplete data 
gathering. It is difficult to determine true incidence rates as the total population 
determining the denominator is unknown. The lower incidence prior to 2005 probably 
reflects changes in vigilance, setting up of cancer networks and the increased use of 
flow cytometry in recent years. Given that the estimate of incidence of new cases of 
CLL is comparable to national figures, it might be reasonably claimed that coverage of 
the local population is reasonably comprehensive and the patients in our clinical 
network under consideration are representative of the general population. 
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5.2.8 Median Follow up 
The median follow-up for patients was only 2.86 years (range 0-35 years), as data 
gathering processes were more comprehensive in the past 5 years (see figure 5.2). This 
limits the generalisability of conclusions derived from such a short follow up period.  
Figure 5.2: Follow up period of patients 
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Treatment free and overall survival 
Data available on 863/1182 patients, 54% received treatment at some point during 
follow up (figure 5.3), with many patients not requiring treatment lost to follow up. 
Figure 5.3: TFS and OS of patients with available data 
 
 
5.2.9 Cytogenetics 
Of 1,182 patients with CLL/SLL, only 377 (32%) had cytogenetic data  using  the 
standard fluorescent in situ hybridisation (FISH) panel used for lymphoproliferative 
disorders.  
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In the original Dohner et al26 publication, cytogenetic subgroups were classified 
according to a hierarchy. The five major categories were defined as follows: patients 
with a 17p deletion; patients with an 11q deletion but not a 17p deletion; patients 
with 12q trisomy but not a 17p or 11q deletion; patients with a normal karyotype; and 
patients with a 13q deletion as the sole aberration. Table 5.3 compares the groupings 
of our patients with that published by Dohner et al: 
Table 5.3: Patients in Barts database with cytogenetic data  
Classified according to hieracrchical group and compared to Dohner et al paper. 
Cytogenetic subgroup Number % in Barts database Dohner et al % 
normal 85 23 18 
13qdel alone (inc biallelic) 164 44 36 
tri 12 (no 11q or 17p del) 66 18 14 
11q (no 17p del) 27 7 17 
17p 35 9 7 
 
The proportions in each hierarchical cytogenetic subgroup in our group of patients 
appear similar to that expected. The relative prognostic impact of the different 
cytogenetic groups is also similar to that found by Dohner et al (Fig.5.4). 
 
The poor prognostic effect of 17p deletion is seen, with a median survival of 123 
months for 17p deletion vs not reached for 13q deletion. Median overall survival for 
the patients with 17p deletion in Dohner et al was only 32 months. Studies subsequent 
to Dohner et al have tended to find longer survival in 17p deleted subgroups467, which 
may partly explain our findings. 
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Figure 5.4: OS &TFS by cytogenetic subgroup  
Below is the published OS by subgroup from the original Dohner et al paper  
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5.2.10 Prognostic markers 
The association of immunophenotypic markers with prognosis was derived. Both CD38 
(at 30% expression) and ZAP70 positivity (at 5% expression) were associated with 
reduced overall survival (Figure 5.5): 
 
Fig 5.5: Overall survival by immunophenotypic prognostic marker group 
CD38 
 
ZAP70 
 
IGHV gene mutation status and Prognosis 
IGHV gene mutation status data were only available for 69/1182 patients. There was 
no effect on OS, but a significant effect on TFS (Fig 5.6): 
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Fig 5.6:Survival by IGHV gene status 
 
 
 
In order to confirm known associations between prognostic markers, categorical data 
were compared using Fisher’s exact test. Despite low numbers of patients with 
overlapping prognostic factor data available, the known associations of IGHV gene 
mutation and CD38 positivity (n=65, p=0.041) and ZAP70 positivity (n=56 p=0.0022) 
were confirmed in our series. In summary, published prognostic factors maintained 
their predictive value and known associations in our data set, suggesting that the 
patients in our database were comparable to published series. 
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5.2.11 Results: Peripheral Blood IgD and IgM expression in CLL clinical database  
 
Measurement of surface IgM has historically been part of the routine 
immunophenotyping panel when CLL or another B-lymphoproliferative disorder (BLPD) 
is suspected. Measurement of IgD was initiated in a few cases in 2003, and became 
routine in 2008.  Repeated measurements of surface immunoglobulin isotypes (Igs) 
have been made in a limited number of cases. Most cases have had Ig determination 
on one occasion only, most consistently of IgM. There are many instances where IgD 
has not been determined. There are also cases where the assay failed. Repeated 
determination of Ig seems to give mainly consistent results, though there are a 
number of cases where isotype expression appears to have changed over time. 
Whether this is due to variability in the assay, or true variability in disease 
characteristics, is difficult to ascertain. 
 
847 patients had IgM, and 204 patients had IgD determined on at least one occasion. 
Figures 5.7 and 5.8 demonstrate the range of expression: 
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Figure 5.7: Surface expression of IgD as determined by clinical immunophenotyping 
service. 
 
Figure 5.8: Surface expression of IgM as determined by clinical immunophenotyping 
service. 
 
To assign a case of CLL to a categorical classification based on positivity of expression 
of an isotype, it is necessary to decide on a threshold value of expression.  The local 
clinical immunophenotyping service sets a threshold of 30% of CD5+CD19+cells 
expressing a particular isotype. There is, however, a clear continuum of expression 
seen for IgM, and to an extent with IgD. It could also be claimed that a cut-off of 10% 
might be employed, based on a visual inspection of the data. The cut-off of 10% mainly 
alters the proportion of cases that are defined as IgM positive/negative, and the 
majority of patients would still be classed as either IgM or IgD positive (see table 5.4). 
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Table 5.4: Proportion of patients classified by two different positivity thresholds 
 
Threshold for positivity 30% of cells expressing 10% of cells expressing 
Percentage of patients IgD+ 74.5 78.9 
Percentage of patients IgM+ 66.9 81.4 
 
When the percentage of cells expressing IgD is compared to IgM in the same patient, it 
seems that IgD expression is significantly higher than that of IgM (Fig 5.9) 
Figure 5.9: expression of IgM vs expression of IgD. The horizontal bars represent the 
mean values 
 
  
By plotting the expression of IgM against the expression of IgD (see figure 5.10), it can 
be seen that there is a weak correlation between IgM and IgD, but with linear 
regression showing an R2 of 0.05, the relationship between the two is extremely weak 
and unlikely to be of biological significance. 
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Figure 5.10: Expression of IgM vs IgD for the 204 patients with both determined 
 
By using a threshold at 30% or 10% of CD5+CD19+cells expressing the relevant 
isotype, positivity and negativity for the various isotypes is defined (see Table 5.5 and 
figure 5.11).  This classifies patients into subgroups of IgM/IgD positivity, considering 
simultaneous expression of IgM and IgD in the 204 cases where this has occurred: 
Table 5.5: Frequencies by subgroup classification 
 Frequency at 30% cut-off % 
Frequency at 10% cut-
off 
% 
M-D- 39 19.1 24 11.8 
M+D- 13 6.4 19 9.3 
M-D+ 72 35.3 34 16.7 
M+D+ 80 39.2 127 62.3 
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Figure 5.11: Proportion by subgroup classification 
 
 
Depending on the cut-off employed, there were 39 (30% cut-off) or 24 (10% cut-off) 
defined as IgM-IgD-. Of these cases defined as negative for both IgM and IgD, 79% (at 
10% cut-off of IgG expression) and 67% (at 30% cut-off) were positive for IgG (see Fig. 
5.12). Presumably, those that did not express IgG, IgM or IgD would be positive for IgA 
or IgE, as all had clonal expression of surface light chains demonstrated. An alternative 
explanation is that the assay failed or Ig expression was too low for detection. 
 
Figure 5.12: Proportion of IgG expressing cells in IgD-IgM- CLL cases 
 
5.2.12 Stability of isotype expression 
Because it is anecdotally observed that the immunoglobulin isotype appeared to 
change over time in a small number of cases, an attempt to estimate the stability of 
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this measurement was made. The number of times (in percentage of all cases) the 
isotype was determined is given below (Table 5.6): 
 
Table 5.6: Repeated measurement of immunoglobulin isotype 
Number of measurements 
IgM 
(total 847) % 
IgD 
(total 204) % 
1 occasion 83.5 93.0 
2 occasions 11.3 6.5 
≥3 occasions 5.2 0.47 
 
In total 140 (16.5%) of patients had IgM measured on more than one occasion, and 15 
(7%) had IgD measured on more than one occasion. By assigning a threshold of 30% for 
positivity or negativity in determination of isotype, we can calculate the number of 
cases that had different classifications of isotype expression on different occasions, i.e. 
the proportion of all cases that appeared to change their surface immunoglobulin 
isotype over time (Table 5.7). 
Table 5.7: Changes in isotype expression on repeated measurement 
Change in isotype? 
IgM 
(total 140) % 
IgD 
(total 15) % 
No change on repeat measurement 72.9 86.7 
Change between 2 occasions 27.1 13.3 
 
Thus we see that a sizeable minority appear to change their isotype expression from 
positive to negative or vice versa (at least for the 30% threshold). In general, this 
change between sample dates was small, for example the mean change in sIgM 
expression between samples was only 8%, and the majority (74%) of cases that 
changed their classification from positive/negative had a less than 30% change in 
expression levels. Perhaps this change is more marked with IgM. 
 
5.2.13 Isotype expression in relation to diagnostic date 
The proximity of the Ig measurement to the diagnostic date was also determined (see 
Table 5.8). 
 
 122 
Table 5.8: Chronological separation between date of diagnosis of CLL and date of 
immunoglobulin isotype determination.  
Shown are the numbers (n) and percentages (shaded) of patients in each group 
 IgM n IgM % IgD n IgD % 
Date of Ig=diagnosis date 677 79.8 136 63.6 
Ig < 30 days from diagnosis date 9 1.1 2 0.9 
Ig 30 to 360 days after diagnosis date 32 3.8 11 5.1 
Ig 1-2 years after diagnosis date 19 2.2 10 4.7 
Ig >2 years after diagnosis date 111 13.1 55 25.7 
 
 
Therefore, approximately 80% of IgM measurements were performed at diagnosis. 
This is lower with IgD determination as the assay was introduced later. 
 
5.2.14 Isotype expression and prognosis 
The association of Ig expression as a continuous variable was compared with known 
prognostic factors (see Fig. 5.13). The mean level of IgM was slightly higher in CD38 
positive cases, but no other associations were noted  
 
When these data are considered as categorical variables, the association of CD38 
positivity with IgM positivity is also significant when 30% threshold for positivity is 
used (Fisher’s exact test, p=0.0057), but not at the 10% threshold. No other marker 
(CD38, ZAP70 or IGHV status) is associated with IgM positivity at 10% threshold, or 
with IgD positivity by either the 10% or 30% thresholds.  
 
Simultaneous cytogenetic and Ig data were available for 238 IgM and 52 IgD patients. 
There is a significant association between deletion of 11q and IgM positivity at 10% 
threshold (p=0.022), but not at 30% threshold (p=0.19). Similarly, trisomy 12 is 
associated with IgM negativity at 10% threshold (p=0.005) but not at 30% threshold 
(p=0.06). There is no significant association between del 17p or del13q and IgM 
positivity, and no associations between IgD positivity and any cytogenetic group. 
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Figure 5.13: Expression levels of IgM and IgD in various groups defined by published 
prognostic markers.  
Horizontal bars represent the mean. 
 
 
 
 
 
 
 
 
 
The effect of Ig isotype on prognosis was determined. All 204 patients with IgD data 
had survival data available. There appears to be no effect of Ig isotype on overall 
survival (see below) or treatment-free survival (Fig. 5.14) 
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Figure 5.14: Influence of IgD and IgM expression as a categorical variable on 
prognosis as judged by Overall Survival (OS) and Treatment Free survival (TFS) 
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When the IgD and IgM levels are used to divide patients into IgM-IgD-, IgM+IgD-, IgM-
IgD+ and IgM+IgD+ subgroups, there is no significant influence on survival at either 10% 
or 30% thresholds. When IgM-IgD- patients (12-19% of total) are compared to patients 
with at least one isotype expressed, there is no difference in OS or TFS at either 
threshold for positivity. 
 
5.2.15 Summary and Discussion: Peripheral Blood IgD and IgM expression in CLL 
clinical database 
 
Detection of monoclonal surface Ig (sIg) is a prerequisite for CLL diagnosis. Clonality is 
ascertained by light chain restriction, implying that sIg is present in all cases. 
Classically, IgM and IgD are expressed on CLL cells, often weakly/dimly. We have 
examined a large series (n=1182) of patients seen at Barts Cancer Centre. Data on IgM, 
IgD, other biological characteristics and prognosis is not available for all patients, but 
some conclusions may be drawn. The database appears reasonably comprehensive in 
terms of coverage of all new patients within the local network, and clinical 
characteristics such as prognostic markers appear to be consistent with published 
series. It is derived from the patients seen in a large tertiary centre (as are many 
published series), so may not be representative of the general population.  
 
204/1182 patients had IgD and IgM expression data available. The majority had 
expression levels ascertained close to the diagnostic date. A sizeable minority seemed 
to exhibit variation of expression over time as judged by a change in positive/negative 
status. Follow-up is also short, and altogether these factors weaken any conclusions 
that might be drawn about the use of IgD and IgM as a prognostic factor. Survival 
analysis suggests that the level of expression of IgD and IgM had no effect on overall 
survival or treatment free survival. This data on the lack of prognostic impact of IgD 
and IgM expression on PB CLL cells is in general agreement with several other studies 
(see 5.2.1). This has two implications.  
 
Firstly, PB IgM and IgD levels cannot be used as a biomarker to predict prognosis. Over 
the past two decades, there have been a large number of publications providing 
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evidence for one factor or another having some prognostic impact in CLL16. Of the 
hundreds of prognostic markers, only disease stage and P53 gene abnormalities have 
shown any real use as a biomarker/prognostic factor to guide therapy in a clinical 
context, though prospective trials are attempting to incorporate factors such as IGHV 
gene mutation status. The aim of this analysis is not to add to the list of potential 
biomarkers but to gain insight into CLL biology.  
 
This leads to the second implication: Expression level of the BCR in peripheral blood 
CLL cells has little influence on disease biology. Many of the prognostic factors in CLL 
have been investigated in depth in an attempt to gain greater insights into 
tumourigenesis, with varying success. The finding that expression level of a molecule 
conveys prognostic impact does not automatically imply its importance in disease 
biology, though it is generally taken as supportive evidence for such a role. Also, the 
lack of prognostic impact of expression level does not automatically imply lack of 
effect of that molecule on disease biology. Many authors have provided evidence that 
suggests the centrality of the BCR to CLL pathogenesis. Since it is felt that proliferation 
of the CLL clone occurs in the microenvironment of the lymph node and bone marrow, 
it may be that peripheral blood CLL cells do not reflect events in the 
microenvironment, which may also account for the lack of prognostic impact of PB BCR 
expression levels.  
 
Despite this, several conclusions can be drawn from our data. The majority of patients 
express a BCR isotype of IgD/IgM specificity on CLL cells at some level. It may be that a 
more sensitive assay would detect lower expression levels. We have some data that 
IgM (and to an extent IgD) expression changes over time within a patient. This may be 
due to variation of assays, or may be an interesting effect of biology. More relevantly, 
we suggest IgD expression is generally more common than IgM expression, with dual 
IgM+IgD+ cells forming the biggest group. This implies that any studies that seek to 
examine the role of the BCR in CLL cannot ignore IgD. Most studies have looked at the 
effect of signalling via IgM. Accompanying a reduced IgM expression, there is a lack of 
correlation between IgM and IgD expression within patients, suggesting that IgM and 
IgD expression levels are regulated independently, which is puzzling if their function is 
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identical, as many authors imply. Furthermore, the clonal nature of the BCR requires 
that both IgD and IgM bind the same antigen, so independent regulation may imply 
differing responses to antigen. Conversely, this differential regulation may be taken as 
evidence against ongoing antigen encounter, at least in PB cells. 
 
We use these and published data to guide the further examination of IgD and IgM 
expression and signalling in vitro.   
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5.3 IgM and IgD expression in peripheral blood: mononuclear fractions from tissue 
bank 
5.3.1: Methods  
IgD and IgM expression was assessed on thawed stored CLL samples that had been 
separated by density-gradient centrifugation and frozen. Patient samples were 
selected based on high WBC, untreated and to reflect a range of recognised prognostic 
factors. Each sample was assessed by CD5/CD19 dual staining to assess purity. 
Generally, studies were only performed on samples from untreated patients with 
>90% CLL B-cells as assessed by CD5 and CD19 dual staining. Example flow cytometric 
plots are shown below (Fig 5.15). 
 
Figure 5.15: Example cytometric plots from assays to assess CD19+CD5+ dual positive 
cells as a marker of CLL B-cell purity.  
In red are plots from isotype controls, with quadrants drawn at 99th centile for these. 
In blue are the dual stained samples. Each quadrant contains percentages of dual 
positive cells present in each quadrant. 
 
 
 
 
20 samples were studied extensively in vitro, and their characteristics are below. 
(Table 5.9) 
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Table 5.9: Characteristics of patients.  
UPN: Unique patient number assigned for the purpose of experiments. P signifies 
peripheral blood source. 
IGHV: Immunoglobulin IGHV gene mutation status (M=mutated, <98% homology to 
baseline, U=unmutated, 98% homology to baseline) 
Cytogenetics: FISH panel for CLL performed 
CD38: peripheral blood flow cytometric expression (1=>30%, 0=<30%) 
ZAP70: peripheral blood flow cytometric expression (1=>5%,0=<5%) 
CD19+CD5+: percentage of mononuclear cells dual positive for CD5/CD19 by flow 
cytometry 
X: assay not performed or failed. 
 
IgM and IgD dual staining was performed. The expression levels of IgD and IgM did not 
separate clear populations from isotype controls, and semi-quantification was 
performed based on quadrants drawn for isotype controls at the 99th centile of 
fluorescence intensity (see Fig. 5.16). A percentage of cells positive for IgM and IgD is 
derived using this method, but as the fluorescence intensity is a product of the 
proportion of cells expressing the immunoglobulin and the expression by the individual 
cells, this percentage cannot necessarily be assumed to be the percentage of cells that 
are genuinely ‘positive’.  
UPN IGHV cytogenetics CD38 ZAP70 CD19+CD5+ 
P1 M del13q 0 0 96.9 
P2 X del13q 0 0 97.1 
P3 U del13q 1 X 87.9 
P4 X del13q 0 0 96.5 
P5 X X 0 0 94.2 
P6 M del13q 0 0 91.8 
P7 U del13q del11q 0 0 95.9 
P8 M del13q 0 0 98.2 
P9 X del13q 1 1 95.6 
P10 X +12 del17p 1 1 90.6 
P11 X normal 1 1 96.3 
P12 X X X X 96.7 
P13 X del13q 0 0 98.4 
P14 X del13q 1 1 96.5 
P15 M del13q 0 0 96.8 
P16 U del17p 1 X 93.2 
P17 M del13q 1 0 91.7 
P18 M del13q 0 X 92.9 
P19 M del13q 0 0 93.5 
P20 U del13q 1 X 91.4 
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Figure 5.16: Example flow cytometric plots of IgD positive and IgM positive cases. 
 
An alternative analysis method would be report the Median Fluorescence Intensity 
(MFI) difference between isotype control and IgD/IgM staining (sometimes referred to 
as Specific MFI). Shown below (Fig 5.17) are the frequency histograms for patients 5 
and 13. 
 
To provide a specific MFI, the MFId/m is divided by the MFIi. The results are shown 
below as compared with the percentage above isotype threshold method. 
(Fig. 5.18). 
 131 
Figure 5.17: Histograms showing staining for IgM/IgD as compared to isotype control 
at 99th centile.  
Shown are the percentages of cells positive above the isotype control, and the 
Median Fluorescence Intensity (MFI) for isotype (MFIi) and stained (MFIm/d) 
Patient 5 
 
Patient 13 
 
Figure 5.18: Comparison of specific Median Fluorescence Intensity method to 
percentage of cells above 99th centile of isotype control. 
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It is seen that there is a clear correlation between these two measures. In general, the 
in vitro quantifications by the specific MFI fold change and percentage above isotype 
are highly correlated with each other, and there seems little basis to suggest choosing 
one measure rather than another, so we have henceforth used percentage cells above 
isotype control. Because most comparisons using these data will rely on non-
parametric statistics that consider rank comparisons rather than the quantifications, 
an absolute quantification of Ig level may not be important for many subsequent in 
vitro assays.  
 
There is also a clear outlier in patient 3, with a much higher IgD MFI as compared to 
the percentage of cells above the isotype threshold. The reason for this is shown 
below (Fig. 5.19). There are two populations of IgM+IgD+ cells, and the larger 
population has a clearly increased IgD-related MFI, with some with MFI >103 , which is 
unusual when compared to the other patients. It may be that this CLL aberrantly 
expresses high levels of IgD (which would be described as ‘bright’ in some 
publications), and this will need to be taken into consideration. 
Figure 5.19: Flow cytometric plots of IgD and IgM expression for patient 3 
 
 
In an attempt to validate the method further, the percentage> isotype method was 
compared with the expression levels from the clinical database. There was limited 
overlap, with 15/20 having IgM expression levels measured by both techniques, but 
only 6/20 for IgD. The time between samples used for clinical immunophenotyping and 
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samples taken for freezing in the tissue bank ranged from 0.5-8.7 years (mean 3.6 
years). There was generally an agreement between the percentage positive cells 
measured via the in vitro method and the results from the database, as assessed by 
Spearman correlation, however the in vitro method appears to provide lower values 
than that in the database (particularly for IgM). The comparisons are shown below (Fig 
5.20):  
 
Figure 5.20: Comparison of IgM and IgD expression levels by flow cytometry by two 
methods.  
Expression in database (percentage positive cells as compared to negative internal 
control lymphocytes) vs expression as compared to isotype control  in vitro. The in 
vitro method of determining IgM levels produced lower values when compared to 
database values, and this significant difference in means is maintained when outlier 
P6 is removed from the analysis. 
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5.3.2: Results: IgM and IgD expression in vitro 
Within this group of 20 patients for which frozen samples were used, there was no 
correlation between levels of expression of IgM and IgD, and no significant difference 
in expression (figs 5.21 & 5,22): 
 
Figure 5.21: Comparison of IgD and IgM expression by flow cytometry for thawed 
samples.  
  
Figure 5.22: Comparison of IgM and IgD expression in thawed samples.  
Horizontal bars represent means. 
 
There was no pattern of association with IGHV mutation status, CD38 expression or 
ZAP70 expression (data not shown).  
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5.3.3 Summary and Discussion: IgM and IgD expression in peripheral blood: 
mononuclear fractions from tissue bank 
To summarise, 20 samples from untreated patients were selected based on high 
tumour proportion as judged by CD5+CD19+ fraction. Levels of IgD and IgM expression 
were determined by flow cytometry and quantified based on comparison to isotype 
controls. This method had reasonable correlation with flow cytometric determination 
of IgD/IgM staining as assessed by the clinical immunophenotyping laboratory using a 
somewhat different method. However, there seemed to be a consistently lower 
estimation of the level of IgM positive cells with the in vitro method as compared with 
levels on the database. Various explanations may be offered for this inconsistency. 
There is a large time difference between the dates of samples taken from patients (up 
to 8.7 years), and so if IgM expression changed over time a difference may be 
detected. However, there is still a correlation of expression levels using the two 
techniques even with this time difference, and thus a change in IgM level over time 
would require a consistent fall in IgM expression over time if this explanation were 
correct.  
 
A more likely explanation is that the in vitro method (comparison to isotype control) is 
not directly comparable to the methods used by the clinical laboratory (comparison to 
internal negative lymphocytes), and consistently underestimates IgM expression. The 
freezing process may also have an influence.  Whilst percentage positive greater than 
isotype control may be presumed to correlate with the number of CLL cells that are 
genuinely positive for that immunoglobulin, it does not necessarily follow that this 
percentage measure is equivalent. Furthermore, the number of molecules per cell may 
be higher or lower (reflected in ‘bright’ and ‘weak’ expression on individual cells), 
which will be reflected by our method that does not separate a discrete population of 
cells from isotype control. What might reasonably be assumed is that the in vitro 
method used provides an estimate that reflects both the number of cells positive for 
an immunoglobulin isotype and the expression level of that isotype on individual cells. 
It could therefore be argued that one patient has ‘more’ IgD or IgM than another, 
when the same method is used.  
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These 20 characterised samples were used for further in vitro studies of the effect of 
ligating IgD or IgM (see Chapter 6). 
5.4 Bone marrow and lymph node IgD and IgM expression 
5.4.1 Introduction 
As discussed, the microenvironment of many tumours has an influence on malignancy, 
and there is evidence that this is particularly important in CLL. Whilst the peripheral 
blood compartment exhibits the most obvious (and conveniently accessible to 
researchers) involvement with leukaemia, it is generally thought that the proliferation 
of CLL cells occurs within the secondary lymphoid tissues: The lymph nodes, spleen 
and bone marrow. Collectively, these form the CLL microenvironment468,469. The 
historical view of CLL was as an accumulative disease whereby long-lived malignant B-
cells proliferate and die slowly, however seminal studies using heavy water labelling 
have shown that the proliferative rates of CLL cells are higher than was initially 
appreciated and that a substantial portion of the malignant clone (0.1-1%) divides 
daily470. This proliferation is higher in the lymph nodes than the bone marrow.  
 
One view of CLL cells in the peripheral blood may simply is as a ‘spill over’ from the 
more important lymph node/bone marrow compartments where proliferation and 
microenvironmental interactions occur469. This does not necessarily imply that 
peripheral blood cells do not re-enter these compartments and proliferate, as happens 
with healthy B-cells. Many of the more recent publications involving in vitro studies of 
CLL cells have attempted to provide various ligands that simulate microenvironmental 
stimuli, including chemokines such as CXCl12, cell adhesion molecules such as VLA-4, 
T-cell signals such as CD40, other factors such as BAFF, as well as cellular elements 
such as nurse-like cells and other stromal cells22. Generally, these studies have 
managed to prolong CLL cell survival in culture, and mediate resistance to 
chemotherapeutic agents, but inducing proliferation of primary CLL cells in vitro has 
proved more challenging. Various publications have compared CLL cells found in the 
bone marrow and lymph node microenvironment to paired peripheral blood samples 
from the same patient. CD38471 and Zap70 expression54 and an anti-apoptotic balance 
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of BCL2-family member expression472 is known to be higher in the lymph nodes of 
patients as compared to paired PB samples. Evidence of NF-kB signalling and of BCR 
signalling in the microenvironment is also becoming apparent53. 
 
Early studies highlighted the existence of pseudofollicles/proliferation centres in SLL, 
with perhaps 40% of SLL lymph nodes having this architectural pattern, the remaining 
cases displaying a diffuse infiltrate473. Pseudofollicles are generally defined as 
aggregates of lymphoid cells, which are larger and paler staining than surrounding 
lymphocytes. They often have more abundant cytoplasm, with most having nuclei 
morphologically similar to surrounding lymphocytes. However, the pseudofollicles are 
also enriched for prolymphocytes with larger nuclei, often Ki67 positive, providing the 
pseudofollicle with its alternative name of proliferation centre51. The size and 
abundance of these pseudofollicles has been associated with prognosis by some 
authors, as has Ki67 positivity, though publications are inconsistent about the 
relationship between Ki67 expression and prognosis51,474-476. One group have data 
suggesting that the cells within pseudofollicles are enriched for cytogenetic 
abnormalities as compared to surrounding non-pseudofollicle cells477.  
 
Peripheral blood CLL cells generally express Ki67 at a low level (generally <2%)468, and 
proliferation is presumed to occur within the LN and BM compartments (as with 
normal lymphocytes) where Ki67 levels are of the order of 2-30%53,474. The bone 
marrow in CLL is known to demonstrate a pseudofollicular pattern in some instances, 
but generally, this is only in later stage disease478. Studies using heavy water to 
examine CLL cell proliferation suggest that bone marrow is perhaps not a major 
proliferative compartment in CLL patients with stable disease, as compared to lymph 
nodes 479. 
 
Pseudofollicles are also associated with markers of activation of the NF-kB 
pathway469,480. A recent paper examined the gene expression profiles and selected 
protein phosphorylation (by western blot and phospho-flow cytometry) of paired 
peripheral blood (PB), bone marrow (BM) and lymph node (LN) CLL cells53. Comparing 
gene expression of BM, LN and PB, they suggest that greater differences are found 
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between lymph nodes and the other two compartments. Gene Set Enrichment analysis 
of the lymph node upregulated genes suggested higher expression of genes involved in 
BCR signalling and NF-kB signalling pathways. Stimulation of PB CLL cells with anti-IgM 
in vitro upregulated similar BCR pathway genes, and this was more apparent in U-CLL. 
Anti-IgM stimulation also caused phosphorylation of the proximal BCR signalling 
pathway kinase SYK, and increased SYK phosphorylation was noted in LN cells as 
compared to PB. They suggest that the differences observed were supportive evidence 
of BCR signalling within the lymph node (LN) microenvironment. Whilst bone marrow 
(BM) did exhibit similar changes, the differences between PB and BM were less than 
that between PB and LN, leading them to suggest that the LN is a more critical 
compartment in terms of CLL proliferation53. If antigen is stimulating CLL survival 
and/or proliferation, this is likely to occur within the lymph node microenvironment 
rather than the peripheral blood, recapitulating the normal immune response of B-
cells to antigen. 
 
There are few data examining sIg expression in LN compartments. One recent study of 
72 cases identified many markers that distinguished pseudofollicles from interfollicular 
areas, but state that IgM and IgD do not differentiate between these areas481. 
Anecdotally, our histopathologists report occasional differences in IgM and IgD 
expression between pseudofollicle and interfollicular areas. No studies have compared 
peripheral blood to lymph node or bone marrow compartments in terms of Ig 
expression. 
5.4.2 Methods: Bone marrow CLL immunophenotyping 
In a limited number of cases (n=6), paired bone marrow and peripheral blood samples 
had flow cytometry performed whereby IgD and IgM expression could be compared. 
Flow cytometric methods were the same as for peripheral blood studies, and were 
performed by the clinical flow cytometry laboratory. Only 1 of 6 patients had the BM 
and PB samples taken on the same day. The period between the BM and PB analysis 
ranged up to 20 months. In general, PB immunophenotyping was performed prior to 
BM, which was generally performed when therapy was planned. 
 
 139 
PB and BM IgD was available for 4 of 6 patients. Table 5.10 summarises their 
characteristics. 
Table 5.10: Characteristics of paired bone marrow v peripheral blood samples 
Patient Date of PB Date of BM 
Period elapsed 
between BM & PB 
sample (days) 
IgD% 
BM 
IgD% 
PB 
IgM% 
BM 
IgM% 
PB 
BM1 29/3/2010 29/3/2010 0 0 1 22 12 
BM2 29/1/2010 6/4/2010 67 3 7 40 78 
BM3 24/5/2009 1/7/2009 38 9 2 16 10 
BM4 30/7/2008 31/3/2010 609 98 98 86 96 
BM5 12/9/2007 30/8/2007 -13 ? ? 18 5 
BM6 10/8/2009 22/12/2008 -231 ? 78 98 73 
5.4.3 Results: Bone marrow CLL immunophenotyping 
Fig. 5.23 compares expression levels in paired samples. 
Figure 5.23: Comparison of IgD and IgM expression in paired bone marrow and 
peripheral blood (PB) samples. 
 Wilcoxon rank tests suggest no difference of means between PB and BM for both 
IgD and IgM. 
 
  
As is seen, where PB IgM/IgD expression is low/high, BM expression is also low/high. 
Sample size is small which presumably results in lack of significant p-values for this 
correlation, and limited generalisability. However, it could be claimed that the 
correlation of the limited number is consistent with BM and PB IgM/IgD expression 
being similar. 
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5.4.4 Methods: SLL lymph node immunohistochemistry  
As part of the tissue bank of Barts Cancer Institute, patients are invited to consent to 
storage and use of tissue taken for diagnostic or therapeutic purposes. 240 SLL/CLL 
patients had available paraffin-embedded tissue blocks from lymph node 
biopsies/splenectomy biopsies. There were 204 CLL patients with PB IgD and IgM data. 
There were only 19 with both, and 10 lymph node/spleen tissue blocks were readily 
identified. All sections were stained with Haematoxylin-Eosin (H&E), Ki67, IgM and IgD. 
Sections of reactive tonsils removed from children/young adults were used as positive 
controls for IgD and IgM staining. Further details are available in Chapter 3. Images 
were captured using the 3D HISTECH scanner microscope and Panoramic Viewer 
software. Cells were counted manually using the Panoramic Viewer Marker Counter 
function.  
 
The characteristics of the 10 patients with lymph node biopsies/sections of spleen and 
peripheral blood immunophenotyping for both IgD and IgM are shown in Table 5.11. 
Table 5.11: Characteristics of paired peripheral blood (PB) and lymph node (LN) 
samples from patients with SLL/CLL.  
The date of PB is the date at which IgD and IgM analysis was available. Shaded = 
treated prior to biopsy 
Patient Date of PB 
Date of LN/ 
splenectomy 
Period elapsed 
between LN & PB 
sample (days) 
Treated? IGHV Cytogenetics CD38 
L1 24/11/2008 31/10/2008 -24 01/08/2008 X normal 0 
L2 21/01/2009 03/06/2009 133 01/02/2007 M del13q del17p 1 
L3 12/11/2008 12/03/2008 -245 30/01/2006 X del13q 0 
L4 21/01/2009 06/10/2010 623 01/11/2008 X del17p +12 0 
L5 22/01/2009 22/09/2010 608 01/05/2010 X X 0 
L6 18/03/2009 25/11/2009 252 01/01/2005 X del11q del17p 1 
L7 10/11/2008 19/01/2009 70 05/09/2003 X del11q 1 
L8 28/01/2009 26/01/2009 -2 04/12/2010 X X 0 
L9 17/03/2010 20/08/2008 -574 01/10/2007 X del13q del17p 0 
L10 10/03/2010 12/05/2010 63 01/05/2007 X del13q 0 
 
Paraffin-embedded sections were taken and stained with H&E (for morphology), CD20, 
IgD, IgM and Ki67 (see Fig. 5.24). Pseudofollicles could be clearly identified by H&E 
staining in 3 of 10 sections (L2, L3, L10). In the other sections, the pattern of infiltration 
was either diffuse or suggestive of coalescent pseudofollicles/somewhat 
heterogeneous. CD20 staining was almost universally diffuse and uniform, but LN2 and 
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LN10 both had the suggestion of greater CD20 staining within pseudofollicles as 
compared with interfollicular areas, though the majority of cells within interfollicular 
areas were also CD20 positive.  
 
Ki67 was strongly positive within the pseudofollicles of LN10, but other samples were 
diffusely positive, albeit with some heterogeneity in pattern. Whilst IgM and IgD 
staining was more apparent within the pseudofollicles of LN10, this was not true of the 
other samples with prominent pseudofollicles (LN2 and LN3).  
 
It is not possible to definitively answer the question as to differential IgD/IgM 
expression between pseudofollicle and interfollicular areas given these samples. 
Pseudofollicles were discernible in only 3 samples, the CD20 staining within these 
samples was somewhat heterogeneous, and IgD and IgM differential pseudofollicular 
staining was only present in one sample. Therefore, it is not possible to state that IgD 
and IgM staining differed between pseudofollicles, in fact the data suggest otherwise, 
with 2 of 3 samples exhibiting pseudofollicular pattern having no difference between 
the two compartments. 
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Figure 5.24: Representative examples of H&E, Ki67, IgD, IgM staining.  
Tonsil staining patterns for Ki67, IgM and IgD are shown for comparison. LN4 had a 
diffuse infiltrate with low levels of Ki67, IgD and IgM. LN9 had a widespread yet 
somewhat heterogeneous infiltrate that was strongly positive for all 3 markers. 
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An attempt was made to quantify the levels of expression for IgM, IgD and Ki67. For 
each section, five high power fields (HPF at x100 magnification, 200 mx200 m square) 
were selected from each section. These were evenly spaced and contained 400-800 
cells per HPF. Illustration of the method is shown below in Fig. 5.25 
 
Figure 5.25: Selection of 200 mx200 m for cell counting 
 Example is of IgM stained LN9. All cells within each area are counted as positive or 
negative, and the scores collated.  
 
Where pseudofollicles were prominent, we included pseudofollicular and 
interfollicular areas in the same HPF. All positive and negative stained cells were 
counted within each field. 
 
It is presumed that the more cells are counted, the greater the accuracy in estimation 
of the true proportion of cells positive or negative for a particular marker. Five HPFs 
were chosen as a pragmatic compromise between accuracy and time taken to 
manually count cells. In an attempt to estimate the variability, the coefficient of 
variation (CV, standard deviation divided by mean) was calculated for each of the 5 
HPF counts. The mean CV was 0.23 (23%). When CV is plotted against mean count per 
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sample, it can be seen that the high CVs (and variability between counts in each HPF) 
are all in samples with low proportion of positive/ negative cells, as one might expect. 
The majority of CVs are <50% (Figure 5.26). 
Figure 5.26: Coefficient of variation of counts from 5 high power fields (HPFs) as 
compared to mean counts of positive/negative cells.  
Values for IgM/IgD/Ki67 positive/negative cell counts combined. The high CVs at low 
mean cells/HPF is due to variability being enhanced by low numbers of 
positive/negative cells. 
 
Further validation of the method was provided by a second person with experience in 
such methods (Dr Rita Coutinho) performing a manual count of the same areas for a 
limited number of HPFs (LN4, LN, LN10). Comparison of the percentages positive for 
each of these 15 validation areas was made. Wilcoxon signed rank p-values were all 
>0.05, indicating that there was no significant difference in median proportion of Ki67, 
IgD or IgM cells between the two manual counts, and Spearman correlation 
coefficients were 0.86-0.99 (p<0.001 for all correlations) for each comparison. 
5.4.5 Results: SLL lymph node immunohistochemistry 
Results are summarised in Fig. 5.27: 
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Figure 5.27: Frequencies of IgD, IgM and ki67 positive cells within each sample. 
The bars show the mean of 5 high power fields (HPFs) and the error bars show the 
standard deviation. 
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There was no correlation between lymph node IgM and IgD percentage, or with Ki67 
and IgD/IgM. There is a suggestion that IgM expression (mean 30%) within lymph 
nodes was lower than IgD expression (mean 44%) (Fig. 5.28): 
Figure 5.28: Comparison of IgD, IgM and Ki67 positive cells within each patient.  
Horizontal bars represent means. The outlier L9 is discussed in the text 
  
 
  
A notable outlier is sample L9, with very high levels of IgM (88%) IgD (81%) and Ki67 
(40%). This sample was a section of spleen from a patient who had received multiple 
lines of chemotherapy prior to biopsy, but had no evidence of Richter’s 
transformation. 
Comparison with PB IgD and IgM expression from the clinical database was made. 
There was significant correlation between peripheral blood IgD and lymph node IgD (as 
a percentage of all cells), but not between lymph node and peripheral blood IgM (Fig 
5.29): 
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Figure 5.29: Comparison of Lymph nodes (LN) and peripheral blood (PB) expression  
 
 
 
Comparison of expression between PB and LN suggests that IgM expression in the 
lymph node is slightly lower than that of the peripheral blood (mean 14% difference), 
whereas this is not the case with IgD (Fig. 5.30): 
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Figure 5.30: Comparison of expression levels between PB and LN 
 
 
Finally we attempted to correlate disease biology with the expression of IgM, IgD and 
Ki67 in the lymph node. To do this we classified samples into ‘High’ and ‘Low’ 
expression groups. Survival curves were then plotted for each group. There is no 
obvious threshold for classifying ‘High’ and ‘Low’ and so the data were inspected 
visually (see Fig. 5.31) 
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Figure 5.31: Determination of expression threshold for survival analysis 
Samples were ordered according to the percentage positivity of each marker in order 
to determine an obvious threshold for labelling a sample as High or Low. For IgM & 
Ki67, there seemed to be a ‘step’ at approximately 10%, and this was selected as a 
threshold. For IgD, there was no obvious transition, and so the median was used as a 
threshold. The median was also used as an alternative threshold for IgM & Ki67 
High/Low. 
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These thresholds (10% or median) were used to classify the samples into High and Low 
expression for the purposes of survival analysis (Fig. 5.32). There appeared to be a 
significant effect of IgM expression on overall survival from diagnosis, both at median 
threshold and 10% threshold, with low IgM levels predicting a decreased overall 
survival. This is in contrast to the survival of the same patients segregated into 
different groups by peripheral blood IgM expression. 
 
Figure 5.32:Survival by IgM expression in lymph node and peripheral blood 
 
 
Treatment Free Survival for IgM was not different for either threshold, nor was TFS or 
OS for median or 10% thresholds when groups were segregated by IgD or Ki67 levels. 
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5.4.6 Summary and Discussion: IgD and IgM expression in the Bone marrow and 
lymph node microenvironment 
The expression of IgD and IgM in 10 patient samples was evaluated and compared to 
paired PB samples. Immunophenotyping by immunohistochemistry and flow 
cytometry used different antibody clones, yet are essentially modifications of the same 
technique, so it could be claimed that the percentage cells derived from one method 
might be comparable to that derived by a different method. There are other inherent 
weaknesses – there were often long periods of time (up to 1.7 years) between PB and 
LN samples, with some patients receiving treatment between samples, which may be 
expected to limit interpretation. Lymph node biopsy or splenectomy in patients with 
CLL is generally performed in advanced stages, or when patients are refractory to 
treatment, though some biopsies are performed as part of an operation or to 
investigate lymphadenopathy, with an unexpected finding of SLL. Many of them had 
received treatment prior to LN biopsy. Also, there is a high rate of poor prognostic 
markers such as 17p deletion in this group. Therefore, this group of patients is 
enriched for late stage, treated and poor prognosis cases, and cannot be expected to 
be typical of CLL as a whole. Biopsies are performed for a reason in CLL, and it is 
unethical to perform biopsies in early stage patients who do not require treatment. 
Nonetheless, few studies have examined this question and the studies do provide new 
information.  
 
The intensity of staining of CLL LN samples was variable, and intensity of IgM and IgD 
staining per cell was less than that of tonsils, consistent with the concept of ‘dim’ or 
‘weak’ Ig expression in CLL. Despite positive and negative cells being readily 
distinguishable, the level of Ig expressed on a positive cell of one patient may be less 
that that compared to another, and within patients there were some cells that 
expressed Ig more strongly than others. 
 
There was no correlation of IgM/IgD with Ki67, a finding that suggests that the 
expression of BCR does not associate with the proliferation of CLL cells in the LN. A 
caveat to this is that the Ki67-positive cells may themselves express IgD/IgM at a 
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higher level than their Ki67-negative counterparts. To determine this would require 
double staining for Ki67/Ig on individual cells. This highlights the fact that only a small 
proportion of the clone is proliferating at any one time and the methods for IgD and 
IgM determination examine the bulk population.  
 
 
A tentative association between shorter overall survival and low expression of IgM in 
lymph node is suggested by the present findings, but this requires investigation in a 
larger patient set. IgM expression is lower than IgD expression in LN. IgD expression in 
lymph node/spleen appeared to correlate with PB Ig expression in the same patient, 
however, there appeared to be a consistent lower percentage of IgM expressing cells 
in the LN compared to PB.  
 
If genuine, these data demand a putative mechanism. The critical issue is the 
relationship between the circulating PB CLL compartment and the presumed 
proliferative LN compartment. If they were biologically equivalent and in equilibrium, 
then similar levels of Ig expression would be expected. To an extent, this is seen in the 
case of IgD: PB levels correlate and are not different from LN levels. However, IgM LN 
expression is not correlated with PB expression, is lower in LN, and this effect is 
perhaps associated with more aggressive disease. This suggests that either the LN cells 
are composed of a population that expresses lower IgM, or that cells reduce their IgM 
levels on migration to the LN (or both). There are at least two plausible mechanisms 
for this.  
 
Firstly, if BCR signalling in terms of binding antigen in LN is occurring, as we and others 
have suggested, then it might be expected that CLL cells would adopt an anergic 
phenotype in the LN. This involves reducing IgM expression whilst maintaining IgD. The 
teleological argument for this, as for PB anergic cells, is that the cell is attempting to 
limit strong antigenic stimulation that might either cause apoptosis or result in 
autoreactive phenomena.  
 
The second and not mutually exclusive explanation suggests that CLL cells utilise IgM 
as an aid to migration into its LN microenvironment. Normal B-cells recirculate 
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multiple times between the PB and LN compartments, searching for antigen. Once 
antigen is encountered in the LN (recognised via BCR signalling), the cell may become 
activated and cease its wanderings. This process is associated with changes in 
chemokine receptors to enable location within the nascent germinal centres and to 
associate with helper T-cells. It can be postulated that once a CLL cell locates antigen, 
IgM is downregulated as it has served its role. Chiorazzi’s group has offered a similar 
speculative model to explain the role of CXCR4 in CLL cell migration482. It is known that 
PB CLL has higher levels of the CXCR4 chemokine receptor than LN counterparts, and 
that stimulation (for example via the BCR) results in lower CXCR4 expression.  They 
suggest that the CXCR4dim CLL cells appear to have recently divided and exited the LN 
(as evidenced by higher Ki67 and deuterium enrichment in heavy water studies). The 
life cycle of cells continues in the PB, whereby cells upregulate CXCR4 in an attempt to 
return to the LN compartment where they will again encounter antigen and other 
survival signals482. The process of changing chemokine expression to modulate B-cell 
migration and localisation is well recognised, and perhaps IgM serves a similar 
chemotactic role.  
 
These speculations do not explain why IgD does not exhibit a similar pattern, but the 
IgM/IgD expression pattern seen in anergic cells is analogous. The implication is that 
IgM and IgD expression is modulated differently in the PB and LN compartments. 
 
5.5 General Discussion: IgD and IgM expression in CLL 
There are a number of issues with methodology that are difficult to address. We 
attempt to compare IgM and IgD expression using immunophenotyping by three 
different methods. Each method derives a ‘percentage of cells positive’ value. Whilst it 
may be justifiable to claim that this may reflect genuine expression of IgD or IgM on 
cells, it is difficult to state exactly how exactly this can be interpreted, and whether 
different techniques may be directly compared. Are the cells deemed negative for IgD 
or IgM truly negative, or is the assay simply insensitive for low expression levels? B-cell 
survival is incompatible with absence of BCR expression, and so the question of 
whether IgM-IgD- cells are genuinely ‘negative’ must be asked118. The in vitro flow 
cytometry assays may claim to detect dual IgM+IgD+ cells, but the other techniques 
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used do not. For example, when a method suggests that 75% of cells are positive for 
IgD or IgM, it does not imply that 75% are IgM+IgD+, though presumably some must be. 
These arguments apply to any study using monoclonal antibodies to detect antigens 
and that compare expression levels and positive/negative staining. We believe we 
have offered reasonable arguments as to the veracity of using the methods to 
determine IgD and IgM expression in CLL. 
 
Given these issues with methods, any conclusions drawn should not be over 
interpreted. With these caveats in mind, we suggest that IgD and IgM expression levels 
are different from one another in PB and LN, with IgD levels being higher. 
Furthermore, we suggest that there are differences between IgM expression in the PB 
and LN CLL compartments. IgD expression in the LN appears to reflect that in the PB. 
These data suggest that IgD and IgM expression levels are differentially regulated, 
implying that they have differing functional roles. 
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6. Results: Outcomes of BCR ligation in vitro: Calcium Flux, apoptosis and 
cell proliferation 
 
6.1 Introduction 
B-Cell Receptor signalling is often discussed as if it is a unitary concept, with the 
capacity, or lack therefore, of B-cells to undergo activation after antigen binding or 
BCR crosslinking presented as an all-or-none phenomenon. What is implied is the 
quantification of a measure of BCR signalling, and different authors have used different 
indicators383. Most commonly, two general measures of BCR signalling are employed:  
1. Immediate events in the seconds, minutes and hours after BCR ligation. This 
can involve visualisation of the mobility of single BCR molecules, or of 
multimolecular complexes involved in the B-cell immune synapse250. Calcium 
flux after BCR ligation is a rapid event that occurs within seconds and is often 
taken as a surrogate for the capacity to signal326. Other early events involve the 
phosphorylation of various known proximal BCR signalling pathway 
components including LYN, SYK and BTK, or of molecules further downstream 
including AKT, NFKB and ERK483. Later events (hours to days) include changes in 
gene expression and cellular morphology. 
2. Outcome events involving the fate of the individual B-cell. This may imply cell 
proliferation or death by apoptosis, migration from one compartment to 
another, or interaction with other cells122. A wider context may include 
phenomena such as antibody production, tumour growth or death of the 
organism. 
 
All of the above measures may be taken as ‘readouts’ of BCR signalling, but most 
commonly, calcium flux, protein phosphorylation and apoptosis/proliferation are used 
as surrogates for BCR signalling122,250,308, and have been used to study the BCR in 
CLL114,115,186,249,360,484,485.  The aim here was to examine and compare the outcomes of 
IgM and IgD signalling in primary CLL samples in order to confirm and extend published 
findings. 
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6.2 Calcium flux after BCR ligation in CLL 
6.2.1 Introduction 
In normal B-cells, initial BCR signalling events include abrupt rises in cytoplasmic 
calcium concentration ([Ca2+]i), also known as calcium flux326. Calcium flux is often 
taken as a surrogate for BCR signalling capacity. Duration and degree of these calcium 
bursts is modified by the nature of antigen, the developmental stage of the B-cell and 
the presence or absence of co-signalling326. Calcium is one of the most important small 
molecule second messengers employed by cells for signal transduction. Eukaryotic 
cells maintain calcium concentration in their internal milieu 2-4 orders of magnitude 
below that of extracellular fluid (the typical concentration of which is 2mM)326. This is 
maintained via the regulation of voltage or ligand-dependent calcium channels and 
pumps, which permit cytoplasmic influx of calcium from the extracellular medium or 
from intracellular endoplasmic reticulum (ER) stores. The classic mechanism of 
activation involves agonist binding to a membrane receptor, causing a downstream 
intracellular signalling cascade that activates phospholipase C (PLC). Activated PLC then 
hydrolyses membrane phosphatidyl 4,5-bisphosphate (PIP2) to inositol 1,4,5-
trisphosphate (IP3) and 2-diacylglyceraol (DAG). Specific IP3-gated channels are present 
in the ER membrane, and activation causes a rapid influx of Ca2+ into the cytoplasm. 
Sustained calcium influx is mediated by subsequent opening of surface membrane Ca2+ 
channels to permit entry of extracellular Ca2+ when intracellular stores are depleted. 
The burst of intracellular Ca2+ concentration ([Ca2+]i) then modifies a diverse range of 
intracellular processes326.  
 
Calcium signalling has been explored in the Hen-Egg Lysozyme (HEL) mouse model of 
anergy. Naïve (nontolerant) cells whose BCRs are ligated with HEL or anti-IgD/M show 
a biphasic calcium response: a large, transient rise (>1mM) followed by a smaller 
plateau (>500nM)326. Anergic B-cells, resulting from constitutive HEL exposure, exhibit 
elevated baseline [Ca2+]i, and BCR ligation fails to evoke calcium flux
234,369. Single cell 
analysis shows that the mean elevation in [Ca2+]i is produced by asynchronous calcium 
oscillations (200-300nM range) which are decreased when these cells are transferred 
to mice that do not express HEL, indicating that this response is due to continued 
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stimulation of the self-reactive BCR369. Disengagement of antigen from the anergic BCR 
results in restoration of low basal [Ca2+}i, reduction of constitutive ERK 
phosphorylation, extension of B-cell lifespan and restoration of the ability to respond 
to BCR ligation with the burst of [Ca2+}i that characterises Ca flux486.  
 
Approximately 50-75% of CLL cells are able to display Ca flux in response to 
crosslinking IgM327,328. The ability of CLL cells to undergo Ca flux after IgM crosslinking 
has been associated with widespread tyrosine phosphorylation. In particular, 
phosphorylation of SYK is correlated with the ability to undergo Ca flux337, and 
defective PLC phosphorylation may be a putative explanation for the absence of Ca 
flux in many cases327, with greater phosphorylation in U-CLL320. There are also 
suggestions of greater calcium flux in CD38 positive cases307. Attenuated Ca flux after 
IgM ligation has been noted recurrently in CLL, and some studies suggest that Ca flux is 
generally required for subsequent downstream events such as phosphorylation of BCR 
pathway components, and alterations in apoptosis/proliferation49,305-307,317,319,320,329. In 
contrast, IgD signalling as judged by Ca flux seems to be relatively preserved116,305,306. 
Few publications have compared IgD and IgM signalling. 
 
IgM and IgD signalling have been studied in CD38-positive cases in order to enrich for 
cells that demonstrate robust BCR signalling306. The data on IgM/D-induced Ca flux are 
not explicit in this study, although they suggest similar amplitude of Ca flux after anti-
IgM and IgD ligation, but shorter duration after IgD signalling. They also suggest similar 
temporal patterns when the profile of SYK phosphorylation is monitored. 
 
Professor Stevenson’s group has studied IgD signalling more extensively. In one study 
of 40 CLL samples, all expressed IgM and IgD, yet 15 (38%) did not respond to IgM 
cross-linking as measured by Ca flux and SYK phosphorylation. Of these 15 non-
responding samples, 10 (66%) were responsive to anti-IgD and 12 (80%) were 
responsive to CD79a crosslinking. The 3 samples that did not respond to anti-CD79a 
were also nonresponsive to both anti-IgM and anti-IgD. The study was used as an 
illustration of dysfunctional IgM signalling, with relative preservation of IgD and 
general downstream signalling in CLL305. They subsequently comment on their own 
 158 
unpublished data that suggests that whilst IgD responses (as measured by Ca flux and 
ERK phosphorylation) are more common, they are transient compared to IgM249. The 
same group have published similar data demonstrating preserved IgD signalling in the 
presence of decreased IgM signalling in another study of a larger cohort of 112 
patients116. They suggest that 53% of cases could be designated as ‘responders’ to IgM 
ligation, as judged by the presence of >5% of cells exhibiting Ca flux. Responders 
tended to be U-CLL, have high IgM expression and be CD38 and ZAP70 positive. By 
considering cases with discordant IGHV gene mutation status, CD38 and ZAP70 status, 
they suggest that the IGHV gene mutation status is a greater determinant of signalling 
capacity than CD38/ZAP70 expression. Higher IgM expression was associated with Ca 
flux, particularly within the M-CLL group. However, no marker completely 
dichotomized samples into responding or non-responding groups. In particular, cases 
with equivalent IgM expression frequently had divergent Ca flux responses, indicating 
that IgM expression alone does not determine Ca flux capacity, and that the IgM had 
become ‘disconnected’ from downstream signalling pathways. In contrast to this 
defective IgM signalling, IgD crosslinking produced Ca flux in 95% of cases, and the 
majority of cases exhibited higher levels of Ca flux when compared to IgM-induced Ca 
fluxes. Although the data is not shown, the authors state that co-addition of anti-IgM 
with anti-IgD does not affect the IgD-induced Ca flux.  
 
Intriguingly, the findings of this study also suggest that IgM expression and signalling 
capacity can be restored by incubation of cells in vitro, analogous to the scenario with 
anergic B-cells. They selected a group (n=14) of responders and non-responders to IgM 
as judged by Ca flux and incubated them in medium alone for 24-72 hours, assessing 
recovery as an increase in >10% cells responding with Ca flux. In 10 of 14 cases there 
was a clear recovery of IgM-induced Ca flux that was generally evident by 24 hours. 
This included 6 of 7 initial non-responders, and 4 of the 7 responders also showing an 
improvement in Ca flux.  
 
In the initial responders group, the 4 that increased their responses also showed an 
accompanying increase in expression of IgM (as judged by Median Fluorescence 
Intensity of the CD5+CD19+ population), with 2 cases increasing IgM but not increasing 
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Ca flux. In the non-responder group, most cases increased IgM expression, including 
the case that did not recover Ca flux capacity. In general, improvement in Ca flux 
ability was associated with increases in IgM expression, but this IgM increase was not 
sufficient to permit increase in Ca flux. IgD-induced Ca flux increased in one case, but 
was otherwise stable over 24-72h, and IgD expression tended to decrease during 
incubation. 
 
Furthermore, when selected cases were incubated with anti-light chain to crosslink the 
BCR and cause internalization of the surface Ig, this resulted in an immediate reduction 
in IgM and blockage of Ca flux after IgM ligation, with partial recovery after incubation 
in vitro for 24h. In the 6 cases tested, IgM and Ca flux after 72 hours incubation 
exceeded that present in the original cells. These data suggest that CLL cells can 
increase IgM signalling capacity by re-expression of Ig after endocytosis. IgD levels and 
calcium flux followed a similar pattern after Ig internalization, though the levels of Ca 
flux/IgD expression did not exceed those seen at baseline. 
 
Because of the similarities to the HEL mouse model of anergy, Mockridge et al suggest 
that anergy to IgM ligation is reversed in vitro by the removal of antigen, permitting re-
expression of IgM, and/or ‘re-connection’ of the downstream signalling apparatus to 
the expressed IgM. Not all cases manifest this phenomenon, and the authors speculate 
that in this situation a putative autoantigen is expressed by the CLL cells themselves, 
leading to the anergic phenomenon being perpetuated in vitro. This reversible model 
of IgM anergy with preserved IgD is a plausible mimic of mouse models of anergy, 
whereby removal of autoantigen results in re-expression of IgM and regaining of its 
ability to signal236,486. IgD expression and signalling is less affected by these 
manoeuvres, though it is known to exhibit limited downregulation and defective 
signalling capacity after chronic BCR engagement in mouse models292. 
 
In summary, many authors use Ca flux as a surrogate for BCR signalling, with other 
proximal events such as phosphorylation of proteins correlating with the burst of 
cytoplasmic ([Ca2+]i, dependent on SYK-induced phosphorylation of PLC. Both anergic 
and CLL cells seem to have defective IgM BCR signalling, as measured by Ca flux. This is 
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often associated with reduced IgM expression, though defective IgM signalling is also 
exhibited when IgM expression is high. In contrast, IgD signalling in anergic and CLL 
cells appears relatively preserved. This IgM-anergic phenotype can be reversed by 
incubation in vitro, with the suggestion that removal of the putative chronic 
autoantigen exposure permits increased expression and/or capacity for signalling via 
IgM. 
 
Similarly, I use Ca flux as a measure of early events in BCR signalling and studied the 
effect of IgM and IgD ligation. 
6.2.2 Methods 
6.2.3 BCR ligation 
In vitro methods that attempt to recapitulate the physiological response of B-cells to 
antigen follow two approaches. Either the known cognate antigen for that B-cell is 
used as a stimulus (e.g. Hen Egg Lysozyme in mouse models with BCRs of known 
specificity), or the BCR is crosslinked using monoclonal antibody to Ig heavy or light 
chains. With the unavailability of known antigen, studies in CLL have taken the latter 
approach. Table 6.1 summarises relevant publications. 
 161 
Table 6.1. Characteristics of the stimuli used to crosslink the BCR in various studies of 
CLL.  
Reagent Concentrations 
Supplier 
References 
Anti-IgM 
Rabbit polyclonal anti-   F(ab’)2 15 g/mL
327
 
10ng/mL-
100mg/mL
307
 
40 g/mL.
324
 
 
Jackson 
Immunoresearch 
laboratories
327
, 
Accu specs
307
 
Michel et al 1993
327
 
Zupo et al 1996
307
 
Gordon et al 2000
324
 
Goat polyclonal antihuman 
IgM/  F(ab’)2 
10ng/mL-
100 g/mL
306,307
 
(mostly 10 g/mL) 
 
5 µg/mL
348
 
10 g/mL 
62,115,317,320-
322,330,341,364,487
 
20 µg/mL
116,305,364
 
Southern 
Biotech
116,305-
307,320,321,348,487
 
Jackson 
Immunoresearch
 
Laboratories
317,364
 
Caltag 
Laboratories
115,330
 
Sigma
322
 
MP Biomedicals
341
 
American Qualex
62
. 
Zupo 1996
307
 
Bernal 2001
62
 
Lanham 2003
305
 
Petlickovski 2005
320
 
Zupo 2000
6
 
Allsup 2005
317
 
Contri 2005
330
 
Deglesne 2006
321
 
Abrams 2007
364
 
Gobessi  2007
348
 
Mockridge  2007
116
 
Muzio 2008
115
 
Guarini 2008
322
 
Gobessi 2009 
487
 
Quiroga 2009
341
 
Rabbit anti-human  10 g/mL Sigma
306
 Zupo 2000
306
 
Anti IgM IgG 10 g/mL Tenovus labs Cragg 2002
488
 
Goat antihuman IgM/  IgM 10 g/mL. Southern Biotech Petlickovski 2005
320
 
Goat anti-human IgM/  IgG 20 g/mL. Southern Biotech Lanham 2003
305
 
Anti-human IgM 10 g/mL. Not stated Minuzzo 2005
489
 
Goat anti IgM/IgD 10 g/mL Not stated Baudot 2009
335
 
Biotinylated goat antihuman 
IgM F(ab’)2 followed by avidin 
2-10
329
, 10-
20
318,346,484
-, 
20
423
g/mL 
Southern Biotech Lankester 1995
329
 
Chen 2002
346
 
Chen 2005
318
 
Vallat 2007
423
 
Chen 2008
484
 
Mouse anti-  followed by goat 
anti-mouse Ig 
5 g/mL Beckton 
Dickinson
307
 
Zupo 1996
307
 
 
Anti-IgD 
Goat antihuman IgD/ F(ab’)2 20 g/mL Southern Biotech Mockridge 2007
116
 
 
Goat polyclonal anti-  10ng/mL-100 g/mL 
(mostly 10 g/mL)
306
 
Sigma
306
 Zupo 2000
306
 
 
Rabbit anti-human  10 g/mL Caltag
306
 Zupo 2000
306
 
Biotinylated  anti– , 
subsequently cross-linked with 
streptavidin 
2 to 10 g/mL Southern Biotech Lankester 1995
329
 
 
Goat anti-human IgD/  IgG 20 g/mL. Southern Biotech Lanham et al 2003
305
 
 
The use of F(ab’)2 rather than complete antibody has been discussed by various 
authors, with the concern that the Fc component of antibodies may stimulate cells via 
Fc  receptors, and this is well known to have a general inhibitory effect on B-cell 
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activation307,320. Despite this, studies comparing complete antibody or F(ab’)2 
fragments have found no obvious differences in outcome, and in a limited number of 
experiments, I found no difference in Ca flux or apoptosis. The nature of the BCR 
crosslinking agent is discussed further in 6.4.7. I selected a stimulus of 10 g/mL of 
anti-sIg F(ab’)2 obtained from Southern Biotech for most experiments, as this seemed 
to be the most common published reagent. 
6.2.4 Calcium Flux in Cell lines 
The RL lymphoma cell line was used to optimise Ca flux methods as it displayed robust 
Ca flux with both IgD and IgM crosslinking. Live cells are selected on FSC/SSC 
characteristics of lymphoid cells (figure 6.1) and fluorescence at 525nm (FL1 channel) 
is plotted against time (figure 6.2): 
Figure 6.1: Gating population of interest, RL cell line.  
 
Figure 6.2.: Fluorescence against time afters IgM stimulus.  
A bivariate plot of median fluorescence intensity against time. 
 
This can be analysed further by presenting the data as a median intensity vs time using 
FloJo software. Figures 6.3-6.5 demonstrate the effect of the various media used for 
stimuli, as well as the effect of chelation of extracellular Ca2+ using ethylene glycol 
tetraacetic acid (EGTA). The ionophore Ionomycin was used as a positive control in all 
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experiments as it produces a large and rapid rise in cytoplasmic Ca2+ by allowing influx 
of calcium from the endoplasmic reticulum and the extracellular space. Roswell Park 
memorial Institute (RPMI) medium was used as a suspending medium for subsequent 
experiments as it was felt to be more ‘physiological’ than phosphate-buffered saline, 
and more robust Ca fluxes were exhibited. 
Figure 6.3: Use of F(ab’)2 fragments to crosslink IgM and induce calcium flux in RL cell 
line 
In RPMI (Ca2+ concentration 0.42 mM ) and PBS (Ca2+ concentration 0 mM). Calcium 
flux is expressed as the median fluorescent intensity (MFI) in the FL1 channel of the 
flow cytometer  
 
Figure 6.4: Ionomycin induced calcium flux-median fluorescence intensity in RL cell 
line, in RPMI and PBS. 
 
Figure 6.5: Calcium flux in RL cells in the presence of EGTA (calcium chelator) 
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Despite their expression on the RL cell line, crosslinking with a monoclonal IgG specific 
to CD10 or CD20 did not cause Ca2+ flux (Fig 6.6), suggesting that calcium flux was not 
due to non-specific crosslinking of surface receptors in general. 
Figure 6.6: Surface expression of CD10 and CD20 and crosslinking of sIgM, CD10 and 
CD20 and resultant calcium flux in RL cell line 
  
 
Most publications simply state the presence or absence of calcium flux, a qualitative 
judgement of whether the median fluorescence intensity (MFI) increases or not306,326-
328,364. These qualitative assessments may be valid within an experimental setting but 
create difficulties in comparing results between experiments. In order to produce 
comparability of calcium flux between samples, Stevenson’s group set a background 
threshold pre-stimulation at the 85th percentile, considering the percentage of cells 
that exhibit fluorescence above this baseline threshold after stimulus116. This then 
provides us with a measure of the proportion of cells responding (see figure 6.7). 
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Figure 6.7: Calcium flux in RL after differing concentrations of anti-IgM and anti- 
IgD.  
Shown in the accompanying table are the derived quantifications of calcium flux 
(time of peak fluorescence intensity and proportion of cells above threshold 
intensity) 
 
 
 
 
Stimulus 
Time of peak 
post stimulus 
(s) 
Peak % of cells 
above threshold 
Anti-IgD 
2.5 g/mL 
144 77.6 
Anti-IgM 
2.5 g/mL 
144 71.6 
Anti-IgD+IgM 
2.5 g/mL 
112 76.3 
Anti-IgD 
20 g/mL 
98 79.5 
Anti-IgM 
20 g/mL 
88 79.1 
Anti-IgD+IgM 
20 g/mL 
63 84.7 
 
There appears to be a dose effect, with more rapid and maximal stimulation at a 
concentration of 20 g/mL F(ab’)2. Noticeable effects were seen at 1 g/mL (data not 
shown). Crosslinking IgD produced similar responses to crosslinking IgM.  
 
After optimization in the RL cell line, the same methods were used to study Ca flux in 
characterized primary CLL cells. Cells were thawed, rested for 2-3 hours by incubation 
in medium alone at 4x106/mL before loading with Fluo3 dye and stimulation. The anti-
IgM/D F(ab’)2 fragments were used at concentrations of 10 g/mL, as this had been 
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shown to produce robust and maximal responses, when they occurred, and is in 
keeping with most published methods. When IgD and IgM were added simultaneously, 
a mixture of stimuli at 5 g/mL was used, as this would equate to a total concentration 
of stimulus of 10 g/mL, and it is expected that IgM and IgD would compete for the 
same antigen at a fixed concentration in vivo. 
 
The 20 patient samples characterised by IgM and IgD expression in Chapter 5 were 
studied. Ca flux was performed on samples from the same patient twice in 4/20 cases, 
and thrice in 3/20 samples. Three of these repeat samples were taken and frozen on 
different occasions. In all cases, the same pattern of Ca flux was exhibited (5 IgD>IgM, 
2 IgM>IgD), suggesting that the patterns of Ca flux are a relatively stable phenomenon, 
at least in the time shortly after thawing. Where quantification for Ca flux is used 
(percentage cells Ca flux at 1 minute, see below), the mean of these repeated samples 
is taken.  
6.2.5 Results 
6.2.6 Calcium flux via IgD is greater than via IgM 
Representative calcium flux profiles are shown (Fig 6.8). In general, most (13/20) CLL 
followed a pattern of dual IgM- and IgD-induced Ca flux, with 11/20 having greater 
IgD-induced Ca flux, and 2 having IgM>IgD. 5/20 displayed no calcium flux to anti-IgM, 
despite IgD calcium flux. 2 samples (13 and 10) displayed no calcium flux to either anti-
IgD or IgM. When combined IgD+IgM stimuli are used, Ca flux levels are intermediate 
between those exhibited after each stimulation alone. 
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Figure 6.8: Representative Ca flux profiles of primary CLL cells after IgD or IgM 
ligation 
Compared with ionomycin or control (borate buffer vehicle). Note that the method 
uses a baseline at the 85th centile of unstimulated cells, therefore the baseline 
proportion of cells is 15%. 
 
P1-Exhibits calcium flux with IgD, low level with IgM 
 
P14-Exhibits calcium flux with IgD and IgM 
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P10-Exhibits calcium flux with ionomycin only 
 
P5- Exhibits calcium flux with IgD only 
 
 
 
 
In all samples, there was no obvious difference in the time course of IgD and IgM-
induced Ca flux, though samples were not studied beyond 6 minutes, as the number of 
cells became limiting, and cooling of the medium was thought to have an influence at 
longer timepoints. In order to derive a quantification of Ca flux, the level (percentage 
of cells) of Ca flux at 1 minute after stimulus was taken. This was normalised into a 
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percentage of cells responding by subtracting the 15% baseline, and dividing by the 
percentage of cells undergoing Ca flux with ionomycin. The ionomycin value was 
generally 75-100%, and normalisation to this value is expected to compensate for 
differences in dye loading and viability.  Figure 6.9 shows that the level of calcium flux 
for IgD was significantly higher for IgD stimulus as compared to IgM stimulus. 
 
Figure 6.9: Comparison of Ca flux after IgD and IgM ligation in 20 CLL samples.  
The proportion of cells exhibiting Ca flux 1 minute after stimulation was compared. 
 
 
6.2.7 Whilst IgD expression correlates with IgD-induced calcium flux, IgM expression 
and calcium flux do not 
A prerequisite for BCR signalling is expression of the BCR. The levels of Ca flux were 
compared with the expression of the relevant BCR isotype for the 20 primary CLL 
samples studied. When the percentage cells exhibiting calcium flux at one minute after 
stimulation is plotted against the level of expression of the corresponding isotype (see 
Chapter 5.2), a significant correlation between expression of IgD and calcium flux after 
IgD ligation is apparent (fig 6.10).  
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Figure 6.10: Calcium flux at one minute after stimulation with anti-IgD, compared to 
expression of IgD.  
The two samples without IgD expression did not exhibit calcium flux. These same 
two samples expressed IgM but did not exhibit Ca flux after IgM crosslinking. 
 
 
In contrast, 7/20 samples exhibited no IgM-induced calcium flux, despite some of 
these samples expressing relatively high IgM levels. Of the 13/20 samples exhibiting 
some level of Ca flux after anti-IgM stimulation, there was no clear relationship 
between IgM expression level and the level of calcium flux (see Fig 6.11) 
Figure 6.11: Calcium flux at one minute after stimulation with anti-IgM, compared to 
expression of IgM. 
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In order to associate the capacity to undergo calcium flux with known prognostic 
markers, samples were grouped by IGHV, CD38 and ZAP70 status. There was no 
obvious relationship between these markers and IgD expression/calcium flux (see fig 
6.12), and the mean Ca flux was not different in these different prognostic groups. 
Figure 6.12: Calcium flux at one minute after stimulation with anti-IgD, compared to 
expression of IgD, by prognostic group. 
Samples are coloured according to the indicated prognostic marker. NK= status not 
known 
 
 
 172 
The same data are shown for IgM stimulation in Figure 6.13. Whilst the mean values of 
Ca flux after IgM ligation were higher in each of the poor prognostic groups (U-CLL, 
CD38 and ZAP70 positive), there is much overlap and none of these differences were 
significant at p<0.05 levels.  
Figure 6.13: Calcium flux at one minute after stimulation with anti-IgM, compared to 
expression of IgM, by prognostic group. 
 Samples are coloured according to the indicated prognostic marker. 
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It may be that the greater capacity of cells to undergo Ca flux via IgD was simply 
related to the possibly higher expression of IgD (see Fig 5.22 in Chapter 5). However, 
there were several samples where clear expression of IgM was not associated with the 
capacity for IgM-induced Ca flux. Figure 6.14 calculates the amount of Ca flux divided 
by expression of the BCR isotype to demonstrate that Ca flux ‘per molecule’ was less 
for IgM. 
 
Figure 6.14: Ca flux divided by expression of IgM/IgM. 
The percentage of cells undergoing Ca flux at 1 minute after BCR ligation is divided 
by the expression of the relevant BCR isotype. Note the axes indicate that IgD Ca flux 
is generally higher relative to the expression of IgD, and there are several cases with 
no IgM Ca flux. When the different prognostic subgroups are considered, there is no 
obvious relationship between the derived values of Ig Ca flux/ Ig expression (not 
shown). 
 
Also, the inherent capacity of cells to undergo Ca flux at all does not determine the 
variability of responses, as samples that undergo Ca flux after IgM are not those that 
have the greatest degree of Ca flux after IgD ligation, and vice versa (see Fig. 6.15).  
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Figure 6.15: Ca flux at 1minute after IgD or IgM ligation.  
There is also no relationship with prognostic markers (not shown). 
 
 
6.2.8 Restoration of IgM signalling on in vitro incubation 
4 samples were selected to see if in vitro incubation restored the capacity to undergo 
Ca flux after BCR ligation. They were selected based on their known Ca flux 
characteristics (see table 6.2): 
1. P14: A sample exhibiting Ca flux after both IgD and IgM engagement. 
2. P1: A sample exhibiting Ca flux with IgD and low (5.7% of cells) IgM Ca flux. 
3. P5: A sample exhibiting IgD but no IgM Ca flux. 
4. P10: A sample with absence of Ca flux with after IgD or IgM ligation. 
Table 6.2: Characteristics of 4 selected samples 
Sample 
Expression IgD 
(% cells) 
Expression 
IgM 
(% cells) 
Calcium flux IgD 
(% cells at 1 min. after 
stimulation, as % of 
ionomycin) 
Calcium flux IgM 
(% cells at 1 min. after 
stimulation, as % of 
ionomycin) 
P14 63 46 77 16 
P1 22 6 25 6 
P5 85 27 38 0 
P10 0.3 48 0 0 
 
The samples were incubated for 24h in medium alone, or ‘treatment’ with vehicle 
borate buffer, IgM (10 g/mL), IgD(10 g/mL) or IgD+IgM (5 g/mL each). Expression of 
 175 
IgD and IgM and apoptosis was assayed at t=0 and 24h. Ca flux was assayed at baseline 
and at 24h. 
 
In order to evaluate Ca flux in viable cells only, cells were gated on a population 
negative for Annexin V staining, but many of the Annexin V positive (AnV+) cells in 
early apoptosis also had the capacity for calcium flux after stimulation (Fig 6.16): 
 
Figure 6.16: Selection of viable population for calcium flux assays using AnV-Alexa 
Fluor 647.  
An AnV-  population was selected for calcium flux measurements, though it can be 
seen that many of the cells gated as apoptotic (AnV+) could undergo calcium flux, 
albeit at reduced amounts. Even the AnVhigh cells could undergo a degree of calcium 
flux after ionomycin stimulus. 
 
In general, apoptosis increased over time (see fig 6.17).  
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Figure 6.17: Viability (annexinV Propidium Iodide dual negative AnV-PI-) cells in cells 
incubated in medium alone. 
 
And the different treatments resulted in different levels of apoptosis at 24h: 
Figure 6.18 viability in P14 samples at baseline and 24hours, with different treatment 
stimuli: 
1c=control medium alone 
1v=borate buffer vehicle 
1m=anti-IgM 10 g/mL 
1d=anti-IgD 10 g/mL 
1dm=anti-IgD 5 g/mL + IgD 5 g/mL 
 
The plots for each patient at baseline and after 24h are shown below. It can be seen 
that despite a fall in viability over 24h, the CLL cells exposed to medium alone still 
maintained a viable population that were able to undergo calcium flux in response to 
stimulus, and in fact, the response to IgM ligation appears to have increased (Fig 6.19): 
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Figure 6.19: Calcium flux at baseline and 24hours after culture in medium alone. 
Ca flux was measured after ionomycin, IgM, IgD, IgD+IgM stimulus or vehicle control.  
The same stimuli were used after 24h culture. 
 
The level of response to IgD stimulation appears to be similar (>80% of cells 
undergoing Ca flux) at 24h when compared to baseline. 
 
When the ionomycin responses for each treatment stimulus are compared, it seems 
that the vehicle borate buffer appears to impair calcium flux. This may be due to the 
low viability of these cells at 24h, but it might be expected that the similar viability of 
control (medium only) cells might display the same pattern (fig 6.20): 
Figure 6.20: Ionomycin responses after 24h exposure to different treatment stimuli.  
The ca flux response to ionomycin is shown for cells cultured in various conditions. 
The top lines represent culture with IgD, IgM, IgD+IgM or medium alone. The lower 
line (‘Vehicle stimulus’) represents culture in the presence of vehicle. 
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Similar data can be plotted for the responses to IgM and IgD ligation after 24hours 
(figure 6.21): 
Figure 6.21: Calcium flux responses to anti-IgM and anti-IgD after differing treatment 
stimuli: 
 
 
 
It appears that the response to IgD is impaired by 24h exposure to anti-IgD, and that 
IgM induced calcium flux is impaired by 24h of anti-IgM treatment. Furthermore, IgD 
treatment reduces calcium flux response to anti-IgM, whereas the converse is not true. 
These differences are not simply due to differences in viability, as IgD and IgD+IgM 
treatment resulted in greater viabilities, yet reduced Ca flux. 
 
Using a combination of FITC-conjugated anti-IgM or IgD and propidium iodide, the 
expression of IgD and IgM in viable (PI negative) cells was monitored. The expression 
of IgD declined in all samples, but more so in anti-IgD or IgM+IgD treated samples. The 
expression of IgM seemed unaltered by treatments and incubation in medium alone in 
vitro. 
 
 179 
Similar responses to in vitro culture were seen for P1 (Fig 6.22) and P5 (Fig 6.23), 
though with these samples, there was also an increase in response to IgD stimulation 
after incubation, perhaps because of the relatively low levels of IgD response at 
baseline. In P5, the response to anti-IgM was higher than to anti-IgD at 24h, which is 
remarkable considering the absence of Ca flux after IgM stimulation at baseline. IgD 
expression declined in all samples, whilst IgM expression was unchanged in P5 and 
increased slightly in P1 samples (from 6% to 10-15% in all treatments). 
 
Figure 6.22 P1 viability and Ca flux after incubation 
 The decrease in viability is similar for all treatments. There is a recovery in IgM and 
IgD calcium flux after 24h culture in medium alone. Vehicle treatment stimulus may 
be associated with decreased calcium flux to ionomycin, but this is not apparent with 
the other treatment stimuli. Ca flux response to anti-IgM at 24h is most impaired by 
24h anti-IgM treatment, but also by treatment with anti-IgD, and a similar effect is 
seen with IgD  ca flux responses. 
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Figure 6.23: P5 viability and Ca flux after incubation 
IgD+IgM or IgD treatment stimuli seems to result in a general increase in viability 
compared to the other treatments. The absence of response to anti-IgM at baseline 
is altered to high levels after 24h culture in medium alone.  This recovery is impaired 
by vehicle or IgD treatment, though curiously not by IgD+IgM treatment. Also 
different is the recovery of ca flux response to anti-IgM after anti-IgM treatment, 
though the level is not as great as for medium alone.  
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Finally, Sample P10 did not display any recovery in Ca flux after incubation in vitro (Fig 
6.24). There was a slight increase in IgD expression (0% to 4%) over 24 hours, and a 
decrease in IgM expression. 
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Figure 6.24: P10 viability and Ca flux after incubation 
Treatment stimuli did not result in large differences in viability at 24h. The absence 
of response to IgM & IgD at baseline is unaltered after 24h culture in medium alone.  
Similarly, there is no recovery of ca flux with vehicle, IgD or IgM treatment. 
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6.2.9 Summary and Discussion 
Crosslinking the BCR with anti-IgM or IgD F(ab’)2 fragments produces robust Ca flux in 
the RL cell line and in the majority of primary CLL samples. The use of F(ab’)2 fragments 
is consistent with most of the published studies (see table 6.1), which used the same 
approach, and I used the same supplier that most frequently provided the reagents for 
these studies. However, the caveats and potentially less physiologic nature of soluble 
stimulus must be kept under consideration, particularly in the light of several studies 
that show increased survival and proliferation with anti-IgM antibodies that have been 
immobilised by conjugation to beads or culture plates (see below section 6.4.7)320,321.  
 
The calculation of [Ca2+]i in absolute terms (to provide a value in nM) is possible by a 
variety of methods (use of calcium buffers, or combination of dyes such as fluo-3 with 
Fura Red)490. I did not pursue an absolute quantification, as I sought to compare 
calcium flux within the context of studies that compared IgD and IgM flux, and 
amongst primary samples. Furthermore, the degree of fluorescence using the Fluo3 
methods has a linear relationship with the cytosolic [Ca2+]i concentration when 
methods are compared490. The use of the 85th centile is consistent with approaches 
used by others, and provides a quantitative measure of the proportion of responding 
cells within a sample. The relation of this to the Ca flux induced by ionomycin is felt to 
give an indication of the number of cells that have capacity to undergo Ca flux, taking 
into consideration variations in dye loading, temperature changes and cell viability. 
Whilst all samples exhibited viability greater than 90% using the trypan blue dye 
exclusion method (and most had levels >97%), the level of viability as estimated by 
dual AnV/PI negativity was less than this. 
 
The capacity of most (18/20) CLL to exhibit Ca flux after IgD crosslinking was 
confirmed; and there was a correlation between the expression level of IgD and 
quantification of Ca flux. The two samples with zero IgD expression exhibited no Ca 
flux after crosslinking IgD, despite Ca flux with ionomycin. These samples also had 
absent Ca flux after IgM crosslinking (despite expression of IgM on >40% of cells). In 
contrast, reduced IgM-induced Ca flux was noted, both in terms of the number of 
samples showing any response (13/20) and the level of response of each sample, with 
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IgD Ca flux greater than IgM Ca flux in most samples studied. This was not simply an 
effect of the expression level of IgD being generally greater than IgM, as samples with 
high IgM expression did not necessarily exhibit Ca flux, and Ca flux after IgD ligation 
was often high in samples with relatively low IgD expression. Similarly, the absence of 
correlation between IgD and IgM Ca flux indicates that reduced IgM Ca flux is not 
simply due to defective Ca flux per se. This confirms the known phenomenon in CLL of 
capacity of the IgD BCR isotype to undergo the initial events in the BCR signalling 
cascade, coupled with an anergic pattern with IgM.  
 
Furthermore, I have confirmed the findings of Mockridge et al in demonstrating the 
ability of CLL cells to regain capacity for signalling after in vitro culture in a limited 
number of samples116. This was partially suppressed by simulating antigen exposure. 
The reversal of ca flux signalling defects by in vitro incubation mimics anergic B-cell 
models. The addition of anti-IgD or -IgM F(ab’)2 fragments to the in vitro culture 
system, perhaps simulating the presence of antigen, partly inhibits this reversal of 
anergy, again similar to mouse models. These data confirm the findings of Mockridge 
et al, though I did not monitor signalling at further time points after 24h as viability in 
the studied samples was low. It would be desirable to extend these findings by 
evaluating recovery from anergy in more patient samples. For pragmatic reasons this 
was not pursued as large numbers of primary cells and reagents are required for each 
experiment, and Mockridge et al published larger numbers in any case. Together these 
data support the model of anergic BCR signalling in CLL: IgD expression and Ca flux is 
preserved, whilst IgM Ca flux is often absent despite high IgM expression. 
 
In contrast to Mockridge et al, I did not find marked increases in BCR expression after 
in vitro incubation. My method differs from theirs in that I tried to gate expression on 
viable cells only, however one would expect any BCR expression increases to therefore 
be greater with my method. In their study, most increases in IgM were apparent at 48 
hours rather than at the 24-hour timepoint I used, which may explain my findings. One 
sample (P10) that exhibited no expression of IgD seemed to slightly increase IgD 
expression to 3-4% after incubation; otherwise all samples exhibited a decrease in IgD 
expression after 24 hours. One sample (P1) exhibited a slight increase (6% initially, 10-
 186 
15% after 24h) in IgM expression, which accompanied an increase in Ca flux. IgM 
expression was similar in samples P5 and P10, and decreased slightly in P10. My data 
therefore suggest that changes in Ca flux at 24h are not accompanied by consistent 
changes in expression of IgM or IgD, implying that reversal of anergy is not due to 
increase of BCR expression. However, it could be claimed that comparing flow 
cytometric expression from experiments performed on cells with low viability on two 
different occasions may not be a valid quantification method, even if one considers the 
IgM/D expression method a valid one for relative quantification of BCR expression 
within a single experiment (see chapter 5). 
 
In summary, the early events in BCR signalling were evaluated by measuring Ca flux in 
20 primary CLL samples. I confirmed the general capacity for IgD signalling in the 
presence of reduced IgM signalling, mimicking the anergic models of B-cell anergy. 
Incubation of cells in vitro for 24h can lead to recovery of IgM signalling capacity, and 
this phenomenon is seen to an extent with IgD. This is consistent with a model 
whereby the expression and signalling capacity of IgM (and IgD) is a dynamic 
phenomenon in CLL. This model suggests that antigen engagement in vivo may be 
occurring in the lymph node microenvironment, resulting in an anergic phenotype, and 
that removal of the putative antigen during in vitro incubation results in recovery of 
BCR signalling capacity. 
 
However, I was unable to show consistent alterations in expression of IgM or IgD to 
accompany this reversal of anergy, which may suggest that the technique for 
measuring expression in the experiment is insufficiently robust, or that anergy is 
dependent on more than downregulated BCR expression. In support of the second 
interpretation, the absence of Ca flux after IgM ligation is common in CLL samples 
cases with apparent high IgM expression. I therefore suggest that anergy is partly a 
result of ‘disconnection’ of downstream signalling pathways from IgM.  
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6.3 Proliferation of CLL cells after BCR ligation 
Cell cycle analysis of cell lines and primary leukaemia cells was performed (see figure 
6.25). CLL samples were stimulated with anti-IgD or anti-IgM F(ab’)2 fragments and 
compared to vehicle control at 24 and 48 hours, in triplicates. CLL cells reliably 
remained in G0 (89-99%) despite stimulus with IgM and IgD at 24 and 48 hours after 
stimulation. Only 5 patient samples were stimulated, as no effects were seen. 
Figure 6.25: Cell cycle analysis in RL cell line and primary CLL. 
Representative examples. CLL cells were fixed, permeabilised and stained with anti-
Ki67-FITC antibody and Propidium Iodide (PI). Cells positive for Ki67 alone were 
defined as in G1 stage of cell cycle, Ki67-PI dual positive as S/G2/M and dual negative 
in G0. CLL cells remain in Go, whereas the cell line is predominantly in G1 or S/G2/M 
stages. Quadrants based on isotype controls 
 
 
 
 188 
 
 
PB CLL cells are generally in a quiescent stage of the cell cycle with typically greater 
than 90% of cells in G0
491
. Whilst BCR stimulus via IgM or IgD had differing effects on 
the RL cell line (IgM and IgD stimulation causing shift from G1 and G2/S into G0, 
IgM>IgD), CLL cells reliably remained in G0 despite different stimuli in 5/5 patient 
samples tested. This is generally in keeping with the published literature, whereby CLL 
cell entry into G1 is only caused by BCR stimulation in conjunction with cytokine 
stimulation (such as IL-4), stromal cell support, or nonphysiological stimuli such as 
phorbol 12-myristate 13-acetate (PMA)472,491-498. In contrast to my own data and that 
of most of the published literature, there are a few publications where a significant 
fraction of CLL cells in vitro enter the cell cycle after BCR stimulus alone319,475. These 
discrepancies may be due to methodological differences, the characteristics of the 
patients, or other unknown factors. My data are in keeping with most of the literature. 
Further attempts to induce changes in CLL cell proliferation with BCR stimulus in other 
conditions were felt to be outside the scope of this study, and were not pursued. 
 
6.4 Apoptosis after BCR ligation in CLL 
6.4.1 Introduction 
The term apoptosis was first used in 1972 to describe a morphologically distinct form 
of cell death499. Apoptosis has become acknowledged as a mode of ‘programmed’ cell 
death, occurring normally during development and ageing. It also acts as a 
homeostatic mechanism to maintain cell populations in tissues and as a defence 
mechanism when cells are damaged500. Several methods exist for the detection of 
apoptosis500. Annexin V assays have been most widely used in studies of CLL cell 
apoptosis306,319,320,372,423,501-503.  
 
Cells undergoing apoptosis translocate phosphatidylserine (PS) to the outer membrane 
under certain conditions by the action of scramblases504. Annexin V (AnV) is a 35-
36kDa, calcium dependent phospholipid-binding protein that binds specifically to PS.505 
Conjugation of AnV to fluorophores such as Fluorescein Isothiocyanate (FITC) can allow 
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labelling of apoptotic cells using flow cytometry or microscopy. Addition of a non-
permeable DNA binding dye such as Propidium Iodide (PI) can allow discrimination of 
apoptotic cells from necrotic/late apoptotic cells that have both exposed intracellular 
DNA and exposed PS. The technique has high sensitivity, being able to detect single 
apoptotic cells500. 
 
Multiple authors have examined apoptosis as an endpoint after BCR stimulation in 
CLL62,307,317,319,320. These have mostly addressed signalling through IgM, by crosslinking 
IgM with antibody or F(ab’)2 fragments. Given the data regarding the role of the BCR in 
CLL, the obvious hypothesis is that BCR stimulation will result in a decrease in 
apoptosis. However, this is a field that contains often-contradictory results. Some 
authors find that IgM stimulation results in decreased apoptosis when measured 24-48 
hours after stimulation62,320,341, whereas others find the opposite: a consistent 
induction of apoptosis with IgM stimulation307,322,423. To further complicate matters, 
some studies find reduced apoptosis with certain patient samples, no change with 
some and increased apoptosis with other patients319. These differing outcomes have 
been linked to prognostic factors such as IGHV gene mutation status, CD38 or ZAP70 
positivity, and the apoptotic outcome after IgM stimulation may have prognostic 
impact in itself319.  
 
To an extent, these divergent responses to IgM crosslinking have been accounted for 
by the different protocols used, in particular the use of soluble vs immobilised anti-IgM 
antibodies, but these do not entirely explain the divergent responses.  Many studies do 
not account for the presence or absence of proximal BCR signalling events such as Ca 
flux, and given the often anergic responses of CLL to IgM stimulation, these may well 
have an impact. These considerations are explored in greater depth in section 6.4.7. 
 
Only one group has studied the effect of IgD stimulation on CLL apoptosis, but 
methodological details are occasionally obscure in the relevant paper306. Zupo et al 
studied 10 CD38 positive CLL patients, as they had previously shown that IgM-induced 
apoptosis and Ca flux was more prevalent in CD38+ cells. They utilised both polyclonal 
goat/rabbit antibodies and F(ab’)2 fragments to IgM or IgD, but state that the use of 
antibody vs F(ab’)2 fragments made no difference. Their control was normal goat 
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immunoglobulin, but no details on the nature of this are provided. Anti-IgM 
consistently induced apoptosis at periods 24 hours to 5 days after stimulus, whereas 
anti-IgD resulted in no difference from control at early timepoints, and in some 
patients, IgD stimulation resulted in lower apoptosis after 3 days of culture. In three 
patients studied, there was no change in cell proliferation with either stimulus, 
including in combination with interleukins 2,4,6 or 10. However, the combination of 
interleukin 2 with IgD stimulation resulted in apparent plasma cell differentiation and 
production of secreted immunoglobulin after 5 days of culture, an effect not seen in 
control culture or IgM stimulation.  
 
These studies suggest that the effects of IgD and IgM stimulation result from differing 
signalling pathways activated by the two isotypes, with IgD ligation activating pro-
survival pathways and the authors attribute this effect to the neoplastic 
transformation of B-cells at a particular stage of differentiation where IgD produces a 
predominant anti-apoptotic effect as compared to IgM. Therefore, there are 
suggestions that IgD and IgM signalling play differing roles in CLL, at least in terms of 
cell survival in an in vitro system. 
 
The same group have subsequently explored IgD signalling in a larger cohort of 106 
patients506, but methodological details are not stated in this study. Apoptosis was 
measured (by PI exclusion only) 48h after anti-IgD antibody. In this context, responses 
were divided into three groups, without a consistent pro-survival effect of IgD. Group I 
(n=33) displayed inhibition of spontaneous apoptosis, Group II (n=8) exhibited 
increased apoptosis, whilst group III (n=65) did not exhibit changes in apoptosis 
(greater than 20% change in viability). Groups I and II were combined and called 
‘responders’, and this group had a significantly shorter treatment free survival 
compared to non-responders. This was also independent of ZAP70, CD38 or IGHV gene 
mutation status. Responders also had greater levels of tyrosine phosphorylation and 
surface IgD expression. The authors also state (but do not show data) that IgM ligation 
in the same cohort results in apoptotic responses that also correlate with prognosis, 
though this was not an independent prognostic factor on multivariate analysis. These 
findings are analogous to another study that linked the apoptotic response of IgM 
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signalling to prognosis319. Nedellec et al studied 41 cases and showed that these could 
be divided into three groups depending on the outcome of IgM crosslinking: Group 1 
(n=15) demonstrated no Ca flux and no changes in apoptosis. Group 2a (n=7) showed 
capacity for Ca flux but decreased apoptosis, whereas Group 2b (n=19) showed 
increased apoptosis in addition to Ca flux. Poor prognostic markers were associated 
with Group 2. 
 
In summary, data on the effect of IgM or IgD stimulation in CLL are often contradictory. 
In a limited number of cases there may be a difference in terms of IgD vs IgM 
stimulation. The effects on cell survival have not been consistently linked to Ig 
expression or Ca flux responses. I aimed to clarify the role of IgD and IgM signalling in 
my characterised cohort of patients, and relate apoptotic responses to expression of 
these two isotypes and the Ca flux responses to ligation. 
6.4.2 Methods 
Primary CLL cells were thawed, rested for 2-3 hours and levels of apoptosis measured 
as a baseline. They were then stimulated with vehicle borate buffer, IgM (10 g/mL), 
IgD (10 g/mL) or IgD+IgM (5 g/mL each). Apoptosis was then measured at 24 and 48 
hours after stimulation. Each sample is stimulated in triplicate. The AnV/PI method 
(see fig 6.26) classifies cells as either viable (AnV-PI-), early apoptosis (AnV+PI-) or late 
apoptosis (AnV+PI+). For statistical comparisons, the percentage of viable cells was 
compared. 
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Figure 6.26: The Annexin V/Propidium Iodide (AnV/PI) method for evaluating 
apoptosis.  
Shown is a representative plot. 
 
18 of the 20 characterised patients were studied using this method. 
 
In order to estimate the inherent variability of this experimental setup, stimulations 
were repeated in two patient samples (based on sample availability). Two patients (P1 
and P7) had repeated experiments, one repeat from the same sample thawed and 
stimulated on different occasions, the other from different samples taken from a 
patient 3 months apart (Fig 6.27). As shown, IgD and IgM stimulus generally resulted in 
significant improvements in viability, whilst there are no differences when the repeats 
are compared. The lack of differences was apparent when both more powerful yet less 
appropriate parametric (t-test) and non-parametric (Mann Whitney) comparisons 
were made. 
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Figure 6.27: Comparison of apoptosis levels 24 and 48 hours after different stimuli in 
the same patient samples.  
 Shown are the mean percentages of viable cells, subtracted from the values of 
vehicle control, with error bars representing standard deviation. 
C= vehicle control, M-C= IgM stimulus vs control, D-C= IgD stimulus vs control, DM-C, 
IgM +IgD stimulus vs  control 
For each comparison (t-test) of the same stimulus in the repeats, there was no 
significant difference at p<0.05. Not shown are the p values comparing each stimulus 
to control, which are significant for all stimuli. 
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6.4.3 Results: Borate buffer vehicle control has an effect on CLL apoptosis 
The anti-IgD and anti-IgM F(ab’)2 stimuli are suspended in sterile borate buffer 
composed of sodium tetraborate and boric acid at a pH of 8.2. The pH of RPMI is 8, 
which falls slightly when incubated in 5% CO2. Upon addition of anti-IgM/D in borate 
buffer at 10 g/mL, there is a slight noticeable colour change in the medium, 
presumably as a result of pH change. There was therefore concern that the borate 
buffer may affect the physiology of the CLL cells. In order to verify this, the effect of 
stimulation with anti-IgD/M was compared with various control conditions. In many 
cases, comparison of anti-IgD/M stimulation with medium alone resulted in increased 
apoptosis. However, when sterile borate buffer was used as the control condition, this 
resulted in a general relative increase in viability after anti-IgD/M stimulus. There was 
therefore the suspicion that the borate vehicle has some toxicity. This was confirmed 
by experiments comparing different conditions. Control anti-human IgG goat F(ab’)2 in 
the same medium was compared to borate buffer, ionomycin in borate buffer, and 
medium alone. Each of the stimuli using borate buffer (buffer alone, ionomycin, anti-
IgG) resulted in a significant decrease in viability (see figure 6.28). Since the effect of 
IgD/M stimulus would therefore be a combination of increased apoptosis as a result of 
toxicity of the vehicle in addition to  any effect of IgD/M itself, all experiments 
subsequently used sterile borate buffer as a control. In early experiments, anti-IgG 
F(ab’)2 was also used, but one patient sample (not amongst the 20 characterised used) 
was noted to exhibit Ca flux after this stimulus (presumably as a result of IgG class 
switching or adsorbed IgG), and so this control condition was not used for apoptosis 
experiments. Note that there was no effect on Ca flux of the borate buffer. 
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Figure 6.28: Comparison of viability at 24h after stimulation with a variety of 
conditions.  
Error bars show standard deviations. 
 
6.4.4 Results: Some residual viable cells after 48 hours of culture are non-B-cells 
Whilst all samples were formed of a majority of CD5+CD19+ CLL B-cells at baseline (all 
>87%, the majority>95%), this may not be true after 24-48h in culture. To estimate the 
proportion of B-cells amongst viable cells remaining after 48h, staining with CD19-FITC 
and propidium iodide was also performed (in 14/18 samples), and the proportion of 
viable (PI negative) that were also CD19 positive was calculated (see figure 6.29). The 
mean proportion of CD19+ viable cells at 48h was 69% (range 37-92%), indicating that 
whilst B-cells generally formed the majority of cells alive after incubation in vitro, in 
some cases the remaining viable population was often comprised of a large proportion 
of non-B-cells. This measure of viability will include AnV positive cells, and so is not the 
same measure of viability as used in most of my experiments examining apoptosis. 
Interestingly, PI positive cells are generally also CD19 positive. 
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Figure 6.29: Estimation of proportion of viable cells that are also B-cells at 48h. 
Shown is a representative plot, with quadrants drawn at the 99th centile for isotype 
controls. Shown below are the proportions of viable (PI negative) cells at 48h, in blue 
are the viable B-cells also CD19+, in red the viable CD19- cells.  
  
 
 
 
 
 
6.4.5 BCR stimulus via IgM and IgD results in decreased apoptosis 
In general, stimulation with anti-BCR antibodies led to increase in viability. 
Vehicle control stimulated cells had the typical decrease in viability over time (Fig 
6.30): 
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Figure 6.30: Proportions of viable cells at different times after stimulation. 
a) The mean values for all 18 samples in the control condition 
  
b) the derived mean for these controls 
 
c) the mean values of all 18 samples for each of the different stimuli (c=control 
vehicle, m=anti-IgM, d=anti-IgD, dm=anti-IgD+anti-IgM) 
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The differences between stimulated and control is highlighted when the percentage of 
cells is subtracted from the mean control value at that time point (see Fig 6.31). 
Heterogeneity of response is seen. 
 
Figure 6.31: The effect of IgM stimulation on viability.  
Shown are the mean viabilities of each IgM-stimulated sample subtracted from the 
vehicle control means. Error bars represent standard deviations of each triplicate. 
  
The most apparent effect is that IgD or IgM stimulus results in a decrease in apoptosis 
as compared to vehicle control (fig 6.32). However, when IgD is compared to IgM 
stimulation, there is a small but significant difference, with IgD stimulation resulting in 
greater viability. 
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Figure 6.32: Mean viabilities for all samples combined 
Viability after stimulus subtracted by viability with vehicle control. P values are 
derived from comparisons using the wilcoxon signed rank test. 
 
This reflects the underlying heterogeneity of responses (fig6.33): 
 
Figure 6.33 Comparison of mean viabilities for each sample, IgD stimulated–IgM 
stimulated. 
 
The reasons for this heterogeneity were explored further. Higher expression of IgD 
generally led to higher viability after IgD stimulus at 24h, with low/zero expression of 
IgD being associated with no change in viability compared to control (Fig 6.34). 
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However, the correlation between IgD expression and viability after IgD stimulation 
was not significant at the p<0.05 level, and any relationship is weaker after 48h. 
Figure 6.34: Percentage expression IgD vs mean viability change after IgD stimulation 
compared to control 
24h 
  
48h 
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Despite this increased calcium flux after IgD stimulus is significantly correlated with 
viability at 24h (fig 6.35), though the relationship is lost after 48h: 
 
Figure 6.35: Mean change in viability after IgD stimulus compared to Ca flux after IgD 
stimulus 
 
48h 
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Conversely, IgM expression and calcium flux was not correlated with viability after 
stimulus and some cells increased viability in the absence of ca flux (Fig 6.36): 
Figure 6.36: Percentage expression IgM vs mean viability change after IgM 
stimulation compared to control.  
Also shown is the mean change in viability after IgM stimulus compared to Ca flux 
after IgM stimulus 
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Finally, dual stimulation with anti-IgD+anti-IgM also led to increased survival, and this 
was more correlated with IgD signalling (Fig 6.37): 
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Figure 6.37 Change in viability after IgD+IgM stimulus versus Ca flux after IgD or IgM 
stimulus 
 
 
 
 
There was no obvious association between stimulus-induced viability and IGHV gene 
mutation, CD38 or ZAP70 status. Finally, there was a strong correlation (Spearman 
r=0.83, p = 0.0001) between the ability of a sample to respond to either IgM or IgD 
stimulus with an increase in viability (see Fig 6.38). This was not associated with IGHV 
mutation status, CD38 or ZAP70 positivity. 
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Figure 6.38: Change in viability after IgD or IgM stimulus.  
Below is shown the data according to prognostic factor. 
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6.4.6 Summary and Discussion: Apoptosis after BCR ligation  
Apoptosis was assayed using the Annexin V-Propidium Iodide method and 
comparisons made using the percentage of viable cells present at 24 and 48 hours 
after stimulation with anti-IgD or IgM F(ab’)2 fragments. When frozen samples from 
the same patient are thawed and stimulated on different occasions, the same pattern 
of responses is seen, and this holds for samples from the same patient taken and 
frozen on different dates, though this repeat experiment was only attempted with two 
patients. This suggests that a particular patient sample responds in the same way. 
 
Whilst many studies examine CLL cell apoptosis after BCR ligation, it is not always 
possible to compare methods. The most common methods involve Propidium Iodide 
(PI) exclusion, often in combination with Annexin V (AnV) staining and examination by 
flow cytometry. Many reports showed data comparing PI positive (designated 
apoptotic) vs PI negative (designated viable)62,307,317. Others compared AnV positive 
(designated apoptotic) vs AnV negative (designated viable)62,321.  Some appeared to 
use combinations of AnV and PI, but it is impossible to judge from the published data 
whether they designate AnV positivity alone or AnV+PI+ cells as apoptotic.317 Many 
studies did not account for the presence or absence of proximal BCR signalling events 
such as Ca flux, and given the often anergic responses of CLL to IgM stimulation, these 
may well have an impact 
 
Though there is much variation and it is sometimes difficult to directly compare 
results, my findings regarding the general decline of CLL cell viability in medium alone 
are in keeping with published results306,319,320,372,423. Whilst I have studied a limited 
number of samples, the size of the cohort is similar or greater than those of published 
series  
 
In general, stimulation with IgD, IgM or a combination of both led to small but 
significant increases in cell survival at 24 and 48 hours. A small difference between IgD 
and IgM is also seen, with IgD appearing to promote survival at greater levels than 
IgM, though the average effect is relatively small. 
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When the amount of improvement in viability is related to expression of the relevant 
isotype, there was no statistically significant correlation with IgD or IgM expression. A 
significant correlation exists between IgD-induced Ca flux and viability at 24 hours after 
IgD or IgD+IgM stimulation, the only suggestion that relates the capacity of BCR 
signalling via IgD to a role for IgD on promoting CLL cell survival. There are puzzling 
findings that improvements in viability after IgM stimulation may occur in cells that 
have low expression of IgM or exhibit no Ca flux with IgM. One explanation for this 
may be that Ca flux is not required for the pro-survival effects of IgM.  However, given 
the findings of recovery of IgM Ca flux after incubation in vitro, an alternative 
explanation may be offered. I speculate that a period of incubation permits IgM 
signalling to recover over 24-48h, at which time binding to the F(ab’)2 stimulus may 
occur, resulting in a survival signal. This may occur to a lesser extent with IgD 
 
 
What is clear is that both IgD and IgM stimulation exert a pro-survival effect. However, 
the degree of viability change does not correlate in a straightforward fashion with the 
expression of the BCR isotype, or the Ca flux induced after stimulation. Limited data 
suggest a relationship between the degree of IgD-induced Ca flux and decreased 
apoptosis. 
 
Figure 6.38 suggests a correlation between responses to IgM and IgD in terms of 
improved viability. This suggests that a particular patient sample may have an inherent 
ability to respond to BCR stimulation. This is not correlated with the usual prognostic 
markers that are often invoked to explain differing responses to BCR ligation. Whilst 
microenvironmental signals are important, the intrinsic characteristics of the 
leukaemic cell will have a major impact on disease biology. A general ability to respond 
to BCR stimulation by whichever isotype may vary between patients. 
 
There are some differences between IgM and IgD, with IgD appearing to exert a 
greater anti-apoptotic effect. Possible explanations for this include greater IgD 
expression relative to IgM; greater IgD Ca flux; unconsidered effects of the F(ab’)2 
stimulus, such as the affinity of the antibody; the 2-3 hour ‘rest’ period after thawing 
 208 
may have different effects on IgD and IgM signalling capacity. The phenomena of 
reversal of IgM (and to an extent IgD) anergy by incubation in vitro adds another level 
of complexity to this attempt to correlate the amount of BCR signalling with the 
amount of pro-survival effect of BCR signalling. A dose response relationship is often 
used to infer causality. Where this dose-response exists, these limited data suggest IgD 
may have a greater effect on survival than IgM, but it is difficult to draw strong 
conclusions from these data. 
 
 I suggest that there may be genuine differences in IgD and IgM signalling that account 
for these data, particularly considered in the light of the Ca flux data. 
6.4.7: Choice of Stimuli 
The choice of control as a comparison appears to be critical. When IgD or IgM 
stimulation is compared to culture in medium alone, IgM and IgD often appear to 
induce apoptosis. In contrast, when the same stimulations are compared to borate 
buffer vehicle controls, IgD and IgM are seen to promote cell survival. Therefore, the 
borate vehicle used for dissolving the stimulating F(ab’)2 appears to have a degree of 
toxicity. It is clear that if this effect of vehicle is not taken into account, and medium 
alone is used as a control, then stimulation with IgD/IgM will often lead to induction of 
apoptosis. This is discussed further in relation to the published literature. 
  
It is often considered straightforward to stimulate B-cells via their BCR, one simply 
cross-links sIg and marked changes in biochemical cascades and cellular behaviour 
occur. This simplistic model has been enormously successful in elucidating crucial 
signalling pathways in B-cells. Most studies in CLL have crosslinked  sIg on B-cells by 
monoclonal antibody to sIg components, an approach that is well tested in studies of 
healthy B-cells.  
 
How does the surface immunoglobulin that constitutes the BCR transduce the signal 
caused by antigen encounter across the membrane to the interior of the cell? It has 
often been thought that the simplest model for this is by crosslinking of multiple BCRs 
by polyvalent antigen, and this explains the more robust responses seen in vitro by 
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using multivalent antigens, but monovalent antigens are also able to stimulate B-cells 
as well. Other perturbations, perhaps involving conformational changes in 
immunoglobulin, lipid rafts or the cytoskeleton have been postulated308,311. It is likely 
that many different factors are crucial in mediating this initial step of BCR signal 
transduction, but despite much work in this area, the exact process is not clear-cut. 
Whilst crosslinking the BCR using anti-sIg antibodies clearly produces a robust 
response in B-cells that mimics effects seen when B-cells bind their cognate antigen, it 
may not recapitulate the situation in vivo as closely as is commonly assumed.  
 
Some studies suggest that soluble antigen produces different responses from 
membrane-bound antigen, with immature cells encountering membrane-bound self-
antigen undergoing apoptosis, whilst soluble self-antigens induce anergy235,507. Some 
argue that this is due to the multivalent nature of membrane-bound antigens 
providing a stronger BCR signal508. Soluble antigen is taken up and internalised by B-
cells, which can continue activating cells via BCR signalling and endosomal Toll-like 
Receptors, as well as undergo further processing for presentation to T cells509,510. Full 
B-cell activation is dependent on both BCR signalling at the plasma membrane and T-
cell help received when B-cells act as antigen-presenting cells, so internalisation of 
antigen is an important mechanism. Soluble antigen is a well-recognised potent 
immunogen, as small molecules such as toxins can readily enter follicles within lymph 
nodes, bind follicular B-cells and cause activation250. However, increasing attention is 
focussed on the recognition of antigen on the surface of membranes, in particular on 
the surface of antigen-presenting cells511.  
 
Antigen within the lymph node is often expressed on the surface of other cells such as 
macrophages, dendritic cells and follicular dendritic cells250. This generally produces 
more robust signalling, though this may be attributed to co-stimulation or adhesion 
molecules expressed by these antigen-presenting cells, rather than the spatial context 
per se. The formation of BCR microclusters on encountering membrane-bound antigen 
is dependent on CD19 and rearrangements of the cortical cytoskeleton298.  
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Some authors have increased signalling strength by using anti-sIg monoclonal 
antibodies linked to streptavidin and crosslinked with biotin (though presumably these 
can subsequently be internalised), 329. Others have used anti-IgM conjugated to the 
polysaccharide Dextran, which has been shown to produce a multivalent BCR stimulus 
that may have greater potency in activating B-cells508,512, and which can induce pro-
survival responses in CLL, as compared to medium alone or soluble anti-IgM F(ab’)2
513. 
Interestingly, one study did not observe Ca flux after use of dextran-conjugated anti-
IgM, a finding which has been noted in healthy mouse B-cells, and which suggests that 
Ca flux may not be necessary for mitogenic responses514.     
 
Some investigators have attempted to make their in vitro models of BCR stimulation in 
CLL more physiologic by immobilizing the anti-IgM to simulate membrane-bound 
antigen encounters. One early study noted CLL cell proliferation after use of Sepharose 
bead-coupled anti-IgM.329 More recently, Petlickovski et al have used anti-IgM coupled 
to magnetic beads.320 They noted marked differences of behaviour of CLL cells 
simulated with either soluble or immobilized anti-IgM, with greater pAkt and pERK 
with immobilized anti-IgM, and induction of CLL cell survival rather than apoptosis. 
They have found similar effects in more than one study.487 372 
 
An alternative approach to immobilizing anti-IgM antibodies involves coating culture 
plates with the antibody before adding cells. 321 This form of immobilized F(ab’)2 and 
IgM has been shown to exert an antiapoptotic effect on CLL cells, compared to no 
stimulus or soluble antibody515 400. In a different protocol, Nedellec et al and Guarini et 
al used plates coated with anti-goat antibody, added CLL cells, then added 10 g/mL 
goat anti-IgM F(ab’)2. They suggest that this approach was an immobilised stimulus, 
though presumably some stimulus would have also occurred in a ‘soluble’ form. This 
may explain both these groups’ findings: some cases exhibited a decrease in apoptosis 
and some an increase. Guarini (n=9) found an increase in apoptosis in M-CLL, and an 
increase in proliferation in U-CLL (increase in G1 from 1% to 2.7% after stimulation).  
 
Despite following the same published protocol for coupling beads to anti-sIg 
monoclonal antibodies, I was  unable to produce beads that appeared to bind cells 
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known to be IgM positive (RL cell line). Correspondingly, there was no apparent effect 
of ‘conjugated‘ beads on calcium flux, apoptosis, or cell proliferation, compared to 
unconjugated beads, and so this approach was abandoned. Due to lack of published 
methodology, the coating of culture plates was not pursued. It is uncertain as to how 
to judge the success of the process. This lack of use of immobilised stimuli is a 
weakness in my work that will make comparisons with other studies somewhat 
difficult. 
 
There is therefore a consensus that immobilised vs soluble anti-IgM may well account 
for some of the differences between the studies of BCR signalling in CLL, a finding that 
makes sense considering similar findings in healthy B-cells and considers the 
physiological context in which most antigens are encountered. However, it does not 
explain why some groups using soluble anti-IgM find an increase in viability whilst 
others find an increase in apoptosis. It may be helpful to consider the exact methods of 
BCR stimulation in each of the published studies.  
 
Burger’s group report an increase in viability after IgM crosslinking, compared to 
medium alone, an effect blocked by SYK inhibition 69,341. They crosslink with 10 g/mL 
polyclonal anti-IgM F(ab’)2 supplied by MP biomedicals. This appears to be a 
lyophilized reagent that is reconstituted with medium before stimulus, therefore there 
is no effect of vehicle in addition to F(ab’)2, which may explain their consistent findings 
of improved viability after IgM stimulation. 
 
Efremov’s group have published several papers finding improved survival after IgM 
ligation with anti-IgM coupled to beads, in contrast to increased apoptosis with 
10 g/mL anti-IgM F(ab’)2 in borate buffer
320,372,388, and a different group comparing 
soluble F(ab’)2 (borate buffer) vs plate bound F(ab’)2 have shown the same effect
321. 
Similarly, Vallat et al found increased apoptosis with the anti-IgM F(ab)2 coupled to 
biotin, again in borate buffer, as compared to medium alone423. 
 
Two groups have compared soluble anti-IgM F(ab’)2 with some form of vehicle control. 
Allsup et al found increased survival with IgM ligation when F(ab’)2 was compared to 
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an isotype control, both in phosphate-buffered saline317.  Similarly Bernal et al found 
increased survival when anti-IgM F(ab’)2 was compared to polyspecific goat F(ab’)2. 
The company website (American Qualex) does not provide datasheets that provide 
information on the vehicle used in this study, and did not respond to enquiries. 
 
In summary, authors find that soluble anti-IgM F(ab’)2 increases apoptosis when 
compared to incubation in medium alone, with the exception of Burger’s group, who 
reconstituted lyophilized F(ab’)2 with medium. Analogous to my studies, the groups 
that compared some form of vehicle control found improved survival after IgM 
stimulation. Immobilised anti-IgM antibodies, either plate- or bead-bound, resulted in 
increased survival relative to both medium and soluble F(ab’)2. Some groups used a 
method that probably combined soluble with immobilised stimulus, and interestingly 
they found a mixture of responses. It therefore seems that the exact method of 
crosslinking IgM has a critical effect. This is probably in addition to a greater pro-
survival effect of immobilised stimulus (though I suggest that a valid comparison has 
not been made). Additional factors such as CD38 and IGHV gene mutation status 
probably also have an effect, as various studies have found differences in the degree of 
apoptosis in differing prognostic groups. If this argument is accepted as valid, then 
most of the published literature is probably compatible with soluble anti-IgM stimuli 
causing an improvement in CLL survival. 
 
These arguments also apply to my studies, though my main interest was in comparing 
BCR signalling via IgM and IgD. It does suggest that further work clarifying the exact 
method of BCR stimulus would be prudent. 
 
6.4.8: Summary and Discussion: Outcomes of BCR ligation in vitro: Calcium 
Flux, apoptosis and cell proliferation 
 
Teleologically, B-cells respond to BCR signalling with two divergent outcomes. The 
encounter of microbial antigen should result in pro-survival and proliferative stimuli to 
enable antigen-specific B-cells to mount an effective immune response. The encounter 
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of autoantigen ideally leads to an opposite response: pro-apoptotic BCR signals lead to 
deletion from the repertoire, or anergy results in the inability of autoreactive B-cells to 
mount an inappropriate response. Which of these divergent pathways a B-cell takes is 
dependent on a variety of factors. The nature of the antigen, binding affinity, binding 
valency and spatial arrangement is important. One critical factor is the presence of a 
second signal to accompany the primary BCR signal. Classically, this second signal is 
delivered by antigen specific helper T-cells, but additional signals are derived via other 
receptors such as Toll-like receptors that indicate inflammatory processes that may be 
caused by invading microbes. I have not considered these factors in my studies, 
attempting to focus on BCR stimulation alone. To an extent, some investigators have 
simulated these factors in conjunction with BCR stimulus in CLL.  
 
Another critical factor affecting the response to BCR signal is the developmental stage 
of the B-cell. At an early stage in differentiation, BCR signalling is more likely to reflect 
binding of autoantigen, as microbial exposure is unlikely in bone marrow in utero. 
Therefore, BCR signals generally lead to deletion or receptor editing in the process of 
central tolerance. Mature cells are more likely to be expected to deal with foreign 
invaders, and so tend to respond to BCR ligation with proliferation. These differing 
outcomes are thought to be partly due to the pattern of activation of pathways 
downstream of the BCR, with dependence on pro-survival pathways that involve BTK, 
AKT and NF-kB285. It seems that the outcome of BCR ligation is therefore dependent on 
the particular pattern of pathways activated, and B-cells can be primed to respond 
with an apoptotic or proliferative response by altering which signalling cascades are 
connected to the BCR. To an extent, proximal BCR signalling events such as Ca flux are 
common to both pro- and anti-apoptotic pathways, but these proximal events are also 
modulated to determine these outcomes. A classic example is the attenuated Ca flux 
of anergic B-cells. Some mechanism has recognised that chronic antigen stimulation is 
occurring, and down-regulated the expression of IgM, and the ability of IgM to trigger 
Ca flux. The anergic B-cell is therefore thought to be primed to permit tolerance to 
autoantigen. This priming is reversed by removal of antigen. Paradoxically, IgD does 
not exhibit this effect, though there is a lesser degree of reduced IgD expression in 
mouse models of anergy292. There are various explanations. Perhaps IgD is less critical 
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than IgM in determining B-cell responses. The ability of IgD to compensate for the 
absence of IgM suggests that it can fulfil most of its cousin’s roles. There are also 
certain immune defects in IgD-deleted mice, though these are relatively subtle. The 
maintenance of IgD throughout evolution suggests it plays some important role. 
 
An alternative explanation is that IgD signalling is maintained in order to permit 
autoreactive cells to survive. It could be argued that ideally, all autoreactive B-cells 
should be deleted in the process of central tolerance. Why is anergy such a major 
tolerance mechanism? It may be that it simply deals with those cells that have escaped 
central tolerance. Alternatively, there may be some benefit to maintaining this pool of 
autoreactive B-cells. To an extent, newly generated BCRs must provide some signal in 
order for B-cells to survive, and it is well known that a weak level of autoantigen 
binding can provide such survival signals94.  Also, in order to provide a repertoire that 
recognises the almost infinite variety of potential microbial antigens, some 
autoreactive B-cells are maintained that may subsequently be required to fight off an 
invader. This process goes awry during molecular mimicry, where overt autoimmune 
disease is subsequent to an infection and autoreactive B-cells attack autoantigens with 
similar epitopes to those present on microbial antigens212. Finally, there is a population 
of B-cells that produces natural autoantibody that may play an important role in 
clearing cellular debris such as apoptotic cells516. These explanations may provide a 
rationale for maintaining a population of autoreactive B-cells, rather than deleting 
them, with IgD perhaps providing a tonic signal. 
 
In truth, no one has offered a convincing reason why B-cells co-express IgM and IgD, 
nor accounted for signalling differences between these two isotypes. What is known is 
that IgD and IgM are co-expressed in CLL, and that CLL resembles anergic B-cells in 
terms of lower IgM expression and attenuated ability to undergo proximal BCR events 
such as Ca flux. The anergic model is reinforced by the dynamic nature of IgM 
signalling, with reversible anergy after in vitro incubation. This is indirect supportive 
evidence for a model whereby chronic antigen binding is occurring in vivo. It may be 
that a degree of reversal of anergy may occur when CLL cells are in the peripheral 
blood, with re-encounter with antigen and IgM downregulation recurring on entry to 
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the lymph node microenvironment. This might account for cases of CLL that are able to 
undergo Ca flux after IgM ligation, as these circulating cells have had some time away 
from chronic antigen exposure, enabling them to upregulate IgM. 
 
Teleologically, if the antigenic selection hypothesis of CLL is correct, one would expect 
BCR ligation to provide pro-survival signals. Many studies do in fact find that BCR 
ligation in vitro provides such a signal, and my findings agree with these studies. Those 
studies that find apoptosis after IgM ligation may be due to the nature of the stimulus 
used, both in terms of the relevant control for comparison, or soluble vs immobilised 
stimuli.  The reversible nature of anergic IgM signalling also complicates the picture. I 
suggest that IgD and IgM can both deliver pro-survival signals in CLL. This is 
teleologically plausible, as the IgD and IgM isotypes will have identical antigen-binding 
regions, and therefore both bind the putative antigen. There is also the suggestion that 
IgD signalling may have a greater pro-survival effect than IgM, though the effect is 
small, and it is difficult to tease out whether this is due to higher expression of IgD, 
greater capacity to signal, an effect of the crosslinking reagent, or other factors. 
Despite their many similarities, the IgM and IgD isotypes of the BCR appear to play 
differing roles in CLL. The next Chapter describes attempts to describe mechanistic 
differences between IgD and IgM signalling.  
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7. Results-Phosphoproteomic analysis of BCR signalling 
7.1 Introduction 
Mass-spectrometry based phosphoproteomics is a technique that has great potential 
for mapping intracellular signalling pathways. Post-translational modifications (PTMs) 
change the conformation of proteins and thereby alter enzymatic activity, binding 
affinity and other functions428. The most important PTM is conceived to be protein 
phosphorylation on serine (85% of protein phosphorylation), threonine (10-15%) and 
tyrosine (1-2%) residues. This PTM is reversible and can produce rapid changes in 
protein tertiary structure that in turn affect protein function and cellular signalling 
pathways 429. Despite its low relative abundance, regulated tyrosine phosphorylation is 
critically involved in many membrane-proximal signal transduction processes and is 
best characterised, though this may be due to the relative ease with which 
phosphotyrosine can be identified compared to phosphoserine/threonine. The 
number of diseases associated with mutations in tyrosine kinases also reflects the 
importance of phosphotyrosine428. Phosphorylation can regulate a variety of important 
functions, including subcellular localization, degradation and stabilization. It can 
control the binding of transcriptional regulatory elements to their regulatory sequence 
elements and alter the actions of RNA processing enzymes as well as the classically 
conceived regulation of biochemical activities of enzymes such as kinases430. Other 
PTMs such as ubiquitination, acylation and glycosylation are being explored by newer 
techniques. A brief summary of the high-throughput proteomic methodologies follows 
before the insights gained from the phosphoproteomic techniques are discussed. 
 
7.1.2 Phosphoproteomics 
All proteomic experiments are faced by the same challenges: complexity, dynamic 
range and temporal dynamics.428 The PhosphoSitePlus database currently (October 
2012) lists >170,000 phosphorylation sites in a variety of species517, and the numbers 
continue to increase428. Protein phosphorylation can occur extremely rapidly, receptor 
tyrosine kinase (RTK) phosphorylation often starting within seconds after stimulus 
application.518 Tyrosine phosphorylations generally occur faster than serine/threonine 
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phosphorylation. On addition of epidermal growth factor to HeLa cells, most EGFR 
tyrosines become phosphorylated within 1 minute, some within seconds, while serine 
and threonine phosphorylation may require up to 10 minutes519. Despite the low 
abundance of tyrosine phosphorylation, it is very dynamic and can build extensive 
networks with interaction partners through binding motifs, such as src homology 2 
(SH2) domains.520  
 
There are diverse methods for analysis and quantification.521 Previously, the 
identification of protein phosphorylation sites relied on the classical methods of in 
vitro and in vivo labelling with radioactive 32P-phosphate, peptide sequencing by 
Edman degradation, often followed by mutational analysis to verify the modified 
residue. Recent developments in Mass Spectrometry (MS) have had a dramatic impact 
on protein phosphorylation research. Thousands of phosphorylation sites can now be 
analysed in a large-scale manner and new techniques are reported regularly522,523.  
 
Phosphorylated proteins may number hundreds of millions to a few copies per cell, 
and many of the phosphorylation events that are associated with known signalling 
pathways may occur on proteins expressed at a relatively low level. Large scale 
quantitative analysis has shown that up to 30% of the phosphorylation sites can 
change in abundance within 30 minutes after application of a specific stress.520 Most 
changes are less than tenfold, suggesting that phosphoproteome dynamics is 
expressed in changes of threshold levels rather than on-off phosphorylation. Several 
authors imply that phosphorylation only occurs on signalling proteins at low 
abundance, but phosphoproteomic datasets are not overrepresented in terms of low 
abundance proteins, and the profile of abundance distribution is similar for the 
proteome and the phosphoproteome523. It is generally implied that phosphorylated 
versions of a protein comprise a minority of all the molecules representing that 
protein. 
 
Transient and substoichiometric changes in phosphopeptide levels are difficult to 
detect in whole cell lysates with millions of peptides. In order to generate a global view 
of serine, threonine and tyrosine phosphorylation that occurs at low stoichiometry 
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within a sample, enrichment techniques are used. Immunoprecipitation (IP) of 
tyrosine-phosphorylated proteins with high affinity antiphosphotyrosine antibodies 
provides a good yield and specificity524. The large size of phosphotyrosine makes this 
modified amino acid more immunogenic than phospho-serine or –threonine and 
therefore it has been easier to make anti-phosphotyrosine antibodies. Pan-specific 
antibodies for phosphoserine and phosphothreonine tend to be of lower affinity and 
yield unsatisfactory enrichment.428 
 
Another commonly used method involves the use of immobilized metal affinity 
chromatography (IMAC), based on the high affinity of phosphate groups for metal ions 
such as Fe3+, Zn2+ and Ga3+ 525. Detection of phosphopeptides in the femtomole range 
can be achieved, and stable isotope labelling may enhance quantification.526 Titanium 
dioxide (TiO2) has emerged as the most common of the metal oxide affinity 
chromatography (MOAC)-based phosphopeptides enrichment. It has a greater capacity 
and convenience relative to IMAC resins. Phosphopeptide-enriched mixtures can then 
be analysed further. They may be resolved into various molecular weight fractions by 
liquid chromatography–tandem mass spectrometry (LC-MS/MS) for protein 
identification. Much of the initial work on MS-based phosphoproteomics was 
concerned chiefly with identifying novel phosphorylation sites, but in order to identify 
important changes in cellular networks, quantification of changes in phosphorylation is 
necessary.428 Several MS-based quantification methods are available, often using 
labelling of amino acids with stable isotopes, which are then incorporated into 
cultured cells. These techniques are not generally applicable to primary cells, but other 
techniques such as spiking samples with a known concentration of phosphopeptides or 
labelling after enrichment steps have been used successfully527. A label-free method 
that quantifies peptides based on their ion intensity in MS spectra is proving to be a 
reasonably reliable quantitative means of determining relative levels of 
phosphopeptides within a sample439.  
 
Evaluating changes in phosphorylation across a large number of sites in a network is 
required to adequately describe the mechanisms by which phosphorylation controls 
cell biology. Rapid advances in these high-throughput techniques have not been 
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paralleled by equally powerful methods of analysing and interpreting the data 
generated, but the large-scale technologies have driven new approaches to analysis 
and interpretation. Phosphoproteomics by MS may represent an unbiased approach 
capable of monitoring cellular phosphorylation events in the absence of a priori 
knowledge. This would lead to a greater confidence in the interaction and signalling 
networks produced by high-throughput techniques as compared to an approach based 
on a narrow consideration of the curated literature. 
 
7.1.3 Phosphoproteomics in studying haematological malignancies and 
immunoreceptor signalling 
A limitation of the phosphoproteomics techniques is the large numbers of cells 
required per sample, this is reflected in the widespread use of cell lines to provide 
sufficient numbers of cells for experiments. Primary tumour cells are generally hard to 
obtain, but studies of leukaemia have the advantage that large number of malignant 
cells exist in relatively high purity in the nucleated fractions of blood. A small number 
of phosphoproteomics studies have examined myeloid malignancies and have 
identified a few hundred phosphoproteins in acute and chronic myeloid leukaemia cell 
lines528,529. A recent study used IMAC and LC-MS/MS to identify 76 unique 
phosphoproteins in mantle cell lymphoma cell lines.530 These data were correlated 
with information known on copy number gains obtained by Single Nucleotide 
Polymorphism-chip analysis and proteins involved in signal transduction cascades. 
Pathways involving NF kB and PI3K were affected, and potential novel pathways in 
mitochondrial signalling were implicated. Advances in techniques are permitting the 
identification of ten of thousands of phosphoproteins.  
 
The only phosphoproteomic study of CLL examined the consequences of CXCR4 
signalling531. Analysis of 5 CLL samples generated approximately 1200 unique 
phosphosites, but with very little overlap between patients. The ability of this study to 
quantify phosphoproteins was limited, but several phosphoproteins thought to be 
relevant to CLL biology were identified, including LYN, SHIP-1 and HS1. Semi-
quantitative data suggested the involvement of PDCD4 and HSP27 in CXCR4 signalling.  
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Dynamic signalling pathways in immune cells have been examined in a limited fashion 
using MS-based proteomics platforms. Phosphoproteins involved in signalling have 
been examined at various time points after stimulation of the FC RI receptor in mast-
cell lines.532 One recent study has characterised 450 of 2000 proteins in murine T cells 
that were differentially regulated by T Cell Receptor stimulation533. This study 
highlighted novel mechanisms for HDAC7 in T Cell receptor signalling, highlighting the 
power of the technique. One study has examined BCR signalling in B-cell lines by 
examining phosphotyrosine changes.534 In this study, BCR or TCR crosslinking was 
compared to cells with non-specific tyrosine phosphorylation produced by 
pervanadate. The B-cell line Namalwa was incubated with anti-sIgM for 3 minutes then 
washed, lysed, and purified by anti-phosphotyrosine antibody-conjugated sepharose 
column to enrich for phosphoproteins. TCR signalling was also examined. There was 
extensive overlap in identified phosphoproteins involved in signalling via both the TCR 
and BCR, with 128 of 725 proteins identified as being common to BCR and TCR 
signalling. Common proteins included tubulin isoforms, ribosomal proteins, 
chaperones, Cbl, Rho GTPases etc. Proteins not obviously directly involved in signalling 
such as tight junction protein Z02 and translational regulator eIF3 were also identified. 
There was also a stimulation of phosphorylation of RNA processing and endocytosis-
related proteins.  
 
Techniques have evolved whereby each experiment can generate ever-greater number 
of phosphopeptides for consideration. The phosphoproteomic techniques have not to 
date been applied to the study of BCR signalling in primary cells, leukaemic or healthy. 
It is hoped that by using phosphoproteomic methods, the mechanisms of BCR 
signalling will be elucidated in the absence of a priori assumptions about the nature of 
the pathways involved. The use of this technique has not reported in healthy B-cells, 
and so novel aspects of physiological BCR signalling may also be highlighted and 
comparison of the phosphoproteomes of healthy B-cells compared that that observed 
in leukaemia may be informative. In this study, the phosphoproteome of CLL cells is 
considered and compared to that of tonsil B-cells. The effect of BCR stimulation on the 
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phosphoproteome is then considered, with a focus on the differences between IgD 
and IgM, and between CLL and Tonsil. 
7.2 Methods 
7.2.1 Samples  
To determine the phosphoproteome of CLL cells after BCR stimulus, samples were 
selected from untreated patients whose cells exhibited robust Ca flux with both IgM 
and IgD (Fig 7.1). This use of non-anergic samples enabled the study of IgD and IgM 
signalling without the complication of considering complete IgM anergy (absence of 
calcium flux) as a factor in this work.  
 
Figure 7.1 Calcium flux characteristics of samples used for proteomics.  
Empty circles represent other samples tested (for further details see Chapter 6).  
 
 
 To minimise handling and potential activation of cells by selection techniques that 
involve the use of monoclonal antibody binding, samples with known high proportions 
of malignant B-cells were used, as well as cases that had a range of prognostic markers 
in order to represent the known molecular heterogeneity of this disease. Patient 
characteristics of the samples used in this study are shown in table 7.1: 
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Table 7.1 Characteristics of patients studied in phosphoproteomic experiments 
UPN: Unique patient number (see chapter 5) 
IGVH: Immunoglobulin IGHV gene mutation status (M=mutated, <98% homology to 
baseline, U=unmutated, 98% homology to baseline) 
Cytogenetics: FISH panel for CLL performed 
CD38: peripheral blood flow cytometric expression (1=>30%, 0=<30%) 
Ca flux: Percentage of cells undergoing Ca flux at 1 minute, as a proportion of 
calcium flux with ionomycin (see Chapter 6) 
CD19+CD5+: percentage of cells dual positive for CD5/CD19 by flow cytometry 
UPN 
Proteomics 
ID 
IGHV Cytogenetics CD38 
Ca flux 
IgM 
Ca flux 
IgD 
CD19+ 
CD5+ 
P7 UM1 U del13q del11q 0 23 37 95.9 
P20 UM2 U del13q 1 21 59 98.3 
P16 UM3 U del17p 1 52 44 98.4 
P17 M1 M del13q 1 19 70 91.7 
P19 M2 M del13q 0 15 27 98.6 
P18 M3 M del13q 0 50 30 98 
 
Tonsillar B-cells were used as a control, as they displayed robust Ca flux with IgD and 
IgM and provided sufficient numbers of cells for the analysis. Cell suspensions were 
derived from fresh tonsil, and negative selection for B-cells performed before freezing 
and storage. Apart from the negative selection process, cells were treated identically 
to the CLL samples. Purity was assessed by CD19 staining (Fig 7.2) 
 
Table 7.2 demonstrates that the selection technique used to purify tonsillar B-cells 
achieves >90% purification, and figure 7.3 indicates that these are predominantly 
(94%) naïve B-cells (defined by CD27 negativity) that express IgD, or both IgM and IgD, 
in keeping with the results obtained with calcium flux after stimulation (Fig 7.4). 
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Figure 7.2: CD19-determined purity of tonsillar B-cells 
 a) before and b) after negative selection for B-cells (representative plots). Isotype 
control (red) is compared to FITC-conjugated antibody specific for the B-cell marker 
CD19 (blue). Selection increases B-cell proportions to 95.3% of all cells 
a     b 
  
Table 7.2: Characteristics of of negatively-selected tonsillar samples  
Ca flux: Percentage of cells undergoing Ca flux at 1 minute, as a proportion of 
calcium flux with ionomycin (see Chapter 6) 
CD19+: percentage of cells positive for CD19 by flow cytometry 
Tonsil number CD19+ Ca flux IgM Ca flux IgD 
1 95.3 57 71 
2 97.9 50 64 
3 96.9 83 75 
4 94.3 56 67 
5 92.1 74 84 
  
Figure 7.3: Surface isotype  and CD27 expression of purified tonsillar B-cells (tonsil 
number 1).  
Quadrants based on isotype controls.  CD27 negativity is taken as a measure of 
naivety 
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Figure 7.4: Calcium flux responses in tonsillar B-cells (representative results). 
T1  
 
T4 
 
 
Upon thawing, all samples were divided into replicates and rested for 2-3 hours before 
experiments. All samples had viability >95% as assessed by trypan blue dye exclusion. 
An aliquot of each was assessed for their ability to undergo Ca flux on the same day as 
stimulation for the proteomics experiments to confirm viability and ensure the 
capacity for proximal BCR signalling events. Triplicates of 15-20x106 cells were used to 
provide sufficient protein for proteomics. An additional aliquot of 5-10x106 cells for 
western blotting validation were stimulated in parallel. Three replicates per condition 
were stimulated separately and simultaneously. This led to a total of 9 proteomics 
samples (triplicates of baseline, IgM and IgD-stimulated) per patient. These biological 
replicates (same source) are subsequently treated as technical replicates except where 
indicated. With 6 CLL and 5 Tonsil ‘patient’ samples, 99 samples for proteomics were 
processed. 
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Similar to previous methods (see Chapter 6), cells at 4x106/mL were stimulated with 
10 g/mL anti-IgM or IgD F(ab’)2 fragments, or control borate buffer. After 5 minutes at 
37oC, samples were transferred to chilled falcon tubes, and washed twice in chilled 
phosphate buffered saline (PBS) containing phosphatase inhibitors. After washing, 
pellets were snap frozen in dry ice and kept at -80oC until lysis. 
 
Cells were lysed in cold 8M Urea in 20mM HEPES (ph8) with additional 
phosphatase/kinase inhibitors (Na3VO4, NaF, β-Glycerol Phosphate, Na2H2PO4). The 
Bradford assay was used to quantify protein concentrations. 500 g of protein was 
then denatured with dithiothreitol, cysteines alkylated with iodoacetamide and 
proteins digested over 16 hours with trypsin beads. The digest was then acidified with 
trifluoroacetic acid. 
 
Samples were de-salted, followed by enrichment of phosphopeptides with Titanium 
Dioxide beads immobilised on reversed-phase C-18 resin spin columns. The 
phosphorylated peptides were dried and reconstituted in buffer for LC-MS analysis. 
Liquid chromatography Mass spectrometry (LC-MS/MS) analysis on an orbitrap mass 
spectrometer was performed with our collaborator Alex Montoya. Data analysis was 
carried out using MASCOT (phosphopeptide identification) and PESCAL (quantification 
based on normalised peak height) software 440,535 by Alex Montoya and Dr Pedro 
Cutillas.  
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7.3 Results 
7.3.1 Overall analysis strategy 
There are no established analysis methods for analysing high-throughput 
phosphoproteomic data. Where useful, methods from gene expression analysis have 
been employed536-541. The experiments provided quantitative data on large numbers of 
phosphorylation sites within several thousand proteins. Estimates of the degree of 
experimental ‘noise’ within the dataset were made, and appropriate analysis methods 
were specified. Following this, differences between leukaemic and healthy B-cells were 
considered, and the effects of B-cell Receptor stimulation. The phosphosites derived 
from these analyses were then characterised. One interpretation considers the nature 
and function of the phosphorylated proteins, based on the presumption that 
phosphorylation alters the function of a protein. Methods adopted from gene 
expression analysis consider the proteins as components within specified biological 
pathways, or their known alterations in disease states. This involves gene set 
enrichment analysis and comparison to curated databases designed for this function. 
Beyond this, the data can also provide an interpretation of the activities of kinases 
responsible for the phosphorylations themselves. A minority of phosphorylation sites 
have experimentally confirmed kinases, and where possible these were identified. 
Various algorithms for prediction of kinases exist, and these methods are pursued to 
an extent. An exhaustive account of all analyses performed is beyond the scope of this 
thesis, but I aim to provide example of analyses that represent both the potential and 
challenge of phosphoproteomic data analysis. The primary aims were to use the data 
to gain insights into CLL biology and BCR signalling in general. 
7.3.2 Characteristics of data 
 
5088 unique phosphopeptide entities (‘features’) were identified. Each identified 
feature has various characterising data, as well as a derived quantification/expression, 
the sequence of amino acid residues, probability of misidentification, phosphorylation 
site (phosphosite) and other chemical modifications such as oxidation and formylation. 
Quantification/expression based on the peak height is used. Each sample is given a 
total phosphopeptide content of 1, which is the sum of all peak height quantifications 
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identified in that sample439. The expression values of each feature therefore reflect the 
fraction of the total that the feature contributes to the total signal of a sample. In 
discussion of the results, the Uniprot ID is referred to when describing a protein, with 
phosphorylations indicated by pY (phosphotyrosine), pS (phosphoserine) or pT 
(phosphothreonine) followed by a number indicating the phosphorylated residue. 
Triplicates, stimuli and patients are described as in Figure 7.5. 
 
Figure 7.5: Proteomics Replicates and Patients.  
5 Tonsil and 6 CLL patient samples were used. Triplicates were stimulated with IgM 
(M), IgD (D) or vehicle control (Baseline, B). 
 
 
7.3.3 Proteomic quantifications: expression and ‘zero’ normalisation 
To better consider the expression levels, quantifications were converted to log base 2. 
As can be seen in fig 7.6, it is likely that values  <-23 are likely to be equivalent to zero 
where, in essence, these values are likely to be ’noise’ that reflects such low levels of 
peptides that they may be ignored in analyses. The analysis was applied separately to 
the CLL and tonsil data in Fig 7.7. 
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Figure 7.6: log2 expression frequency in all samples.  
The second chart shows the frequencies around the minimum from the previous 
chart.   
 
 
Figure 7.7: Log expression values for tonsil and CLL samples separately 
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Overall, 54% of all feature quantifications have expression values <-23, as not all 
samples contain every feature. For the CLL sample, this is 47%, for tonsil 62%.  
 
Since it is likely that values below -23 are equivalent to zero for both CLL and tonsillar B 
cells, this cut-off was used to define a zero/minimum as 1.19209x10-7 (-23 on log2 
scale). Subsequent data analyses are performed using the data set with the data 
normalised (‘zeroed’) to this cut-off/zero threshold of -23.  Apart from reducing ‘noise’, 
the rationale for this is that analysis of the expression differences (fold changes) 
between two samples will be strongly affected by lack of zero normalisation. The use 
of a cut-off/threshold for the minimum value allows proper comparisons in terms of 
fold changes between samples. The use of a minimum value instead of a zero avoids 
problems with dividing by zero. The technique is derived from gene expression 
analysis541,542. 
 
86/5088 (1.7%) features contain a tyrosine phosphorylation, 5034/5088 (98.9%) 
serine/threonine phosphorylation. This is similar to published data428. 1652 unique 
proteins were phosphorylated, with 3179 unique phosphosites producing the 5088 
unique features. 1028/5088 had more than one feature per unique phosphosite, with 
one (HNRPC pS260) having 16 different features representing the same phosphosite. 
This is partly due to a phosphoprotein being trypsin digested into peptides of different 
fragment lengths, oxidised/formylated peptides derived during sample processing, and 
differing fragmentation within the mass spectrometer. This presents an analytical 
challenge when attempting to quantify a particular phosphosite as multiple features 
may represent it, each of which may provide an indicator of the abundance of the 
parent phosphoprotein. 
 
It might be expected that the quantifications of different features derived from the 
same phosphosite would correlate with each other. Alternatively, it may be that 
trypsin digestion varies between different samples due to alterations in pH or other 
variables, such as chemical instability of particular peptides, ionization efficiencies of 
differing phosphopeptides or alterations in cleavage site produced by phosphorylation 
itself 543,544. Therefore one might also expect some variation between samples as to 
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the relative levels of features derived from one phosphoprotein. Furthermore, some 
features may be misidentifications. Even when there is great confidence in 
identifications, it might be expected that quantifications based on low abundance 
features may be less accurate in terms of both identification and quantification. 
 
To estimate the similarities and differences between quantifications of different 
features derived from the same phosphoprotein, we examined correlations between 
multiple features derived from the same phosphoprotein. Of 3179 unique 
phosphosites, 1028 are represented by more than one feature. The distribution of 
these is below in table 7.3 
Table 7.3: Number of features representing each unique phosphosite.  
Of 5088 features, 3179 unique phosphosites are present.  
 
Number of features Frequency Notes 
16 1 HNRPC pS260 
15 0  
14 0  
13 1 HDGF pS165 
12 0  
11 4  
10 4  
9 7  
8 7  
7 13  
6 28  
5 43  
4 90  
3 211  
2 618  
1 2152  
total 3179  
 
Of note, the two phosphosites producing the most features were ranked 33rd (HNRPC) 
and 13th (HDGF) in terms of mean expression, which is consistent with a model 
whereby more abundant phosphoproteins produce greater numbers of features. This 
hypothesis is supported by a significant negative correlation between the number of 
features representing each phosphosite and the rank mean expression (se fig 7.8), 
though this is not invariably the case. 
 231 
Figure 7.8 Number of features per unique phosphosite vs the rank mean expression.  
The number of features representing a phosphosite is summed to yield a 
quantification of a phosphosite, and the mean value for all 9 samples taken and 
ranked to provide an estimate of the relative abundances of each phosphosite. 
 
The two phosphosites represented by the highest number of features were considered 
in more detail. The phosphosite HNRPC pS260 was represented 16 times. The two 
most abundant phosphopeptides representing this are p0227 and p0686, 
quantifications of the same fragment: 
MESEGGADDSpAEEGDLLDDDDNEDRGDDQLELIK 
These differ only in that the initial methionine is oxidised. Their quantifications are 
similar but not identical across samples (see figure 7.9), with Pearson r 0.65 
(p<0.0001), spearman r 0.34 (p=0.0007). The Spearman r is increased to 0.44 when 
zero normalised data are used. 
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Figure 7.9 Expression values of two most abundant features representing HNRNPC 
pS260 
 
 
 
To formally quantify this similarity, the correlations between all 16 features were 
considered for all 99 samples. Of the 240 resulting correlations, most were positive, 
with 61% being significant at p<0.05 level (73% for zero normalised data). The 
distribution of correlation coefficients is represented in fig 7.10. 
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Figure 7.10. Distribution of correlation coefficients of all features of HNRPC pS260. 
Each of the 16 feature abundances was correlated with the 15 other features to 
generate 240 spearman r correlation coefficients. Most were positive, and the 
distribution of values is shown for both zeroed and unzeroed data. The same analysis 
is shown for HDGF (zero-normalised ) 
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Therefore, whilst there is often a positive correlation between features within a 
sample indicating similar quantifications of features derived from the same 
phosphosite, the correlation is often zero or occasionally negative. To an extent, lower 
abundance features exhibit less correlation, as one might expect if noise/variability is 
more prominent with low abundance features (Fig 7.11), but this does not account for 
the majority of the poor correlations between features. 
 
Figure 7.11: Spearman r correlation coefficients for each feature representing HNRPC 
pS260.  
For each of the 240 correlations calculated, the spearman r was compared to the 
expression value of the lower abundance feature of the correlation pair. The lower 
the expression value, the greater tendency to a negative correlation coefficient. 
 
 
 
Therefore, whilst the features representing a particular phosphoprotein are generally 
related to each other in terms of expression value, there is a large amount of variation, 
only partly due to low abundance features. One interpretation might be that the 
analysis inaccurately assigns the identification to each feature. Another is that these 
fragments are produced differently in different samples/experiments, for the reasons 
stated (Trypsin cleavage sites, differing pH). A combination of these effects may be 
possible. Regardless of the cause, it presents a challenge: it is not always clear which 
measure of abundance should be considered in analyses. The most abundant feature 
might most accurately represent the phosphoprotein abundance. However, the most 
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abundant feature in one sample/ experiment may not be the same as that in another. 
Furthermore, it can be seen that even highly abundant features do not always 
correlate with other high abundance features, indicating that at least one of them is 
non-proteotypic. A derived value that takes into account all feature abundances would 
be most appropriate. An obvious candidate would be the mean expression value of all 
features representing a particular phosphosite. However, a highly abundant 
phosphoprotein produces several fragments, so the mean value of each of multiple 
fragments would produce an inaccurate underestimation of the abundance of the 
parent phosphoprotein. We have chosen to take the sum of all features as a marker of 
phosphosite abundance, summing the expression value of each feature to produce an 
overall expression value for each phosphosite. The expression values of 5088 features 
were thus combined to 3179 individual unique phosphosites to give expression values 
for each phosphosite.  
 
This method also partly compensates for the variability that is due to ‘noise’ at low 
abundance levels, with features of higher abundance contributing more to the derived 
value. Misidentifications will hopefully be counteracted by this combination of their 
data with true identifications that might be expected to occur at higher abundance. 
 
We therefore have two datasets used in further analyses: 
1. P for ‘Primary’, consisting of 5088 phosphosites, many of whom will be duplicates 
2. J for ‘Joint’, consisting of 3179 unique phosphosites 
It might be expected that the J datasets would have somewhat less variability/noise, 
but also that the results from the two datasets would largely overlap. 
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7.3.4 Variability and clustering 
Attempts were made to estimate the variability between replicates and samples using 
a variety of methods. The coefficient of variation was calculated, the correlation 
coefficients were calculated, and clustering was performed.  
 
1. Coefficient of variation. 
For each triplicate, the standard deviation of the expression values for a particular 
feature was divided by the mean value to yield the coefficient of variation (CV). The 
mean CV for each sample and all samples were calculated (Fig 7.12).  
 
Figure 7.12: Coefficients of variation calculated for each triplicate of the 5088 
features in P dataset.  
The mean value for each sample is plotted, and the frequency distribution of all CVs 
is also shown 
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The mean CV for all samples was 0.52 (52%). The same analysis on the data before 
‘zeroing’ yielded a mean CV of 0.64, lending support the use of zero normalisation as a 
means to reduce ‘noise’. There was no reduction of mean CV by consideration of only 
the top 50% abundant features (implying that variability is not due to more ‘noise’ at 
low expression values). The J dataset had a mean CV of 0.53. 
2. Correlation coefficients 
Pearson’s r was calculated for each replicate pair, with each sample yielding three 
values (Fig 7.13). For example, patient M1 had three baseline samples: M1B1, M1B2, 
M1B3. The correlation coefficents for M1B1 vs M1B2, M1B2 vs M1B3 and M1B3 vs 
M1B1 were calculated. Mean pearson’s r for all replicate pairs was 0.82, which is 
unchanged by zero nomalisation. Correlation was not higher when the top 50% 
abundant features were considered. The mean correlation coefficient was 0.91 with 
the J dataset. 
 
Figure 7.13: Correlation coefficients for each sample.  
Pearson r was calculated for each replicate pair within an experimental condition. 
Each coefficient is plotted for each sample pairing. 
A Primary dataset 
 
 
B Joint dataset 
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Pearson’s correlation is an analysis that should be applied to normally distributed data, 
and the low values may reflect this. We were unable to perform Spearman’s r on the 
large dataset, and so clustering techniques were employed to assess similarities 
between samples. 
3. Clustering 
Two clustering techniques were used, hierarchical clustering using the Cluster 
software537, and Principal Components analysis using Metaboanalyst software545 with 
standard parameters derived from gene expression analysis541. 
Unsupervised Hierarchical clustering 
The expression values were logged, centred by median values and distance calculated 
using the spearman rank correlation method. Average linkage was used for 
hierarchical clustering. The means of triplicates were calculated and the same 
clustering algorithm was applied to the means of each triplicate. Heatmaps and 
hierarchical trees were generated using TreeView software546. See Figs 7.14 and 7.15 
 239 
Figure 7.14 Heatmap and unsupervised hierarchical clustering of all 99 samples  
(P dataset). Note that the hierarchical tree is enlarged and rotated by 90o to facilitate 
viewing. 
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Figure 7.15 Heatmap and hierarchical clustering of 33 means of triplicates  
(P dataset). Note that the hierarchical tree is enlarged and rotated by 90o to facilitate 
viewing. CLL samples are coloured red and tonsil green. 
M=CLL IGHV mutated, UM= CLL IGHV unmutated T=Tonsil 
B=baseline, M= IgM stimulated, D= IgD stimulated. 
 
 
Whilst there is clear clustering by patient, replicates do not appear to cluster together, 
there is no clustering of baseline, IgM- and IgD-stimulated samples, and there is 
overlap between the CLL and tonsil samples using this method, though these are 
partially separated. Hierarchical clustering was identical between joint and primary 
datasets. 
Principal Components Analysis 
The MetaboAnalyst software provides a principal components analysis (PCA) algorithm 
often used for mass spectrometric data. Using standard techniques, there was good 
separation of Tonsil and CLL samples when considered together, though individual 
replicates within samples did not generally group together using PCA. Figure 7.16-7.17 
shows representative examples. 
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Figure 7.16: PCA of P dataset.  
Ellipses represent 95% confidence intervals. 
A All samples grouped by CLL vs tonsil 
 
B all means grouped by sample   
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C all means grouped by IGHV mutation status 
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Figure 7.17: Summary PCA plots for all 
replicates in each sample, grouped by 
stimulus condition
 244 
It seems that although there is high overlap between replicates and stimuli, there is 
clear separation of ‘patients’ from each other. Joint and primary datasets produced the 
same patterns.  
 
The lack of clustering of replicate conditions with each other may seem concerning, 
but this is often seen in gene expression data. Most of the clustering is dominated by 
which patient the sample comes from. There is also a large amount of ‘noise’, as 
discussed. We would expect only a small proportion of the total phosphosites to alter 
on stimulation of the BCR, and this is indeed the case (see section 7.4). Less than 2% of 
the total phosphosites were significantly altered by BCR stimulation, and the pattern 
was often unique to each patient. Therefore, it is not surprising that the replicate 
variability is dominated by the 98% of phosphoproteins not consistently altered by BCR 
stimulation. When supervised clustering is performed on each of the patients with only 
the phosphoproteins significantly altered by BCR stimulation, then clear clustering is 
seen. Figure 7.18 demonstrates this graphically.  Full details are present in section 7.4, 
but these data are shown here to explain the lack of replicate clustering when all data 
are considered. The effect of BCR stimulus is small, but statistically significant. 
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Figure 7.18: Supervised clustering of patients M1 and T5 
The replicates of these samples do not cluster together when all phosphosites are 
considered by unsupervised clustering (see figure 7.17). When only phosphosites 
significantly altered by IgM or IgD stimulation are considered then clear separation 
of the replicates by stimulus is seen. Patient M1 had 10 phosphosites significantly 
altered by IgM stimulation, and 10 by IgD stimulation, with no overlap. Patient T5 
had 145 phosphosites altered by IgM stimulation, 104 by IgD, with an overlap of 47 
phosphosites. Shown are the supervised clusters for the IgM- and IgD-altered 
phosphosites combined. See section 7.4 for details.  
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7.3.5 Characteristics of phosphoproteins 
 
The nature of the detected phosphoproteins was considered. The abundance of a 
phosphoprotein was estimated by summing all of its component phosphosites. The 
twenty most abundant phosphoproteins were calculated by taking the mean for all 
samples, and are shown below in table 7.4.  
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Table 7.4: nature of most abundant phosphoproteins in all samples.  
The mean expression values of all samples for each phosphosite were calculated. Different phosphosites for the same protein were 
then summed. The expression values derived are as a fraction of total proteins. 
Uniprot 
ID 
Protein Expression Function 
H12 Histone H1.2 0.112 Histone 
LSP1 Lymphocyte-specific protein 1 0.042 intracellular F-actin binding protein 
LIPS Hormone-sensitive lipase 0.037 lipase 
K1C13 Keratin, type I cytoskeletal 13 0.031 cytoskeletal protein 
TR150 Thyroid hormone receptor-associated protein 3 0.019 Plays a role in transcriptional coactivation. 
BCLF1 Bcl-2-associated transcription factor 1 0.019 Death-promoting transcriptional repressor 
HMGA1 High mobility group protein HMG-I/HMG-Y 0.016 transcription regulation/RNA processing 
DDX51 ATP-dependent RNA helicase DDX51 0.015 biogenesis of 60S ribosomal subunits 
ARF5 ADP-ribosylation factor 5 0.012 GTP-binding protein 
ZN774 Zinc finger protein 774 0.011 May be involved in transcriptional regulation 
FA40A Protein FAM40A 0.011 regulation of cell morphology and cytoskeletal organization 
CALX Calnexin 0.010 quality control apparatus of the ER by the retention of incorrectly folded proteins 
NMDZ1 Glutamate [NMDA] receptor subunit zeta-1 0.008 glutamate-gated ion channels with high calcium permeability 
TEBP Prostaglandin E synthase 3 0.007 promoting disassembly of transcriptional regulatory complexes 
PPE2 Serine/threonine-protein phosphatase with EF-hands 2 0.007 May function as a calcium sensing regulator of ionic currents 
CN159 UPF0317 protein C14orf159, mitochondrial 0.006 ? 
SHOX Short stature homeobox protein 0.006 Controls fundamental aspects of growth and development. 
ARP3B Actin-related protein 3B 0.006 organization of the actin cytoskeleton 
H13 Histone H1.3 0.004 Histone 
MCCA Methylcrotonoyl-CoA carboxylase subunit alpha 0.003 ? 
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When the nature of the phosphoproteins is considered in terms of their molecular 
function as judged by Protein ANalysis THrough Evolutionary Relationships (PANTHER) 
molecular function547, the largest classes of phosphoproteins function were nucleic 
acid binding, unclassified and transcription factor (fig 7.19).  
Figure 7.19: PANTHER protein classifications of all phosphoproteins.  
Frequency of molecules in the 30 most frequent protein classes. 
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The use of Ingenuity Pathway Analysis (IPA) has a somewhat simpler classification 
system, and also permits assignment to particular cellular localisation (figure 7.20) 
 
Figure 7.20 IPA classification of molecular function and cellular localisation for all 
detected phosphoproteins 
A 
  
B 
 
 
The top 10% most abundant proteins were compared to the 10% least abundant 
proteins in terms of molecular function (Fig 7.21). The more abundant proteins were 
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enriched for RNA binding proteins, cytoskeletal components, and histones, though 
these were also present at low abundance. The least abundant proteins tended to 
have enzymatic or regulatory functions.  
Figure 7.21: Most and least abundant 10% of phosphoproteins. 
Taken from the mean expression values of baselines for CLL and tonsil combined. 
The molecular function of those proteins was classified using PANTHER.  
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% enriched in lowest 10% expression % enriched in highest 10% expression 
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7.3.6 Ingenuity Pathway Analysis of detected phosphoproteins 
To gain more insight into the functions of the phosphoproteins present in the baseline 
CLL and tonsil samples, IPA was used to provide an estimation of which known cellular 
pathways are active based on the detected phosphoproteins, analogous to gene 
expression analysis (Table 7.5). Interestingly, several pathways were significantly 
enriched, including the B-Cell receptor pathway (fig. 7.22). Because of the general 
similarities between CLL and Tonsil expression profiles (93% of phosphoproteins with 
non-zero mean expression in tonsil samples were also in CLL), the results are similar.  
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Table 7.5 Top 10 most significantly enriched cellular pathways.  
Ingenuity (IPA) software used Fisher’s exact test to calculate p-value of enrichment. 
The ratio represents: 
number of phosphoproteins in our dataset/total number of proteins in pathway 
A: The results from analysis of mean baseline CLL samples  
B: The results from Tonsils  
Fig 7.22: The highlighted proteins from the ERK/MAPK & BCR IPA pathways 
 
A: CLL baseline pathways 
Ingenuity Canonical Pathways p-value Ratio 
ERK/MAPK Signalling 1.62E-07 42/199 
DNA Methylation and Transcriptional Repression Signalling 3.24E-07 11/23 
B Cell Receptor Signalling 6.17E-07 34/157 
Protein Kinase A Signalling 1.20E-05 61/384 
Synaptic Long Term Potentiation 1.26E-05 26/115 
Telomerase Signalling 1.70E-05 23/99 
Telomere Extension by Telomerase 1.95E-05 8/16 
14-3-3-mediated Signalling 2.00E-05 25/114 
PI3K Signalling in B Lymphocytes 3.89E-05 27/128 
EIF2 Signalling 4.17E-05 32/182 
mTOR Signalling 5.62E-05 33/190 
Phospholipase C Signalling 6.03E-05 40/244 
 
B: Tonsil baseline pathways 
Ingenuity Canonical Pathways p-value Ratio 
ERK/MAPK Signalling 8.13E-08 41/199 
DNA Methylation and Transcriptional Repression Signalling 1.66E-07 11/23 
B Cell Receptor Signalling 4.07E-07 33/157 
Telomere Extension by Telomerase 1.17E-05 8/16 
Synaptic Long Term Potentiation 1.20E-05 25/115 
Telomerase Signalling 1.91E-05 22/99 
Protein Kinase A Signalling 2.75E-05 57/384 
Estrogen Receptor Signalling 3.55E-05 26/133 
Insulin Receptor Signalling 7.24E-05 25/131 
DNA Double-Strand Break Repair by Non-Homologous End Joining 7.24E-05 7/16 
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Fig 7.22 ERK/MAPK and B-Cell Receptor pathways from IPA.  
Highlighted in orange are the components of the pathway that are significantly enriched in the CLL dataset (all phosphoproteins 
detected).                                                                                                            
 
 254 
7.3.7 Kyoto Encyclopaedia of Genes and Genomes (KEGG) Pathway analysis 
The use of KEGG as an alternative method to indicate biological pathways may be 
complementary to Ingenuity. Table 7.6 shows the demonstrated KEGG pathways 
derived from the same datasets as Table 7.5 
Below (Fig. 7.23) is the KEGG pathway with the BCR components from the CLL samples 
highlighted: 
Figure 7.23 KEGG BCR pathway.  
Phosphoproteins enriched in CLL baseline samples are highlighted in red. 
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 Table 7.6 KEGG pathways significantly enriched in CLL and Tonsil baseline samples.  
P-values are from the modified Fisher’s exact test. The ratio represents: 
number of phosphoproteins in our dataset/total number of proteins in pathway 
A CLL 
KEGG pathway p-value ratio 
Spliceosome 0.0000 39/126 
B cell receptor signalling pathway 0.0004 17/75 
Ribosome 0.0007 18/87 
Fc gamma R-mediated phagocytosis 0.0008 19/95 
Long-term potentiation 0.0013 15/68 
Nucleotide excision repair 0.0029 11/44 
Insulin signalling pathway 0.0039 22/135 
Endocytosis 0.0054 27/184 
Fructose and mannose metabolism 0.0206 8/34 
Chronic myeloid leukemia 0.0212 13/75 
MAPK signalling pathway 0.0237 33/267 
Glycolysis / Gluconeogenesis 0.0262 11/60 
ErbB signalling pathway 0.0284 14/87 
GnRH signalling pathway 0.0332 15/98 
Non-small cell lung cancer 0.0340 10/54 
Glioma 0.0355 11/63 
Phosphatidylinositol signalling system 0.0432 12/74 
Pathogenic Escherichia coli infection 0.0462 10/57 
 B Tonsil 
KEGG pathway p-value ratio 
Spliceosome 0.0000 39/126 
Ribosome 0.0003 18/87 
Fc gamma R-mediated phagocytosis 0.0009 18/95 
B cell receptor signalling pathway 0.0016 15/75 
Long-term potentiation 0.0019 14/68 
Nucleotide excision repair 0.0058 10/44 
Insulin signalling pathway 0.0077 20/135 
Endocytosis 0.0147 24/184 
ErbB signalling pathway 0.0159 14/87 
Non-small cell lung cancer 0.0218 10/54 
Glioma 0.0221 11/63 
VEGF signalling pathway 0.0288 12/75 
Pathogenic Escherichia coli infection 0.0301 10/57 
Focal adhesion 0.0373 24/201 
GnRH signalling pathway 0.0386 14/98 
MAPK signalling pathway 0.0393 30/267 
Fructose and mannose metabolism 0.0443 7/34 
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The suggestion of enrichment of components of various pathways detected in baseline 
samples has several possible interpretations. These proteins may coincidentally be 
generally more abundant or more phosphorylated than others and are therefore more 
likely to be detected by the mass-spectrometry technique. It would be expected be 
that B-cells have high expression of proteins (and therefore phosphoproteins) known 
to be important in B-cell physiology, and are enriched for BCR pathway components. 
To support this, a comparison of the CLL and Tonsil proteins with the SAGE database of 
tissue expression of known proteins548 suggested that both lists were enriched for 
proteins present in leucocytes, with the most significantly enriched tissue being ‘lymph 
node Large B cell Lymphoma’ (p=9.4x10-29). An in silico comparison with similar data 
from non-B-cell tissues may confirm this. Constitutive phosphorylation of these 
pathway components may indicate either constitutive activation of the pathways, or 
indicate that there is a constitutive level of phosphorylation of unstimulated pathways. 
Alternatively a degree of baseline pathway activity may indicate the pathway is 
‘primed’ for stimulation. This phosphorylation in the absence of overt stimulation 
could reflect simply the abundance of the pathway components. The high number of 
detected RNA processing proteins is reflected by the spliceosome KEGG signalling 
pathway enrichment. 
7.3.8 CLL vs Tonsil Comparisons 
In order to compare the phosphoproteome of leukaemia and healthy B-cells, the mean 
expression values within the baseline only conditions were compared. The mean 
expression levels of all CLL samples were divided by the mean values for all tonsils to 
provide a fold change CLL/T. These were then logged to base 2. Their distribution is a 
positively skewed normal distribution (see fig 7.24), indicating that perhaps more 
phosphosites are present in CLL cells compared to tonsils, interpreted as a greater 
range of phosphosites present in CLL, rather than overall greater abundance of 
phosphoproteins in CLL, though this is also possible. 
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Figure 7.24: Distribution of CLL/T fold changes in baseline samples. 
 Red indicates higher expression in CLL compared to tonsil, blue lower. 
A P dataset 
 
B J dataset 
 
Because the data were approximately normal in distribution, unpaired t-tests were 
performed to highlight significant differences between CLL and tonsil, followed by 
False Discovery Rate (FDR) of 0.05 correction using the Benjamini-Hochberg (BH) 
method538,539. 
 
In order to reach significance, a particular phosphosite generally required a high fold 
change to be present in all CLL samples as compared to all Tonsil samples. A 
phosphosite highly upregulated in 5/6 CLL samples was therefore generally ignored 
using our approach. Significant mean fold changes ranged from 2.5-1400, with the 
median being 75-fold for the P dataset, 45-fold for the J dataset. There were numerous 
differentially expressed phosphosites, mainly upregulated (increase in CLL relative to 
tonsil). Shown below (Fig 7.25) are the volcano plots for all phosphosites, and the 
effect of Benjamini-Hochberg correction. Figure 7.26 gives an impression of the 
relative expression values in the most significantly altered phosphosite.  
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Figure 7.25 Volcano plots of p-value vs fold change (P dataset).  
A: Unpaired t-tests were performed to calculate a p-value for significant differences; 
B: p values after benjamini-hochberg correction. Log2 fold change (mean expression 
in CLL samples divided by mean expression in tonsil samples) is also calculated  
 
Figure 7.26: Example mean expression values for the most significantly differentially 
regulated phosphosite 
 (see table 7.7). Boxes represent range of expression values of triplicates. Horizontal 
bar indicates mean. 
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184/5088 (3.6%) phosphosites were differentially expressed between CLL and Tonsil in 
primary datasets, 169/3179 (5.3%) in joint datasets. These were not enriched for 
phosphotyrosine, as 1.1% were tyrosine and 99.5% ST (as compared to 1.7% and 98.9% 
in all baseline samples). There was an overlap of 113 phosphosites between the P and J 
datasets. 
Table 7.7 shows the phosphosites exhibiting the greatest fold changes. 
 
Table 7.7: Top and bottom 10 most differentially phosphorylated phosphosites in P 
dataset.  
Shown is the Uniprot ID, protein name, the phosphosite, log fold change, log 
corrected p-value of t-test, function, and upstream kinase. ?kinase indicates  that the 
kinase-substrate relationship is not confirmed, but predicted using Scansite.  
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Top 10 (upregulated in CLL v Tonsil)  
Uniprot protein phosphosite 
log2  
CLL/T 
log2 BH p 
value 
function kinase 
SAMN1 
SAM domain-
containing protein 
SAMSN-1 
SAMSN1 p-
S23 
10.30 -7.16 
Negative regulator of B-cell activation. Promotes 
RAC1-dependent membrane ruffle formation and 
reorganization of the actin cytoskeleton. Stimulates 
HDAC1 activity. Regulates LYN activity by modulating 
its tyrosine phosphorylation 
?AKT 
VIME Vimentin VIM p-S26 10.12 -9.80 cytoskeletal component PAK1 
K1143 
Uncharacterized 
protein KIAA1143 
KIAA1143 p-
S50 
10.09 -5.83 ? ?CK2 
I2BP2 
Interferon 
regulatory factor 2-
binding protein 2 
IRF2BP2 
p-S175 
9.79 -12.86 transcriptional repressor. ?CDK1 
ADDG Gamma-adducin 
ADD3 
p-S681 
9.61 -19.82 
Membrane-cytoskeleton-associated protein that 
promotes the assembly of the spectrin-actin 
network. Binds to calmodulin. 
?CDK1/CDC2/
CDK5 
SAMN1 
SAM domain-
containing protein 
SAMSN-1 
SAMSN1 p-
S90 
9.55 -6.54 
Negative regulator of B-cell activation. Promotes 
RAC1-dependent membrane ruffle formation and 
reorganization of the actin cytoskeleton. Stimulates 
HDAC1 activity. Regulates LYN activity by modulating 
its tyrosine phosphorylation 
?CAMK2/CK2
/CLK2 
AHNK 
Neuroblast 
differentiation-
associated protein 
AHNAK 
AHNAK p-
S5400  + 
Formyl 
9.53 -10.97 
May be required for neuronal cell differentiation 
 
?PKC 
CQ085 
Uncharacterized 
protein C17orf85 
C17orf85 p-
S25 
9.53 -16.81 ? ?ERK1 
DOC10 
Dedicator of 
cytokinesis protein 
10 
DOCK10 
p-T1440 
9.48 -13.03 guanine nucleotide exchange factor (GEF) ?AKT 
ACINU 
Apoptotic 
chromatin 
condensation 
inducer in the 
nucleus 
ACIN1 
p-S561 
9.48 -9.78 
Component of a splicing-dependent multiprotein 
exon junction complex 
?PKA 
bottom 10 (upregulated in Tonsil v CLL)  
Uniprot protein phosphosite 
log2 
CLL/T 
log2 BH p 
value 
function kinase 
SMC4 
Structural 
maintenance of 
chromosomes 
protein 4 
SMC4 
p-S41 
-4.59 -4.39 
SMC-4 is a core subunit of condensin  I and II, large 
protein complexes involved in chromosome 
condensation 
?CDK1 
FA40A Protein FAM40A 
FAM40A p-
S335 
-4.84 -8.19 
Plays a role in the regulation of cell morphology and 
cytoskeletal organization. 
?GSK3B 
DDX21 
Nucleolar RNA 
helicase 2 
DDX21 
p-S89  + 
Formyl 
-5.98 -5.66 
Can unwind double-stranded RNA (helicase) and can 
fold or introduce a secondary structure to a 
?CDK1 
BCLF1 
Bcl-2-associated 
transcription factor 
1 
BCLAF1 
p-S531  + 
Formyl 
-6.33 -5.62 
single-stranded RNA (foldase). Functions as cofactor 
for JUN-activated transcription. Involved in rRNA 
processing 
GSK3B 
KBTBA 
Kelch repeat and 
BTB domain-
containing protein 
10 
KBTBD10 p-
S589 
p-S592 
-7.15 -4.95 
Required for pseudopod elongation in transformed 
cells. Substrate-specific adapter of an E3 ubiquitin-
protein ligase complex which mediates the 
ubiquitination and subsequent proteasomal 
degradation of target proteins 
?CLK2 
ROA2 
Heterogeneous 
nuclear 
ribonucleoproteins 
A2/B1 
HNRNPA2B1 
p-S102 + 
Formyl 
-7.35 -8.19 Involved with pre-mRNA processing ?CLK2/AURB 
RL14 
60S ribosomal 
protein L14 
RPL14 p-S139 -8.15 -7.36 ribosome component ?CDK1/CDK5 
RAN 
GTP-binding nuclear 
protein Ran 
RAN 
p-S135  + 
Formyl 
-8.15 -9.64 
GTP-binding protein involved in nucleocytoplasmic 
transport 
?PAK4/PLK1 
K1C13 
Keratin, type I 
cytoskeletal 13 
KRT13 
p-S427 
-13.64 -6.73 cytoskeletal component 
?CDK1/CDC2/
CDK5 
K1C13 
Keratin, type I 
cytoskeletal 13 
KRT13 
p-S427 + Oxi 
+ Formyl 
-14.46 -5.27 cytoskeletal component 
?CDK1/CDC2/
CDK5 
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The differentially phosphorylated protein classes were similar to those seen in all 
samples, with possibly a higher proportion of proteins with cytosolic localisation (Fig 
7.27) 
 Figure 7.27: Most abundant IPA molecular localisation function classes in 
differentially regulated phosphoproteins, CLL as compared to Tonsil. J dataset 
 
 
Kinases and phosphatases within each list of differentially regulated phosphosites 
were considered. 11/184 (P dataset) and 10/169 (J dataset) phosphosites were on 
kinases. 6/184 and 4/169 were phosphatases (Table 7.8). Of these CSF1R pY561 is an 
activating autophosphorylation, and PTPN6 (SHP-1) pY536 is an activating 
phosphorylation downstream of InsR, Lck & Src kinases. The other phosphorylations do 
not have published functions on the PhosphoSitePlus website549. 
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Table 7.8 phosphosites on kinases & phosphatases different between CLL & Tonsil. 
 J=mean fold change CLL/T phosphosites in J dataset. 
 P= mean fold change CLL/T phosphosites in J dataset 
X=not significantly different in that dataset 
 
Kinase psite Name J P 
CARD11 pS439 caspase recruitment domain family, member 11 99 99 
CDK14 pS95 cyclin-dependent kinase 14 11.4 21 
LYN pS13 LYN kinase X 72 
MAP3K2 pS153 mitogen-activated protein kinase kinase kinase 2 314 314 
NADK pS48 NAD kinase 37 37 
PANK2 pS168 pantothenate kinase 2 115 112 
PGK1 pS203 phosphoglycerate kinase 1 405 405 
PRKAB2 pS108 protein kinase, AMP-activated 77 77 
SGK223 pS694 homolog of rat pragma of Rnd2 X 63 
SIK3 pS493 SIK family kinase 3 9.4 9.4 
CSF1R 
pY561/T567/Y571 
colony stimulating factor 1 receptor 53 X 
PFKL pS775 phosphofructokinase, liver 8.1 X 
 
Phosphatase psite Name J P 
INPP5F pS907 inositol polyphosphate-5-phosphatase F 274 X 
LPIN2 pS243 lipin 2 248 248 
PTPN12 pS435 protein tyrosine phosphatase, non-receptor type 12 5.9 6.6 
PTPN12 pS449 protein tyrosine phosphatase, non-receptor type 12 160 90 
PTPN22 pS414 protein tyrosine phosphatase, non-receptor type 22 303 280 
PTPN6 pY536 
protein tyrosine phosphatase, non-receptor type 6 
(SHP-1) 
167 X 
 
 
IPA analysis of the P dataset proteins suggests the phosphoproteins most upregulated 
in CLL cells compared to tonsil are enriched for components of tight junction signalling, 
RAN (GTP-binding protein involved in nucleocytoplasmic transport) signalling, ATM 
signalling, glucose metabolism and many other pathways (table 7.9). The J dataset 
comparison was similarly enriched for glucose metabolic pathways, but also 
cytoskeletal signalling and other pathways. KEGG analysis also suggested glucose 
metabolism pathways as important in CLL vs Tonsil comparisons. 
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Table 7.9: bioinformatic analysis of differentially phosphorylated proteins, CLL vs 
Tonsil.  
Shaded = p-value <0.05 
Ratio represents proteins in list/total proteins in pathway.  
P=primary dataset, J=Joint 
 
A: IPA pathway analysis 
Ingenuity Canonical Pathways Ratio P p value P Ratio J p value J 
Tight Junction Signalling 0.03 0.0076 0.02 0.1259 
RAN Signalling 0.11 0.0079 0.06 0.1294 
Acetyl-CoA Biosynthesis III (from Citrate) X X 1.00 0.0087 
ATM Signalling 0.05 0.0138 0.02 0.3999 
Glycolysis I 0.04 0.1722 0.09 0.0151 
Caveolar-mediated Endocytosis Signalling 0.04 0.0229 0.04 0.0234 
Actin Cytoskeleton Signalling 0.02 0.0955 0.02 0.0309 
Pentose Phosphate Pathway (Oxidative Branch) 0.25 0.0339 0.25 0.0339 
Branched-chain α-keto acid Dehydrogenase Complex X X 0.25 0.0339 
FAK Signalling 0.03 0.0347 0.02 0.1633 
Protein Kinase A Signalling 0.01 0.1959 0.02 0.0363 
Fcγ Receptor-mediated Phagocytosis in Macrophages 
and Monocytes 
0.03 0.0407 0.01 0.5383 
GDP-glucose Biosynthesis 0.17 0.0417 0.17 0.0427 
3-phosphoinositide Degradation X X 0.04 0.0468 
Glucose and Glucose-1-phosphate Degradation 0.14 0.0501 0.14 0.0501 
Paxillin Signalling 0.03 0.0513 0.03 0.0525 
Sertoli Cell-Sertoli Cell Junction Signalling 0.02 0.0513 0.01 0.4140 
Systemic Lupus Erythematosus Signalling 0.02 0.1754 0.02 0.0575 
Acetyl-CoA Biosynthesis I (Pyruvate Dehydrogenase 
Complex) 
0.14 0.0589 X X 
     
B Cell Receptor Signalling 0.02 0.1349 0.02 0.8431 
 
B: KEGG pathway analysis  
KEGG pathways Ratio P p value P Ratio J p value J 
Pentose phosphate pathway X X 0.12 0.011 
Glycolysis / Gluconeogenesis 0.05 0.057 0.05 0.057 
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C:IPA biological functions enriched in differentially phosphorylated proteins 
 
Category p-value P p-value J 
DNA Replication, Recombination, and Repair 0.0085 0.0004 
Cell Morphology 0.0005 0.0005 
Cardiovascular System Development and Function 0.0005 0.0005 
Haematological Disease 0.0005 0.0024 
Cancer 0.0005 0.0024 
Nutritional Disease 0.0011 0.0011 
Connective Tissue Disorders 0.0011 0.0011 
Skeletal and Muscular Disorders 0.0011 0.0011 
Metabolic Disease 0.0011 0.0011 
RNA Post-Transcriptional Modification 0.0029 0.0171 
Embryonic Development 0.0031 0.0032 
Renal and Urological System Development and Function 0.0031 0.0032 
Cellular Assembly and Organization 0.0039 0.0032 
Cell Cycle 0.0085 0.0032 
Hair and Skin Development and Function 0.0038 0.0038 
Cellular Compromise 0.0085 0.0038 
Gene Expression 0.0039 0.0256 
Cellular Function and Maintenance 0.0039 0.0086 
Cardiovascular Disease 0.0053 0.0054 
Neurological Disease 0.0053 0.0054 
Dermatological Diseases and Conditions 0.0080 0.0086 
Immunological Disease 0.0080 0.0086 
Tissue Development 0.0085 0.0171 
Tissue Morphology 0.0085 0.0171 
Molecular Transport 0.0085 0.0171 
Connective Tissue Development and Function 0.0085 0.0086 
Drug Metabolism 0.0085 0.0086 
Tumour Morphology 0.0085 0.0086 
Developmental Disorder 0.0085 0.0086 
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D: KEGG biological process enriched in differentially phosphorylated proteins 
 
Term P-Value P P-Value J 
haemopoiesis 0.0001 0.0025 
haemopoietic or lymphoid organ development 0.0002 0.0043 
immune system development 0.0003 0.0060 
cytoskeleton organization 0.0006 0.0211 
glucose catabolic process 0.0011 0.0106 
lymphocyte differentiation 0.0013 0.0013 
regulation of cellular response to stress 0.0013 0.0087 
T cell differentiation 0.0144 0.0017 
cell activation 0.0019 0.0253 
hexose catabolic process 0.0021 0.0169 
regulation of stress-activated protein kinase signalling pathway 0.0021 0.0169 
DNA packaging X 0.0022 
monosaccharide catabolic process 0.0023 0.0182 
leukocyte activation 0.0029 0.0416 
regulation of protein kinase cascade 0.0034 0.0135 
leukocyte differentiation 0.0037 0.0037 
alcohol catabolic process 0.0037 0.0257 
cellular carbohydrate catabolic process 0.0044 0.0291 
chromosome organization 0.0863 0.0047 
lymphocyte activation 0.0047 0.0201 
actin cytoskeleton organization 0.0087 X 
negative regulation of transcription 0.0099 X 
regulation of MAPKKK cascade 0.0106 0.0106 
carbohydrate catabolic process 0.0106 0.0541 
RNA processing 0.0106 0.0652 
induction of apoptosis by extracellular signals 0.0578 0.0116 
regulation of protein amino acid phosphorylation 0.0116 X 
actin filament-based process 0.0117 X 
regulation of JNK cascade 0.0144 0.0144 
microtubule-based process 0.0146 0.0487 
 
The Tight Junction pathway was the most significantly enriched pathway (p=0.0076) in 
the P dataset, yet the corresponding p-value for the J dataset was 0.13. Furthermore, 
as is often the case with gene set enrichment, a small number (5/157, yielding a ratio 
of 0.03) of genes from a pathway is enriched. In order to understand the Tight Junction 
Pathway components in our dataset further, we visualised the pathways using IPA. 
Figure 7.28 illustrates the 5 upregulated genes in the pathway: 
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Figure 7.28: Tight Junction Pathway from Ingenuity Pathway Analysis 
Red nodes represented significantly upregulated phosphoproteins (CLL v T) in the P 
dataset. 
 
Since the analysis used only highlighted phosphosites that were significantly different 
in all CLL (n=6) compared to all Tonsil (n=5) baseline samples, we attempted to 
visualise whether alterations in these proteins also occurred in a proportion of 
samples. We also sought to consider the same pathway in the J dataset. To this end, 
the overlapping proteins present in both our datasets and the IPA pathway were 
considered, and the expression levels in each sample visualised. Figure 7.29 is an 
illustration of this concept. It can be seen that the majority of tight junction pathway 
proteins had at least one phosphosite detected in our dataset, and that the majority of 
these had a greater than two fold upregulation (68%) or downregulation (12%) when 
CLL and Tonsil samples are compared. This illustrates the value of closer interrogation 
of pathways derived from bioinformatic tools, where use of data from stringent 
methods may underestimate the representation of pathway components. 
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Figure 7.29: The IPA Tight Junction (TJ) pathway.  
Proteins represented by phosphosites overexpressed in CLL v Tonsil are highlighted in red. In pink are those proteins that have at least 
one phosphosite detected. The 6 circled are representative examples showing the relative quantifications in each sample shown at the 
upper right. Below is the mean log2 fold change CLL/Tonsil for each TJ component. 
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7.3.9 Kinases upstream of CLL vs Tonsil differentially regulated phosphosites 
The CLL vs Tonsil differentially expressed phosphosites were considered in terms of 
known upstream kinases (Table 7.10). The PhosphSitePlus549, PhosphoELM550 and 
PhosphoPoint551 databases were used for identifications.  The fold change of a 
phosphosite was used to infer the different kinase activities. Where more than one 
substrate was identified, kinase activity was derived by using the geometric mean of 
fold changes for each substrate. Some had more than one upstream kinase. 
 
8% of the phosphosites had an identified upstream kinase. There is substantial overlap 
between the two analyses, with multiple cAMP-dependent protein kinase alpha 
(PKACA), protein kinase C alpha (PKCA) and p21-activated kinases 1 and 2 (PAK1/2) 
substrates increased, indicating elevated activities of these kinases in CLL compared to 
Tonsil. Some phosphosite substrates have more than one upstream kinase capable of 
phosphorylating a particular site (substrate promiscuity) For example, the phosphosite 
WASP pY291 (CLL/T fold 107.1) could have been phosphorylated by multiple kinases 
(ABL, ACK, HCK, LCK, LYN, BTK and CK2). 
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Table 7.10: Kinases of phosphosites significantly different between CLL & Tonsil.  
The kinase and number of phosphosite substrates present are shown. The geometric 
mean CLL/T fold change of those substrates was used to derive a fold change of 
kinase activity. Primary (P) and Joined (J) datasets were analysed 
P: 15/184 phosphosite substrates had at least one upstream kinase identified 
J: 13/169 phosphosite substrates had at least one upstream kinase identified 
kinase substrate P 
fold kinase activity 
P 
substrate J 
fold kinase 
activity J 
PKACA 4 65.1 5 45.1 
PKCA 4 58.2 2 34.2 
PAK1 4 41.7 3 52.6 
PAK2 3 83.4 2 32.1 
p90RSK 2 40.0 1 32.1 
CAMK2 1 489.1 0 X 
ABL 1 107.1 1 167.5 
ACK 1 107.1 0 X 
HCK 1 107.1 0 X 
LCK 1 107.1 1 167.5 
LYN 1 107.1 0 X 
BTK 1 107.1 0 X 
CK2 1 107.1 0 X 
HIPK2 1 105.7 0 X 
CDK1 1 63.8 0 X 
JNK 1 20.7 1 20.7 
MAPK8/9/10 1 20.7 1 20.7 
PDHK1 1 15.7 0 X 
PDHK2 1 15.7 0 X 
PDHK3 1 15.7 0 X 
PDHK4 1 15.7 0 X 
PDPK1 1 15.7 0 X 
ROCK1/2 1 5.2 1 5.2 
AURKB 1 5.2 1 5.2 
GSK3B 1 0.01 0 X 
INSR 0 X 1 167.5 
SRC 0 X 1 167.5 
CSF1R 0 X 1 52.9 
BCKDK 0 X 1 19.8 
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7.3.10 Prediction of upstream Kinases 
The Scansite algorithm predicts upstream kinases based on amino acid residue motifs, 
and has been used to predict upstream kinases in a number of publications523,552,553. To 
assess the utility of this method with our dataset, upstream kinases were predicted for 
the 169 differentially regulated phosphosites in the J datasets. There were two groups 
within the dataset: Phosphosites decreased in CLL relative to tonsil (17% of those 
significantly differentially expressed) and those increased. The kinase activity is implied 
by the fold difference. There are therefore two groups of predicted kinases: those with 
higher activity in tonsil relative to CLL, and those with higher activity level in CLL.  
 
Each phosphosite substrate had 0-10 predicted upstream kinases, and each predicted 
kinase had a mean of 7.7 substrates. This partly reflects the ‘promiscuity’ of kinases 
and phosphosites, and probably also the inaccuracy of Scansite as a kinase-substrate 
prediction tool. A number of kinases have predicted substrates that increased in tonsil 
vs CLL, and some that are decreased, which leads to paradoxical and opposing implied 
kinase activities. There are several possible explanations for this. Firstly, we have used 
an averaged ratio that does not fully take into account differences between samples, 
though this is mitigated by the statistical method used. The co-localisation of a kinase 
and its substrate is an important mechanism of regulation, and it may be that within 
normal B-cells, a highly active kinase may be reflected by a highly phosphorylated 
substrate, whereas the same active kinase in CLL cells may be localised in a different 
cellular location to its substrate, or that the substrate is at lower abundance, resulting 
in an apparent lower kinase activity. To a degree, the promiscuity of kinases/substrates 
and phosphatases may also account for these differences. Finally, the prediction 
algorithm of Scansite is likely to be inaccurate in many cases, and demonstrates the 
limitations of kinase-substrate predication based on motif recognition alone. To 
attempt to derive an overall impression of ‘net’ kinase activity, the number of 
substrates that are downregulated is subtracted from those upregulated, but this is a 
crude method and care must be taken that this should not be over interpreted. See 
figure 7.30 
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Figure 7.30: Predicted upstream kinases down- or upregulated in CLL compared to 
tonsil.  
The number of substrates per predicted kinase is reflected in the proportion of the 
pie chart. The net upregulated kinases is derived by subtracting the number of kinase 
substrates downregulated from those upregulated 
 
 
As an illustration of the limits of the method, there appears to be a number of 
substrates of CDK1 paradoxically upregulated in both CLL vs Tonsil and Tonsil vs CLL. 
This is also true of many of the other kinases. However, some kinases such as AKT1 
appear to be consistently upregulated in CLL vs Tonsil.  
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7.3.11 Alternative Strategies for considering kinase activity 
The above analyses are dependent on a list of phosphoproteins derived from 
comparing leukaemia and tonsil samples, and are therefore critically dependent on 
whether tonsils are the most appropriate control. The analysis method is analogous to 
that used for gene expression data. Unlike gene expression data, which is derived from 
comparison of control and disease mRNA levels hybridised to arrays, the 
phosphoproteomic data produce expression values of phosphoproteins that are 
independent of control comparisons. If CLL samples alone had been used, the data will 
still be valid in terms of expression of phosphoproteins, and by extension their 
upstream kinases. This therefore permits a consideration of kinases independent of 
the use of tonsil controls, and suggests alternative analysis methods. The estimation of 
kinase activity using all phosphosite data may be more powerful than consideration of 
only the limited number of CLL vs Tonsil differentially expressed phosphosites. 
 
The upstream kinases for all P dataset phosphoproteins were ascertained. 433/5088 
(8.5%) of features had an identified kinase. The most frequent identified kinase was 
Casein kinase 2 (CK2-A1) with 90/5088 substrates. Numerous substrates of CDK1, 
CDK2, PKACa, PKCA, ERK1 and PAK1 were also present. In the J dataset, 208/3179 
(6.5%) of phosphosites had an identified upstream kinase, with CK2 associated with 
41/3179 phosphosites. These data are shown in fig 7.31 
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Figure 7.31: upstream kinases for P & J dataset phosphosites.  
The number of substrates for each kinase is shown. Kinases with at least 5 substrates 
shown. 
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Note that one of the reasons for a large number of substrates for a given kinase is a 
bias derived from the literature, i.e. CK2 is well known to phosphorylate numerous 
substrates, and these have been reasonably well characterised, possibly creating an 
inflated estimation of its activity in experiments, though it is known to be a 
ubiquitously expressed kinase so might be expected to have high activity.  
 
To derive a better measure of kinase activity, the phosphosite expression values for 
each kinase were summed, providing a number representing  the proportion of total 
phosphosites detected in a sample that can be attributed to the action of a particular 
kinase. This is independent of J and P dataset differences. This analysis was performed 
for the mean expression values of CLL baseline samples and tonsil baseline samples. 
For example, the most active kinase derived from this method is Chk2, with 17% of the 
phosphosite expression within the CLL samples due to the Chk2-dependent 
phosphorlylation of Histone 1.2, the most abundant phosphoprotein within the 
dataset. Note that this is a product of both kinase activity and substrate abundance. 
Because this measure is not of ‘pure’ kinase activity, but of the pathway that involves 
Chk2 phosphorylating Histone 1.2, this derived measure is given the name of ‘kinase 
pathway activity’. The top 30 kinase pathway activities (excluding Chk2) are shown in 
figure 7.32. 
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Figure 7.32: Kinase pathway activity.  
The mean value of all CLL & tonsil (T) baseline samples was derived for each 
phosphosite. The values for each phosphosite attributable to a particular kinase 
were summed. This provides a measure of the proportion of phosphorylations within 
a sample due to a particular kinase. The top 30 kinase pathway activities are shown. 
The data for Chk2 is not shown, as these dominate the data, with the proportion of 
phosphorylations due to Chk2 at 0.17 for CLL, 0.07 for T, making visualisation of the 
other kinases difficult. 
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It might be expected that the more substrates available for measurement, the greater 
the confidence in this derived value for kinase pathway activity. In theory, the 
combination of the number of substrates with the kinase pathway activity may permit 
formal statistical comparisons to be made, in order to derive quantitative measures of 
confidence regarding the kinase pathway actvity. This is rather complex and beyond 
the scope of this thesis, and Dr P Cutillas and colleagues are working on such methods. 
Nevetheless, the principle is illustrated that kinase activity can be inferred  from 
consideration of all phosphosites simultaneously, and independent of comparisons 
with controls.  
 
Figure 7.33 shows a plot of kinase pathway activity against the number of substrates. 
This  gives an  overall impression of kinase activity within the CLL and Tonsil samples. It 
can be seen that CDK1/2, CK2-A1 and PKACa have numerous substrates detected, as 
well as high kinase activity, as might be expected. Chk2 has a high kinase activity, but 
represented by one highly abundant substrate. 
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Figure 7.33: Kinase pathway activity vs  number of substrates 
Proportion of phosphosites in sample attributable to the action of a particular kinase 
vs  number of substrates for that kinase. Shown are the data for the mean of all CLL 
and Tonsil baseline samples. 
 
 
Clearly, it appears that CLL and tonsil kinase pathway activity patterns are similar. This 
is unsurprising, as it would be expected that the ‘core’ B-cell phosphoproteome would 
 278 
be common betweeen CLL and Tonsil, sharing many substrates and kinases. To 
highlight differences, a return to a comparison of CLL and Tonsil is required, and this is 
illustated in Figure 7.34 and 7.35 
 
Figure 7.34: CLL/Tonsil Kinase pathway activity vs number of substrates.  
Proportion of phosphosites in sample attributable to the action of a particular kinase 
vs  number of substrates for that kinase.  The kinase pathway activity of CLL is 
divided by that for tonsil. 
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Figure 7.35: CLL/Tonsil Kinase pathway activity, top 30 kinases 
Proportion of phosphosites in sample attributable to the action of a particular 
kinase.  The kinase pathway activity of CLL is divided by that for tonsil. The top 30 
kinases are shown 
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It can be seen that mTOR and the insulin receptor (InsR) kinase pathway activities are 
highest, yet each is represented by only 2 substrates. By consideration of expression 
values of these 2 substrates within each sample, (figure 7.36) it can be seen that mTOR 
and InsR activity are generally higher, but that not every CLL sample exhibits a high 
phosphosite level, explaining why these kinases are not highlighted by the previous 
statistical comparison of CLL vs Tonsil (see section 7.3.7) 
 
Figure 7.36: Expression values of mTOR and InsR substrates within J dataset for each 
baseline sample  
 
 
It can also be seen that the highly expressed substrates contribute more to the derived 
kinase pathway activity measure, as this is derived from the sum of each phosphosite. 
To derive a measure of kinase activity that is less dependent on the substrate 
expression level, the geometric mean of each substrate in each sample was derived 
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(figure 7.37). This may give a better estimate of the kinase activity independent of the 
level of substrate. Further work in this kind of analysis is required, in order to add 
statistical robustness to these measures, but this demonstrates the potential for 
estimating kinase activity based on phosphoproteomic data. 
Figure 7.37 mTOR and InsR kinase activity for each sample.  
The geometric mean of expression values for each substrate was derived for each 
sample, to yield a measure of kinase activity less dependent on absolute substrate 
expression 
 
 
 
Whilst a potentially interesting method, this analysis is still partly dependent on the 
abundance of substrates, on the comparisons between CLL and Tonsil, and as yet lacks 
the statistical rigour to establish a measure of confidence in the quantifications of 
kinase activity. This is discussed further. 
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7.4 Results: BCR signalling 
7.4.1 Introduction 
Our hypothesis is that BCR signalling in CLL cells differs from that in healthy B-cells. We 
therefore seek to demonstrate differentially phosphorylated proteins between 
baseline and the IgM & IgD stimuli. Clustering analysis indicates that samples cluster 
according to patient rather than stimulus, so differences between patients are likely to 
be greater than between baseline and stimulated conditions in the same patient. 
 
BCR signalling was assessed using two analysis methods. In both methods, the fold 
change in phosphosites was calculated by dividing the mean of M or D replicates by 
the mean of B replicates. 
 
1. Paired t-tests comparing means of replicates 
Each replicate is used as a technical replicate and the mean derived. The means of 
stimulated samples are then compared to baseline means. This should reveal common 
changes shared by patients. 
B1,B2,B3,Bx  vs  M1,M2,Mx    etc  
2. Unpaired t-tests comparing stimulated replicates to baseline replicates within 
each sample.  
Each patient is treated as a different experiment, statistical comparison is made 
between the replicates within each patient 
B1a,B1b,B1c vs M1a,M1b,M1c   etc 
It is envisaged that due to biological variation between patients, the results of 
stimulation may well appear very different in each patient, and this is indeed the case.  
7.4.2 Paired t-tests comparing means of replicates to describe BCR signalling  
Mean log2 values were compared between the 5 tonsil baseline samples and their 
stimuli. When log fold changes are displayed in a histogram (Fig 7.38) it can be seen 
that the majority (74%) are less than two-fold. 
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Figure 7.38 Log distribution of fold changes after IgM stimulation, P dataset. 
 
Fold changes appeared normally distributed, and so paired t-tests were felt 
appropriate and used to analyse differences between the stimuli and baseline. The 
differences between baseline and IgM/IgD mean (of triplicates) phosphosite 
quantifications were considered for each of the 5 tonsil and 6 CLL samples. This 
method should detect phosphosites consistently up/downregulated in all CLL or tonsil 
samples after stimulation. Table 7.12 shows that the number of significantly altered 
phosphosites was low, and in fact fell to zero when more stringent p-values using 
Benjamini-Hochberg corrections were used: 
 
Table 7.12: Number of differentially regulated phosphosites at different p values for 
Tonsil and CLL samples, P dataset.  
Uncorrected Tonsil CLL 
P-value IgM IgD IgM IgD 
p<0.05 
p<0.01 
p<0.001 
41 63 118 180 
8 7 11 22 
0 1 0 1 
 
The most significant tonsil IgD-induced phosphosite at uncorrected p=0.0006 was 
Myosin regulatory light polypeptide 9 pS20, at 18-fold increase. It is involved in actin 
polymerization, so is a plausible candidate for involvement in BCR signalling. The most 
significantly altered after IgM signalling in tonsil (p=0.00157) was Actin-related protein 
2/3 complex, another cytoskeletal protein The most significantly altered after IgM 
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signalling in CLL (p=0.00176) was Microtubule-associated protein 4, a cytoskeletal 
protein. The most significantly altered after IgD signalling in CLL (p=0.000186) was 
Phosphoglucomutase-1, a glycolytic pathway enzyme. Similarly, these and other 
cytoskeletal components were amongst the most significantly altered phosphoproteins 
in the J dataset.  However, Benjamini-Hochberg correction with FDR at 0.05 and 0.1 did 
not result in any significant changes across all tonsil and CLL samples, for both P and J 
datasets. It seems that there are no phosphosites altered after BCR stimulation in all 
cases, using a stringent analysis method. 
 
These results highlight the heterogeneity between patients. Some patients exhibited 
marked (up to 216-fold) changes upon stimulation, but because they occurred in only 1 
or 2 patients, they are not considered significant in this analysis. Possible explanations 
for these results are: 
1. The phosphoproteomic techniques are either invalid or insensitive to the most 
important phosphosite changes with BCR stimulation, and this may be 
swamped by technical noise. 
2. The analysis method is inappropriate 
3. The heterogeneity between patients is greater than anticipated and any 
commonalities are ‘swamped’ 
4. Any combination of the above 
7.4.3 Using unpaired t-tests to compare each technical replicate  
We then made comparisons within each patient. Each stimulated condition triplicate 
was compared in an unpaired t-test to the baseline condition triplicate, with 
Benjamini-Hochberg correction at FDR of 0.05. This indicated whether a given 
phosphosite was altered significantly by stimulation in an individual patient. Different 
samples had differing numbers of phosphosites altered by IgM and IgD stimulation 
(see Fig 7.39). Overall 0.1-4.6% of phosphosites were altered by BCR stimulation. 
Figure 7.18 in section 7.3.4 provides examples of supervised clusters that illustrate 
examples of BCR signalling in patients. 
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Figure 7.39: Number of phosphosites significantly altered by BCR stimulation in P and 
J datasets  
 
 
 
The overlaps between IgD and IgM within each sample were also compared (shown for 
P dataset in Table 7.13). 
 
Table 7.13: Overlapping phosphosites altered by both IgM and IgD stimulation, and 
those altered by each stimulus alone, P dataset 
 M1 M2 M3 UM1 UM2 UM3 T1 T2 T3 T4 T5 
Overlap IgM and IgD 0 18 2 44 7 12 3 2 4 1 54 
IgM only 16 42 22 62 26 19 11 28 54 16 110 
IgD only 21 173 10 67 19 30 33 7 3 14 54 
 
These data are combined to provide the proportions altered by both IgD and IgM or 
each stimulus alone (table 7.14), indicating that overall, 14-16% of the phosphosites 
are regulated by both IgM and IgD stimulation, with the remaining proportion unique 
to IgM or IgD stimulation. It also perhaps may be interpreted as IgD having a greater 
effect in CLL, compared to IgM, with the reverse in tonsil (see table 7.14). Of note, 
there was no correlation between the level of calcium flux induced by IgD or IgM and 
the number of altered phosphosites after the same stimulus. 
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Table 7.14 percentages of all altered phosphosites in each group, overlaps. 
Overlapping phosphosites altered by both IgM and IgD stimulation, and those 
altered by each stimulus alone, P and J datasets combined. 
 
 CLL P CLL J Tonsil P Tonsil J 
Overlap IgM and IgD 16.2 14.5 16.5 15.3 
IgM only 25.0 24.1 43.1 45.3 
IgD only 42.5 46.8 23.9 24.0 
 
Overlaps between patients were also considered, i.e. phosphosites that are 
consistently altered by stimulation in more than one patient (Table 7.15). Overlaps 
were limited, with a differentially regulated phosphosite after IgM stimulation in only 
three of the eleven patients (P dataset), and when tonsil and CLL are considered 
separately, there were only 5 phosphosites altered in at least 2 CLL patients, and 15 in 
tonsil: 
Table 7.15: Number of individual phosphosites significantly altered by IgM 
stimulation, overlaps P dataset. 
Considering presence of the same phosphosite in more than one sample (overlap).  
Number of samples with overlap IgM ALL IgM CLL IgM T 
3 3 0 0 
2 36 5 15 
1 472 260 253 
0 4577 4823 4820 
 
The 3 differentially regulated phosphosites (and their putative functions) were:  
 Pro-interleukin-16 pS844 (pleiotropic cytokine) 
 Serine/threonine-protein kinase B-raf (MAP kinase/ERK signalling) 
 ATP-dependent RNA helicase DHX8 pS460 (RNA processing) 
Similarly, For the J dataset (Tables 7.16 & 7.17): 
 
Table 7.16: Number of individual phosphosites significantly altered by IgM 
stimulation, overlaps J dataset. 
Considering presence of the same phosphosite in more than one sample (overlap).  
Number of samples with overlap IgM ALL IgM CLL IgM T 
3 7 0 2 
2 31 6 14 
1 355 164 228 
0 2786 3009 2935 
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Table 7.17: 7 IgM-induced phosphosites in at least 3 samples (J dataset) 
Phosphoprotein overlap in 3 samples Function 
Protein phosphatase 1 regulatory 
subunit 12A 
Regulator of protein phosphatase 1C.  
Mediates binding to myosin 
Protein LAP2 Adapter for the receptor ERBB2 
Serine/threonine-protein kinase B-raf Transduction of mitogenic signals 
ATP-dependent RNA helicase DHX8 Facilitates nuclear export of spliced mRNA 
Striatin-3 
May function as scaffolding or signalling 
protein 
Cyclic AMP-responsive element-
binding protein 1 
transcription factor 
Translocation protein SEC62 Required for preprotein translocation 
 
Similarly, for IgD, there was only one phosphosite (CD2 associated protein pS80) 
altered by IgD stimulation in 3 Tonsil patients (table 7.18). 
Table 7.18: Number of individual phosphosites significantly altered by IgD 
stimulation, overlaps P dataset. 
Considering presence of the same phosphosite in more than one sample (overlap).  
Number of samples with overlap IgD ALL IgD CLL IgD T 
3 1 0 1 
2 31 15 1 
1 513 373 170 
0 4543 4700 4916 
And for J dataset, the same phosphosite (CD2 associated protein pS80) was altered in 3 
Tonsil patients (Table 7.19). CD2 associated protein is a scaffolding molecule involved 
in regulation of the cytoskeleton. It has recently been associated with proximal BCR 
signalling events554.  
Table 7.19: Number of individual phosphosites significantly altered by IgD 
stimulation, overlaps J dataset. 
Considering presence of the same phosphosite in more than one sample (overlap).  
Number of samples with overlap IgD ALL IgD CLL IgD T 
3 1 0 1 
2 37 14 2 
1 370 256 156 
0 2771 2909 3020 
 
The percentage of phosphotyrosine phosphosites in the BCR altered lists was 1-1.5%, 
similar to the proportion for all detected phosphosites, indicating no enrichment of 
phosphotyrosine in BCR signalling. 
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This limited overlap is a reflection of the results of the analysis in section 7.3.13, 
demonstrating the absence of consistent phosphosite changes across patients.  In an 
alternative strategy to search for generalities, the differentially regulated phosphosites 
after IgM or IgD stimulation in each CLL and Tonsil sample were combined into one list 
for further bioinformatic analysis.  
 
To estimate the degree to which correlation is also caused by direct protein-protein 
interactions, curated databases were considered. The Search Tool for the Retrieval of 
Interacting Genes (STRING) database provides access to access to both experimental as 
well as predicted protein-protein interaction information. By inputting protein 
identifications, known and predicted relationships between proteins can be visualised. 
The network data derived is then imported for visualisation in Cytoscape software 
(Figure 7.40)555. Evidence of interaction is derived from a combination of various 
published data. This includes proximity in genomes, co-expression in tissues, and 
evidence of direct binding from protein-interaction experiments and text mining 
techniques (such as co-occurrence in abstracts). As an example analysis, the 
phosphoproteins in the tonsil J dataset stimulated by BCR signalling were viewed in 
terms of their protein-protein interactions using the STRING database556. There was no 
obvious separation into IgD-stimulated, IgM-stimulated or common induced 
phosphoproteins by this analysis (see Figure 7.40), and this analysis technique was not 
pursued further. 
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Figure 7.40: STRING interactions for Tonsil BCR signalling, J dataset.  
The phosphoproteins altered by BCR stimulation with IgD (red nodes), IgM (blue 
nodes) or both (magenta nodes) were linked by known protein-binding interactions 
using STRING. Cytoplasmic proteins are represented by triangles, nuclear by circles, 
extracellular by diamonds, plasma membrane by arrows, unknown localisation by 
squares. 
 
 
 
 
The cellular localisation of the proteins altered by BCR stimulation did not appear to be 
different from those in the entire dataset, or the CLL v Tonsil proteins (Fig 7.41): 
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Figure 7.41. BCR-induced phosphoproteins by cellular localisation.  
Shown are those altered by BCR stimulation for Tonsil (T) and CLL, J dataset and all 
proteins detected (all proteins) and those differing between CLL and Tonsil (CLL v T)
 
 
 
Similarly, the molecular function of the altered proteins was similar to those in the 
overall dataset, though there may be an increased proportion of transcriptional 
regulators after BCR stimulation (Fig 7.42) 
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Figure 7.42. BCR-induced phosphoproteins by molecular function.  
Shown are the proteins different after BCR stimulation for Tonsil (T) and CLL, J 
dataset, and the proteins in the entire dataset (all proteins) and those differing 
between CLL and Tonsil (CLL v T). 
A: all functions 
 
B: As above, with the category ‘other’ removed 
 
Amongst the phosphosites with altered levels after BCR stimulation were several 
kinases, phosphatases and transcription factors. Figure 7.43 provides a summary of 
these according to stimulus. 
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Figure 7.43 BCR-regulated phosphosites that are also kinases, phosphatases & 
transcription factors.  
There was extensive overlap between the P and J datasets. Italicised kinases were 
present in J dataset only. 
 
 
 
 
 
 
 293 
 
 
 
The most enriched pathways after BCR stimulation are shown below (Table 7.20). The 
IPA analyses from CLL and Tonsil, and P and J datasets were compared. Also, each 
KEGG/IPA analysis was performed for each patient list to demonstrate the enrichment 
for pathway components within each patient, giving an impression of which patients 
are contributing to the enrichment. Note that if a component in one patient is 
combined with another pathway component in a different patient the combined list 
with 2 (or more) components may result in significant enrichment, even if enrichment 
is not considered as significant in an individual patient. 
 
 
 
Table 7.20: IPA and KEGG pathways enriched in proteins significantly altered by BCR 
stimulation.  
The analysis was performed on combined lists of differentially regulated 
phosphoproteins after IgM or IgD stimulus. The same analysis was also performed on 
each separate patient lists. ‘pts’ indicates the number of patients that have a 
pathway identified when the analysis is run for each patient. Pathways enriched in 
50% of patients in at least one dataset are shaded grey 
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Ingenuity Canonical Pathways IgM CLL 
Ratio 
J 
P-
value J 
Pts 
J 
Ratio 
P 
P-value 
P 
Pts 
P 
DNA Methylation & Transcriptional Repression 
Signalling 
0.13 0.0007 1 0.17 0.0001 3 
ERK/MAPK Signalling 0.04 0.0011 4 0.04 0.0027 5 
Systemic Lupus Erythematosus Signalling 0.03 0.0037 5 0.04 0.0018 5 
Phospholipase C Signalling 0.02 0.0437 5 0.04 0.0025 5 
Hereditary Breast Cancer Signalling 0.03 0.0741 3 0.05 0.0035 4 
Insulin Receptor Signalling 0.02 0.0977 1 0.05 0.0063 5 
Role of BRCA1 in DNA Damage Response 0.03 0.0977 3 0.06 0.0079 2 
Protein Kinase A Signalling 0.02 0.0398 5 0.03 0.0081 6 
Tight Junction Signalling 0.02 0.1306 4 0.04 0.0115 5 
Breast Cancer Regulation by Stathmin1 0.03 0.0245 3 0.04 0.0117 6 
iCOS-iCOSL Signalling in T Helper Cells 0.04 0.0120 5 0.04 0.0437 4 
Acetyl-CoA Biosynthesis III (from Citrate) X X 0 1.00 0.0132 1 
DNA DSB Repair by Homologous Recombination 0.06 0.1159 1 0.13 0.0141 2 
Netrin Signalling 0.04 0.0457 4 0.07 0.0145 4 
Telomere Extension by Telomerase X X 0 0.13 0.0162 2 
Dopamine Receptor Signalling 0.04 0.0282 1 0.05 0.0170 4 
Glucocorticoid Receptor Signalling 0.02 0.0245 4 0.03 0.0195 4 
Estrogen Receptor Signalling 0.03 0.0219 3 0.03 0.0759 3 
PI3K Signalling in B Lymphocytes 0.03 0.0219 5 0.03 0.0759 4 
Calcium Signalling 0.01 0.4315 4 0.03 0.0229 5 
Cardiac β-adrenergic Signalling 0.03 0.0240 1 0.04 0.0245 4 
AMPK Signalling 0.03 0.0251 4 0.04 0.0263 4 
IL-4 Signalling 0.04 0.0251 4 X X 3 
Spliceosomal Cycle X X 0 0.14 0.0263 1 
Uridine-5'-phosphate Biosynthesis X X 0 0.50 0.0263 1 
CDK5 Signalling 0.03 0.0407 1 0.04 0.0275 4 
Nur77 Signalling in T Lymphocytes 0.04 0.0741 3 0.05 0.0295 3 
ILK Signalling 0.01 0.4699 1 0.03 0.0316 4 
Role of CHK Proteins in Cell Cycle Checkpoint Control 0.02 0.3784 1 0.05 0.0339 2 
Telomerase Signalling 0.02 0.2056 1 0.04 0.0380 3 
B Cell Receptor Signalling 0.03 0.0417 5 0.03 0.0468 4 
ATM Signalling 0.02 0.4055 1 0.05 0.0427 3 
Cell Cycle: G1/S Checkpoint Regulation 0.02 0.4055 1 0.05 0.0427 3 
April Mediated Signalling 0.05 0.0437 4 0.05 0.0891 3 
B Cell Activating Factor Signalling 0.05 0.0479 4 0.05 0.0977 3 
 
KEGG pathway IgM CLL 
Ratio 
J 
P-
value 
J 
Pts 
J 
Ratio 
P 
P-value 
P 
Pts 
P 
Spliceosome 0.06 0.0024 2 0.03 0.0310 2 
Nucleotide excision repair X X 0 0.09 0.0110 1 
B cell receptor signalling pathway 0.04 0.0634 0 X X 0 
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Ingenuity Canonical Pathways IgM tonsil 
Ratio 
J 
P-
value J 
Pts 
J 
Ratio 
P 
P-value 
P 
Pts 
P 
Phospholipase C Signalling 0.04 0.0005 4 0.05 0.0000 5 
DNA Methylation & Transcriptional Repression 
Signalling 
0.13 0.0019 1 0.17 0.0001 4 
Telomerase Signalling 0.04 0.0339 3 0.06 0.0008 4 
Sucrose Degradation V (Mammalian) 0.14 0.0741 2 0.29 0.0019 3 
Tight Junction Signalling 0.04 0.0023 3 0.03 0.0794 2 
Estrogen Receptor Signalling 0.05 0.0045 2 0.05 0.0026 3 
Glycolysis I 0.13 0.0026 5 0.09 0.0257 3 
Actin Nucleation by ARP-WASP Complex 0.06 0.0048 3 0.06 0.0032 4 
Signalling by Rho Family GTPases 0.02 0.0575 5 0.03 0.0032 5 
Role of NFAT in Cardiac Hypertrophy 0.03 0.0708 1 0.04 0.0037 4 
ATM Signalling 0.03 0.1722 2 0.07 0.0045 3 
Breast Cancer Regulation by Stathmin1 0.03 0.0324 3 0.04 0.0055 3 
Integrin Signalling 0.03 0.0100 3 0.03 0.0055 4 
Protein Kinase A Signalling 0.03 0.0170 2 0.03 0.0081 3 
Hereditary Breast Cancer Signalling 0.03 0.1671 1 0.04 0.0087 4 
RhoGDI Signalling 0.03 0.0537 4 0.03 0.0098 4 
Calcium Signalling 0.02 0.1629 2 0.03 0.0120 4 
Diphthamide Biosynthesis 0.50 0.0126 1 X X 0 
Granzyme A Signalling 0.12 0.0170 0 0.06 0.1671 1 
Thrombin Signalling 0.03 0.0851 4 0.03 0.0186 4 
Nur77 Signalling in T Lymphocytes 0.02 0.4797 1 0.05 0.0200 3 
Spliceosomal Cycle X X 0 0.14 0.0224 1 
NADH Repair 0.33 0.0251 1 X X 0 
Calcium-induced T Lymphocyte Apoptosis 0.02 0.5236 1 0.05 0.0282 3 
Cell Cycle: G1/S Checkpoint Regulation 0.03 0.1722 1 0.05 0.0295 4 
Huntington's Disease Signalling 0.02 0.1219 2 0.03 0.0302 4 
cAMP-mediated signalling 0.02 0.1236 2 0.03 0.0309 2 
Gluconeogenesis I 0.08 0.0316 3 0.04 0.2223 2 
PPARα/RXRα Activation 0.03 0.0501 2 0.03 0.0331 2 
ERK5 Signalling 0.03 0.1905 2 0.05 0.0347 2 
Corticotropin Releasing Hormone Signalling 0.03 0.1611 2 0.03 0.0355 2 
Melatonin Signalling 0.04 0.0537 1 0.04 0.0407 2 
Synaptic Long Term Potentiation 0.03 0.0575 2 0.03 0.0407 3 
       
B Cell Receptor Signalling 0.02 0.2938 2 0.01 0.5070 2 
 
KEGG pathway IgM tonsil 
Ratio 
J 
P-
value 
J 
Pts 
J 
Ratio 
P 
P-value 
P 
Pts 
P 
Spliceosome 0.06 0.0013 1 0.08 0.0000 1 
Antigen processing and presentation X X 0 0.05 0.0499 1 
Pathogenic Escherichia coli infection 0.09 0.0022 1 X X 0 
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Ingenuity Canonical Pathways IgD CLL 
Ratio 
J 
P-
value J 
Pts 
J 
Ratio 
P 
P-value 
P 
Pts 
P 
Telomerase Signalling 0.05 0.0126 4 0.08 0.0003 4 
DNA Methylation & Transcriptional Repression 
Signalling 
0.09 0.0331 2 0.17 0.0004 4 
Estrogen Receptor Signalling 0.05 0.0081 5 0.06 0.0015 5 
IL-4 Signalling 0.05 0.0200 4 0.08 0.0018 3 
Insulin Receptor Signalling 0.05 0.0098 2 0.06 0.0019 2 
RAR Activation 0.03 0.0355 4 0.05 0.0112 3 
Diphthamide Biosynthesis 0.50 0.0145 1 0.50 0.0178 1 
Hereditary Breast Cancer Signalling 0.03 0.0759 3 0.05 0.0148 2 
ERK/MAPK Signalling 0.04 0.0158 2 0.04 0.0162 3 
Glucocorticoid Receptor Signalling 0.03 0.0316 4 0.04 0.0166 3 
Phospholipase C Signalling 0.03 0.0398 4 0.04 0.0178 6 
CDK5 Signalling 0.04 0.0372 2 0.06 0.0200 2 
Assembly of RNA Polymerase III Complex 0.07 0.1718 1 0.14 0.0219 2 
Dopamine Receptor Signalling 0.05 0.0229 2 0.05 0.0457 2 
AMPK Signalling 0.04 0.0363 4 0.04 0.0263 3 
Dopamine-DARPP32 Feedback in cAMP Signalling 0.04 0.0263 2 0.03 0.1510 2 
Calcium Signalling 0.02 0.2208 4 0.04 0.0309 3 
Netrin Signalling 0.04 0.1081 2 0.07 0.0324 2 
Granzyme A Signalling 0.06 0.2070 1 0.18 0.0324 3 
Neuroprotective Role of THOP1 in Alzheimer's 0.05 0.1130 2 0.07 0.0347 2 
Spliceosomal Cycle X X 0 0.14 0.0355 2 
Uridine-5'-phosphate Biosynthesis X X 0 0.50 0.0355 1 
FcγRIIB Signalling in B Lymphocytes 0.04 0.1175 1 0.06 0.0363 2 
Role of NFAT in Cardiac Hypertrophy 0.03 0.1069 3 0.04 0.0372 3 
Natural Killer Cell Signalling 0.03 0.1928 2 0.05 0.0398 2 
Ins(1,4,5)P3 Degradation 0.06 0.2301 1 0.11 0.0407 1 
Renin-Angiotensin Signalling 0.03 0.2037 3 0.04 0.0447 3 
1D-myo-inositol Hexakisphosphate Biosynthesis 0.05 0.2410 1 0.11 0.0447 1 
Ins(1,4,5)P3 Biosynthesis 0.05 0.2410 1 0.11 0.0447 1 
Cyclins and Cell Cycle Regulation 0.03 0.1000 3 0.05 0.0490 2 
PDGF Signalling 0.03 0.3048 1 0.05 0.0490 2 
Integrin Signalling 0.03 0.0537 3 0.03 0.0513 4 
B Cell Receptor Signalling 0.02 0.3631 2 0.04 0.0513 2 
 
KEGG pathway IgD CLL 
Ratio 
J 
P-
value J 
Pts 
J 
Ratio 
P 
P-value 
P 
Pts 
P 
Spliceosome 0.06 0.0024 2 0.10 0.0000 3 
Notch signalling pathway 0.09 0.0146 2 0.11 0.0040 2 
RNA degradation 0.09 0.0243 0 X X 0 
Insulin signalling pathway 0.04 0.0604 0 0.04 0.0394 0 
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Ingenuity Canonical Pathways IgD tonsil 
Ratio 
J 
P-value 
J 
Pts 
J 
Ratio 
P 
P-value 
P 
Pts 
P 
Estrogen Receptor Signalling 0.05 0.0006 2 0.05 0.0007 2 
Signalling by Rho Family GTPases 0.03 0.0028 2 0.03 0.0029 3 
Phospholipase C Signalling 0.02 0.0427 3 0.03 0.0032 4 
Cdc42 Signalling 0.04 0.0047 2 0.02 0.0977 3 
Glucocorticoid Receptor Signalling 0.03 0.0068 3 0.02 0.0245 3 
Granzyme A Signalling 0.12 0.0083 0 0.06 0.1315 1 
SAPK/JNK Signalling 0.03 0.0468 1 0.04 0.0089 3 
Protein Kinase A Signalling 0.02 0.0135 3 0.02 0.0141 3 
Hypoxia Signalling in the Cardiovascular System 0.03 0.0977 0 0.05 0.0162 1 
Spliceosomal Cycle X X 0 0.14 0.0174 1 
Neurotrophin/TRK Signalling 0.04 0.0204 0 0.04 0.0209 2 
ERK/MAPK Signalling 0.03 0.0209 3 0.02 0.0741 3 
GDNF Family Ligand-Receptor Interactions 0.04 0.0214 0 0.04 0.0219 2 
Cardiac β-adrenergic Signalling 0.03 0.0234 3 0.03 0.0240 3 
Integrin Signalling 0.02 0.0234 3 0.01 0.2254 2 
AMPK Signalling 0.03 0.0245 3 X X 1 
Regulation of Actin-based Motility by Rho 0.03 0.0282 2 0.01 0.4887 2 
B Cell Receptor Signalling 0.03 0.0407 1 0.03 0.0417 3 
April Mediated Signalling 0.05 0.0427 1 0.05 0.0437 2 
PPAR Signalling 0.02 0.1841 0 0.03 0.0447 2 
B Cell Activating Factor Signalling 0.05 0.0468 1 0.05 0.0479 2 
PPARα/RXRα Activation 0.02 0.0479 1 0.02 0.1589 2 
EIF2 Signalling X X 0 0.02 0.0490 4 
 
KEGG pathway IgD Tonsil 
Ratio 
J 
P-value 
J 
Pts 
J 
Ratio 
P 
P-value 
P 
Pts 
P 
Spliceosome 0.07 0.000 1 0.10 0.000 2 
 
Highlighted in Table 7.20 are the data indicating enrichment for components of the 
BCR signalling pathway. There are suggestions that our datasets do include these BCR 
pathway proteins. For IPA analysis, IgM CLL, IgD CLL (p=0.0513) and IgD Tonsil all seem 
to include BCR signalling components. The KEGG pathways analysis for IgM CLL has the 
BCR pathway enriched at p=0.06. More strikingly, the ‘Spliceosome’ KEGG pathway is 
significantly enriched in all IgM/IgD CLL/tonsil datasets, and the analogous 
‘Spliceosomal Cycle’ appears in all IPA pathway lists. Also, Notch signalling is also 
enriched in IgD CLL KEGG analysis.  
 
When the analyses are run for each list of phosphoproteins altered by BCR in each 
patient, it can be seen that the majority of pathways highlighted by combination of the 
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individual lists are also enriched in each patient. For example, protein kinase A 
signalling, highlighted in the IgM CLL analysis, is also significantly enriched when each 
of the 6 lists of IgM-stimulated phosphoproteins in the P dataset is considered. This 
suggests that whilst there is great patient-to-patient heterogeneity in the 
phosphoproteins stimulated by a particular stimulus, there is more unity when the 
pathways themselves are considered.  
7.4.4 Notch & Spliceosome signalling is stimulated by BCR ligation 
The IgD-stimulated CLL phosphosites were enriched for Notch signalling components: 
pS4 NUMBL, pS2269 NCOR2 (SMRT), pS224/232 SNW1 (SKIP) (phosphosite 
downstream of CDK2), pS410 HDAC1 (phosphosite downstream of CK2-A1) and 
pS421/423 HDAC2. The NOTCH pathway and the expression levels of the relevant 
phosphosites are shown in figure 7.44. 
 
Altogether, 24 proteins in the KEGG spliceosome pathway were altered by at least one 
of the IgD or IgM stimuli. The KEGG pathway, and each of the altered phosphoproteins 
are shown in Figure 7.45. The alterations of expression by stimuli are complex, with 
the changes depending on sample, stimulus and phosphosite. Two examples (RBM25 
and DDX42 are shown, but it is difficult to discern a pattern amongst all the altered 
phosphosites within the spliceosome components. 
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Figure 7.44: NOTCH KEGG pathway 
Phosphoproteins in IgD CLL lists highlighted in red, and mean expression values for each condition (J dataset). Green=Tonsil, Red = CLL 
 300 
Figure 7.45: Spliceosome KEGG pathway. 
CLL IgM-stimulated phosphoproteins highlighted in red. To the right are the overlaps between the different stimuli and the 
spliceosome components altered by those stimuli, and below are two examples of expression levels in the different samples (J 
dataset) 
 301 
7.4.5 BCR pathways, the differences between IgM and IgD, CLL and tonsil. 
We sought to further clarify the overlaps and differences between IgD and IgM 
signalling, and between CLL and Tonsil. The lists of proteins altered by BCR signalling 
were compared. The characteristics of phosphoproteins altered by both IgD and IgM 
signalling, and those altered by only IgD or IgM signalling were compared. As has been 
shown (Table 7.21), there is a degree of overlap between IgM and IgD, but the majority 
of altered phosphosites are specific to each stimulus: 
 
Table 7.21 percentages of all altered phosphosites in each group, M & D overlap. 
Overlapping phosphosites altered by both IgM and stimulation, and those altered by 
each stimulus alone, P and J datasets shown separately. 
 
 CLL P CLL J Tonsil P Tonsil J 
Overlap IgM and IgD 16.2 14.5 16.5 15.3 
IgM only 25.0 24.1 43.1 45.3 
IgD only 42.5 46.8 23.9 24.0 
Similarly, there is limited overlap between CLL and Tonsil in terms of the phosphosites 
characterising IgM or IgD signalling (Table 7.22) 
Table 7.22 percentages of all altered phosphosites in each group, CLL & T overlap. 
Overlapping phosphosites altered by stimulation in both CLL and Tonsil, and those 
altered in each patient group alone, P and J datasets shown separately. 
 
 IgM P IgM J IgD P IgD J 
Overlap CLL and T 7.1 5.1 5.2 4.9 
CLL only 44.4 35.9 63.9 58.0 
T only 41.4 54.0 25.8 32.2 
 
Figure 7.46 illustrates the overlaps of unique phosphosites altered by stimulation in 
the CLL and Tonsil samples. For each list (IgM CLL, IgM Tonsil, IgD CLL, IgD Tonsil, see 
Table 7.20), the IPA and KEGG pathways were generated and overlaps considered in 
terms of the biological pathways that were enriched in either the P or J dataset.  (i.e 
Phospholipase C Signalling appeared in all 4 lists, and so is placed at the overlap of the 
conditions. The pathway is not derived from analysis of the few phosphosites that 
overlapped in all conditions, though this analysis does suggest similar but fewer 
pathways, data not shown).  
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Figure 7.46. The number of phosphosites altered by BCR stimulation considered in 
their overlaps between IgM & IgM, CLL and Tonsil.  
Each of the 4 lists of IgM/IgD Below are the pathways containing the BCR stimulated 
phosphoproteins 
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7.4.6 Kinases active after BCR ligation 
The BCR-stimulation regulated phosphosites were matched to upstream kinases, with 
a minority being represented. In the P dataset, 9% of phosphosites regulated after IgM 
had identified kinases (figure 7.47): 
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Figure 7.47: Phosphosites with identified kinases (red) as proportion of all 
phosphosites for each stimulus, P dataset 
 
 
Overall, 7-11% of kinases were identified for the IgM & IgD induced phosphosites in 
the P and J datasets. 
 
The identified kinases are shown below (fig 7.48). The kinase data are combined in 
Figure 7.49 to demonstrate the kinases and activated in CLL and Tonsil, by IgD and IgM 
signalling. 
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Figure 7.48 kinases upstream of phosphosites differentially expressed after IgM and 
IgD stimulation.  
The number of patients in which a kinase activity is up/down regulated is indicated. 
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Figure 7.49: Kinases altered by BCR stimulation (in at least one patient) 
 P dataset 
 
 
 
J dataset 
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7.4.7 Substrates of kinases in the proximal B-Cell Receptor pathway are not generally 
detected, more distal kinases are upregulated by BCR stimulation 
The kinases generally associated with BCR signalling are SYK, BTK and LYN, and the 
analysis performed so far has not highlighted them. The generated data were 
examined for known substrates of these kinases. 
SYK: The Phosphosite database lists 39 human phosphosites on 28 proteins as 
substrates of SYK. Whilst 8/28 proteins were in our dataset, none were known 
phosphosites of SYK. 
LYN: Of 48 human phosphosite substrates of LYN, 9/35 proteins were in our dataset, 
with 1 known phosphosite substrate of LYN present: pS291 WASP (also downstream of 
ABL, ACK, LCK). This phosphosite was not significantly altered by BCR stimulation in any 
patient (though was significantly elevated in CLL vs Tonsil). The presumed LYN activity 
is shown in Figure 7.50 
Figure 7.50: Expression of pY291 WASP (and estimated LYN activity) in different 
samples.  
The Tonsil samples are shown at higher scale below. 
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BTK: Of the 13 phosphosites of BTK, 3/7 proteins were in our dataset, none of which 
had a known phosphosite. The phosphoELM database does consider pY291 WASP as a 
downstream substrate of BTK, with one referenced paper557.  
 
When the identified upstream kinases are mapped onto the canonical BCR pathway, it 
can be seen that whilst many of these proximal kinases are not seen to be upregulated 
by stimulation, many of those seen are downstream components of the canonical BCR 
signalling pathway (see fig 7.51) 
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Figure 7.51 The B-Cell Receptor IPA canonical pathway.  
Highlighted in red are the kinases upregulated in our datasets, in yellow are those 
not apparently altered by BCR stimulation in our dataset 
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Kinase prediction 
Due to the issues with the reliability of the Scansite algorithm and the labour-intensive 
nature of the analysis, limited kinase prediction based on BCR-stimulated phosphosites 
was performed, shown in figure 7.52 is the predicted kinases for one stimulus (chosen 
because there were limited numbers of phosphosites to analyse). 
Figure 7.52: M3M P dataset Scansite predicted kinases. 
 Each phosphosite significantly altered by IgM stimulus in samples M3 is shown with 
the fold change after stimulation, the known and predicted upstream kinases 
Phosphosite fold Known kinase(s) Predicted kinases (Scansite) 
AHNAK P-S135 2390   AKT CAMK2    
METTL1 P-S27 784 AKT1 P90RSK CLK2     
PPP1R12A P-S299 59.8   CDK1 CDK5 PKA   
PDCD4 P-S457 0.01 AKT1  CLK2K     
FAM21A P-S333 4.06   AKT1 CK2 PKA   
ARHGEF2 P-T695 61.9   CDK1 CDK5    
MAP3K7 P-S439 0.01   PKA AURB    
PTPRC P-S1297 192   CDK1 CDC2K ERK1 P38MAPK  
PLEKHA7 P-T1013 1.50   AKT1 PKA AURA   
MAVS P-S222 0.05   CDK1 CDC2K CDK5K ERK1 GSK3A/B 
GFRA1 P-Y420 P-
S429 P-T432 
0.01   GSK3A/B     
CCDC86 P-S18 0.01   CDK1 CDK5 ERK1   
EIF3G P-T38 0.02   GSK3A/B     
HNRNPM P-S618 76.8   DNAPK     
TMPO P-S180 P-
S184 
1.59   CK2     
PTGES3 P-S113 I 4.08 CK2  DNAPK     
CAH4 P-S101 5.43   AURB     
EIF2B5 P-S544 0.02 GSK3A/B  CDK1 CDC2K CDK5   
MYL9 P-S20 0.00 CAMK1A  AURB     
LMO7 P-S246 48.9   AKT1 AMPK DNAPK CLK2K  
STK10 P-S951 2.65   CDK1     
IL16 P-S844 3.35   AMPK AURB PKCE   
7.4.8 Summary: The effects of BCR signalling 
There is no simple means to summarise these data on events occurring after BCR 
ligation, or to highlight the differences between CLL and Tonsil, and between IgM and 
IgD. As an attempt, the summary images from above are combined into one image 
(Figure 7.53). 
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Figure 7.53 BCR Signalling Summary.  
 The mean proportions of all phosphosites altered by BCR stimuli, P and J 
datasets shown separately. 
 BCR altered phosphorylations of kinases, phosphatases and transcription 
factors 
 BCR altered IPA pathways 
 BCR altered kinase activities 
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7.5 Results: Validation of phosphoproteomic quantification using western blotting 
7.5.1 Introduction 
In order to validate the results of gene expression microarrays, quantitative real-time 
PCR is used to confirm and validate the relative quantifications of target genes. 
Similarly, quantification of individual phosphoproteins is desirable to validate the 
findings of phosphoproteomic data. In this situation, the analogous technique would 
be detection of phosphoproteins by western blotting533,558. Western blotting is often 
not considered to be a quantitative method, but a qualitative or semi-quantitative one, 
where relative quantifications of proteins detected by western blotting can be used to 
derive conclusions about relative quantifications in the tissue of interest. Beyond 
simple visual inspection of western blot, numerous authors have used quantification of 
proteins using densitometry444, and this technique was used here. 
 
Most known phosphoproteins do not have specific antibodies available for purchase, 
and this is true of the majority of the 3179 phosphosites in our analysis. Antibodies 
were sought for their specificity for phosphoproteins that had been significantly 
different between unstimulated and stimulated samples, or between CLL and tonsil, in 
order to minimise the variability between samples due to technical and biological 
noise.  
7.5.2 Amounts of protein in lysates and available antibodies 
Each sample produced 0.2-2mg/mL of protein, with the tonsil samples (with a lower 
number of starting cells) producing at most 0.6 mg/mL. With 12 well gels, the 
maximum volume that can be loaded is 45 L each well, setting an upper limit on the 
amount of protein that could be run. This led to some tonsil lysates being unusable, 
and when feasible, only 20 g of protein could be loaded into each well. The CLL 
samples, with higher concentrations, were used in a number of electrophoresis runs, 
but again, the amount of lysates was limited to 30 g/well. Furthermore, low protein 
concentrations are often poorly measured using the Bradford assays, and this led to 
unequal well loading in gels, as evaluated by GAPDH staining. Coupled with the 
inherent variability of western blotting, this made reliable quantification of 
phosphoproteins challenging. 
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To select appropriate antibodies for western blotting, the lists of phosphosites that 
were significantly differentially expressed between either CLL vs tonsil (220 in P & J 
datasets combined), or between the different stimuli  (96 phosphosites altered by BCR 
stimulation in at least 2 samples in P & J datasets) were considered. 
  
Of these approximately 300 differentially expressed phosphoproteins, commercially 
available antibodies were available for only 2, both in the lists of sites differentially 
expressed between CLL and tonsil: Anti-Filamin A pS2152 and anti –WASP pY291. 
The search was then extended to the approximately 900 phosphosites that were 
differently expressed in at least one sample after BCR stimulation. After consideration 
of the 300 greatest fold changes between samples, a further 5 antibodies were found 
to be commercially available. 
Anti-phosphosite antibodies, with the full list in table 7.23 
Table 7.23: Proteins and phosphosites of for commercially available antibodies used 
for western blotting 
Protein Phosphosite 
Filamin A FLNA p-S2152 
Wiskott-Adrich syndrome protein WAS p-Y291 
40S ribosomal protein S6 RS6 p-S235/S236 
Lymphocyte-specific protein 1 LSP1 p-S204 
Myosin regulatory light polypeptide 9 MYL9 pS20 
Myosin-9 MYH9 pS1943 
Stathmin 1 STMN1 p-S16 
 
Of these, only FLNA and RS6 provided usable data. The other antibodies either 
produced non-specific staining, or no bands were seen. Briefly, a summary of the 
problems with the antibodies follows. 
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LSP1 p-S204 (52kDa) 
The antibody used for pLSP1 produced two clear bands, neither at the predicted 
molecular weight of 52kDa (see figure 7.54).  
Figure 7.54 Gel electrophoresis of lysates from CRL cell line, probed with anti-
phospho-LSP S204 antibody.  
No band at 52kDa is seen. The higher molecular weight bands are clearly seen, and 
attributed to inappropriate specificity. On the right are shown the molecular weight 
ladders 
 
WAS p-Y291 (60kDa) 
In cell lines and CLL, the anti-pWASP antibody showed prominent staining of the 
pervanadate treated cell line, but no appropriate bands were apparent in any samples 
(see fig 7.55). I interpret this as a capacity to bind phospho-tyrosine non-specifically. 
Figure 7.55: CLL lysates (blot 2a) probed for phospho-WASP.  
The pervanadate-treated cell line (V) stained strongly positive in this and other blots, 
in the absence of a 60kDa band 
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MYL9 pS20 (18kDa) 
No bands seen in cell lines or primary samples. 
MYH9 pS1943 (230kDa) 
No bands seen in cell lines or primary samples. 
STMN1 p-S16 (20kDa) 
Whilst faint bands at 20kDa were seen in cell lines, no sample from primary cells 
displayed any staining. 
 
I also attempted to probe for pBtk (T223) and pSyk (T525/526) in the primary samples, 
as a measure of BCR signalling. There was no apparent pBtk or pSyk or their equivalent 
total proteins in any of the primary samples, attributed to low amounts of protein. 
 
Altogether, the limited amount and concentration of lysates resulted in less than ideal 
amounts of protein being used for electrophoresis, in particular with the tonsil 
samples. Producing good quality, evenly loaded western blots with small amounts of 
protein derived from primary cells was also challenging. The limited number of primary 
antibodies available for probing compounded these difficulties. Most antibodies 
purchased did not detect any phosphoproteins, probably due to the  to the low 
concentrations of protein, and a lack of efficacy of the antibody used. This resulted in 
probing being limited to using the pRS6 and pFLMN antibodies for validation. Both 
antibodies used have been validated by other publications, and the expression of pRS6 
and pFLMN in the proteomic dataset was generally high, which may explain their 
success. 
 
For each CLL sample comparison, electrophoresis was performed twice, with differing 
transfer times of 7 and 9 minutes, as optimisation using cell lines suggested that the 
high molecular weight filamin (280 kDa) appeared to transfer better at longer transfer 
times, whereas the short transfer time appeared to be more appropriate for the lower 
molecular weight proteins such as pRS6 (32 kDa). However, FLMN, RS6 and GAPDH (37 
kDa) had a degree of successful western blotting with both transfer times, and 
therefore some comparisons of identical samples run on separate occasions could be 
made, albeit with different transfer techniques. Each gel was run with pervanadate 
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and untreated RL cell line lysates in order to produce positive controls. Pervanadate is 
a phosphatase inhibitor that generally induces non-specific increase in 
phosphorylation. Densitometry was performed, and correlations (both Pearson and 
Spearman r) made with quantifications derived from phosphoproteomic analysis. Low 
volumes of lysates with low concentrations from the tonsil samples meant that few 
comparisons could be made. Only one gel was run comparing CLL and tonsil, at the 
higher transfer time. Overall, for correlation of western blotting with proteomics data, 
sufficient lysates were available for only 5 electrophoresis runs using 12-well gels, not 
all high quality: 
1a (7 minute transfer) and 1b (9minute transfer) 
1 2 3 4 5 6 7 8 9 10 11 12 
UM1B UM1M UM1D UM2B UM2M UM2D UM3B UM3M UM3D  V C 
2a (7 minute transfer) and 2b (9minute transfer) 
1 2 3 4 5 6 7 8 9 10 11 12 
M1B M1M M1D M2B M2M M2D M3B M3M M3D  V C 
3 (incorporating tonsil samples, 9 minute transfer) 
1 2 3 4 5 6 7 8 9 10 11 12 
UM1B UM2B UM3B M1B M2B T1B T2B T3B T4B T5B V C 
 
7.5.3 Results: Western blotting 
Densitometry was performed to derive quantifications for correlation. Those for 
GAPDH to compensate for loading variation divided the densitometry values for pRS6 
and pFLMN. These were then correlated with phosphoproteomic quantifications, 
initially for those from the J dataset. For example, see figure 7.56: 
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Figure 7.56 Blot 1a (optimised transfer for RS6)-anti-pRS6 
The table shows the distribution of samples. 
Empty box=empty well. V=pervanadate-treated cell line, C=untreated cell line. 
Below is shown the probes for pRS6, RS6 and GAPDH. 
Below this, the figure shows the correlation between the means for each J dataset 
triplicate and the pRS6/GAPDH ratio determined by densitometry. The error bars 
show the range of each replicate in the proteomic data. 
1 2 3 4 5 6 7 8 9 10 11 12 
UM1B UM1M UM1D UM2B UM2M UM2D UM3B UM3M UM3D  V C 
pRS6 
 
total RS6 
 
GAPDH 
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Therefore, there appears to be some correlation between western blotting 
densitometric determination of pRS6 expression and the J dataset means of triplicates. 
In order to determine the equivalent correlation between P dataset means and the 
western blots, correlations were also calculated for each feature representing pRS6. 
Two features, with the same peptide fragment, but differing in that p4405 was 
formylated, represented the pS235/236 phosphosite of RS6 (RLSpSpLR). The 
expression levels and correlations are represented in figure 7.57: 
Figure 7.57: Expression of two features in J dataset representing RS6 pS235/236. 
Shown are the expression levels of p1403 and p4405 (formylated version of p1403). 
Below are shown the correlation coefficients for the comparisons with densitometry 
derived by western blot. The J dataset represents the sum of p1403 and p4405. 
 
 p1403 p4405 J dataset 
Pearson r 0.7221 0.2239 0.7883 
P value (two-tailed) 0.0280 0.5625 0.0116 
Spearman r 0.4833 0.2871 0.6667 
P value (two-tailed) 0.1938 0.4630 0.0589 
 
Thus, it can be seen that the more abundant feature (p1403) produces a higher  (and 
significant) Pearson r, whilst the sum of the two features’ expressions in the J dataset 
produces a higher Pearson and Spearman r (although p=0.059). The same analysis was 
used for subsequent blots. See Figures 7.58 & 7.59 
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Figure 7.58 Blot 2a (optimised transfer for RS6): anti-pRS6 
The table shows the distribution of samples. 
Empty box=empty well. V=pervanadate-treated cell line, C=untreated cell line. 
Below is shown the probes for pRS6, RS6 and GAPDH. 
Below this, the figure shows the correlation between the means for each J dataset 
triplicate and the pRS6/GAPDH ratio determined by densitometry. The error bars 
show the range of each replicate in the proteomic data. 
 
pRS6 
 
total RS6 
 
GAPDH 
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M1B M1M M1D M2B M2M M2D M3B M3M M3D  V C 
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Figure 7.59: Expression of two features in J dataset representing RS6 pS235/236. 
Shown are the expression levels of p1403 and p4405 (formylated version of p1403). 
Below are shown the correlation coefficients for the comparisons with densitometry 
derived by western blot. The J dataset represents the sum of p1403 and p4405. 
 
 
 p1403 p4405 J dataset 
Pearson r 0.9117 0.3881 0.8628 
P value (two-tailed) 0.0006 0.3020 0.0027 
Spearman r 0.7950 0.3167 0.7833 
P value (two-tailed) 0.0138 0.4101 0.0172 
 
Again, p1403 demonstrates the higher correlation, though in this group of samples, 
p4405 has a higher level of expression in certain samples.  
The same was performed for comparisons incorporating tonsil baselines (blot 3, Figure 
7.60), though there was uneven loading. 
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Figure 7.60 Blot 3 (optimised transfer for FLMN): anti-pRS6 
The table shows the distribution of samples. 
V=pervanadate-treated cell line, C=untreated cell line. 
Below is shown the probes for pRS6, RS6 and GAPDH. 
Below this, the figure shows the correlation between the means for each J dataset 
triplicate and the pRS6/GAPDH ratio determined by densitometry. The error bars 
show the range of each replicate in the proteomic data. Because of the poor loading 
of T3B and T5B, correlations are also shown when these samples are removed from 
the analysis 
1 2 3 4 5 6 7 8 9 10 11 12 
UM1B UM2B UM3B M1B M2B T1B T2B T3B T4B T5B V C 
pRS6 (note insufficiently stripped GAPDH above) 
 
total RS6 
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Figure 7.61: Expression of two features in J dataset representing RS6 pS235/236. 
Shown are the expression levels of p1403 and p4405 (formylated version of p1403). 
Below are shown the correlation coefficients for the comparisons with densitometry 
derived by western blot. The J dataset represents the sum of p1403 and p4405. 
Because of the poor loading of T3B and T5B, correlations are also shown when these 
samples are removed from the analysis 
 
 
 p1403 p4405 J dataset 
Pearson r 0.4443 -0.2633 0.2909 
P value (two-tailed) 0.1983 0.4624 0.4148 
Spearman r 0.8061 0.01841 0.5758 
P value (two-tailed) 0.0072 0.9730 0.0883 
 
without T3B and T5B p1403 p4405 J dataset 
Pearson r 0.3532 0.1880 0.4360 
P value (two-tailed) 0.3908 0.6557 0.2802 
Spearman r 0.6905 0.2928 0.7381 
P value (two-tailed) 0.0694 0.4618 0.0458 
 
Again, p1403 has the greater correlation with densitometry, though this is actually 
reduced by removal of the poor-quality T3B and T5B densitometry values, whilst this 
correction results in somewhat improved correlation in the J dataset. 
The same approach was adopted when probing for phospho-FLMN on the blots 
optimised for the transfer at high molecular weights (see Figures 7.62-7.67 ). Of note, 
phospho-FLMN was selected because of its significantly higher expression levels in all 
CLL samples relative to all tonsil samples, which is reflected in the western blots. 
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Figure 7.62 Blot 1b (optimised transfer for FLMN): anti-pFLMN  
The table shows the distribution of samples. 
V=pervanadate-treated cell line, C=untreated cell line. 
Below is shown the probes for pFLMN, FLMN and GAPDH. 
Below this, the figure shows the correlation between the means for each J dataset 
triplicate and the pFLMN/GAPDH ratio determined by densitometry. The error bars 
show the range of each replicate in the proteomic data. 
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Figure 7.63: Expression of 4 features in J dataset representing FLMN pS2152.  
Shown are the expression levels of p0986, p4087, p4146. p4275. Below are shown 
the correlation coefficients for the comparisons with densitometry derived by 
western blot. The J dataset represents the sum of all 4 features. 
 
 
 p0986 p4087 p4146 p4275 
J 
dataset 
Pearson r -0.4356 0.7985 0.5600 0.7239 0.6494 
P value (two-tailed) 0.2412 0.0099 0.1169 0.0274 0.0584 
Spearman r -0.3667 0.6963 0.7833 0.7500 0.7500 
P value (two-tailed) 0.3363 0.0433 0.0172 0.0255 0.0255 
 
Figure 7.63 suggests that 3 of 4 features are correlated to some extent with the 
densitometry values, and in some cases, this relationship is weakened by considering 
their sum (J dataset). Also, the poorly correlated p0986 feature is not the least 
abundant, suggesting that poor correlation is not due to low abundance features. 
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Figure 7.64 Blot 2b (optimised transfer for FLMN): anti-pFLMN 
The table shows the distribution of samples. 
V=pervanadate-treated cell line, C=untreated cell line. 
Below is shown the probes for pFLMN, FLMN and GAPDH. 
Below this, the figure shows the correlation between the means for each J dataset 
triplicate and the pFLMN/GAPDH ratio determined by densitometry. The error bars 
show the range of each replicate in the proteomic data. 
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Figure 7.65: Expression of 4 features in J dataset representing FLMN pS2152.  
Shown are the expression levels of p0986, P4087, p4146. p4275. Below are shown 
the correlation coefficients for the comparisons with densitometry derived by 
western blot. The J dataset represents the sum of all 4 features. 
 
 
 p0986 p4087 p4146 p4275 J dataset 
Pearson r -0.01445 0.4958 0.5655 0.6959 0.6742 
P value (two-tailed) 0.9706 0.1747 0.1125 0.0373 0.0464 
Spearman r -0.1333 0.7167 0.5743 0.7667 0.7667 
P value (two-tailed) 0.7435 0.0369 0.1080 0.0214 0.0214 
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Figure 7.66 Blot 3 (optimised transfer for FLMN): anti-pFLMN 
The table shows the distribution of samples. 
V=pervanadate-treated cell line, C=untreated cell line. 
Below is shown the probes for pFLMN, FLMN and GAPDH. 
Below this, the figure shows the correlation between the means for each J dataset 
triplicate and the pFLMN/GAPDH ratio determined by densitometry. The error bars 
show the range of each replicate in the proteomic data. Because of the poor loading 
of T3B and T5B, correlations are also shown when these samples are removed from 
the analysis. 
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Figure 7.67: Expression of 4 features in J dataset representing FLMN pS2152.  
Shown are the expression levels of p0986, p4087, p4146, p4275. Below are shown 
the correlation coefficients for the comparisons with densitometry derived by 
western blot. The J dataset represents the sum of all 4 features. 
Because of the poor loading of T3B and T5B, correlations are also shown when these 
samples are removed from the analysis 
 
 
 
 p0986 p4087 p4146 p4275 J dataset 
Pearson r 0.8401 0.9095 0.1500 0.5524 0.8314 
P value (two-tailed) 0.0023 0.0003 0.6792 0.0977 0.0029 
Spearman r 0.4356 0.3039 0.1268 0.6319 0.6242 
P value (two-tailed) 0.2044 0.3869 0.7330 0.0544 0.0603 
 
without T3B and T5B p0986 p4087 p4146 p4275 J dataset 
Pearson r 0.8466 0.9098 0.1140 0.5214 0.8382 
P value (two-tailed) 0.0080 0.0017 0.7881 0.1851 0.0093 
Spearman r 0.6108 0.4880 0.2728 0.7425 0.8333 
P value (two-tailed) 0.1150 0.2162 0.5008 0.0458 0.0154 
 
To demonstrate the differences caused by differing transfer times, further 
comparisons were made with the blots transferred at times not optimised for the 
phosphoproteins being probed (i.e. probing for pRS6 of blots optimised for FLMN 
transfer, and vice versa). These are shown in Figures 7.68-7.70 
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Figure 7.68 Blot 1a (optimised transfer for RS6): anti-pFLMN 
The table shows the distribution of samples. 
Empty box=empty well. V=pervanadate-treated cell line, C=untreated cell line. 
Below is shown the probes for pFLMN, FLMN and GAPDH. 
Below this, the figure shows the correlation between the means for each J dataset 
triplicate and the pFLMN/GAPDH ratio determined by densitometry. The error bars 
show the range of each replicate in the proteomic data. 
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The comparisons between the two transfer times show poor correlation between 
them (figure 7.69): 
 332 
Figure 7.69: Comparison of blots produced by different transfer time techniques, 1a 
vs 1b 
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The same comparison was made with RS6. There was again poor correlation of pRS6 
with the proteomics data, though there was a degree of correlation between the pRS6 
expressions when the blots were compared (figure 7.70) 
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7.70 Blot 1b (optimised transfer for FLMN): anti-pRS6 
The figure shows the correlation between the means for each J dataset triplicate and 
the pRS6/GAPDH ratio determined by densitometry. The error bars show the range 
of each replicate in the proteomic data. 
Below is the comparison of blots produced by different transfer time techniques, 1a 
vs 1b 
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To summarise, a limited number of phosphosites of interest had available antibodies, 
and only 2 of 7 of the purchased antibodies appeared to detect the relevant 
phosphoproteins. For these 2 antibodies, there was a degree of correlation between 
densitometry and proteomic expression values, but this was highly dependent on the 
quality of the western blot and the precise transfer method used. Table 7.24 
summarises these data. 
Table 7.24 Summary of correlation coefficients and related p values for each 
comparison.  
The western blot densitometry was correlated to the J dataset proteomic expression 
values.  
Shaded= optimised transfer for that protein. Bold=p<0.05 
 
 Western blot 1a 1b 2a 2b 3 
3 
(without 
outliers) 
pRS6 Spearman r 0.67 0.32 0.78 0.35 0.59 0.74 
 p value 0.059 0.41 0.017 0.36 0.088 0.0458 
 Pearson r 0.79 -0.05 0.86 0.51 0.29 0.44 
 p value 0.012 0.89 0.0027 0.16 0.41 0.28 
pFLMN Spearman r 0.35 0.75 0.33 0.77 0.62 0.83 
 p value 0.36 0.026 0.39 0.021 0.06 0.0029 
 Pearson r 0.32 0.65 0.50 0.67 0.083 0.84 
 p value 0.41 0.058 0.18 0.046 0.0029 0.009 
Therefore, the blots with transfer times optimised for the phosphoprotein being 
probed for have reasonable correlations with the proteomics data. If one considers 
Spearman correlations, then 2 of 3 (excluding blot 3 outliers) have significant 
correlations for pRS6, with the non-significant p value being 0.059. For pFLMN, 3 of 3 
blots show a significant Spearman correlation. Some of the data suggest a better 
correlation with the individual P dataset features, some with the J dataset sum of 
features. In general, I have taken these data as providing a reasonable but highly 
limited validation of the proteomic data.  
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7.5.4 Much of the variation in phosphoprotein expression is secondary to variation in 
total protein expression 
From inspection of the western blots, it is clear that high phosphoprotein expression is 
often related to a high total protein expression. This was formally assed by correlation 
of the densitometry values of phosphoprotein to the total protein (Table 7.25). Many 
of these correlations were significant, indicating that in most cases, the level of total 
protein largely determines the level of phosphoprotein. 
 
Table 7.25 Summary of correlation coefficients and related p values for each 
comparison phosphoprotein vs total protein.  
Shaded= optimised transfer for that protein. Bold=p<0.05. X= total not probed 
 
 Western blot 1a 1b 2a 2b 3 
pRS6 Spearman r 0.62 X 0.78 X 0.96 
 p value 0.086 X 0.017 X 0.000 
 Pearson r 0.73 X 0.81 X 0.96 
 p value 0.027 X 0.009 X 0.000 
pFLMN Spearman r 0.6 0.73 0.57 0.84 0.9 
 p value 0.1 0.03 0.12 0.0046 0.001 
 Pearson r 0.59 0.8 0.62 0.83 0.48 
 p value 0.1 0.009 0.08 0.008 0.16 
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7.6 Correlation of AKT kinase activity with sensitivity to PI3K inhibition 
The activity of PI3K was inferred from the expression of AKT substrates in the samples. 
17 AKT substrates were identified in the P dataset, equivalent to 8 unique 
phosphosites. The geometric mean of all of these was taken to infer the AKT activity 
(see figure 7.71). Because of the differing methods for calculating J and P dataset AKT1 
activity, some differences in predicted kinase activity are seen. 
Figure 7.71: Predicted AKT1 activity in each baseline sample.  
The geometric mean of each substrate (n=17) expression value was combined to 
yield a prediction of the kinase activity in each sample. The same is shown below for 
the combined (n=8) J dataset. See Section 7.3.11 for details. 
 
 
 
 
CAL101/GS1101 is a PI3K delta-selective inhibitor that shows clinical activity in patients 
with CLL and is known to induce apoptosis in CLL cells in vitro358. The effect of 
CAL101/GS1101 at a concentration of 10 M (similar to published data, and a 
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concentration that is achievable in patients) was added to CLL cells (in triplicate), and 
the viable cells at 24 and 48 h were evaluated (fig 7.72): 
Figure 7.72: Effect of CAL101/GS101 on CLL cell viability at 24 and 48 h. 
The percentage of Annexin V/propidium iodide negative (viable) cells is subtracted 
from that with vehicle control. Error bars indicate range of triplicates. 
 
The degree of cell death at 24 and 48 hours was correlated with predicted AKT1 
activity (figure 7.73): 
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Figure 7.73: Correlation of predicted AKT1 activity with CAL101/GS101-induced 
apoptosis at 24 and 48 h. 
 
 
 
Unfortunately, probing for phosphoAkt S743 and total Akt by western blot detected no 
bands. 
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7.7 Discussion 
7.7.1 Validation methods 
Phosphoproteomics is a relatively recent innovation and all techniques, particularly 
novel ones, demand validation by complementary methods. However, there are 
several challenges to the use of western blotting as a method of protein quantification, 
even with the most skilled practitioners. One argument is that western blot detection 
is a qualitative method and that visualising the presence or absence of a protein is the 
only appropriate use of the technique, however many publications routinely suggest 
differences in expression based on the size and density of protein bands by visual 
inspection alone. A natural extension of the subjective judgement of band intensity is 
the use of image software to attempt quantification by densitometry444. Densitometry 
involves image acquisition, selection of bands and computer-aided determination of 
the optical density (OD).  When densitometry is used to determine protein 
quantification and correlated with complementary methods (such as ELISA), differing 
techniques can lead to widely varying statistical measures of correlation. When 
performed using certain guidelines, densitometry can be reasonably correlated with 
known protein concentrations444. There are a few general principles that are 
recommended: Image acquisition should be with charge-coupled camera devices 
rather than office scanners, and background correction should be applied. Intuition 
may suggest that the entire band should be included, but studies suggest that one 
third the diameter of the lane width provides a better correlation444.  
 
Although Densitometry is widely used, most publications are not explicit about the 
techniques or statistical analyses performed. One recent review found that only 1 in 
100 publications using densitometry analysis provided sufficient information to 
adequately assess the validity of the methods used444. Beyond this, the inherent user-
dependent variability in western blotting produces further challenges to the use of the 
method, with poor quality blots resulting from unequal loading and other technical 
issues. It is not clear which correlation statistic is ideal for correlation with proteomic 
data. Spearman rank correlation is probably the more appropriate as the data are not 
expected to be normally distributed, but the continuous quantitative nature of the 
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data is partially lost by this method, reducing the power, so some value might be 
expected to be gained from consideration of the Pearson r. The use of small numbers 
of samples per western blot also reduces the power of these statistical calculations. 
Combination of data from different gels is fraught with difficulties, and was considered 
inappropriate. A further challenge was provided by the fact that western blotting was 
performed on one sample, but the comparison would be with the proteomics 
triplicates. If more cells had been available, a more robust analysis might have 
considered triplicates for western blotting. With these caveats in mind, and in the 
absence of an obvious alternative I chose to validate the proteomic quantitative data 
using western blotting and densitometry. 
 
Western blotting for phosphoproteins rather than total protein adds further 
challenges. Phosphoproteins are present at lower levels than the equivalent total 
protein, therefore ideally western blots should use as much protein as possible to 
maximise sensitivity (ideally 40-60 g per well). In our experiments, the pellets 
produced in parallel to the proteomics that were used for western blotting only 
yielded sufficient protein to produce wells loaded with 20-30 g of protein, particularly 
in the tonsil samples. This may explain the lack of detection of bands when probing for 
pBtk, pSyk, pMYL9 and pMYH9. Successful probing was apparent with pFLMN and 
pRS6, phosphoproteins at high abundance within our samples, as judged by their 
relative expression in the proteomics data. The use of a convenient yet possibly 
relatively insensitive method of transfer (semi-dry iBlot) may have amplified these 
problems. 
 
Furthermore, it is recognised that many commercially available antibodies may not be 
as validated as is often claimed by manufacturers. Antibodies supplied may not bind 
the stated protein at all or may bind to proteins at completely different molecular 
weights. For instance, our anti-pLSP antibody clearly highlighted two bands at a 
completely different molecular weight than predicted, and the pWASP antibody 
strongly bound numerous proteins in pervanadate stimulated cell lines, indicating that 
it is a non-specific phosphotyrosine antibody. Non-specificity is a greater problem with 
phosphoprotein antibodies. Even with antibodies that have previously been found to 
 341 
work well, a different batch from the same manufacturer may fail. Beyond this, 
differential glycosylation, the use of differing blocking reagents and many other factors 
may lead to inadequate optimisation.  
 
Two antibodies seemed to work reasonably well: Anti-pFLMN and anti-pRS6. The high 
molecular weight (280kDa) FLMN may be less reliable because of issues with poor 
migration during electrophoresis, and poor transfer. Transfer time was optimised to 
facilitate FLMN transfer, but this possibly impacted on the transfer of lower molecular 
weight proteins such as RS6, or indeed GAPDH. It is difficult to estimate the variability 
introduced by these factors, but it was observed that greater correlations with the 
proteomic data were observed with the optimal transfer method. Of course, this 
argument risks circularity, as validity of western blotting is then confirmed in reference 
to the proteomic data. 
 
Ideally, further validation of the proteomic dataset would be desirable. One way to 
improve sensitivity might be to use higher cell numbers to yield more protein for 
western blotting, and to use possibly more sensitive transfer methods. The use of 
replicate experiments and western blotting might also lend greater statistical 
reliability, though large numbers of primary cells would be necessary. Further 
optimisation of primary antibodies could then be considered. Even then, the reliability 
of commercially available antibodies must be questioned. The greatest challenge to 
the use of western blotting as a validation method is the lack of availability of primary 
antibodies for the vast majority of identified phosphosites. The number of discovered 
phosphosites continues to rise, and studies using phosphoproteomics are increasing in 
power. The availability of truly validated antibodies for use in western blotting cannot 
keep pace with advances in phosphoproteomics.  
 
A label-free technique for proteomic quantifications was used in this study. The 
traditional approach to quantification in mass-spectrometry-based proteomics 
involves the use of labelling, but these approaches are very difficult when primary cells 
rather than cell lines are used. Label-free proteomics is gaining acceptance as a valid, 
accurate and reliable method of quantification, with the increasing sensitivity of 
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techniques allowing confident quantifications when multiple features are 
detected439,440. The techniques for analysing phosphoproteomic data are still in 
development, and to an extent must be modified according to the experimental 
design.  
 
Somewhat ironically, a well-recognised method for identifying bands detected by 
protein electrophoresis is the use of mass-spectrometry-based proteomics. Discoveries 
in small-scale experiments are often assumed to be of better quality than those of high 
throughput experiments, but many have argued that the opposite is true: high-
throughput experiments require extensive standardization and calibration, while a 
small-scale experiment is performed differently each time430,553,559,560. Furthermore, 
whilst small-scale experiments focus on what the experimenters consider interesting, a 
claim made for high-throughput methods is that they provide a view of the proteome 
and its interactions without presumptions as to what alterations are significant. 
Phosphoproteomics by MS may represent an unbiased approach capable of 
monitoring cellular phosphorylation events in the absence of a priori knowledge. This 
might lead to a greater confidence in the interaction and signalling networks produced 
by high-throughput techniques as compared to a consideration of the curated 
literature.  
 
7.7.2 Noise in data and analysis methods 
The data produced by high throughput methods of mass spectrometry has a 
resemblance to gene expression data in terms of scale. The use of analysis methods 
well established in gene expression studies therefore helped with many aspects of this 
work. However, phosphoproteomic data is not gene expression data, and many 
analysis methods had to be tailored to the experiments performed and the nature of 
the data. One weakness of my analysis is a reliance on the collaboration with 
colleagues in terms of running the HPLC and mass spectrometer, as well as the 
interpretation of the raw mass spectrometry data to produce phosphopeptide 
identifications and quantifications. Our collaborators’ extensive experience and 
publication record in this area nonetheless are reassuring439,440,561,562, and 
collaboration is essential for the use of these kinds of novel techniques.  
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The remarkable increase in the power and sensitivity of proteomics techniques has led 
to an interesting problem in this analysis. Each phosphoprotein produces a number of 
different fragments during digestion and processing that can be identified as features 
by mass spectrometry. Some proteins produced >10 features per phosphosite. Some 
of these will be misidentifications, but it would be expected that most are true 
identifications. Even when peptide fragments are linked to their parent proteins with 
great confidence, there is a phenomenon whereby some fragment abundances appear 
to correlate with the parent protein abundance, whereas other fragment 
quantifications do not440. These ‘non-proteotypic’ peptides whose quantifications do 
not appear to reflect parent protein abundance are a problematic source of error, and 
ideally should be excluded from analyses. However, there is no a priori means of 
identifying non-proteotypic peptides apart from the basis of prior experience. 
Methods are being developed to deal with this issue, but cannot be applied to this 
study. Despite this, our data suggests that most fragments/features derived from a 
parent protein do correlate with each other within a sample, indicating that non-
proteotypic peptides are infrequent and at generally lower abundance, at least for the 
two most abundant phosphoproteins. 
 
To deal with this issue when performing comparisons between samples, two analysis 
datasets were used: the P dataset using individual features, and the J dataset using the 
sum of all features identifying a particular phosphosite. It was hoped that the J dataset 
would compensate for some of the issues regarding non-proteotypic peptides. As 
might be expected, these two different analysis methods produced overlapping, but 
not identical results.  
 
The limited validation using western blotting did not clearly suggest that the use of the 
P dataset was superior to the J dataset or vice versa. The western blotting data are also 
consistent with the assumption that a minority of the features are non-proteotypic. In 
some cases, the more abundant feature had a greater correlation with densitometric 
plots. This might imply that consideration of individual features, as in the P dataset, 
would be most appropriate. However, this was not always true, and in some cases, 
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greater measures of correlation were produced for the J dataset. A theoretical 
argument in support of use of the J dataset is that it will compensate for the presence 
of non-proteotypic or misidentified features to an extent. The limited amount of 
validation does not permit a confident decision on which dataset to employ, and 
consideration of both analyses may be prudent. Caution in interpretation is clearly 
necessary, and highlights the requirement for better validation methods. 
 
There is a large amount of ‘noise’ in the data when replicates are considered. The 
mean coefficient of variation between replicates was 52-53%; lower values would be 
desirable.  An alternative measure of replicate reliability is the Pearson r correlation 
coefficient, which was 0.82 for the P dataset and 0.91 for the J dataset. Even so, this 
contains some replicates with a Pearson r as low as 0.4. To an extent, zero 
normalisation can compensate for some of his noise, but the variability must be taken 
into consideration. The clustering methods used differentiated between CLL and tonsil 
reasonably well, and between each patient, but again, there was much inter-replicate 
variability. Some analysis approaches exclude obvious outliers in order to reduce these 
measures of noise440, but this may risk increasing the rate of inappropriate rejection of 
the null hypothesis, leading to false positives. 
 
Some of this noise will be due to technical variability. In high-throughput mass 
spectrometry workflows, phosphorylation sites may be lost at several stages: some 
phosphoproteins are relatively difficult to purify, kinase and phosphatase activity may 
still be ongoing to different degrees in the lysates and enrichment for 
phosphopeptides favours certain amino acid compositions. In addition, even the most 
advanced LC-MS techniques do not reveal all phosphosites in a single biological 
sample: repeating the LC-MS run may reveal up to 50% more phosphosites when a 
duplicate sample is analysed563. Peaks in mass spectrometric data are selected 
stochastically based on peak size, and undersampling of complex mixtures results in 
problems with absent quantifications of peptides. Missing peptide quantifications 
rather than inappropriate misidentifications therefore often cause high inter-replicate 
variation. 
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Biological variation will also account for some of these differences. Each sample was 
rested for 2-3 hours and stimulated separately, and so may be considered biological 
replicates (same source), though for purpose of analysis their mean values are often 
used as simple technical replicates. One of the consequences of interpretation of high-
throughput data is a greater appreciation of the true level of biological ‘noise’ that is 
present in even carefully controlled conditions. Intraclonal diversity is becoming very 
apparent in cancer biology, and accounts for some of this variability within 
populations.  However, even when individual cells within clonal cell lines are 
monitored in terms of their responses to drugs, a high level of cell to cell variability is 
present, demonstrating that even ‘identical’ cells may respond differently to the same 
stimulus564. Individual cell fate is often dependent on stochastic process that manifest 
as predictable changes when millions of cells are considered at the population level565. 
 
Different researchers when analysing gene expression data favour various methods 
used for gene expression analysis. Many claim that fold changes alone are more 
‘biologically relevant’ than simple statistical significance, and in fact show more 
reliability and correlation with other methods. Also, statistical significance becomes a 
problematic measure when multiplicity of hypotheses are considered: using a p-value 
<0.05 for our 5088 phosphosites would be expected to result in 254 false positives in a 
random dataset, a p value<0.0002 might be more appropriate to rule this out. This 
straightforward Bonferroni correction (multiplying the p-value by 5,088) is generally 
considered too stringent, and so False Discovery Rates (the expected proportion of 
false positives in a generated list of differentially regulated phosphosites) are 
calculated using the Benjamini-Hochberg method538,539. There is no consensus for 
analysing these kinds of data as yet, and so the overlapping results of different 
methods will need to be considered.  
 
I adopted a stringent statistical approach to analysing the differences between CLL and 
Tonsil phosphosites, and the results of BCR stimulation. This will compensate for the 
large amount of ‘noise’ that is exhibited by inter-replicate variability; a phosphosite 
emerging from this noise is likely to be truly differentially expressed. It will also result 
in the rejection of several interesting differentially expressed phosphosites, but these 
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forms of high throughput data require a pragmatic approach to filter large volumes of 
information. In order to reach significance, a particular phosphosite generally required 
a high fold change to be present in all CLL samples as compared to all Tonsil samples. A 
phosphosite highly upregulated in 5/6 CLL samples will therefore generally be ignored 
using our approach. Alternative analysis methods may be able to deal with this aspect, 
but the most appropriate means of increasing statistical power would be an increase in 
the number of samples used. Overall, the statistical methods used for analysing large 
datasets are filters for data to enable hypotheses to be generated and tested. The 
threshold of the filter is set by convention and by the requirements of the researcher. 
 
The high variability may account for the limited number of phosphosite alterations 
after BCR stimulus; these were few when compared to the differences between 
patients. This reduced the power to detect commonalities of BCR signalling shared 
across patient samples. This will reflect true differences between BCR signalling in one 
patient as compared to another. To an extent, the lack of shared BCR-stimulated 
proteins between patients is not seen when BCR stimulus is considered in terms of 
pathways (see below). It may be that our analysis is insufficiently sensitive to detect 
important phosphosite changes that occur in low-abundance phosphoproteins, or at 
low fold changes. It might be expected that BCR stimulus would result in the 
upregulation of substrates of SYK, LYN and BTK. However, since these substrates are 
not detected, no comment can be made about changes in activity of the upstream 
kinase. This is probably because these substrates are present at low abundance. When 
the kinases that appear to be modulated by BCR signalling are considered, they are 
present in distal parts of the BCR signalling pathway. A well-known aspect of signalling 
cascades is the amplification that occurs as signalling proceeds from the surface to the 
interior. A few activated proximal BCR component molecules will result in many more 
distal component phosphorylations, which may be the reason for the detection of 
distal components. Techniques are constantly improving, but it is likely that there will 
be a ‘bias’ for higher abundance phosphoprotein detection. Improvements in MS 
instrumentation and phosphopeptide enrichments techniques will increase sensitivity 
in the future. This study identified over 5,000 phosphopeptides, which provides a level 
of detection power that is surpassed by few other studies. 
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In all detected phosphoproteins, there was an expected low frequency (1-2%) of 
phosphotyrosine-containing proteins, but this proportion did not increase when lists of 
phosphoproteins differing between CLL and tonsil, of after BCR stimulation were 
considered.  This suggests that serine-threonine phosphorylations may be as important 
functionally as tyrosine phosphorylations, which is consistent with some published 
data533. A common view is that phosphotyrosine signalling may be more critical to 
physiology and disease428, but this may simply reflect the fact that enrichment 
techniques have generally favoured phosphotyrosines, and so they have been studied 
more frequently.  Focussing on phosphotyrosine signalling in biological samples would 
require alternative enrichment techniques to those used in this study, and increasing 
numbers of researchers are performing TiO2-enrichment and anti-phosphotyrosine 
antibody based methods in parallel to achieve this. This has the disadvantage of 
requiring even larger amounts of starting protein. Further refinements to increase 
sensitivity include the use of digestion techniques other than trypsinisation to widen 
the spectrum of peptides produced559.  
 
Finally, once unselected approaches have identified changes in phosphoenriched 
samples, repeating mass-spectrometry runs may permit tracking the levels of 
particular proteins in techniques such as in selected/multiple reaction monitoring566, in 
essence following up unbiased approaches with targeted ones to answer more specific 
questions.  
 
7.7.3 Choice of ‘healthy’ B-cell controls 
The cellular origin of CLL is much-debated109,110. CLL is comprised of two different 
subsets with and without IGHV gene somatic hypermutation (SHM), so the cell of 
origin is less obvious than with other lymphomas. There are several themes that are 
prominent in this debate - the fact that gene expression phenotypes suggest a 
memory/antigen-experienced origin, the expression of CD5, the presence or absence 
of SHM and the uncertainties surrounding the precise definitions of normal human B-
cell subsets. Candidate normal B-cell subsets suggested to give rise to MBL and 
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subsequently CLL include human B1 cells, marginal zone cells, memory cells and 
transitional B-cells109,110.  
 
Whether the identification of the normal counterpart/cell of origin will truly influence 
our understanding or treatment of the disease is an outstanding question. It may well 
be that there are several different counterparts that are ‘funnelled’ to the same 
endpoint. There is evidence that both M-CLL and U-CLL derive from antigen-
experienced B-cells. Whether they derive from a single subset of B-cells (naïve, 
marginal zone or CD5+) is less clear109,110. The use of transformed B-cell lines as 
controls has many problematic implications, and it is preferable to use healthy B-cells 
where possible, though cell lines are useful for certain studies and for optimisation of 
techniques.  
 
Other investigators have used various approaches to healthy B-cell controls in CLL. In 
previous studies from our own laboratory examining gene expression changes after 
BCR ligation, total B-cells from healthy donor peripheral blood were negatively 
selected and stimulated.423 This decision was based upon the results of the gene 
expression studies of CLL demonstrating that memory cells most closely resembled CLL 
cells219,343. However tonsil gene expression profiles were more similar to CLL than CD5+ 
cord blood B-cells. In this study, tonsils were taken from children. The median age of 
patients with CLL is 72, and so the controls are not age-matched. Tonsils are also not 
necessarily ‘healthy’, exposed as they are to bacteria and other aspects of the outside 
world, and tonsil removal may be performed for recurrent infections, though generally 
not during an ongoing infection. 
 
The methods of phosphoproteomics dictated a pragmatic approach to achieving 
sufficient numbers of healthy B-cells as controls. The experiments outlined here 
require more than 107 cells per experimental condition. This is not possible if cells are 
separated into different subsets. Also, there are issues with positive selection using 
magnetic bead or flow cytometry-assisted cell separation, as these techniques will 
often require ligation of the BCR (for instance sIgD-sorted cells to obtain naïve 
populations), or of molecules known to be involved in BCR signalling (such as CD19). 
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Therefore, a negative selection method is desirable, further reducing potential cell 
numbers in each sorted subset.  
 
In order to provide sufficient cells, total B-cells from tonsils were used, which provide a 
mixture of naïve and memory B-cells. BCR signalling in this mixture of healthy B-cells is 
similar to CLL in terms of calcium flux after IgD and IgM stimulation. One of the 
primary aims of this study was examining differences between IgD and IgM, and this 
can only be achieved with the use of naïve B-cells, memory B-cells would have been 
inappropriate for this aspect. The choice of control is most important when analyses 
directly compare tonsil and CLL. Alternative analysis strategies that do not consider CLL 
versus Tonsil comparisons may be valid methods for inferring upstream kinase 
activities. Since the analysis of BCR signalling compares within patients, the issues with 
controls are less relevant in this consideration. 
 
In the future, comparisons of malignant cell signalling pathways to the B-cell subsets 
that are the putative normal counterparts will hopefully be made. Currently, the 
normal counterpart(s) to the CLL cell have not been identified, though there are some 
likely candidates. In terms of comparing IgM and IgD signalling, the tonsillar B-cells are 
probably the most appropriate controls. 
7.7.4 Challenges in analysing phosphoproteomic data 
A global view of cellular phosphoproteomes is hampered by the size and complexity of 
the proteome: there are tens of thousands of proteins in any one cell, and hundreds of 
thousands of potential interactions. Several databases of protein interactions and 
post-translational modifications have been curated from the literature and from the 
results of high-throughput experiments, and are continuously updated. These include 
MINT, networKIN, STRING, phosphoELM, PhosphoPoint, PhosphoSitePlus and 
Phosida549,550,556,567-569. The overlap between the databases is sometimes small, partly 
due to the differing aims of the databases. Different experimental protocols have 
differing preferences for detecting particular modifications. Most of the variation is 
probably derived from the different model tissues and experimental conditions 
employed. The gaps in knowledge are highlighted by the fact that estimates of the true 
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size of protein interaction networks exceed the number of interactions stored in these 
databases430,560.  
 
In protein signalling networks, nodes correspond to individual post-translational 
modifications (PTMs), with the connecting edges indicating how nodes interact with 
each other. The most common and important PTMs considered are those of 
phosphorylation on tyrosine (Y), serine (S) and threonine (T) residues. The node will 
represent a quantitative variable, such as concentration of a particular protein’s 
phosphorylation at a particular residue: a ‘phosphosite’. Graphical representations of 
these networks do not resemble the usual linear flow diagrams hitherto employed to 
understand cell signalling, but complex networks, with known pathways distributed 
across multiple nodes, and many pathways sharing nodes563. One of the puzzling 
aspects of bioinformatic pathway analyses such as IPA is that the same molecule is 
often labelled as being a component of multiple different pathways. This may create 
difficulties in deciding which pathway is important in a particular cancer cell or 
stimulus, but it also perhaps highlights the futility of attempting to conceptually 
confine particular molecules to one or two pathways, as in truth they act as multiply 
connected nodes in complex signalling networks.  
 
Consideration of computational network models of interactions has led to the finding 
that most interactions follow a power-law, indicating that these are ‘scale free’ 
networks421. This implies that a majority of proteins interact with only a few partners, 
whilst a minority have multiple partners. These occasional protein ‘hubs’ are key 
members of the network, with removal of these highly connected members producing 
a greater perturbation of the entire network topology than if one of the less-
connected nodes is removed. This model is supported by the finding of a correlation 
between the connectivity of protein nodes and lethality when these highly connected 
nodes are knocked out in yeast experiments421.   
 
In line with this, phosphoproteins in yeast and mammals follow a power-law 
distribution with respect to the number of phosphorylation sites570. This reflects the 
fact that most proteins have few phosphorylation sites, whilst a few have multiple 
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sites. Phosphorylation/dephosphorylation has often been assumed to act as a 
fundamental on/off switch for protein function. Even this overly simplistic picture is 
complicated by the fact that most proteins in eukaryotic cells harbour multiple 
phosphorylation sites571.  Because this increases the possibilities for regulating protein 
function considerably, multisite phosphorylation may provide a method for fine-tuning 
responses and enable combinatorial regulation of responses571. Proteins with more 
phosphorylation sites tend to accumulate even more sites during evolution523. This 
supports the model whereby these highly phosphorylated proteins are densely 
connected and important members of the signalling networks. 
 
Comparison of phosphoproteomes from different species has revealed significant 
overlaps in signalling pathways, and the set of proteins with phosphorylation sites 
identified in different species of eukaryotes is enriched for disease-associated genes420, 
implying important physiological roles. Phosphorylation sites are evolutionarily 
conserved, relative to their unphosphorylated counterparts, suggesting their 
important functional role. Whilst there is extensive species overlap in phosphosites 
that play important roles, consideration of all phosphosites implies that the overlap 
between species is small. The small overlap is not only due to real differential 
phosphorylation, but also in limitations of experimental techniques563. This makes it 
difficult to estimate the full size of the phosphoproteome (all phosphosites present 
within one tissue or species) as there is no ‘gold standard’ to compare against. 
Nevertheless, estimates can be made. There are currently approximately 25,000 
human phosphosites within databases568. Estimates of the full phosphoproteome 
range up to 200,000 phosphosites within the total 1.7 million S, T and Y residues in the 
human proteome420,563. The minority of these that form the tyrosine 
phosphoproteome appears to be more comprehensively mapped, either because 
tyrosine phosphorylation is more important functionally, or because the enrichment 
strategies have greater efficiency for phosphotyrosine. Clearly, more phosphosites are 
yet to be discovered. 
 
Although some proteins are constitutively phosphorylated or fluctuate regularly 
throughout the cell cycle, some are only phosphorylated under specific conditions and 
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in specific tissues. Therefore, comprehensive understanding of a single phosphosite 
requires multiple experiments with a range of different conditions433.  Whilst the 
number of identified phosphosites continues to increase at an alarming rate, it is likely 
that most of these phosphosites will only be significant in particular tissues and 
experimental conditions, and that the phenotypic differences between tissues and 
stimuli will largely be determined by a limited subset of the total known 
phosphoproteome.  
 
The generation of large amounts of data from phosphoproteomic techniques leads to 
difficulty with analysis and interpretation. New phosphosites are being discovered at a 
rate far exceeding the growth in understanding of how a phosphosite affects protein 
function. Whilst upregulation of expression of a particular gene might reasonably be 
expected to result in increase protein expression and activity in many cases, an 
alteration in the stoichiometry of a phosphosite will generally not translate to a simple 
increase or decrease in activity.  
 
It is generally assumed that phosphorylation of a protein will alter its function in some 
way. Classically, phosphorylation increases or decreases kinase activity. Probably more 
important is phosphorylation-induced modulation of protein-protein binding to induce 
complex formation or alter localisation. Evolutionary pressures exert their effects on 
protein phosphorylation, and natural selection might be expected to eliminate non-
functional phosphorylations (a waste of ATP?). Nonetheless, it has been suggested that 
many phosphosites may not convey a functional alteration on a protein, although 
absence of evidence is not absence of evidence, and it is difficult to prove that a 
particular phosphosite labelled as non-functional will have no effect under all 
conditions and tissues572. It must also be remembered that a decrease in a protein’s 
level of phosphorylation may be as likely to confer functionality as an increase, in 
contrast to gene expression data where an increase in RNA levels is presumed to 
reflect an increase in the functionality of the resultant protein. In this study, no 
assumptions regarding a phosphosite’s function have been made, decreased 
phosphorylation presumed to be as relevant to protein function as an increase. 
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7.7.5 Analysing phosphoproteomic data in terms of biological pathways 
High throughput techniques such as gene expression analysis and mass-spectrometry-
based proteomics are producing increasing volumes of data. The main driver has been 
improvements in technology, but it is also driven by a realisation that biologists must 
embrace complexity in order to understand the behaviour of cells, tissues and 
organisms at the molecular level. Whilst these complex datasets may be felt to 
accurately reflect cellular processes, the human brain is ill suited to deriving meaning 
from this kind of data directly. To an extent, these advances in experimental methods 
have also driven advances in bioinformatic techniques to analyse these unwieldy 
amounts of data. To overcome this challenge, curated databases have that reflect 
known pathways and disease processes can be interrogated. Two widely used pathway 
databases are Ingenuity Pathway Analysis (IPA) and the Kyoto Encyclopaedia of Genes 
and Genomes (KEGG). Despite the wide use of Ingenuity (curated by a commercial 
company) and KEGG (curated by a single laboratory), the databases, algorithms and 
output formats are surprisingly different and non-overlapping573. In this study they 
were both used in an attempt to illustrate how they may be applied to 
phosphoproteomic data, as well as to gain insights in B-cell biology and BCR signalling. 
Other groups have applied these methods to phosphoproteomic data with a degree of 
success553,574. These methods can begin to make sense of the large amounts of data 
generated and lend plausibility to the techniques used. However, these tools were 
generated for analysing expression of the 23,000 known genes in the genome, as 
compared to the >100,000 largely unknown phosphosites in the phosphoproteome. 
 
IPA and KEGG Databases were used to derive pathways at three levels of 
interpretation. Firstly, a consideration of all detected phosphoproteins in the CLL and 
Tonsil samples was made. The most abundant phosphoprotein was Histone 1.2, 
followed by various RNA binding proteins, cytoskeletal components and transcription 
factors. Strikingly, the top 3 IPA pathways enriched amongst the detected proteins 
were ‘ERK/MAPK Signalling’, ‘DNA Methylation/Transcriptional Repression Signalling’ 
and ‘B-Cell Receptor Signalling’. The top three KEGG pathways were ‘Spliceosome’, ‘B-
Cell Receptor Signalling’ and ‘Ribosome’. A number of interpretations are possible. The 
abundance of RNA binding proteins and transcription factors within 
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phosphoproteomes has been noted by others523,534, and may explain enrichment for 
the ‘Spliceosome’, ‘DNA Methylation/ Transcriptional Repression Signalling’ and 
‘Ribosome’ pathways. The presence of the BCR signalling, ERK and other identified 
pathways would be expected in B-cell tissues. The enrichment of BCR signalling 
components may be taken as evidence that these proteins are highly expressed 
because of the tissue origin, rather than activity of the BCR pathway itself, though this 
is also very possible. One study of mantle cell lines found constitutive phosphorylation 
of multiple BCR components, and the authors interpreted this as evidence of 
constitutive BCR signalling575. Further conclusions regarding pathway activity in resting 
cells are difficult to make with our data. Comparison with other tissues and 
phosphoproteomes of B-cells from other subsets may be helpful.  
 
 At the next interpretation level, the phosphoproteins differentially expressed between 
CLL and Tonsil were considered. One intriguing finding was that there appeared to be 
more phosphoproteins identified in CLL than in tonsil (see figure 7.23). One 
interpretation is that CLL has higher overall phosphoprotein levels in a given amount of 
total protein (all samples were enriched from 0.5mg of protein) when compared to 
tonsil. This is not inconceivable, and one study in CLL compared total phosphotyrosine 
levels on western blot with tonsil B-cells, and found markedly higher levels in CLL330. I 
am unaware of similar studies in phosphoproteomics. A more plausible, yet not 
mutually exclusive explanation is that CLL has a greater variety of phosphorylations, at 
least detected using our methods, supported by the finding that more phosphosites 
had a zero value in tonsil when compared to CLL.  This would manifest as generally 
higher CLL/Tonsil fold changes. 
 
IPA analysis suggests that the phosphoproteins most upregulated in CLL cells 
compared to tonsil are enriched for components of tight junction signalling 
(unreported in literature), RAN (GTP-binding protein involved in nucleocytoplasmic 
transport) signalling576, ATM (recognised association with CLL because of 11q23 
deletions) signalling30, glucose metabolism, cytoskeletal signalling and many other 
pathways. Abnormalities of the cytoskeleton in CLL have been recognised for some 
time577, and Professor Caligaris-Cappio’s group suggest that the importance of the 
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prognostic marker Hematopoietic cell–specific Lyn substrate-1 (HS1/HCLS1) in CLL lies 
in its role in regulating the cytoskeleton and cell trafficking578. Multiple phosphorylated 
forms of HS1 were detected in our data, but whilst BCR stimulation did result in 
altered HS1 phosphorylation, it was not differently expressed between CLL and Tonsil. 
An associated protein of unknown function, HCLS1-binding protein 3 was also present, 
and was differentially phosphorylated between CLL and Tonsil. IPA and KEGG analyses 
also suggested glucose metabolism pathways as important in CLL vs Tonsil 
comparisons. Abnormalities in CLL glucose metabolism and glycolysis have been 
reported by many studies since an original report in 1969579, but there are few 
publications linking glucose metabolism to CLL in more recent years, though a recent 
study suggests that the pentose phosphate pathway may be important in CLL and a 
number of other B-cell malignancies580, and some studies link CLL gene expression to 
more general abnormalities in ‘cell metabolism’581.  
 
Aside from IPA pathway analysis, the IPA and KEGG ‘biological functions’ suggested 
enrichment for various processes such as ‘Haematological Disease’, ‘Cancer’, 
‘Haemopoiesis’ and ‘Immune system development’ (see Table 7.9). Whilst not 
particularly illuminating in themselves, they at least suggest that the use of these 
bioinformatic techniques in combination with our experimental data is producing 
plausible results. 
 
I engaged in exploratory analyses with closer focus on the Tight Junction Pathway, 
suggesting more pathway component involvement than initially highlighted.  TJ 
pathway components were also altered by BCR stimulation in CLL. A pathway 
classically associated with epithelium rather than B-cells seems implausible in this 
context, but the TJ pathway is known to link transmembrane signalling to the 
cytoskeleton more generally, and the only other study examining BCR signalling in a 
cell line found several TJP components altered after IgM ligation534.   
 
Further analysis of this kind may be instructive in exploration of the pathogenesis of 
CLL, but there is a critical dependence on the use of Tonsil as a control comparison 
with these and other analyses, and caution is therefore required. It may be instructive 
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to examine co-expression patterns in the entire phosphoproteome in an analogous 
fashion, but this is beyond the scope of this study. 
 
The principle aim of this study was an exploration of BCR signalling in CLL at the next 
level of interpretive analysis. Statistical comparisons using clustering techniques and 
paired t-tests suggested that there were no consistent phosphoprotein differences 
after BCR stimulation in all CLL or tonsil samples. Whilst this may seem discouraging, it 
is not entirely surprising. The limited sensitivity and large amounts of technical noise 
have already been discussed. It appears that the differences between patients are 
much greater than those after BCR stimulation. Each patient seemed to have a 
relatively unique alteration in phosphoproteome after BCR stimulation. We found that 
each patient had 0.1-4.6% of phosphosites altered by BCR stimulation, and when 
considered collectively, 19% of all unique phosphosites were altered in at least one 
sample after IgD or IgM stimulation. It is difficult to make valid comparisons with 
published data. Most studies of stimulus-induced phosphoproteome changes use 
quantitative labelling techniques without use of replicates and equivalent statistics, 
analyses most often used cell lines and often pooled lysates from different samples 
when primary samples were studied. Estimates of the proportion of the detected 
phosphoproteome that changes after stimulation varied from 3-30%, with the higher 
percentage representing a pooling of data from multiple cell line experiments533,558,582-
584. Our data showing at most 3.7% of all phosphosites altered per sample, or 17% (P 
dataset) to 21% (J dataset) when all phosphosites are considered is generally 
consistent with published data.  
 
There was a disappointing lack of overlap of BCR-induced phosphoproteins across all 
patients. The handful of overlaps included pro-IL16 (a cytokine released by 
lymphocytes that binds CD4, thereby attracting T-cells585), B-RAF (known to be 
involved in ERK signalling, BCR signalling368, and known to be mutated in some cases of 
CLL416), DHX8 (involved in the spliceosome585), CREB1 (a transcription factor known to 
be phosphorylated after BCR ligation586) and CD2AP (recently suggested to involved in 
proximal events in BCR signalling, linking the cytoskeleton to BLNK554). Interestingly, 
CD2AP was altered by IgD signalling in 3 of the 5 tonsil patients in both the J and P 
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datasets, but not by IgM ligation, so may be a candidate component of an IgD-specific 
BCR signalling pathway. Therefore, whilst there are limited overlaps, these 
differentially phosphorylated proteins are all plausible candidates for involvement in 
the BCR signalling cascade. 
 
The phosphoproteins altered by BCR stimulation contained a higher proportion of 
transcription factors  (TFs) than all of the phosphoproteins detected, suggesting TFs 
were altered by BCR signalling, as is well-recognised122. The canonical IPA pathway 
terminates with the TFs CREB1, ATF2, JUN, BCL6, EGR1, ELK1, OCT2, ETS1, and NFAT. 
Of these, CREB1, JUN and NFAT were all differentially phosphorylated by BCR ligation 
in this study.  
 
The pathways altered in each patient were considered in two approaches. Firstly, the 
lists of differentially phosphorylated from each patient were combined into lists to give 
a general view of IgM or IgD signalling in CLL or tonsil samples. These were then used 
in bioinformatic analyses. Using the results of these, the individual lists from each 
patient were then considered in a ’look back’ manner. The value of this approach was 
illustrated by the findings overlapping pathways activated by BCR ligation shared 
across patients, even when the individual pathway components themselves were not 
shared across patients. For instance, the ‘Phospholipase C signalling’ IPA pathway 
(known to be a central component within the BCR signalling cascade, leading to 
calcium flux) was significantly enriched in the IgM-stimulated tonsil phosphoprotein 
list, and also in all 5 separate patient lists. Therefore, I suggest that whilst each patient 
may appear to undergo BCR signalling with a unique pattern of phosphosite changes, a 
consideration at the level of biological pathways suggests greater unity than is initially 
appreciated. 
 
One group has used phosphoproteomic analysis to predict the migration behaviour of 
ErbB2-overexpressing mammary epithelial cells in response to ligands587 or 
pharmacological inhibition of key kinases588. Partial least-squares regression analysis 
produced a quantitative combination of a limited number of phosphorylation sites (5-
10) on a few key proteins (a ‘network gauge’, or ‘rheostat’) that could successfully 
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interpret the effects of kinase inhibitors on cell migratory behaviour, or predict 
response to ligand stimulation. No individual phosphorylation site could predict the 
behaviour alone, suggesting that models attempting to predict cell behaviour will need 
to include markers of multiple pathway activity, and that attempting to predict cellular 
behaviour on the basis of individual pathway components will be futile411. 
 
The IPA and KEGG pathways highlighted after BCR stimulation contain some expected 
pathways (such as BCR signalling, ERK/MAPK signalling, phospholipase C signalling), 
some plausible ones (PI3K signalling in B lymphocytes, BAFF signalling, regulation of 
actin motility by Rho, Systemic Lupus Erythematosus Signalling) and some surprising 
pathways (Tight Junction Signalling, Insulin Receptor Signalling, Spliceosomal Cycle). To 
an extent this can be explained by a deeper consideration of the IPA/KEGG results, and 
a degree of caution about over interpreting results of these analyses. Usually only a 
handful of proteins within a pathway are highlighted by a particular analysis, though 
this is often all that is required to achieve a significant enrichment to indicate the 
involvement of a pathway. As discussed, each protein is expected to be a component 
of multiple, interlinked pathways in a complex network. This conception of a particular 
pathway component might lead to rejection of the entire idea of discrete pathways as 
units of analysis. Alternatively (but not exclusively), it points to the increasing 
realisation that one molecule may truly be an important component of multiple 
pathways. For example SNW1 (SKIP) is well recognised to be involved in both the 
spliceosome and NOTCH signalling pathways.  
 
This draws attention to a striking finding of the analysis: the recurrent finding of 
multiple components of the spliceosome pathway as differentially phosphorylated 
after BCR stimulus in both CLL and Tonsil samples. This may partly reflect the high 
proportion and abundance of RNA-binding proteins within the entire dataset, as 
‘Spliceosome’ is also highlighted when considering all detected proteins (though not in 
the CLL vs Tonsil comparisons). The patterns of spliceosome component 
phosphorylation after BCR stimulus are complex, different in Tonsil and CLL, and after 
IgD or IgM stimulus. This creates a huge challenge in deriving a simple model for how 
BCR stimulation may be linked to alterations in the spliceosome complex. BCR 
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stimulation is known to have pleiotropic effects in all B-cells, and it is certainly 
plausible that it may cause change in the function of this complex, but published data 
has not called attention to such a link, and I suggest that further investigation of a 
possible relationship between BCR signalling and the spliceosome may be fruitful in 
both CLL and general B-cell physiology. Given the recent findings of recurrent 
mutations in SF3B1 in CLL44, this may prove an interesting link.  
 
The other striking pathway derived from this analysis is the IgD-induced change in 
phosphorylation of several NOTCH signalling components (as judged by KEGG pathway 
analysis) in CLL. Given that the other recurrent mutation recently described at high 
frequency in CLL is in NOTCH140, this again suggests an as yet unpublished link 
between BCR signalling and NOTCH signalling in CLL which may well be worth 
exploring. 
 
Overall, many intriguing pathways were highlighted, each of which might warrant 
deeper consideration and validation. 
7.7.6 Phosphatases and anergy 
In humans, the genome contains 518 protein kinases and 140 phosphatases431,432. 
There are a number of diseases that result from mutations in particular protein kinases 
and phosphatases430. With most proteins having multiple phosphosites and most 
kinases and phosphatases numerous substrates, phosphorylation cannot be 
understood as simple pair-wise interactions in linear pathways. Phosphorylation 
networks are defined by the promiscuous relationships of kinases, phosphatases and 
substrates. Furthermore, analysis of isolated kinase-substrate relationships in a 
simplified in vitro assay fails to capture the regulatory molecules, subcellular 
localisation and other influences that operate in vivo433. Phosphoproteomic analysis of 
lysates from cells can begin to capture some of this context. 
 
This study detected several phosphoproteins that are also kinases and phosphatases, 
and some are differentially phosphorylated between CLL and Tonsil, and by BCR 
stimulation. The phosphatase PTPN6 (SHP-1) pY536 phosphorylation was significantly 
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higher in CLL vs Tonsil samples (168-fold in J dataset, p=0.048). This phosphorylation 
increases phosphatase activity and is downstream of InsR, Lck & Src kinases (and 
possibly Abl and Lyn)517. SHP-1 is well-known to act as a negative regulator of BCR 
signalling and to be an important mediator of B-cell anergy234, and to exhibit 
abnormalities in CLL589. Similarly, differential phosphorylation of the phosphatase 
regulator SET was observed after IgD stimulation in CLL, and is known to be 
overexpressed in CLL and lymphoma590.  The SHIP1 (stimulated by IgD and IgM ligation) 
and CD45 (IgM stimulated) phosphatases were altered in the CLL samples, and these 
are also important regulators of BCR signalling and anergy234,591. Interrogating the 
detected proteins for other molecules involved in anergy234, we did not detect DOK, 
CD72, PIR-b or CBL.  STIM1 (pS257, phosphosite of unknown function) was detected 
but not different between CLL vs Tonsil or BCR stimulated conditions. The 
transcriptional regulator NFAT1 is critical to anergy maintenance in B-cells234, and is 
known to be active in CLL cells, a finding which led to the initial analogy of CLL cells 
with anergic B-cells115. Multiple phosphorylations of NFAT1 (of unknown function and 
kinase) were detected in this study, several were differentially expressed between CLL 
and Tonsil, and were significantly altered by IgD and IgM stimulation in CLL. 
Collectively, these data are suggestive of involvement of the known molecular 
mediators of anergy in CLL, and in CLL BCR signalling. There are some differences 
between IgM and IgD-induced phosphatase/NFAT phosphorylation, but also overlaps. 
Because the function of the individual phosphosites is mostly unknown, it is difficult to 
claim that this is direct evidence of anergic BCR signalling in CLL, but it is certainly 
consistent with this model. The choice of CLL samples able to undergo IgM calcium flux 
may also have confused the picture, as we are examining signalling in cases where 
anergy might be expected to be less relevant (discussed further in Chapter 8).  
 
Despite similar calcium flux responses to IgM and IgD in all patients, there are 
suggestions that greater numbers of phosphosites were altered after IgD ligation in 
CLL, when compared to IgM-induced phosphosites, and that the reverse is true in 
Tonsil. There was no correlation of the level of calcium flux and the number of 
phosphosites altered in each patient. If we consider the number of altered 
phosphosites as a measure of the level of BCR signal strength (a rather large 
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assumption), then it appears that IgM signalling in CLL is ‘weaker’ than that of IgD, 
again consistent with an anergic model. The converse, with IgM signalling in tonsil 
being ‘stronger’ is consistent with the classical model of IgM signalling being more 
important in normal physiology. This may be an over interpretation of the data. 
 
Finally, the phosphatase PTPN22 was also differentially phosphorylated in CLL (303-
fold overexpressed relative to tonsil, unknown function/kinase of phosphosite), and 
several recent publications have focussed on its higher expression in CLL, with one 
suggesting that it blocks pro-apoptotic BCR signals by selectively activating the pro-
survival AKT pathway after IgM ligation388. 
 
7.7.7 Kinases 
Perhaps the greatest potential of phosphoproteomic data is in exploring the activities 
of kinases. Several Kinases were themselves phosphoproteins in the CLL vs Tonsil list 
(Table 7.8). Increased phosphorylation of CARD11 and LYN (both involved in BCR 
signalling) kinases were seen in CLL vs Tonsil. Several unexpected kinases such as an 
activating phosphorylation of the Colony-Stimulating Factor Receptor Kinase (CSF1R) 
were also found, and a search of the literature suggests that CSF1R has elevated 
expression in CLL592. The approach looking at ‘kinase pathway activity’ (Figure 7.36) 
also suggested high activity of the CSF1R. Several kinases involved in glucose 
metabolism (PFKL, PGK1, NADK) were also altered. Most of these phosphorylations 
have unknown effects on the kinase activity. Only one (Lyn) phosphorylation was 
associated with evidence of altered kinase activity as judged by its effect on 
downstream substrates. 
 
There were also numerous BCR-induced kinase phosphorylations (Figure 7.47), some 
of which were also observed to have differing downstream effects when their kinase 
activities were considered (figure 7.52), for instance with MARK and PKACA, but the 
overlaps were limited. BRAF was induced by IgM ligation in both CLL and Tonsil, and 
has been identified as one of the targets of infrequent somatic mutations in CLL416.  
The same study found mutations in NEK1, which has overlapping substrates with NEK2 
(upregulated by IgM and IgD stimulation in this study). 
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One study has used array methods to examine upregulation of gene expression of 
kinases in CLL593. Amongst many others, they found upregulated LCK, LYN, MAP3K2, 
MAPK8/9 and STK10 kinases, which have evidence of increased activity in CLL vs Tonsil, 
or after BCR ligation in CLL in this study.   Similarly, others have found elevated CK2 594 
and  Aurora Kinase595 activity in CLL and other malignancies. The elevated expression 
of constitutive activation of LYN in CLL that was suggested in the CLL vs Tonsil data has 
been recognised for some time330.   
 
The kinase pathway activity method suggested that mTOR pathway activity may be 
elevated in CLL in this study. The known elevated mTOR activity in CLL is already 
leading to clinical trials of mTOR inhibitors596. A superficially less plausible suggestion 
for increased kinase activity in CLL is that of the insulin receptor (InsR) kinase, but a 
recent study has indeed found elevated levels of InsR and functional significance in 
CLL597. One might even speculatively link elevated InsR kinase activity to the numerous 
suggestions in this study of glucose metabolic abnormalities. 
 
The ‘kinase pathway activity’ approach raises important points about the relationship 
between kinases and their substrates, and the relationship between phosphorylated 
proteins and the total amount of protein. Generally, a particular phosphoprotein is 
conceived as forming a minor component of the total protein. However, there is a 
clear correlation between the total amount of a protein and the amount of 
phosphoprotein. Several authors imply that phosphorylation only occurs on signalling 
proteins at low abundance, but phosphoproteomic datasets are not overrepresented 
in terms of low abundance proteins, and the profile of abundance distribution is 
similar for the proteome and the phosphoproteome523. One of the major determinants 
of the amount of a phosphoprotein is the amount of the parent protein, as is seen 
when the total protein levels are detected with western blotting. This makes the 
interpretation of phosphoprotein levels as simple readouts of kinase activity 
somewhat less straightforward than is often presented.  
 
The levels of a particular phosphoprotein are a product of the abundance of the parent 
protein substrate and the activity of the responsible kinases (and phosphatases). If no 
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substrate is present then even a kinase that is highly active will be unable to manifest 
activity in terms of that substrate. A higher level of phosphoprotein may therefore be 
partly due to a higher level of the parent protein. Conversely, if the kinase is absent, 
then high levels of parent proteins do not translate into high levels of 
phosphoproteins. A highly abundant phosphoprotein is therefore not a simple 
measure of the kinase activity, though it is clearly related to this. A more appropriate 
conception might be that it reflects the activity of particular pathways that are defined 
by the kinase-substrate pairing. Regulation of the pathway can be via both alteration 
of kinase activities and substrate levels, and neoplastic changes may affect both of 
these pathway components. It might be expected that kinase activity modulation is a 
more rapid means for regulating signalling, and that changes in substrate abundance 
will vary over longer timescales, but protein turnover can be quite rapid, particularly in 
terms of degradation. These issues may be less relevant when considering the changes 
seen after 5 minutes of BCR stimulation, but will hugely affect considerations of 
differences between healthy and tonsil phosphoproteomes. 
 
In this study, I have partially used the ‘kinase pathway activity’ approach to 
acknowledge this relationship between kinase activity and substrate levels and to 
attempt to move away from a dependence on comparison with tonsil controls. I 
attempted to derive kinase activity values less dependent on substrate levels by using 
the geometric mean of phosphosite expressions. This is inspired by the work of Dr 
Pedro Cutillas and others, who use the term ‘net kinase’ activity to describe the 
number of times a kinase has phosphorylated its substrates before measurement, as 
opposed to ‘specific’ kinase activity, which describes the inherent ability of a kinase to 
phosphorylate a substrate598, which is rather more difficult to measure. I have often 
implied that phosphosite quantification implies kinase activity, but it is clearly not a 
straightforward relationship It could be argued that conceptions of kinase activity 
independent of substrate is relatively meaningless in some ways, that the net activity 
of a pathway involving a kinase is more relevant for most applications.   
 
The net activity of a kinase can be inferred from the abundance of its phosphorylated 
substrates. If several phosphorylated substrates of a kinase are present and at high 
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abundance then we might have greater confidence regarding high kinase activity than 
if only one substrate is providing this readout, particular in the face of substrate and 
kinase promiscuity. In principle, this confidence can be translated into a p-value that 
relates to the number of substrates being measured. If this approach is taken, then net 
kinase activities could be inferred from consideration of all the known substrates of all 
known kinases in a particular biological sample, in a statistically robust manner. This 
would be a much more powerful method of assessing kinase activity from a 
phosphoproteome, as compared to the methods used in this study, which considered 
lists of differentially phosphorylated proteins generated using statistics used for 
analysing gene expression data. Dr Cutillas is pioneering such methods.  
 
The greatest challenge to progress in this field is the lack of well-defined kinase-
substrate relationships. Whilst >170,000 different phosphosites have been 
characterised, the majority of these do not have a defined upstream kinase. An 
estimate of the size of this challenge in 2004 was that 35% of phosphosites then 
known had a clearly identified kinase599. The same database in 2011 suggested that 
this proportion had decreased to 12%, due to the rapid increase in identification of 
novel phosphosites without an accompanying increase in understanding kinase-
substrate interactions550. In a high proportion of cases ( 60%) the upstream kinase can 
be predicted by considering the preference of particular kinases for serine, threonine 
and tyrosine residues in the context of amino acid motifs, particularly when contextual 
data such as cellular localisation are incorporated600. As more confirmatory data 
accumulate, this proportion is likely to rise. However, there is still great scepticism as 
to the accuracy of such prediction tools, and validation by other methods is still felt to 
be necessary. The widely used Scansite algorithm based on motifs alone cannot claim 
great accuracy552, and the limitations of its use as a prediction tool are highlighted in 
this study. To fully unleash the potential of phosphoproteomic data, a huge 
collaborative effort to establish kinase-substrate relationships is required, a ‘human 
phosphoproteome’ project analogous to that which sequenced the entire human 
genome.  
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In cosmology, Dark matter is hypothesized to account for 84% of the matter in the 
universe. It does not absorb light or any electromagnetic radiation and so cannot be 
detected by telescopes. Its existence is inferred from its gravitational effects on 
conventional matter, radiation and the large scale structure of the universe, but the 
nature of dark matter is unknown601. Similarly, the thousands of human phosphosites 
are the result of kinases that we know must exist, but we do not know the details of 
the vast majority of kinase-phosphosite relationships, in fact our ignorance is 
increasing. Whilst the effects of the kinases can be inferred by alterations in thousands 
of phosphosites, kinases still constitute the dark matter of intracellular signalling 
cascades.    
7.7.8 Translational aspects of this study 
Drugs that inhibit protein kinases or phosphatases are being developed to target 
cancer and other diseases. The overexpression of growth factor receptor tyrosine 
kinases or their mutation to constitutively active forms is important in the 
pathogenesis of several cancers. An example of a particularly successful targeting of a 
constitutively active kinase is imatinib, which is a potent inhibitor of the Abelson 
tyrosine kinase (abl) that is abnormal in chronic myeloid leukaemia (CML). The use of 
imatinib has revolutionised the treatment of this disease434.  
 
Growth factors such as epidermal growth factor (EGF) activate the classical mitogen-
activated protein kinase (MAPK) cascade to cause cell proliferation. The uncontrolled 
activation of this pathway can cause cancer437. One of the best-characterized 
phosphoproteomes is that downstream of the Epidermal Growth Factor Receptor 
(EGFR)435,436. Time-course studies have detailed the multiple phosphorylations that 
occur after EGF ligation. Increasing levels of particular EGFR mutants shifts signalling 
away from ERK and STAT3 towards the PI3K pathway, and induces phosphorylation 
and transactivation of the hepatocyte growth factor MET. Consequently, combination 
of EGFR and MET inhibitors synergized to kill tumour cells in vitro, a rational 
combination based on analyses of phosphoproteomic signalling networks435.  
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In this study, an estimation of the activity of the AKT1 kinase was derived for each CLL 
sample. This showed a significant correlation with the degree of apoptosis induction 
with PI3K inhibition.  This is clearly a very limited experiment that should not be over 
interpreted, but it does begin to show how the technique of phosphoproteomics might 
be used as a means for biomarker prediction and the use of rational drug combinations 
in cancer therapy. This is discussed further in Chapter 8. 
 
The particular combination of kinase and phosphatase activation determines the 
topology of intracellular signalling networks. The understanding of these networks in 
cancer cells will be necessary to understand how therapies that target tumour cells 
affect signalling, and how resistance to therapy arises by bypassing particular network 
elements. Inhibitors of kinases are promising in their efficacy and lack of toxicity, often 
due to their selective targeting of kinases. Phosphoproteomics will be instrumental in 
determining the modes of action of these kinases, as well as the off-target effects and 
mechanisms of resistance of these kinases. This understanding should lead to better 
treatments for patients.  
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7.7.9 Summary: mechanisms of IgM and IgD signalling in CLL and healthy B-cells 
I set out to determine the mechanisms of BCR signalling using a phosphoproteomic 
approach. It might seem straightforward to pose the questions ‘how does BCR 
signalling differ between leukaemic and healthy B-cells?’ or ‘How do IgM and IgD 
signalling differ?’ However, the nature of how we ‘measure’ BCR signalling depends on 
the tools that are available for examining events after a BCR binds a ligand, and on the 
models used to interpret and extend those data. BCR signalling can be defined by 
abrupt rises in cytosolic calcium ions, by phosphorylation of particular proteins (that 
have been previously shown to be recurrently phosphorylated by BCR ligation), or by 
alteration in B-cell fate that is an appropriate deployment of the immune system 
against a harmful or harmless antigen.   
 
There are several other ways of ‘measuring’ BCR signalling. One argument is that the 
phosphoproteomic methods used in this study would suggest that any alterations in 
phosphorylation seen after BCR stimulus would define BCR signalling, regardless of 
assumptions about known pathways. However, to be valid, recurrent changes in a 
variety of experimental settings would be required before novel findings are accepted 
as defining a canonical pathway. Whilst this study provided huge amounts of data, 
with an accompanying large amount of analysis, it was still performed on a limited 
number of primary samples, and more insights will be provided by extension to more 
patient samples, in different conditions depending on the question to be asked. 
 
There is an increasing realisation that each patient’s cancer may be almost unique in 
terms of the repertoire of mutations, compounded by the issue of tumour 
heterogeneity and evolution. This may also be true for signalling networks defined by 
phosphoproteins, if our data are valid. To gain insights into the characteristics of BCR 
signalling, changes in phosphosites were sought that were consistent across different 
patient samples. Whilst BCR stimulation occasionally led a significant change in 2 or at 
most 3 samples, this was the limit of the consistency. It seemed BCR signalling was 
characterised by a near unique pattern of phosphosite changes. To an extent this is 
due to lack of sensitivity and noisy data.  
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When considered using a pathway-centric approach, greater overlaps between 
patients were seen. This concept is mirrored in some suggested interpretation of the 
results of whole genome sequencing efforts in CLL and other tumours44. Multiple 
infrequent mutations may be more usefully considered as components of a few 
pathways that are recurrently abnormal in a particular form of cancer. Perhaps then, 
recurrent changes in the same phosphoproteins might not be the unit of consideration 
when describing a signalling cascade. In truth, there may be multiple levels at which it 
is valid to describe signalling pathways.  
 
It might be desirable to have a visual summary of a pathway that sums up my 
conception of BCR signalling, and to an extent I have attempted this in Figure 7.53. This 
is an attempt to highlight how BCR signalling varies between CLL and Tonsil, between 
IgM and IgD. A more faithful depiction of BCR signalling would probably look like a 
complex network of nodes representing proteins linked by connections representing 
their relationships. Each node would have several attributes describing the protein’s 
function, which phosphosites are present, cellular localisation, and so on. Some of 
these nodes would also be kinases or phosphatases that alter the connections 
between other nodes, adding further complexity. The network may extend into three 
or even more dimensions. Furthermore, because of the current lack of scientific 
knowledge regarding the relationships between kinases and substrates and other 
protein-protein interactions, the majority of this network would be full of holes. It 
would be as hard to comprehend as it would to construct. The true value of these 
kinds of model will be the insights provided, the predictions that can be tested, and 
the translations into therapy for patients. 
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8. Discussion 
8.1 Introduction 
This thesis set out to determine the role of the IgM and IgD isotypes of the B Cell 
Receptor in Chronic Lymphocytic Leukaemia. CLL, like other malignancies, is 
dependent on the microenvironment for pro-survival signals, and many lines of 
evidence suggest that antigen acting via the BCR may be a critical microenvironmental 
ligand49. The restricted repertoire of IGHV genes, stereotyped CDRs and autoantigenic 
specificities all indicate that the antigen specificity of CLL B-cells has been influential at 
some point in transformation. These findings also highlight the degree to which 
‘healthy’ B-cells exhibit autoreactivity, and that these autoreactive cells may play 
important roles in physiology200. 
 
A recent study has led to the suggestion that in a number of cases, the binding 
specificity of the CLL BCR is reactive for part of the framework region of BCRs on the 
same cell, that the antigen stimulating the BCR is the BCR itself216, although, a very 
limited repertoire of patient samples was studied, so this finding may not extend to all 
cases of CLL. If, however, this model does apply to all CLL cases, it is difficult to 
reconcile with many other studies of the BCR in CLL. For example, other autoantigens 
and microbial antigens have been shown to bind CLL BCRs, and would presumably also 
exert an effect185. IgM signalling anergy is present in many CLL cases, and whilst this 
model may explain anergy, the reversal of anergy on in vitro incubation is not 
explained, as the antigen cannot be removed116. If BCR signalling occurs, as suggested, 
in the LN microenvironment53, how would this fit with a model where the antigen is 
not localised in a tissue compartment but on the same cell? Perhaps other 
microenvironmental factors known to be important then come into play22. If BCR 
ligation is constantly occurring, why would in vitro BCR ligation have any effects in CLL 
in terms of apoptosis and other changes? Perhaps all studies examining in vitro BCR 
stimulus are using a supraphysiologic stimulus with crosslinking, and that only a limited 
amount of BCR stimulation is required for survival in vivo. Clearly, the exact model and 
stimulus conditions have a huge influence on the results of BCR stimulation in CLL320. 
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Whilst several in vitro studies suggest the importance of BCR ligation via its IgM 
isotype in CLL, there has been relatively little exploration of the role of IgD. 
My aims were to: 
1. Establish and confirm the patterns of expression of the IgM and IgD isotypes on the 
surface of CLL cells in peripheral blood, bone marrow and lymph nodes. 
2. Clarify the outcomes of in vitro BCR ligation of the IgM and IgD isotypes in CLL. 
3. Explore the mechanisms of BCR signalling in CLL and tonsil B-cells using a 
phosphoproteomic approach, and compare IgM and IgD signalling. 
8.2 Immunoglobulin Expression in CLL 
Surface immunoglobulin expression in CLL is a pre-requisite for diagnosis, and is often 
described as ‘dim’ or ‘weak’, suggesting low expression compared to healthy B-cells5. It 
is not clear whether ‘dim’ applies to both IgM and IgD. Laboratories often only 
measure surface IgM, but it is well known that IgD is commonly co-expressed with IgM, 
recapitulating the immunophenotype of naïve B-cells449. When immunophenotyping 
methods are considered in depth, straightforward interpretations of the levels of IgD 
or IgM are elusive. Expression is a function of the percentage of cells expressing an 
isotype, and the levels per cell, even before issues regarding binding affinity and 
fluorescence are considered. Comparing IgM and IgD, or peripheral blood flow 
cytometry to lymph node immunohistochemistry has many caveats. Nonetheless, 
results can be interpreted if a sufficiently critical approach to the data is taken.  
 
In peripheral blood CLL cells, IgD and IgM expression seem to be continuous 
variables449. They can both be detected on cells in the majority of patients. In this 
study, IgD expression was more common than IgM expression, with dual positivity 
forming the largest group.  IgD expression was also generally higher than IgM 
expression. The presence or absence of IgM or IgD as defined using thresholds did not 
appear to correlate with prognosis, suggesting that variation of BCR surface levels in 
peripheral blood do not obviously influence disease biology. It may be that BCR 
expression alone supports survival, but that the level does not influence disease 
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aggressiveness. The BCR isotype expression in cases defined as IgM-IgD- would need 
exploration in greater detail to clarify this. To an extent IgG expression may provide 
the pro-survival signals in those cases apparently IgM-IgD-.  IgM and IgD levels do not 
correlate with each other, suggesting that they have differing modes of regulation and 
differing functional roles.  
 
When the lymph node microenvironment is considered, albeit in a limited number of 
patients, it appears that IgD expression in LN is higher than that of IgM and expression 
of the two isotypes is not correlated, again suggesting differential regulation and 
function. Whilst IgD levels in the LN reflect those in PB, IgM levels in the two 
compartments differ, with apparently lower levels of IgM levels in LN than in PB in the 
same patient. It should be remembered also that lymph node biopsies are not typical 
of the general population of patients with CLL and that some patient selection may be 
involved in examining this group of patients in whom both tissues are available. 
However, it does suggest that IgM and IgD may play differing roles in the LN 
compartment. I suggest a model where IgD expression is generally unchanged as CLL 
cells traffic between the PB and LN compartment, whereas IgM expression may be 
downregulated in LN, in line with models of B-cell anergy. In line with other results481, 
no consistent differences in BCR expression between pseudofollicular and 
interfollicular areas were noted, implying that CLL cells with higher proliferation do not 
appear to modulate their BCR expression within the LN. Perhaps factors such as T-cell 
help become more important. 
 
It is easier to study cells isolated from PB, but important events in leukaemogenesis 
probably occur in the LN microenvironment22,53. Various studies have modelled the 
microenvironment using cytokines and stromal cells in vitro, and suggest that these 
effects are better mimics of in vivo events than culture in medium alone22,380,602. 
Perhaps immobilised BCR stimulus also simulates the mode of antigen encounter seen 
in vivo better than a soluble stimulus320. Whereas it is difficult to judge how one 
experimental condition may be ‘more physiological’ than another, it would seem a 
logical step to combine different putative microenvironmental stimuli that have been 
shown to have effects in isolation in an attempt to simulate the full complexity of the 
 372 
microenvironment. It would remain difficult to avoid supraphysiological stimuli in such 
relatively crude in vitro models.  
 
The recent study by Herishanu et al suggests that gene expression differences between 
the CLL LN and PB compartments imply BCR signalling53. They mimicked LN-
upregulated gene expression patterns by IgM stimulus of PB cells. A similar strategy 
could be attempted using phosphoproteomics. Paired lymph node and peripheral 
blood CLL phosphoproteomes could be compared. If different, then stimuli such as BCR 
ligation, CXCR4 exposure or culture with stromal cells could be attempted, followed by 
phosphoproteome analysis. If BCR stimulus resulted in a phosphoproteome more akin 
to LN CLL, then this might be evidence for its importance in the microenvironment. An 
attempt to combine the different stimuli might result in phosphoproteomes that 
increasingly mimic that seen in the microenvironment, the conditions recapitulating 
the signalling pathways seen in the microenvironment might then be declared the 
‘most physiological’. These conditions could then be used to evaluate drug sensitivity. 
The design and performance of these experiments would be highly challenging, and it 
would be surprising if in vivo states could be precisely mimicked in vitro. 
 
Regardless of whether IgM levels are truly modulated in the fashion suggested by an 
anergic model, my data suggest that IgD expression is more common and/or higher 
than IgM expression in CLL. If BCR plays a role in CLL, then it follows that IgD may play 
a more important role than IgM in this disease. However, the same data can be used 
to support an opposite argument: the downregulation of IgM in CLL and anergy may 
imply that signals received via the IgM isotype are more ‘potent’ than via IgD and so 
need to be reduced to prevent autoimmunity or apoptosis. This model, though 
plausible, has the disadvantage of greater complexity. It is likely that both IgM and IgD 
play a role in normal B-cell physiology, as well as in disease. If CLL is binding antigen, it 
will do so via both IgM and IgD. The retention of IgM and IgD in the genome since the 
immunoglobulin genes arose 500 million years ago is a potent argument for the 
importance of both isotypes255. It is has been suggested that one of the functions of 
IgD may be in the maintenance of autoreactive pool of naïve B-cells94. CLL would be 
missing a trick if it did not co-opt IgD-induced survival signals for its own purposes. In 
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the context of published research, this study suggests that whilst there are many 
functional similarities between IgM and IgD, there are also important differences. Any 
study claiming to investigate BCR signalling in CLL will be required to examine IgD as 
well as IgM signalling. 
8.3 Outcomes of BCR ligation in vitro 
Defining or measuring BCR signalling is not as straightforward as is often implied. The 
definitions generally encompass early events such as calcium flux and/or 
phosphorylation or later cellular outcomes such as cell proliferation and death383. 
Interpreting these outcomes implies a teleological view of the function of the B-cell: 
‘successful’ BCR signalling should result in activation and proliferation such that an 
offending pathogen can be eliminated. However, given that most antigens 
encountered by B-cells turn out to be autoantigens, it can be argued that ‘successful’ 
BCR signalling should in many cases manifest as apoptosis or anergy. When in vitro 
stimulation of the BCR can result in both activation and apoptosis as outcomes of 
‘successful’ BCR signalling, the picture can clearly become quite complex and studies of 
BCR signalling become difficult to compare and interpret. It is clear that other contexts 
such as secondary signals derived from T-cells or inflammatory mediators play an 
important role, as does the developmental stage of the B-cell and nature of the 
antigen122. 
 
There is evidence that antigen is critical at some stage in CLL development, but it is not 
clear when. It may be that CLL arises from transformation of a normal B-cell subset 
that is enriched for autoreactive cells. There is circumstantial evidence for ongoing 
antigen encounter in CLL. The phenotype and gene expression profile of CLL cells most 
closely resembles that of antigen-experienced memory B-cells219. There is some 
evidence for ongoing intraclonal diversification in terms of SHM and CSR, events that 
imply ongoing antigen selection processes involving AID494. Ongoing BCR stimulus in 
itself may be mutagenic, as AID is known to have many non-V gene targets that can 
result in lymphomagenesis99. The finding in this and other studies that BCR ligation in 
vitro can promote CLL survival suggests that antigen may be utilised by CLL cells in vivo. 
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The phenotypic and functional resemblance of CLL cells to anergic B-cells is also 
evidence that antigen engagement may be occurring in vivo, and the reversal of anergy 
after incubation in vitro is consistent with the model whereby the anergic state is 
dependent on continuous antigen exposure115,116,234. Teleologically, it might be argued 
that it would be in the cells’ best interests to use antigen as an opportunity to trigger 
activation. The absence of clinically relevant autoantibody production by CLL cells 
might be taken as evidence that such activation does not occur. It may be that the CLL 
cells simply retain enough of the behaviour of normal B-cells that include anergy in the 
face of chronic autoantigen binding. Proliferation despite anergy may be permitted 
because of defects in apoptosis that are known to exist in CLL603, or by other 
mechanisms and one such mechanism might be aberrant BCR signalling. The pattern of 
intracellular pathways activated after BCR ligation is a critical determinant of the 
outcome of antigen binding122. This study suggests that BCR signalling in CLL cells 
differs in multiple ways from that seen in non-malignant B-cells. It might be suggested 
that aberrant BCR signalling pathways are responsible for the proliferation of CLL cells. 
In normal physiology, B-cells encountering autoantigen in this context should undergo 
anergy and fail to survive and proliferate. The BCR signalling pathway may be 
corrupted in CLL, permitting inappropriate use of autoantigen as a pro-survival ligand. 
 
An anergic model of CLL BCR signalling may permit further explanations and 
predictions. The time course of anergy induction and reversal seems to vary from a 
few minutes to 48h, depending on the model and antigen used234. In this study, all 
cells were ‘rested’ for 2-3 hours after thawing, as this was presumed to allow time for 
recovery of physiological functions, but some reversal may occur during this time.  This 
study suggests that most of the reversal of anergy occurs after this, over the 
subsequent 24h, and Mockridge et al suggest that this can increase further over 48-
72h116. If, as suggested, the antigen is the BCR itself, or an autoantigen expressed by 
CLL cells themselves, then reversal would not be expected to occur. Those advocating 
the model of CLL as anergic cells suggest that PB cells have left a LN microenvironment 
rich in antigen, and that a degree of reversal may occur in PB116. Some support for this 
is my finding of lower IgM expression in LN compared to PB. Presumably those cells 
exiting the LN most recently have lower levels of IgM and/or anergic signalling. Over 
 375 
time, IgM expression and signalling would recover and as the cell re-enters the LN it 
would again derive survival signals. This links anergy to a model involving cell 
trafficking, and it would be interesting to examine co-expression of IgM and molecules 
involved in trafficking, or use in vivo labelling techniques to examine cell trafficking. 
 
In the phosphoproteomic explorations of BCR signalling mechanisms, CLL cells that had 
capacity for IgM calcium flux were selected to ensure the comparability of IgM and IgD 
signalling. This ignores any signalling that may occur via IgM in the absence of Ca flux, 
which may be very relevant, but difficult to study. It may be that the conditions used 
measure a partially anergic IgM pathway. This hypothesis is consistent with the finding 
of numerous molecules involved in B-cell anergy in the CLL subset, providing further 
evidence for an anergic model of CLL. But this raises further questions regarding the 
definition of anergy. Can anergic signalling occur in the presence of apparently robust 
calcium flux? Are there degrees of anergy? What are the apoptotic responses of CLL 
cells that have undergone reversal of anergy? Are the high levels of phosphatase 
activity characterising CLL BCR signalling reversible in the same way as calcium flux, or 
are they fixed attributes of transformation? Further studies of the dynamics of anergy 
will be required to answer these questions.  These may help answer certain questions 
raised regarding the recent Nature paper describing the BCR itself as the putative 
antigen in CLL216. Because antigen ligation of the BCR is only one amongst many 
survival signals derived from the microenvironment, many other factors will also need 
to be considered. 
8.4 Phosphoproteomics and signalling networks 
"... the totality is not, as it were, a mere heap, but the whole is something besides the 
parts ..."604  
 
This is the first time that BCR signalling has been reported in primary B-cells using a 
phosphoproteomic approach. In fact, phosphoproteomics has seldom been used on 
primary tumour samples, presumably due to difficulties with cell number and labelling. 
The number of phosphopeptides detected is amongst the highest using these kinds of 
techniques. Despite the increasing power of MS-based phosphoproteomics, increased 
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sensitivity is desirable. Proximal events in signalling pathways occur at low 
stoichiometry, and low abundance phosphoproteins will not be detected. There are 
also issues with large amounts of noise and fundamental issues regarding 
quantification of non-proteotypic peptides.  
 
I have suggested that multiple kinases may be more active in CLL compared to healthy 
B-cells, and that the kinases active after BCR ligation also differ from that seen in 
healthy cells.  The frustrating inability to link kinases to most of their substrates limits 
the power of this study to identify the full extent of signalling networks. Further 
increase in the power of phosphoproteomic approaches is anticipated with novel 
analysis methods, but these will still be limited by ignorance of the substrate 
specificities of most kinases. To an extent this ignorance affects any study of 
intracellular signalling pathways, the high-throughput techniques simply make the 
scale of our ignorance more apparent. Extensive efforts to better characterise the 
human phosphoproteome are needed. 
 
Recent genomic studies of CLL have discovered numerous but infrequent somatic 
mutations40,44. In searching for unifying principles, some have suggested that a 
pathway-centric approach can be useful, whereby multiple seemingly disparate 
mutations may perturb a common pathway48. To an extent, an analogous approach 
has proved useful in this study; seemingly disparate changes in phosphoproteins after 
BCR stimulation can be seen to lie in the same pathway. Often these pathways are 
what one might expect, most obviously the BCR pathway itself. The purpose of these 
studies is to generate novel hypotheses regarding CLL pathophysiology, and the 
suggestions of links between BCR signalling and the spliceosome or Notch signalling 
pathways are intriguing and require verification.  
 
Attempts to describe intracellular signalling better typically result in complex networks 
of proteins that are not confined to any one classically conceived pathway605. The 
teleological purpose of BCR signalling is to alter the behaviour of the B-cell, and this 
will result in the BCR pathway feeding into the diverse pathways involved in 
metabolism, cell cycling and antibody synthesis. Beyond this network formed of linking 
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simpler linear pathways, intracellular signalling is probably better conceived as being 
distributed across multiple nodes606. The cell could best be described as analysing 
inputs in a massively parallel fashion, integrating signals and producing multiple 
outputs, much as a computer. The most important word in the intracellular signalling 
dictionary is phosphorylation. 
 
It has been repeatedly suggested that phosphoproteomics may provide an unbiased 
approach to the elucidation of intracellular signalling pathways in the absence of a 
priori assumptions about which pathways are important426,553. Whilst this may avoid 
prejudices based on the scientific paradigm of the researchers, it substitutes them with 
the assumption that phosphorylation is the most important determinant of signalling. 
We have seen that interpretation of the phosphoproteome is critically dependent on 
the total proteome, and inferring kinase activity is not straightforward. Increasing 
focus is placed on other post-translational modifications (PTMs) such as glycosylation, 
acetylation, sulfation and ubiquitylation, which may be very important but have been 
relatively neglected544. Phosphorylation may still turn out to be the dominant PTM in 
signalling networks, but other modifications will find their place in the vocabulary of 
cells. New discoveries are partly driven by technological innovations that permit 
detection of these molecular changes.  Validation, analysis and bioinformatic methods 
are still lagging behind detection methods553. 
 
This degree of complexity can seem overwhelmingly intractable. The emergence of 
complex phenomena from deterministic simple interactions is much discussed within 
the context of complexity theory, which is rooted in chaos theory607. The interactions 
of hundreds of atoms within a molecule are difficult to model, yet we derive chemistry 
as an emergent property of physics. Organisms are complex in themselves yet the 
study of ecology where organisms are the unit of consideration is possible. Despite 
great complexity and non-linearity, emergent properties will arise from the large-scale 
properties of protein networks that can make predictions about cell biology. In fact 
networks are more robust in the face of perturbations than linear pathways605. 
Removal of nodes in a network (for example by mutation) may not be as catastrophic 
as removal of a node in a linear pathway. However, it is known that removal of 
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critically connected nodes (such as P53) can result in widespread changes throughout 
the network426. Certain nodes are more important than others, but their importance 
lies in their connectedness. High-throughput techniques are demanding new 
theoretical models. Researchers have been promising profound insights into biology 
for some time, yet there is much work to be done before we see findings that can be 
translated into improvements in human health. 
8.5 Translational aspects of this study 
Despite remarkable advances in the treatment of CLL, there is still an unmet need in 
the treatment of this disease, as the standard of care still exhibits significant toxicity in 
a group of patients less suited to tolerate this. New therapies showing great efficacy 
with reduced toxicity are often stated to exert their effects via inhibition of BCR 
signalling, but their effects may depend partly on interference with other important 
pathways involving the microenvironment360. The new small molecule inhibitors of 
BTK, PI3K and SYK all have a class effect whereby treatment leads to a pronounced 
lymphocytosis, as lymph nodes shrink. This mobilisation of CLL cells to exit the LN is 
felt to be an important component of their efficacy, and have led to the need to adjust 
response criteria608.  It seems that these drugs interfere with some aspect of the CLL 
cell localisation to their microenvironment. BCR binding antigen may be this 
localisation signal, but these drugs interfere with multiple pathways, including CXCR4 
signalling, which may be just as or even more important in this context360. Whatever 
the mechanism, the efficacy of these new agents is heartening. 
 
This study produced estimations of AKT kinase activity and correlated them with 
sensitivity to PI3K inhibition. If there had been no correlation, one of the explanations 
would have been the bypassing of the PI3K pathway by parallel pathway activation, a 
mechanism of drug resistance. Clearly, there are much simpler methods to predict 
drug sensitivity, but the power of the phosphoproteomic mechanism may be to enable 
prediction of rational combinations to target multiple pathways that may be active in 
cancer cells606. One study has suggested links between phosphoprotein profiles and 
responses to tyrosine kinase inhibitors in chronic myeloid leukaemia609. Another study 
successfully predicted a rational combination of EGFR inhibitors and MET inhibitors 
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that showed synergy in killing cancer cell lines610. Studies need not be confined to in 
vitro work, it would be interesting to study CLL samples from patients being treated 
with kinase inhibitors, particularly in the context of clinical drug resistance or relapse. 
It is conceivable that each patient will have unique patterns of pathway activation and 
sensitivity to inhibition, so this approach can appeal to notions of personalised therapy 
or biomarker prediction48. 
 
One disadvantage of the phosphoproteomic approach is the need for large amounts of 
protein from large numbers of cells (<107 per sample). This limits its applicability with 
primary samples, but haematological cancers may be amenable to this approach. 
Consideration of bulk populations also ignores issues such as intratumoral 
heterogeneity, and it is increasingly recognised that a major challenge to successful 
therapy is intraclonal diversity412. Great excitement has been produced by the use of 
small molecule kinases inhibitors in cancer therapy, and this is true of CLL. The early 
success of these drugs requires longer follow up, and it is expected that development 
of resistance is likely. Combination therapy is likely to become the paradigm, and if 
these combinations are rationally based on pre-clinical studies they might be more 
successful48. A deeper understanding of leukaemia biology will surely aid the 
development of new treatments for patients. 
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